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Abstract 
The interactions between specific proteins (PPIs) is known to be critical for numerous 
biological processes, implicating them in many pathological conditions, thus 
modulation of PPIs has substantial therapeutic potential.  The complexity, topography 
and, in some cases, the hydrophobic nature of the PPIs presents a considerable 
challenge.  One important PPI of therapeutic interest, that has been implicated in the 
treatment of bi-polar and schizophrenia disorders, occurs between neuronal calcium 
sensor 1 (NCS1) and the dopamine receptor 2 (D2). 
The research detailed in this thesis describes the application of structure-based drug 
design (SBDD) to select small molecule compounds for synthesis and biophysical 
assessment against the NCS1 D2 target.  The use of a structure-based drug design 
method, has been seen in previous PPI studies and uses a combination of 
techniques, including computational modelling used in conjunction with “hit 
identification” and ”hit to lead” optimisation processes in a drug discovery pipeline.  
The biophysical analyses of the first generation synthesised were hampered by 
problems associated with limited aqueous solubility, restricting the determination of 
accurate affinity values.  Thus a second generation of ligands were developed with 
addition of solubilising groups to the scaffold, based on that of the compound 1-
benzyl-N-((2-methoxy-4,6-dimethylpyridin-3-yl)methyl)-3,5-dimethyl-1H-pyrazole-4-
carboxamide (Inhibitor 2).  The second generation of compounds displayed 
improved aqueous solubility, in particular; 1-(4-chlorobenzyl)-3,5-dimethyl-N-((5-
(morpholine-4-carbonyl)pyridin-3-yl)methyl)-1H-pyrazole-4-carboxamide (Inhibitor 
5), presented the most promising hit.   
A fragment based approach was also investigated, adapting the SBDD approach by 
developing a computational pipeline to select 28 compounds from a library of 1137 
for biophysical screening.  A two-step biophysical screening protocol was developed; 
employing high throughput NMR techniques, five fragments were identified alongside 
a hit fragment candidate 5-methyl-3-phenyl-1H-pyrazole (4.21). 
This research presents two applications of an in silico screening protocol able to 
identify ligands targeting PPIs.  Through verification via biophysical techniques, a 
number of compounds were determined as hits however, no affinity for the target was 
determined.  This project highlights that despite some successes, many challenges 
remain in the development of targeting PPIs with small molecules. 
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1 Introduction 
 Neuronal Calcium Sensor Proteins 
This thesis is concerned with a class of Ca2+ binding proteins that has been implicated 
in a number of neurological disorders.  Such proteins can be subdivided into two 
classes (a) buffers and (b) sensors, depending on their affinity for Ca2+, binding off 
rates and functionality.[1]  Members of the Ca2+buffer class include parvalbumin, 
calbindin and calretinin however, they shall not be discussed further as it is members 
of the sensors that are of interest to this research.[2] 
The neuronal Ca2+ sensors (NCS) are a family of EF-hand containing Ca2+ binding 
proteins.[1]  The NCS proteins can be subdivided into five groups (A - E), depending 
upon their appearance in evolution, or their sequence similarity and have been 
identified in numerous organisms from yeast to man.[1,3]  The members of the five 
sub-classes include: class A (NCS proteins), class B (neurocalcin and hippocalcin), 
class C (recoverin), class D (guanylyl cyclase activating proteins, GCAPs) and finally 
class E (potassium channel inactivating proteins, KChIPs).   
Members of the NCS family are able to bind Ca2+ with varying affinity and as such 
have different purposes, NCS proteins regulate signal transduction in the brain and 
retina.[4]  Recoverin is only expressed in the retina, where it has been found to be a 
sensor in rod and cone cells whereby it controls the desensitisation of rhodopsin.[4]  
Many other NCS proteins are expressed in the brain and have diverse functions for 
example, neurocalcins and visinin-like proteins are implicated in synaptic plasticity 
through their regulation of guanylate cyclase and nicotinamide acetylcholine 
receptors.[5]   
Other proteins such as KChIP, hippocalcin and NCS1 are involved in the control of 
neuronal excitability through their interactions with ion channels.[6–8]  Within the NCS 
proteins, there is a large degree of sequence identity which would suggest that they 
would have conserved three dimensional structures.[3,4]  This is observed in both the 
X-ray crystallography or NMR structures of Ca2+ bound un-myristoylated NCS 
proteins (Figure 1.1).[4]   
The evolutionary conservation of the NCS proteins can be observed, all are 
approximately 200 amino acid residues in length and possess four EF hands (four 
helix loop helix motif’s).[3,9]  Of those four, only three are able to bind Ca2+ (although 
recoverin and KChIP1 can only bind two).[3,9]  Furthermore it is the first EF hand in 
the N-terminal region of all NCS proteins that is inactive in the binding of Ca2+ and of 
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the 14 mammalian NCS proteins 11 are N-terminally myristoylated which enables 
them to anchor to cell membranes, albeit using different mechanisms.[3,10]   
Despite the similarities, the ability of the different NCS proteins to recognise different 
sets of physiological ligands suggests that they must have some distinguishing 
structural difference, which therefore makes the NCS family potential druggable 
candidates.[4]  
No PPI inhibitors have as yet been identified for NCS1 a member of this important 
class of proteins. 
 
Figure 1.1- A comparison of some of the different NCS protein structures- (Top) a generalised 
representation of the secondary structure of a member of the NCS proteins colour in accordance to the 
four EF hands, light blue (EF-1), light green (EF-2), light pink (EF-3), and pale yellow (EF-4). (a) 
Myristoylated mammalian recoverin (PDB 1iKU [11]) the myristoyl group coloured in purple, the four EF 
hands can be seen in light blue (EF-1), light green (EF-2), light pink (EF-3), and pale yellow (EF-4) (b) 
Myristoylated mammalian GCAP1 (PDB 2r2I [12]) the myristoyl group coloured in purple, with the Ca2+  
as orange spheres, again the four EF hands can be seen in light blue, light green, light pink, and pale 
yellow. (c) Rat NCS1 (PDB 5AEQ [13]) the four EF hands are coloured in accordance with the previous 
structures and the Ca2+ as orange spheres. (d) S.cerevisae frq1 (PDB 1FPW [14]) the four EF hands are 
coloured in accordance with the previous structures and the Ca2+ as orange spheres. 
1.1.1 NCS1 and the dopamine receptor D2 
Mammalian NCS1 also known as human frequenin (Figure 1.1 c) has been implicated 
in numerous physiological functions including the regulation of neuro transmitter 
release, synaptic plasticity, learning and memory function.[15–18]  An investigation 
into the interacting partners, indicate that NCS1 is involved in many protein-protein 
interactions in both a Ca2+ dependent and independent manner.[19] Amongst the 
Introduction  
3 
 
interacting proteins identified are phosphatidylinositol-4-kinase (PI4K) and its yeast 
orthologue pik1, the dopamine receptors D2R and D3R, ARF1, the interleukin 
receptor accessory protein like-1 IL1RAPL1, TRPC5 channels and InsP(3) 
receptors.[19–27]  Of these wide ranging interacting partners, one of considerable 
interest and importance is the dopamine receptor D2 due to its role within the central 
nervous system. 
The dopamine receptor D2R is a member of the G-protein coupled receptors 
(GPCRs) of which there are five (D1-D5) that can be subdivided into two families; the 
D1 like family which include D1 and D5 and the D2 like family including D2, D3 and 
D4.[28]  Comparisons between the dopamine receptor D3 and D2 lead to the 
prediction that D2 is composed of seven transmembrane α helices, which are 
connected through three intracellular and three extracellular loops.[29]  Alongside an 
amphipathic α helical C-terminal domain as seen with D3, the amino acid sequence 
in the C-terminus of D3 differs from that of D2 by only one residue (Serine D3 for 
Histidine D2, Figure 1.2).[29] 
 
Figure 1.2- The structure of the dopamine D2/D3 receptor (PDB 3PBL) with the C-terminal helix coloured 
magenta and the amino acid sequence annotated. The D2R peptide is predicted as being α helical, the 
C-terminal region of D3 which only differs from the sequence of D2R peptide by one residue is also 
known to form an amphipathic α helix as shown here.[27,29] 
The biological implications of the dopamine receptor D2 include dopaminergic 
signalling within the central nervous system, addictive behavioural disorders, bi-polar 
disorder and schizophrenia.[30,31]  Interestingly, the expression levels of NCS1, are 
increased in patients with bi-polar disorder and schizophrenia when under an 
antipsychotic regimen such as haloperidol 1.1 or clozapine 1.2 (Figure 1.3).[30] 
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Figure 1.3- The chemical structures of the antipsychotic drugs haloperidol 1.1 and clozapine 1.2. 
The mechanism for the interaction of NCS1 with D2 is both direct and indirect in 
nature; the Ca2+ sensitive interaction between NCS1 and D2 causes the 
desensitisation of the D2 receptor towards dopamine to be reduced (the direct effect 
Figure 1.4).[32]  However, the interaction between NCS1 and the glycoprotein 
coupled receptor kinase 2 (GRK2) blocks the GRK2 mediated phosphorylation of the 
D2 receptor (this is the indirect effect Figure 1.4).[32]  The Ca2+dependent  nature of 
the NCS1 interactions are regulated through changes in the Ca2+ concentration, this 
occurs through the release of Ca2+ from intracellular stores and Ca2+ channels (Figure 
1.4).[32] 
 
Figure 1.4- A representative view of the interaction between NCS1 and dopamine receptor D2 
(D2R) at the synapses (adapted from [32]).  The Ca2+ sensitive interaction between NCS1 and D2R 
causes attenuation of the D2 receptor desensitisation. The interaction of NCS1 with the glycoprotein 
coupled receptor kinase 2 (GRK2) is also Ca2+ dependent and it blocks the GRK2 mediated 
phosphorylation of the D2 receptor. The Ca2+ dependent nature of NCS1 is regulated through changes 
in the Ca2+ concentration through the release from intracellular stores and Ca2+ channels. 
The physiological relevance of the NCS1-D2 interaction has heralded it as a 
promising target for molecular intervention. No PPI inhibitors have as yet been 
identified for NCS1. 
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With the structures of numerous members of the NCS proteins already determined 
using X-ray crystallography or NMR spectroscopy, it was suggested that the NCS1-
D2R interaction could occur in a similar manner.[33]  It was observed in the previous 
cases, that the interaction of a ligand or peptide occurred in a large hydrophobic cleft 
that was formed by a number a hydrophobic residues.[4,34–37]  The residues in 
question were known to be conserved throughout the NCS family, suggesting that 
this mode of binding could be adopted across the NCS proteins.[38]  However, the 
specificity of each interaction would occur through differences in the size of the cleft 
most likely in relation to the size of the binding partner.[38]  In the case of NCS1 it 
was found that the presence of Ca2+ caused a large hydrophobic cleft to become 
exposed as with previous NCS proteins, this furthered the assumption that this could 
be the site for the interaction of a protein or ligand.[33] 
More recently an extensive study into the different crystal structures of NCS1 
complexes and truncated Ca2+ bound proteins by Lian et al. elucidated a number of 
interesting and significant features (Figure 1.5).[13]  Utilising a number of techniques 
including X-ray crystallography, it was confirmed that two D2R peptide molecules 
bound to NCS1, as had been postulated by previous computational and NMR 
spectroscopic based studies.[13,38]   
 
Figure 1.5- Structure of rat Ca2+ NCS1 complexed with dopamine receptor D2R peptide (PDB 
5AER).  (a) Cartoon representation of the NCS1 structure when in complex with the dopamine receptor 
D2R peptide omitting the D2 peptide.  The EF hands are coloured accordingly EF-1 pale blue, EF-2 pale 
green, EF-3 pale pink and EF-4 cream the three Ca2+ orange spheres. (b) The molecular surface of 
NCS1 coloured as before, with the hydrophobic ligand binding site observed running down the centre. 
(c) Cartoon representation of the NCS1 D2R peptide complex, NCS1 coloured as before with the two C-
terminal helices of two D2R peptides observed in magenta and teal, Ca2+ orange spheres, the two 
peptides bind to NCS1 independently of one another. (d) Molecular surface representation of the NCS1 
D2R peptide complex coloured as before (adapted from [13]). 
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A number of key hydrophobic residues within the conserved hydrophobic groove were 
implicated in the binding interaction between the protein and the peptide (Figure 
1.6).[13]  The binding of NCS1 to the two peptides can be split into two specific 
regions of the protein, the N-lobe and C-lobe, with one peptide molecule binding to 
each region separately.  The two D2R peptides were found to bind to NCS1 with their 
C-termini orientated towards the centre of NCS1 (Figure 1.5).  Those implicit residues 
of NCS1 found to undergo an interaction within the N-lobe include Trp30, Phe34, 
Phe48, Ile51, Tyr52, Phe55, Phe85 and Leu89.[13]  Interestingly when compared to 
other NCS protein and peptide complexes, the evolutionary conservation of these 
residues indicate their importance for binding within the complexes.[13]  In 
comparison, the C-lobe was found to make fewer intermolecular contacts which 
include Phe54, Ile128, Tyr129, Met131, Val132, Val136, Leu138, Ala182, Tyr186 
(Figure 1.6 b and Figure 1.7).  However, despite having fewer contacts to the D2R 
peptide, it appeared to undergo significant structural changes upon binding.  These 
changes include the induced-fit structural stabilisation of one side of the hydrophobic 
crevice between residues Val132 - Leu138.  In the uncomplexed protein (Figure 1.1 
c) this region was found to be unstructured, however in the presence of the D2R 
peptide (Figure 1.5 b) a helical conformation is adopted.[13]  Interestingly it is this C-
lobe made up of the EF-3 and EF-4 regions that are the least conserved within the 
NCS family members.  It could be suggested that the residues within this region that 
are stabilised upon D2R peptide binding could give rise to target specificity and as 
such could be key for therapeutic purposes. 
 
Figure 1.6- Structure of rat Ca2+ NCS1 in complex with D2R peptide-the key hydrophobic residues 
(PDB 5AER).  (a) Molecular surface of NCS1 coloured grey, the key hydrophobic residues that interact 
with the C-terminal helix of the D2R peptides 1 (magenta) and 2 (cyan) coloured yellow and orange 
respectively. (b) As with (a) but the two D2R peptide helices removed and the key residues annotated 
(Adapted form [13]). 
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Figure 1.7- The Intermolecular interactions of rat Ca2+ NCS1 with the D2R peptide. (a) A detailed 
zoom of the hydrophobic interactions of the sidechain residues from the N-lobe of NCS1 (coloured as 
Figure 1.5) with the C-terminal helix of D2R peptide 1 (magenta). (b) A detailed magnification of the 
hydrophobic interactions of the sidechain residues from the C-lobe of NCS1 (coloured as before) with 
the C-terminal helix of D2R peptide 2 (teal). 
1.1.2 Frq1 and pik1 
As well as mammalian NCS1, it has been found that the yeast Saccharomyces 
cerevisiae and Schizosaccharomyces pombe genomes encode a protein that shares 
a sequence homology of greater than 60% with mammalian NCS1.[4]  These 
homologs have different roles in their respective genomes.  For example in the fission 
yeast S. pombe the homologue known as Ncs1 is responsible for the regulation of 
sporulation and Ca2+ tolerance.[39,40]  In the budding yeast S. cerevisiae, the 
orthologue is known as frq1 and it is essential for cellular growth.[26]  A key protein-
protein interaction has been found to occur between frq1 and phosphatidylinositol 4-
kinase (pik1) (Figure 1.8).  The pik1 protein is fundamental for vesicular trafficking in 
the late secretory pathway, nuclear functions and cytokinesis, frq1 is necessary for 
optimal pik1 activity.[34,41]   
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Figure 1.8- The frq1 pik1 complex. (a) View from the binding interface and (b) the binding face rotated 
180°, both cartoon representations of NMR structure of the interaction between yeast frq1 and pik1.  The 
four EF hands of frq1 can be seen in light green, light pink, light blue and cream, with the two alpha 
helices of pik1 in magenta. (c) and (d) Space fill representations from the binding interface (c) of frq1 
alone with its key hydrophobic residues in yellow (d) frq1 and pik1 with the key residues of pik1 annotated 
(adapted from [34]). 
The pik1 peptide is composed of two α-helices, the N-terminal helix from residues 
127 - 135 and the C-terminal helix 156 - 167, the two helices are connected by a 
twenty residue loop.[34]  The stoichiometry of binding deduced from NMR studies 
was defined as 1:1, in contrast to that of the 2:1 stoichiometry determined for the D2R 
peptide NCS1 interaction .[34]  As with the NCS1 D2R peptide interaction the protein-
protein interaction between frq1 and pik1 involves two lobe regions of frq1 interacting 
independently with two α helices of pik1.  The hydrophobic residues of the N-terminal 
helix of pik1 interacts with the C-terminal residues of frq1.[34]  Similarly, the 
hydrophobic residues on the C-terminal helix of pik1 contact the N-terminal 
hydrophobic groove of frq1 (Figure 1.8).[34]   
It was discovered through the results of NMR studies by Strahl et al. that in the 
complex of frq1 and pik1 the terminal residues of frq1 at both the N and C terminus 
are solvent exposed and disordered.  This lead to the possibility that the N-terminal 
myristoyl group of uncomplexed frq1 may actually be involved in recruiting pik1 to the 
membranes.[34]   
Work by Lim et al. found that frq1 underwent a large conformational change induced 
through Ca2+ binding, whereby the myristoyl group was extruded, this caused the 
Introduction  
9 
 
hydrophobic residues in the C-terminal to become solvent-exposed enabling it to 
interact with pik1.[4]  Furthermore through their NMR analysis, the interaction 
between the C-terminal helix of pik1 and frq1 was found to be more stable in 
comparison to the corresponding interaction of the N-helix of pik1.[34]  A number of 
hydrophobic residues on the C-terminal helix of pik1 were found to make extensive 
contacts with the aromatic and other hydrophobic residues on frq1 (Figure 1.9 a).   
 
Figure 1.9- (a) Close up view of the C-terminal helix of pik1 (magenta) with the sidechains of the N-
terminal hydrophobic groove of frq1 (pale yellow).  (b) Close up view of the N-terminal helix of pik1 
(magenta) with the sidechains of the C-terminal hydrophobic groove of frq1 (pale yellow) (adapted from 
[34]). 
The network of strong and intricate intermolecular hydrophobic interactions explain 
the high affinity of the interaction between the two proteins.[34]  It suggested that the 
interaction of the C-terminus of pik1 was the anchoring point between the peptide and 
the protein, facilitating further interaction between the second N-helix of pik1 and 
frq1.[34] 
Frequenin has been found to have a high degree of evolutionary conservation with a 
similar secondary structure to the mammalian NCS1, with the EF hand motifs EF-2, 
EF-3 and EF-4 bound to Ca2+ ions.[41]  Another similarity drawn between the two 
homologues and other NCS proteins is that they have a hydrophobic pocket, found 
at the surface between two of the EF-hand-containing lobes as well as the solvent 
exposed N and C termini.[41]   
The structural similarities and the fact that the two orthologues NCS1 and frq1, both 
interact with pik1, suggest that NCS1 may be responsible for the regulation of the 
activity of pik1 in mammalian cells.[34]  The knowledge that the hydrophobic residues 
within the C-terminal helix of pik1 make considerable contact with aromatic and other 
hydrophobic sidechains of frq1, could be useful when designing inhibitors.[34]  Such 
important hydrophobic residues include Val156, Ala157, Ala159, Leu160, Val161 and 
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Met165.[34]  This small cluster of hotspot residues could be used to generate a 
starting template or three dimensional representation, from which a computational 
structure-based drug design (sbdd) method could be applied.  The sbdd method 
would allow for the selection of novel compounds, able to replicate the area of 3-D 
space that the hotspot residues represent for a pharmacophore based search.  The 
compounds would subsequently be synthesised and tested using a variety of 
biophysical methods.[34]   
There are a variety of different computational applications used in structure-based 
drug design process (Section1.4), and a number of protein-protein interactions (PPIs) 
have been targeted therapeutically, using computational applications in development 
of drug-like compounds. 
 Protein-Protein Interactions (PPIs) as Drug Targets 
PPIs are involved in nearly all biological processes and cellular function is therefore 
reliant on their regulation.[42]  Due to their ubiquitous nature and central role, there 
has been an increasing interest in targeting the interface between two interacting 
proteins as a potential therapeutic target.[42,43]  Inhibition of protein-protein 
interactions has seen significant recent advances, although it does present a number 
of challenges because of the nature of protein-protein interaction surface.[43]  The 
surfaces involved in PPIs are typically large, often flat with complicated topography, 
and a large portion of the surface area of the interfaces are buried.[44,45]  Despite 
these large interfaces there may only be a small number of influential residues 
essential for a high affinity binding interaction [46–48], thereby, reducing the actual 
challenges posed when developing small molecule inhibitors and making the 
targeting of protein-protein interactions a realistic and viable drug development 
strategy. 
A typical passively absorbed drug profile follows Lipinski’s ‘Rule-of-five’ which 
includes a MW < 500 Da.  Due to the nature of protein-protein interfaces molecules 
which are targeted at them tend to have a high molecular weights.[43,49]  They also 
tend to have an increased hydrophobicity, a higher number of hydrogen bond donors, 
hydrogen bond acceptors and a higher ring complexity in comparison to other 
drugs.[50] 
At present excluding peptidomimetics there is no well-established structure-based 
approach for the design of PPI modulators using defined computational pipelines. 
There is also a general lack of small molecule starting points for drug design as there 
are very few known naturally occurring small molecules that bind to protein 
Introduction  
11 
 
interfaces.[44,50]  It can be difficult to distinguish between true binding from 
artefactual binding and current small molecule compound libraries tend to be biased 
towards certain protein classes, making them more specific to certain targets and less 
general.[44,50]   
Despite the difficulties PPI targets present, there have been a number of notable 
success stories with several drugs are already in clinical use and some others are 
being evaluated in clinical trials.[51] 
 The inhibition of PPIs past and present 
Research into the design and synthesis of small molecule inhibitors has been 
conducted for a number of key protein-protein interactions that are believed to play a 
vital role in many biological processes.  Due to the central role of PPIs the number of 
systems studied is increasing very rapidly, with some of the most interesting being, 
studies on binding to IL-2, HPVE2, ZipA, TNf, HDM2 and Bcl-XL.[43]  Here we shall 
briefly discuss some of the approaches developed to target these interactions, in 
particular those of HDM2 and Bcl-XL (Sections 1.3.5 and 1.3.6). 
1.3.1 IL-2 
IL-2 (Interleukin-2) is a cytokine that is of particular interest due to its role in the 
activation of killer T-cells in an immune response and has been linked to the rejection 
of tissue grafts.[52]  The design of a series of small molecules able to bind to the 
receptor of IL-2, was conducted by Sunesis Pharmaceuticals, without prior knowledge 
of the structure of the IL-2 bound to its receptor (IL-2R).[53]  The initial hit to lead 
process started with a small peptidomimetic designed to mimic the structure of IL-2 
binding region; however it was found to bind to IL-2 itself rather than the IL-2 receptor 
and so was not taken any further.[54]   
Interestingly, the subsequent discovery process was carried out utilising a 
combination of techniques and using the original unsuccessful compound as a 
template starting point.  The compound was divided into its four constituent 
fragments, from which the subsequent structure activity relationship studies (SAR) 
elucidated one key fragment.  Optimisation of this fragment was carried out through 
a number of steps including further compound library screening processes to evolve 
the target compounds.[43,54]   
To ensure a greater success rate at each separate stage the lead compounds were 
characterised using a number of assays including enzyme-linked immunosorbent 
assay’s (ELISA); this confirmed binding of the small molecule to the IL-2R hotspot.[54] 
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The most successful small molecule designed was SP4206 (1.3 Figure 1.10) which 
interestingly, does not resemble the IL-2R.[53]  In fact it is believed that if the crystal 
structure of the IL-2 receptor complex had been used in the design process then 
SP4206 would not have been discovered, highlighting the occasional unpredictability 
and sometimes serendipitous nature of drug discovery.[43]   
1.3.2 Interactions involving the human papilloma virus HPV 
The protein-protein interaction between the viral transcription factor E2 and the viral 
helicase E1 is important in the life cycle of the human papilloma virus (HPV).[55]  HPV 
is associated with cervical cancer and warts, and small molecule treatment regimens 
are available with limited success.[56]  Therefore the development of such drugs to 
target HPVE2 and prevent its interaction with E1 is a key target for pharmaceutical 
companies.[56]  A research group at Boehringer Ingelheim was able to utilise High 
Throughput Screening (HTS) to identify a class of compounds known as 
indadiones.[56]  These compounds were found to disrupt moderately the protein-
protein interaction between E2 and E1; however, further target optimisation and 
medicinal chemistry efforts led to the development of the 1.4 (Figure 1.10).  This 
compound exhibited a lowered IC50 value of 6 nM, with a higher ligand efficiency than 
the original binding partner target E1.[55,57,58]  Thought to be due to the ability of 
the compound to bury its hydrophobic surface area, rather than spanning across the 
vast protein-protein interface.[55,58] 
 
Figure 1.10- Structures of two developed small molecule inhibitors (1.3) SP4206 an inhibitor developed 
for targeting IL-2 (1.3) the so called “Compound 23” developed by Boehringer Ingelheim for the HPV: E2 
interaction (structures adapted from [53,55,58] ) 
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1.3.3 ZipA and FtsZa 
In another study the interaction between ZipA and FtsZa was examined, ZipA is a 
membrane anchored protein that interacts with a homologue of eukaryotic tubulin, 
FtsZa through terminal carboxy domains.[59]  These proteins were found to be the 
main constituents of a structure known as a septal ring found in gram negative 
bacteria, and is responsible for their separation and replication.[59]  The interaction 
between the proteins was studied using X-ray crystallography, NMR spectroscopy 
was employed to screen a diverse set of 825 compounds.[60]  The NMR study found 
seven hits that bound to ZipA at the same site as FtsZa and is an example of early 
drug design processes.[60]  However, despite this early indication that ZipA may be 
“druggable” further medicinal chemistry and SAR were unable to generate any small 
molecules able to penetrate deep within the surface of ZipA which is in stark contrast 
to the findings of studies on IL-2, HPVE2, HDM2 and Bcl-XL.[43,60,61]  This is an 
excellent example of the challenges that are involved in targeting complex 
interactions associated with two interacting proteins.  
1.3.4 TNF  
Tumour Necrosis Factor (TNF) is also a cytokine and is an important biological target 
due to its involvement in the inflammatory response.[62]  It is the interaction between 
TNF and its receptors, TNFR1 and TNFR2, that the small molecule inhibitors are 
designed to disrupt, these targeted therapeutics have been approved for the 
treatment of arthritis.[62]  Fragment screening lead to the development of a group of 
small molecules, that were found to interfere with TNF binding, through the 
displacement of one of the three monomers that constitute the TNF-α homotrimer.[63]  
However due to their moderate affinities, these compounds are not considered as 
potential drug candidates.[63]   
 
Figure 1.11- The chemical structures of two small molecules, (1.5) was developed to target the ZipA 
interaction and the TNFα inhibitor (1.6) (adapted from [60] and [63]). 
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1.3.5 Case Study 1: Developing small molecule modulators of P53 and 
MDM2 over the decades… 
An extensively investigated protein-protein interaction is that between the tumour 
suppressor gene p53 and HDM2.   
HDM2, also known as the human protein double minute, was found to be an excellent 
target in the treatment of cancer.[64]  The initial research into MDM2, the mouse 
orthologue, found that it bound to the tumour suppressor protein p53, increasing its 
degradation and blocking its transcriptional activity which results in tumour 
suppression.[65]  The interaction of MDM2 with p53 also results in the nuclear 
movement of p53 into the cytoplasm and away from its site of action.[66]   
The design and synthesis of compounds to modulate this interaction has been of 
substantial interest over a number of decades.  However despite keen research 
interest, the development of small molecule modulators was not successful for a long 
period of time, indicative of the complexity involved in the design of modulators for 
PPI targets.[67]   
The interaction between the two proteins MDM2 and p53 was found to involve of a 
small segment of the N-terminus transcription activation domain of p53 (residues 13-
19) and a hydrophobic pocket within MDM2.[68]  Furthermore X-ray crystallography, 
indicated the primary involvement of three sidechains of the hydrophobic residues; 
Phe19, Trp23 and Leu26, which form a short α helix on p53 located within a deep 
pocket in MDM2 (Figure 1.13).[67,69]   
One of the earliest success stories of inhibiting the two interacting proteins was 
reported by Vassilev et al. who developed a series of cis-imidazoline compounds, 
more commonly known as Nutlins (Figure 1.12).[70]  High-throughput NMR 
spectroscopy screening of a diverse library of compounds, followed by extensive 
optimisation strategies from the initial leads resulted in three racemic hit compounds 
Nutlin-1 and Nutlin-2.  However interestingly, of the two enantiomers of Nutlin-3 only 
one is active and this is known as Nutlin-3a.[70]  The three Nutlin compounds were 
found to disrupt the p53-MDM2 interaction with IC50 values of 260 nM, 140 nM and 
90 nM, respectively.[70]  Determination of the crystal structure of the complex 
between MDM2 and Nutlin-2, indicated that the compound was able to mimic the 
sidechains of Phe19, Trp23 and Leu26 on the p53 helix, through investigations of the 
corresponding interaction sites on MDM2.  Since its initial publication Nutlin-3a has 
been evaluated for its therapeutic potential for cancer treatment.[70] 
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Figure 1.12 The chemical structure of Roche’s cis-imidazoline compounds the Nutlins, designed to 
inhibit the p53 MDM2 interaction.  The two racemic compounds Nutlin-1 and Nutlin-2 and the active 
enantiomer Nutlin-3a. 
Cummings et al. at Johnson and Johnson used the proposed three key residues from 
the interacting sequence of a p53 9mer segment (Figure 1.13), as a template in the 
design of their benzodiazepine derived inhibitors.[67]  When screened against their 
biological target, these benzodiazepine derivatives presented half maximal 
concentration (IC50) values ranging from 125 μM - 0.4 μM.[67]  A crystal structure of 
one of the benzodiazepine inhibitors with MDM2 (PDB 1T4F), indicated it was able to 
successfully mimic the three sidechain residues, this structural data further supported 
a competition assay with the native peptide.[67,71]   
 
Figure 1.13- The three hydrophobic sidechain residues of the p53 helix (purple) highlighted in the deep 
pocket of MDM2 (cyan) (PDB 1T4F), against the corresponding 9mer segment of p53 with the sidechains 
highlighted below (adapted from [67]). 
Ding et al. elucidated a key hydrogen bonding interaction between the NH of the 
indole ring of sidechain from Trp23 to the MDM2 backbone using x-ray 
crystallography.[68]  Therefore the design strategy of small molecule inhibitors 
developed by Ding et al. involved searching for chemical moieties that could mimic 
this interaction.[68]  They found that in addition to the indole ring an oxindole could 
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mimic the hydrogen bonding and hydrophobic contributions of the Trp23 sidechain 
and this was therefore used as a core structure for the starting point of the structure-
based strategy.[68]  From here a substructure search was conducted to identify 
natural products that contained the oxindole ring, among those identified were 
spirotryprostatin which contained a spiro-oxindole core.[68]   
Molecular modelling studies using computational docking, found these compounds 
fitted poorly into the MDM2 cleft due to steric clashes, but the spiropyrrolidone ring 
presented a rigid scaffold from which the residues of Phe19 and Leu26 could be 
mimicked through the addition of hydrophobic sidechains.[68]  Candidate compounds 
were then designed through the variation of the sidechains, their most potent inhibitor 
1.10 (Figure 1.14) was found to have a KD value of 86 nM with MDM2.[68]  It was an 
effective inhibitor of cellular growth in cancer cells with WT p53 and exhibited 
selectivity over cancer cells with deleted p53, with minimal toxicity to healthy cells and 
presented a promising lead compound for optimisation.[68]   
 
Figure 1.14- The chemical structures of three non peptidic inhibitors of p53 and MDM2, a product of the 
structure-based design and synthesis process approach developed by Ding et al. (adapted from [68,69]). 
The three residue mimic was also used to design other inhibitors; however through 
the use of fluorescence polarisation assays it was discovered that despite the high 
binding affinities of these molecules they were significantly less potent.[69]  This 
indicated the presence of other interactions, confirmed with the discovery of a fourth 
residue Leu22 involved in the binding interface (Figure 1.15).[69]  Molecular modelling 
techniques such as computational docking using the crystal structure was then used 
to optimise 1.10 bound to MDM2.[69]  The findings suggested that a chain extension 
at the carbonyl end could interact with the desired fourth residue.[69]   
The computational docking programme GOLD was the next step in the process, 
predicting binding modes of several different chain extensions.  The fact that the 
Leu22 residue was not buried within a hydrophobic pocket, but rather solvent exposed 
meant that the group could experiment with different polar moieties that could also 
aid the solubility profile of the compound.   
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Through fluorescence polarisation (FP) assays, the initial target 1.11 (Figure 1.14) 
displayed an inhibition constant (Ki) of 13 nM and an increased potency, six times 
greater than 1.10.[69]  The synthetic route to obtain 1.11 utilised an asymmetric 1, 3-
dipolar cycloaddition reaction as the main step in the stereospecific synthesis and is 
shown in Scheme 1.1. 
 
Figure 1.15- X-ray structure of p53-MDM2 complex (PDB 1YCR).  In addition to the three residues 
Phe19, Trp23 and Leu26, Leu22 was also found to play a role in the interaction.  MDM2 cavity is coloured 
according to its depth, the deep buried region coloured in yellow with the external solvent exposed 
regions in blue and the sidechains of the key residues in magenta (adapted from [69]). 
Further medicinal chemistry driven optimisation of 1.11, involved attempts to improve 
the metabolic stability of the compounds through the incorporation of fluorine groups 
on the benzene lead to a reduction in their potency.  However, development of 
another ligand 1.12 from the scaffold of 1.11 with the incorporation of a fluorine group, 
resulted in a Ki of 3 nM.  When Ding et al. used their fluorescence polarisation assay 
to compare their newly designed inhibitor to that of Hoffman la Roche’s most 
successful candidate 1.9 Nutlins 3a, they found that 1.12 was 12 times more potent.   
 
Introduction  
18 
 
 
Scheme 1.1- The three step stereospecific synthetic route to spiro-oxindole derived p53 MDM2 
modulators 1.11 and 1.12 developed by Ding et al. (adapted from [69]). (a) 4 Å molecular sieves, 
toluene; (b) 2-morpholin-4-yl-ethylamine/THF or 1(2-aminoethyl)-piperadine/THF, RT; (c) Pb(OAc)4, 
CHCl2-MeOH (1:1), 0 ˚C. 
This is an excellent example by Ding et al. of the use of rational drug design and 
guided by computational modelling used alongside chemical synthesis and structural 
biology to develop and optimise small molecule inhibitors of PPIs.   
More recently an extensive investigation into the structure-based rational design 
behind the discovery of a novel piperidinone series of p53 MDM2 inhibitors was 
reported by Rew et al. (Figure 1.16).[72]  Their investigative studies were based on a 
rigid core that was capable of holding two aromatic rings, to again target the key 
residues of p53.  Initial results led to the development of 1.19 a 1,3,5,6-tetra 
substituted piperidinone which had an IC50 of 2.42 μM.[72]  By simply changing the 
configuration of the acetic acid component and converting the diaryl from cis to trans 
followed by isolation of the active enantiomer 1.20, increased the potency up to 70 
fold.   
This new optimised inhibitor was found to be capable of forming electrostatic 
interactions between the acetic acid component and an imidazole sidechain of 
MDM2.[72]  They subsequently reported that optimisation processes of the N-alkyl 
substituent on 1.20 resulted in compounds that were designed to occupy the Phe19 
pocket, improved solubility through increasing the polarity of the compound and 
creating van der Waals contacts to MDM2.[72]  Furthermore the discovery of a third 
hit compound 1.21 came from optimizing the piperidinone scaffold so that the trans-
diaryl conformation was stabilised with substitution of a methyl moiety on the same 
carbon as the acetic acid functionalisation (C3 Scheme1.2).[72]  The most potent 
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compound 1.22 was obtained through optimisation of 1.21, it demonstrated an 
excellent efficacy with a binding constant (KD) of 0.4 nM and was selective for its 
target with an improved oral bioavailability and pharmacological studies predicted it 
to have a long half-life in humans.[72] 
 
Figure 1.16- The five piperidinone inhibitors developed by Rew et al.  The development process 
involved the initial hit compound 1.19, optimisation processes led to 1.20, which in turn was optimised 
to compound 1.21 and ultimately led to the most potent compound 1.22 which had a KD of 0.4 nM. 
The synthetic procedures employed in this vast hit to lead optimisation project 
followed multi step syntheses which are summarised in Scheme 1.2.  From the simple 
starting compound 2-(3-chlorophenyl) acetic acid 1.23 a six step synthetic procedure 
(a) involving such processes as conjugate addition, NaBH4 reduction and the 
Staudinger reaction lead to 1.24 in its cis-diaryl form.   
A further three steps converted the cis-diaryl 1.24 into the first hit compound the cis-
diaryl 1,3,5,6-tetrasubstituted piperidinone 1.19.  The second hit compound 1.20 was 
generated from the enantiomer of trans-diaryl 1.24, the reactions include N-alkylation, 
followed by allylation at the C3 position and finally oxidative cleavage of the alkene at 
C3 using catalytic amounts of ruthenium tetroxide.  The six synthetic procedures to 
obtain 1.21 included some of the following protection of the amide nitrogen of the 
trans-aryl piperidinone 1.24, methylation at C3, deprotection followed by N-alkylation 
and oxidative cleavage of the alkene as before.   
A further three successive reduction and oxidation reactions using the Des-Martin 
periodiane from an analogue of 1.21, resulted in the final and most successful lead 
compound 1.22 in a yield of 75%.  This is an excellent example of a scaffold based 
synthesis that is able to utilise a wide variety of synthetic organic chemistry 
techniques to achieve optimisation of hit to lead.  Although the processes may be 
lengthy and not high throughput, the synthesis which revolves around further 
functionalisation of a core scaffold, works in sequential manner that is efficient at 
producing the hit compounds numerous analogues for biological testing. 
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Scheme 1.2- The general synthetic approach to obtain the hit compounds 1.19, 1.20, 1.21 and 
1.22.  The processes involved multistep syntheses originating from the parent starting material 2-(3-
chlorophenyl) acetic acid 1.23 which is converted to the piperidinone core 1.24 in a six step synthesis 
87 – 88% yield (a).  The piperidinone core is presented as a general scaffold without any 
stereochemistry, however to achieve the desired stereochemistry of 1.19, 1.20, 1.21 and 1.22 the 
reagents and conditions of (a) were altered as necessary. The cis-diaryl 1.20 is converted to the first hit 
compound the cis-diaryl 1,3,5,6-tetra substituted piperidinone 1.19 in a four step synthesis 79% yield 
(b), the second developed compound the trans-diaryl carboxylic acid 1.20 was synthesised from trans-
diaryl 1.22 in a three step synthetic procedure 89% (c).  A six step synthetic procedure 47 – 80% (d) 
was used to transform the trans-diaryl scaffold of 1.24 to the carboxylic acid 1.21 and finally a nine step 
procedure (e) was employed to achieve the most successful hit compound 1.22 80% yield.[72] 
Further to these examples of the numerous compounds developed as MDM2 
inhibitors, at least two compounds have more recently reached clinical development.  
MDM2 inhibitors include an oral treatment for advanced stage solid tumours (Johnson 
and Johnson, Phase 1), and R7112 (Hoffmann-La Roche, Phase 1) an oral treatment 
for hematologic neoplasms and advanced solid tumours.[73] 
1.3.6 Case Study 2: Targeting the interaction of Bcl-XL and BaK 
The second case study to be discussed is that of Bcl-XL and BaK, within the Bcl2 
family, Bcl-XL inhibits programmed cell death and BaK promotes apoptosis.[74]  The 
interactions between the two proteins controls the sensitivity of the cell towards 
apoptosis through the antagonism of the two different functions.[74]  Bcl-XL contains 
two central hydrophobic α-helices which are in turn surrounded by five amphipathic 
helices, it binds tightly to a 16 amino acid region (BH3) of BaK (residues 72-87) 
thereby inhibiting the promotion of cell survival (Figure 1.17).[74]   
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Figure 1.17- The Bcl-XL (blue) / BaK (Violet) complex derived from NMR studies by Sattler et al. (PDB 
ID 1BXL, adapted from [74]). 
Considerable research has been conducted by Hamilton et al. into targeting the 
interface with small molecule antagonists to promote apoptosis in unhealthy cells.[75]  
Several approaches were used to identify small molecule inhibitors of Bcl-XL, including 
oligomeric aryl-aryl and aryl-carboxamide components, in these instances the 
substituent’s would mimic the distance and angular projection of the sidechains from 
the α helix of its binding partner BaK3.[75]  Hamilton utilised intramolecular hydrogen 
bonds along with the steric interactions to help position the peripheral functionalities 
and instil a rigidity to the structure to aid pre-organisation at a molecular level.[75]  
Through the use of chemical synthesis alongside structural biological techniques 
such as, X-ray crystallography, fluorescence polarisation (FP), isothermal titration 
calorimetry (ITC) and NMR spectroscopy studies, Hamilton was able to develop 
enaminone 1.25, benzoylurea 1.26, terphenyl 1.27 and terepthalamide 1.28 
scaffolds.[75–77]  These four novel scaffolds were able to successfully mimic the 
residues of an α-helix (Figure 1.18).[75–77]   
 
Figure 1.18- The α-helix small molecule mimetics developed by Hamilton and co-workers. 
enaminone 1.25, benzoylurea 1.26, terphenyl 1.27 and terepthalamide 1.28 scaffolds where R1, R2 and 
R3 are the different positions of functionalisation.[75–77] 
The BaK3 helix has been shown through crystallographic evidence to contain four 
key hydrophobic residues Val74, Leu78, Ile81 and Ile85 whose sidechains play a vital 
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role in its interaction with Bcl-XL.[77]  The original terphenyl derivatives 1.27 were the 
first compounds synthesised to mimic projection of these sidechains, they adopted a 
staggered conformation with substituents that projected their groups at the i, i+4 and 
i+7 positions as with the α helix of BaK3.[76]  The synthesis was developed using O-
alkylated phenols and sequential Suzuki aryl-aryl cross coupling reactions.[76]  The 
synthesis was lengthy and the compounds were found to be extremely hydrophobic 
with a predicted logP = 9.25 and low aqueous solubility logS = -10.76.[77]   
The terephthalamides 1.28 were developed as a second generation of small 
molecules and were simplified in terms of structure; they were also designed to have 
a better solubility profile. [77]  The two terphenyl rings of 1.27 were replaced by two 
functionalised carboxamides, which were able to replicate the planar nature of the 
phenyl rings through the rigidity and restricted rotation about the amide bond.[77]  The 
synthesis of these compounds was simplified when compared to that of the 
terphenyls, involving O-alkylation and amide couplings and was found to be much 
more efficient.[77]  In comparison to the terphenyls, terephthalamides predicted logP 
= 4.42 and a solubility constant logS= -5.35 were much more desirable.[77]  The 
enamine scaffolds 1.25 were synthesised using an even faster and efficient synthesis 
(Scheme 1.3).  This involved initial Claisen condensation reaction to give the di-
ketone 1.30.[78]  Subsequent reaction with BF3OEt2 resulted in the 1,3-
diketonatoboron difluoride complex which in the final reaction was reacted with m-
toluidine to produce the desired enamine 1.25.[78]   
 
Scheme 1.3- The synthetic approach to the enamine scaffold 1.25.  The synthetic approach involves 
a Claisen condensation reaction of 1.29 using (a) NaH, EtOAc, EtOH and ether to give the diketone 
1.30.  (b) The subsequent reaction of the diketone with BF3OEt2 to give the di-fluoride compound 1.31 
in 84% yield,  (c) which is finally reacted with m-toluidine to give the target compound the enamine 1.25 
in 70% yield. 
Finally, the benzoylurea compounds 1.26 were designed based on the enamine 
scaffold, the synthetic approach involved the synthesis of two fragments; an amide 
and an isocyanate which were coupled to form 1.26 (Scheme 1.4).[75]  The two 
substituent fragments were synthesised using similar synthetic approaches involving 
Wittig reactions, reductions, iodonations, O-alkylations and Heck reactions.[75] 
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Scheme 1.4- Coupling of an amide and isocyanate substituents to give the benzoylurea scaffold 1.26 in 
43% yield (adapted from [75]). 
These examples of the extensive investigations conducted by Hamilton et al. not only 
produced efficient small molecule inhibitors of the Bcl-XL protein.  They were also able 
to provide a detailed understanding of the small molecule bound Bcl-XL structure 
through informed computational docking programmes and numerous biophysical 
techniques.[75–77] 
With these case studies of different PPIs and the alternate approaches employed to 
target them, it is clear that the process involves the combination of many techniques 
and iterative of design, synthesis and testing.   
The successful compounds were developed using computational modelling to predict 
aspects such as binding poses and solubility.  A variety of medicinal chemistry 
techniques were used alongside diverse synthetic organic chemistry, to realise a 
range of scaffolds that were able to either mimic the positions of amino acid 
sidechains, or target certain hotspot residues.  When used in conjunction with 
structural knowledge of the biological target and a number of biophysical techniques, 
it lead to improving the initial hit compounds towards lead molecules and in some 
cases, ultimately to the clinic.   
This interdisciplinary approach was successful in targeting protein-protein 
interactions implicated in numerous biologically relevant viruses, diseases and 
disorders such as cancer, arthritis, gram negative bacterial infections and HPV. 
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 Computational applications of structure-based drug design  
In designing inhibitors for protein-protein interactions, the complex nature of the 
systems involved means that conventional high throughput screening methods may 
not be an effective way to generate hit compounds.  This may be observed in a high 
number of false positives that occur due to the hydrophobic nature of many binding 
sights.  Indeed it is clear that a new pre-screening strategy is necessary.[79]   
 
 
Figure 1.19- The computational workflow applied in this thesis, following a general structure-based drug 
design process.  Pharmacophore generation is used to screen a library of compounds to replicate an 
area of three dimensional space, the compounds are then docked into the target and their ADMET 
properties subsequently calculated.  The information is then combined and a balanced selection protocol 
is undertaken to select the best possible candidate for synthesis.  At each stage the number of potential 
hits is reduced. 
As discussed previously, computational applications have found use in the 
development of drug-like compounds to target protein-protein interactions.  As seen 
with the development of inhibitors to target the Bcl-XL and BaK3 interaction (Section 
1.3.6), Hamilton et al. designed four novel scaffolds which are able to mimic the amino 
acid sidechains at positions i, i+4 and i+7 of the BaK3 helix.  Once two scaffold 
structures had been designed, the computational programme QikProp was used to 
calculate certain drug-like parameters, such as the solubility profile of each ligand to 
compare and contrast the two and determine if the scaffolds were suitable.[77]  The 
conformations of the compounds in solution were then investigated using the 
molecular modelling facility MacroModel, wherein they employed energy minimisation 
with the MM2 force field.[77]  Subsequently the poses or orientations generated from 
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MacroModel were then superimposed onto the native BaK3 α-helix, to compare the 
positions of the functionalised substituents, to the i, i+4 and i+7 amino acid sidechain 
positions on the BaK3 α-helix.[77]   
Ding et al. also used the computational docking programme Gold, to calculate the 
binding pose of their initial hit spiro-oxindole 1.10 (1.3.5) and from that develop a 
number of analogues including their lead compound 1.12.[69]  These simple 
computational processes aided in the selection of the compounds to synthesise and 
is an example of how computational techniques can aid success when used in the 
process of targeting PPIs.   
The use of a structure-based drug design method, as seen in previous PPI studies 
(1.2) uses a combination of techniques.  The methodology involves computational 
modelling, used in conjunction with “hit identification” and ”hit to lead” optimisation 
processes in a drug discovery pipeline (Scheme 1.5).[80,81]  Furthermore, to improve 
this computational screening process, it is more favourable to start with the best 
selection of ligands to be computationally analysed and selected for synthesis.  
Application of a pharmacophore filter could be one such way to do this.  
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Scheme 1.5- The structure-based drug design pipeline.  The flow process applied in the SBDD 
protocol follows two phases, the “hit identification” phase and the “hit to lead” phase. A number of 
processes occur in the hit identification phase and these include (a) Target identification and preparation 
of the binding-site. (b) Preparation of the compound library used to screen hits for the target. (c) 
Molecular docking methods, analysis of the compounds predicted binding interactions with the target.  
This is followed by the hit to lead phase, selection of a lead compound (adapted from [82]). 
1.4.1 Pharmacophore Modelling 
The term pharmacophore was defined by Ehrlich as ‘a molecular framework that 
carries the essential features responsible for a drug’s biological activity.[83]  The 
composition of the pharmacophore encompasses the steric and electronic 
characteristics necessary to ensure optimal interactions between a molecule and 
target ligand.[83]  Selection of the correct three-dimensional disposition of chemical 
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features is important for the development of a successful pharmacophore model.[84]  
There are two types of pharmacophore model, ligand-based and structure-based.  
The first works in the absence of a 3-D structure of the macromolecular target; it takes 
a group of active molecules and compares their common 3-D features.[83]  A 
structure-based pharmacophore model works directly with the 3-D structure of a 
macromolecular target or macromolecule-ligand complex.[83]   
1.4.1.1 Ligand-based pharmacophore modelling  
The ligand-based method was not used for the purposes of this thesis and so shall 
not be discussed in great detail.  However, briefly the method involves two main steps.  
Firstly the conformational flexibility of each ligand has to be represented by creating 
conformers, and secondly the ligands then have to be aligned and the common 
features extracted to generate the pharmacophore.[83]  This approach does not come 
without a number of challenges such as the ability to model the ligands flexibility and 
selecting the best method to align the molecules.[85,86]  Perhaps a more challenging 
question is finding a way to select the best group of compounds to generate the 
pharmacophore, ensuring that the selection is diverse and not biased.[86]   
1.4.1.2 Structure-based pharmacophore modelling  
In the work presented here structure-based modelling was used.  This involves 
analysis of the complementary chemical features of the active site and the spatial and 
chemical relationships, allowing a pharmacophore model with selected features to be 
built.[83]  It can be further subdivided into two categories: (i) macromolecule-ligand-
based whereby the complex structure is available to determine the hotspot residues 
between the two binding partners.[83], and (ii) macromolecule- based which is simply 
the macromolecule target without the natural ligand.   
There are a number of modelling programmes which are able to determine the key 
residues, either in the complex or within the macromolecule itself and these can be 
used to generate a pharmacophore.[83]  As with the ligand-based model, this 
approach does have a number of limitations, such as the need for the structure of a 
macromolecule target or macromolecule-ligand complex.  Even if the complex or 
structures are available there are often a vast number of chemical features that have 
to be rationalised before a pharmacophore can be generated computationally.[83]  To 
overcome these problems a number of algorithms have been developed with the 
ability to generate hotspot pharmacophores from the structure of the macromolecule 
itself.  It does so by identifying cavities within the structure and comparing these 
cavities to the ligand binding pockets of other known complexes.[87]   
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The structure-based method has proven useful in drug design as the model can be 
used to generate a pharmacophore from structural information of the target.  This 
leads to a more informed screening process for complimentary ligands that are able 
to interact at the desired locations on the macromolecule.  Generation of the 
pharmacophore subsequently enables the searching of databases for potential 
ligands in a process known as ‘pharmacophore-based virtual screening’.[83,88] 
1.4.2 Pharmacophore-based virtual screening 
Pharmacophore-based virtual screening has been applied to a number of disease 
targets and has proved useful in the hit identification and lead optimisation strategies 
in drug design.[85,89]  It is a process which allows for millions of compounds to be 
screened in silico to find those which fit the specific points defined in three 
dimensional space.  As discussed previously the generation of a pharmacophore can 
be carried out with the knowledge of a target’s structure and as such a number of 
functional groups including hydrogen bond donors and acceptors, charged moieties 
and aromatic groups can be included.[90,91]   
The process of pharmacophore-based virtual screening has seen a dramatic increase 
in use for a number of studies on various disease targets; a review by Kim et al. 
highlights recent applications.[88]  Examples are given of the success stories of hit 
generation through pharmacophore-based virtual screening of a variety of targets 
within numerous disease states such as cancer, viral infections including HIV, 
diabetes, obesity and Alzheimer’s disease.[88]  It presents excellent examples of how 
pharmacophore-based virtual screening can be used and demonstrates how the 
technique has developed.   
Pharmacophore-based virtual screening is not without its problems.  It can be time 
consuming when screening compound libraries that contain a large number of flexible 
molecules.  However, this problem can be overcome by the application of a series of 
filters, the first of which reduces the number of unsuitable ligands so that the 
subsequent selection processes are conducted on a more refined selection of 
compounds.[91]   
There are a number of databases / compound libraries that can be used, which are 
able to utilise a filtering process.  ZINCPharmer is the online interface to one such 
database ZINC; this online resource conducts pharmacophore searches of a library 
of around 35 million purchasable compounds.[92]  The compounds within the library 
are of explicit conformations of each compound within ZINC, the screening process 
matches the conformers to the three-dimensional pharmacophore generating hits.   
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To do this ZINCPharmer uses the open-source Pharmer software which uses an 
index approach to search more than 176 million conformations of 35 million 
purchasable compounds, in a very short space of time.[93]  The Pharmer method is 
relatively recent approach to pharmacophore modelling; previous methods such as 
fingerprint-based or alignment-based were much more time consuming in their 
searches.[85,94]  The interface allows for different filters to be applied to a 
pharmacophore query, meaning that the compounds can be filtered using e.g. the 
number of conformations of a single compound and also their molecular 
properties.[92]  Such property filters include molecular weight (mw), root mean 
squared deviation (RMSD with respect to the desired pharmacophoric features) and 
the number of rotatable bonds, all of which have been implicated in the design 
process of drug like molecules.[95]  Filtering using RMSD diminishes the number of 
hits to those who best fit the geometric requirements of the pharmacophore query.[92]  
Once a set of compounds has been identified, it is possible to download the individual 
files for the subsequent analysis and processing.   
1.4.3 Molecular Docking 
The resultant steps in the computational pipeline of a structure-based drug design 
process, involves molecular docking of the hit compounds from the pharmacophore 
virtual screening studies (Scheme 1.5).  Docking is a prediction of a ligand’s 
conformation and orientation within the target macromolecular structure.  There are 
a number of algorithms that are available within docking programmes to rationalise 
the interactions between a ligand and a protein.[96]  The current available techniques 
include; molecular dynamics, genetic algorithms, Monte Carlo, point 
complementarity, distance geometry and fragment based methods, “tabu” and 
systematic searches.[96]  The details of these different algorithms shall not be 
discussed further here as they are summarised in some excellent reviews.[96–108] 
Independent of the variety of algorithms used, there are a number of characteristics 
any docking programme should have, including the ability to accurately represent the 
experimental binding modes of a ligand in silico.[99]  The docking process should be 
quick and efficient and have the ability to score and rank compounds.[99]  GOLD 
(genetic optimisation for ligand docking) developed by Jones et al., is able to fulfil 
these prerequisites and for the purposes of this thesis the compounds were docked 
and scored using a genetic algorithm approach.[99,109]   
Nissink et al. were able to demonstrate GOLD’s ability to replicate the experimental 
binding modes of 305 ligand protein complexes in silico with a 68% success rate.[110]  
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GOLD is composed of three main constituents: (i) a scoring function that is able to 
rank different binding modes (Goldscore), (ii) a mechanism by which it places a ligand 
in the binding site and (iii) the genetic search algorithm that investigates the different 
binding modes of a ligand.[99]  It works by performing automated docking within the 
volume around the active site of a partially flexible protein, allowing for full acyclic 
ligand flexibility and partial cyclic ligand flexibility.[99,109]   
The Goldscore scoring function is a molecular mechanics based function that is the 
sum of four explicit terms: the protein ligand hydrogen bond score, the protein ligand 
Van der Waals score, the intramolecular hydrogen bonds of the ligand and the 
intramolecular strain of the ligand.[97,99,109]  The mechanism by which the ligand is 
docked into a binding site involves fitting points which are added to hydrogen bonding 
sites on both the ligand and the protein.[97,99,109]  The respective donor and 
acceptor points are mapped onto the complex and the CH groups of the ligand are 
matched to the hydrophobic points within the proteins surface.[99]  This process is 
exclusive to GOLD.  The genetic algorithm used to search the different possible 
binding modes of the complex, is programmed to modify a number of specific 
variables.[99,109]  The modifications include: the dihedrals of the protein and the 
ligand, OH and NH3+ groups within the protein and those bonds of the ligand that are 
rotatable.[99,109]  The geometries of the ring systems within the ligand and the 
position of the fitting points between the ligand and the proteins binding site.[99]   
As well as Goldscore the programme enables a variety of different scoring functions 
to be applied, such scoring functions include Chemscore, Chem Piecewise Linear 
Potential (PLP) and Astex Statistical Potential ASP.[82]  ASP uses a protein-ligand 
database to measure the atom-atom potential, Chemscore estimates the change in 
energy that occurs upon ligand binding and Chem PLP is an empirical fitness function 
which models the steric complementarity between the protein and the 
ligand.[99,111,112]   
1.4.4 Physicochemical parameters 
The assessment of a molecule to be “fit for purpose” is to determine the 
physiochemical parameters which will be used alongside the docking results to select 
the best possible candidates for synthesis.   
The Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) properties of 
molecules are in a sense generic, meaning they represent ‘the action of the body on 
the drug’ rather than a more specific process of ‘the action of the drug on the 
body’.[113]  The calculation of these ADMET parameters are essential in the selection 
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process, optimisation of ADMET properties from lead generation to optimising in vivo 
profiles, is now a process that is carried out prior to candidate selection.[113]  Within 
the ADMET setting, oral bioavailability is an important consideration for the 
development of a biological molecule as a therapeutic agent.[95]  Correlation between 
the physical properties of an orally administered drug and drug candidate, with 
successful drug development was conducted by Lipinski and lead to the “rule of five” 
(RO5).  This guideline proposed that an increased chance of drug absorption and 
permeability, is more likely when the molecular weight is < 500 Da, logP is < 5, the 
number of hydrogen bond acceptors is < 10 and the number of hydrogen bond donors 
is < 5.[113]  It was found that failing a single “rule of five” was acceptable, as there 
was no statistical significance between not failing any and failing one.  However, 
failing two was detrimental to the oral bioavailability of the drug with 90% of oral drugs 
in phase II clinical trials meeting these criteria.[113]  However, the “rule of five” 
perhaps should be thought of as a guideline for oral bioavailability, rather than a strict 
rule for an “ideal drug”.  In addition to the parameters set by Lipinski, molecular 
flexibility for membrane permeation was postulated as being desirable by Navia.[114]  
With the complexation of water to amide bonds as a negative factor for oral 
bioavailability deduced by Hirschmann.[115]  Other negative factors towards oral 
bioavailability include the number of rotatable bonds within a compound which should 
be no more than 10, high polar surface area on intestinal absorption, failure to achieve 
membrane permeation, first pass metabolic processes and active transport from the 
blood into the excretory system such as to the gut or the liver.[95,116]   
There has been great debate on the topic of “ideal drug-like compounds” since the 
RO5 was suggested by Lipinski et al. almost two decades ago in 1997.  The 
guidelines for a good orally bioavailable drug remain clear, however the ideals of “the 
perfect drug-like molecule” are constantly changing as we learn more about the 
molecular targets and the ADMET properties of the compounds used to treat them.  
It has been suggested that perhaps we are too obsessed with the oral bioavailability 
of a compound and that we should consider drug space from the toxicological view 
point.[117]  A number of guidelines have been developed from this point of view that 
relate toxicity to other physiochemical properties such as lipophilicity which is directly 
related to a drugs solubility profile and can be predicted through the computational 
calculation of the partition coefficient ClogP. 
One such rule has been developed by researchers at the pharmaceutical company 
Glaxo Smith Kline (GSK), where they screened 30,000 compounds and found a link 
between, ClogP, molecular weight and more favourable physiochemical 
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parameters.[118]  The rule is aptly named 4/ 400 as it relates to those more favourable 
compounds having a ClogP < 4 and a molecular weight < 400.[118]  Another 
pharmaceutical company Pfizer investigated the in vivo tolerability of a group of 245 
compounds and found a connection of ClogP and topological polar surface area 
(TPSA) with a reduction of toxicity.[119]  Those compounds with a ClogP < 3 and 
TPSA > 75 were found to have a six fold reduction in toxicity, in comparison to those 
compounds with a ClogP > 3 and TPSA < 75 where the reduction in toxicity was 
increased to 24 fold and as such this became the Pfizer 3/75 rule.[119]  A major cause 
of toxicity can be attributed to target promiscuity; a screen of 2133 compounds found 
a direct correlation between ClogP and increased chances of compound 
promiscuity.[120]  Those compounds with a ClogP < 3 had a reduced chance of being 
promiscuous whereas those with a ClogP > 4 were found to be less specific towards 
their target and more promiscuous in nature.[120] 
It has also been suggested that the higher the lipophilic nature of a compound, the 
more likely it is to be insoluble.  The lipophilicity of a compound can be improved by 
reducing the number of aromatic rings, generally less than three is acceptable.[121]  
However if a compound is not lipophilic enough, then it may not be absorbed through 
the intestinal wall.  Another way to improve the administration of a poorly soluble 
compound is through changes in the formulation, but by doing so the body will have 
to work much harder to metabolise and eventually excrete it.  This would, therefore, 
result in the drugs needed for a longer duration of action and is an excellent example 
of the issues facing medicinal and computational chemists.   
There is a fine balance needed for circumventing the issues associated with 
increasing lipophilicity in the search for improved drug potency.  One method 
developed by medicinal and computational chemists to overcome these issues could 
be the use of a universally applicable index, the ligand efficiency.  Ligand efficiency 
is defined as the energy of binding per non hydrogen atom and is very much 
dependent upon the size of the compound.[122]  It is a direct correlation between the 
docking results and the physiochemical property of a ligand and can be useful for a 
more balanced selection of a subset of compounds. 
1.4.5 Pareto Ranking 
A balanced selection of a subset of compounds takes into account not only ADMET 
parameters but also all the scoring functions under a Pareto ranking system in order 
to determine ideal hit compounds with the best overall profile (potency and safety).  
The balanced selection or multi-objective optimisation is the linear combination of 
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multiple objectives into a single-objective function.[123]  Furthermore it is the process 
to detect a ‘pool’ of optimal equivalent solutions that meet a wider range of attributes 
relevant to a problem.[123]   
Research into multi-objective optimisation was conducted by Pareto, whose 
methodology was based on equivalent solutions, also known as non-dominated 
solutions being equally good as they represent numerous possible compromises 
among the objectives.[123]  One solution can dominate another if it is better in at least 
one objective; the solutions are then ranked according to their dominance value.[113]  
Pareto selection enables many aspects of a compound to be assessed 
simultaneously.  Once the solutions have been ranked in the Pareto format a number 
could be selected for synthesis and subsequent biophysical analysis.  
A balanced compound selection can be achieved through the use of a number of 
different computational programs including Pipeline Pilot and Knime.[124,125]   
Pipeline Pilot is a chemo-informatics tool developed by Accelrys that can be used to 
develop protocols to calculate the physiochemical properties of small molecules, data 
manipulation and computational filtering.[126]  Knime uses a workflow methodology; 
it is based on the open source platform Eclipse and Java.[127]  It was not originally 
intended as a chemo-informatics tool and is in fact used in many other disciplines that 
require data handling such as the finance industry.[126]  However, its data mining 
background makes it a useful tool to use in conjunction with Pipeline Pilot to calculate 
to carry out a multi-objective assessment, such as the calculated physiochemical 
parameters, combined with the docking data for each individual compound to assess 
the overall profile.   
. 
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 Synthetic approaches to targeted PPIs 
The challenges associated with modulating protein-protein interactions (PPIs) have 
meant that the area of high-throughput organic synthesis has become an established 
strategy in the development pipeline.  Significant challenges in organic synthesis and 
our knowledge and understanding of protein-protein interactions have occurred in 
parallel to one another, with the development of structural biology techniques and 
specifically designed chemical libraries.  As such the two techniques can be used 
together to establish methods for the chemical intervention of PPIs.[42]  Research 
into the design and synthesis of small molecule inhibitors has been conducted for a 
number of key protein-protein interactions that are believed to play a vital role in many 
biological processes.  Due to the central role of PPIs the number of interactions 
studied is increasing exponentially and some of the most interesting include, IL-2, 
HPVE2, ZipA, TNf, HDM2 and Bcl-XL.[43]  There are three chemical approaches for 
targeting these different PPIs using small molecules including peptide-based, natural 
product inspired and chemistry inspired/ diversity orientated synthesis as outlined 
below. 
1.5.1 The peptide-based approach 
The peptide-based approach involves the design and synthesis of small molecules 
that are able to mimic the secondary structure of proteins whether that be α-helix, β-
turn or β-strand.[128–130]  The peptide-based approach can be further subdivided 
into peptidomimetics and non-peptide small molecule structures, the first of which has 
been used extensively and has seen numerous successes, for example in targeting 
glycoprotein coupled kinase receptors.   
Extensive investigations, include mimetics of peptides, peptide-turn and β-peptides 
to target PPIs for example those by Zhao et al., Stigers et al. and Fletcher et 
al.[128,131–133]  However as the main focus of this thesis is the design of small 
molecule modulators we shall discuss the design and synthesis of non-peptide small 
molecules.  These compounds are able to mimic the secondary structure of a 
particular protein binding partner through the interactions of a particular motif.[42]  
Benzodiazepines were amongst the first classes of small molecules synthesised for 
the purpose of PPI modulation.[42]  They are successful β-turn (1.34) and α-helical 
(1.35) mimetics, depending upon the orientation of their functional groups.[42]   
Extensive investigations in this area have meant that there have been significant 
developments in synthetic strategies, particularly solid phase synthesis, more 
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specifically the modifications and linker chemistry domains where the developments 
of triazene linkers for post cleavage aza-Wittig reactions.[134,135]   
 
Figure 1.20- The benzodiazepine structures as β-turn and α-helix mimetics (adapted from [42]). 
This class of compounds have been successful in targeting the p53 & HDM2 
interaction, where an α-helix mimetic was developed and synthesised from a library 
of 22000 novel benzodiazepines.[136]  The process involved using the Ugi-
lactamization strategy in a two-step synthesis, the initial step involved combining four 
components in a condensation reaction (Scheme 1.6).[136]  Subsequently, 
lactamisation of 1.36 involved acid catalysed cleavage of cyclohexenamide and 
simultaneous Boc deprotection to expose the anthranillic nitrogen to allow 
cyclisation.[136] 
 
Scheme 1.6- The synthesis of P53 MDM2 inhibitors.  The synthesis of the benzodiazepine library of 
22,000 compounds using the Ugi-lactamisation strategy.  The initial step involved combining four 
components in a condensation reaction, followed by the post condensation lactamisation of 1.36 which 
involved acid catalysed cleavage of cyclohexenamide and simultaneous Boc deprotection to expose the 
anthranillic nitrogen (adapted from [42]). 
Hamilton et al. have extensively investigated α-helix mimetics that are based on rigid 
non-peptide scaffolds, such as terphenyl 1.37 and trispyridylamide 1.38 compounds 
(Figure 1.21).[77,137,138]  Other rigid non-peptide scaffolds include biphenyl, indane, 
terpyridine, polycyclic ether, terephthalamides and trisbenzamides.[77,139–144]  The 
functional groups displayed by these scaffolds adopt a particular orientation which is 
able to mimic the orientations of the α – R groups of the amino acid within an α 
helix.[42]  Due to the issues associated with the solubility of these compounds, they 
have had limited use although the Hamilton scaffolds have been shown to be more 
suitable.  An example of the biological uses of these scaffold types include the specific 
targeting of the Bcl-w Bak interaction.   
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Dӧmling et al. developed a diphenyl-imidazole scaffold using a multi component 
reaction in a one pot synthesis.[145]  They generated 60 compounds to screen using 
cell proliferation assays and fluorescence polarisation assays which indicated three 
hit compounds for the intended target.[145] 
 
Figure 1.21- Hamilton’s α-helix mimetics.  The rigid scaffolds of the α-helix mimetics developed by 
Hamilton et al.  The R groups are designed to mimic the amino acid side chains at positions i, i + 4 and 
i + 7 within an α-helix, with rigid terphenyl or tris pyridyl-amide core scaffolds maintaining the specific 
position along the mimetic.(adapted from [42]). 
β-Turns play a key role in molecular recognition and the mimetics are often bicyclic 
with modified amide structures.  There are several key scaffolds including 
benzodiazepines, diketopiperazines and isoindolines (Figure 1.22).[42]  To identify 
modulators of the c-myc-max interaction, around 240 isoindoline scaffolds (120 amide 
derivatives and 120 acid derivatives) were prepared by Boger et al.[146,147]  These 
bicyclic isoindoline-5,6-dicarboxylic acid templates contained three functionalised 
positions and were synthesised using solution based techniques.[146,148]  The use 
of fluorescence resonance energy transfer (FRET) screening investigations led to a 
single hit compound that exhibited selectivity against the desired target with an IC50 
of 20 μM.[149]   
The bicyclic diketopiperazines are another rigid non-peptide scaffold that is able to 
mimic β-turns, synthesised using solid phase synthesis.[150]  A high diversity of the 
different bicyclic fused and spiro structures can be introduced using different synthetic 
sequences.[151,152]  An example of the ease of synthesis and diversity of 
compounds can be observed with the 5000 scaffolds prepared by Kahn et al., 
designed to modulate the interaction between β-catenin and cyclic AMP which would 
hence stop the TCF-mediated transcription processes.[153,154] 
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Figure 1.22- Small molecule compounds able to mimic a type-1 β-turn including benzodiazepines 1.34, 
isoindolines 1.39 and diketopiperazines 1.40.  The R group substitutions of each small molecule 
compound can be varied to mimic the side chains of amino acids at the R1, R2, R3 and R4 positions on 
the type-1 β-turn (adapted from [147]). 
1.5.2 Natural Product-inspired ligand design 
Many drugs currently on the market have their structures derived from natural 
products.  This may be due to their predisposition to interact with proteins from 
evolutionary development.[155,156]  These are often large and complex molecules 
that derive their activity from PPI inhibition, contain specific functional groups 
responsible for their action.  It is the challenge of synthetic medicinal chemists to 
recognise these important chemical features and develop inspired chemical libraries 
to aid the discovery of new PPI inhibitors.[157,158]  There are a number of natural 
product inspired scaffolds that have been discovered as modulators of a number of 
PPIs including guanidine-tricycles 1.41, spiroketals 1.42 and oxindoles 1.43. 
 
Figure 1.23- The core scaffolds of three natural-product inspired small molecule compounds developed 
from natural products and synthesised to target PPIs. 
Tricyclic guanidine containing alkaloids such as batzelladines and crambescidines, 
both of which are marine natural products, were found to be PPI inhibitors.  
Batzelladines are able to disrupt CD4 interactions through either inhibition of binding 
or by inducing complex disassociation.[159–164]  Both batzelladine and 
crambescidine analogues were found to disrupt a number of interactions related to 
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Nef complexes with p53, actin and p56lck.[162,165]  Analogues of these complex 
scaffolds were synthesised using a number of complex total syntheses.[166]   
Spiroketals are a motif that is common in many biologically important natural products 
that are structurally complex and have been shown to be active against a number of 
protein targets.  Such spiroketal containing scaffolds include: altohyrtins 
(spongistatins) which are able to modulate microtubule formation bistramide A which 
suppresses cellular proliferation and didemnaketals A and B that target HIV-1.[167–
172]  Due to the diversity of their biological targets there has been keen interest in 
the development of libraries of spiroketal containing scaffolds for screening 
purposes.[173]  A library containing a diverse set of compounds was developed by 
Porco et al.[173]  They devised an efficient synthetic approach to an initial core 
spiroketal scaffold from an entiomerically pure epoxide.[173]  The core scaffold was 
then diversified into 90 compounds using a three step synthesis to introduce a high 
level of structural complexity.[173]   
There are a number of other groups that have applied different approaches to 
synthesising these scaffolds such as Lay et al. & Tan et al.[174–176]  Finally spiro-
oxindoles are another example of successful natural product like scaffolds that are 
found in numerous alkaloid natural products, including spirotryprostatin, pteropodine 
and alstonisine.[177]  They have been implicated in inhibition of numerous biological 
systems, such as the p53 MDM2 interaction.  Using the p53 MDM2 crystal structure, 
Wang developed a compound that was able to mimic the key side chain belonging to 
W23 of p53, with 3nM activity in the disruption of the p53 MDM2 interaction.[68,178–
180]   
There have been numerous libraries of spiro-oxindole like compounds developed 
using novel efficient synthetic approaches.  Schreiber et al. employed a three-
component strategy along with a split pool approach in a solid phase approach.[181]  
Using 16 spiro-oxindole core scaffolds they produced 3000 derivatives, using 
Sonogashira couplings, amidation reactions and N-acylations.[181]  Following 
biological screening, the group further developed a hybrid library that contained 384 
diverse compounds.[181,182]  These scaffolds are of key interest to a number of 
researchers and have led to the development of numerous compound libraries 
through a variety of synthetic approaches. 
1.5.3 Chemistry inspired through Diversity Orientated Synthesis (DOS) 
Diversity orientated synthesis describes the synthesis of collections of structurally 
diverse small molecules, developed without any prior knowledge relating to the 
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structural requirements of a biological target.[42,183]  The libraries are refined to 
contain molecules that have a better probability of surviving the “hit to lead” 
optimisation processes and this can be done in a number of ways. 
One can invoke a number of structural requirements based on “the rule of five” 
developed by Lipinski et al. in 1997, “the rule of three” developed by Oprea and finally 
lead likeness.[184–186]  However, compared to compounds aimed at targeting other 
biological targets such as enzymes, most current PPI inhibitors are essentially not 
“drug- like”.  They tend to have high molecular weights, are complex and lipophilic, 
therefore targeting these interactions will require screening of diverse compound 
structures obtained by diverse orientated synthesis.[187–191]  The compositions of 
each library and the synthetic approaches used to generate the compounds may differ 
somewhat.   
One such library was developed by Boger et al., who believed that due to the 
structural prerequisites of the large interaction sites of many protein-protein 
interactions, the compounds to target them would have a greater chance of doing so, 
if they themselves were much larger.[192,193]  The initial library of compounds had 
a high degree of molecular complexity and the synthetic approach was fast and 
efficient.  It involved iminodiacetic acid diamides 1.44 (Figure 1.24) which were 
subsequently dimerized using alkene metathesis to produce solutions (pools) 
containing a mixture of cis and trans alkenes 1.45.[192,193]  By doing so, the initial 
screening procedures were made more efficient at screening higher numbers of 
compounds against their target.  However, the disadvantage to this process was the 
tricky deconstruction of the results even if the number of compounds in each pool 
were low.  It was also found that the diversity of SAR contributions was low, this was 
because the contributions of less potent compounds were not taken into 
consideration, instead the most potent compounds of the pools dominated.[192,193]   
To overcome this problem the group designed a second library which eliminated the 
possibility of alkene isomers by not using alkene metathesis to dimerize the diamides, 
instead a more rigid di-acyl linker was introduced 1.46 (Figure 1.24).[192–195]   
The secondary library contained 60 pools of 10 compounds which were screened 
against the protein complex of mmp2 and αvβ3.  Of the 60 pools three were believed 
to contain hits and so the 30 individual compounds were synthesised and purified, 
furthermore the most potent single compound of the 30 was selected.[192–195]  This 
compound was diversified into a further 77 diverse analogues, the most successful of 
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which was water soluble and found to have a high degree of potency towards the 
inhibition of angiogenesis.[192–195]    
 
Figure 1.24- Small molecule scaffolds from the Boger diversity oriented synthesis library, the initial 
imino-diacetic acid-derived diamide 1.44 undergoes dimerization using alkene metathesis to form 1.45.  
Optimization of the core scaffold of the library involves replacement of the flexible alkene linker with a 
more rigid alkyl or aryl one 1.46 (adapted from [42]). 
There are many other examples of different DOS libraries such as those synthesised 
by Janda et al. to contain a central flat aromatic core, utilising quinoline 1.47 and 
napthalene 1.48 structures (Figure 1.25).[196,197]  Schreiber et al. used solid support 
split pool synthesis to develop a number of different libraries containing diverse 
dioxolanes, biaryl macrocyclic ethers and amides (Figure 1.25).[198,199]  Finally 
Bienayme used an efficient alternative to multistep synthesis, the multicomponent 
reactions (MCRs) were key in the development of the library of 8160 compounds from 
which an inhibitor of the VEGF/ NRP1 interaction was discovered.[200] 
 
Figure 1.25- Other core scaffolds from different diversity oriented synthesis libraries developed by Janda 
et al. and Schreiber et al. to target PPIs using diverse small molecules(adapted from [42]). 
Thus three different approaches: peptide based, natural product inspired and 
chemistry inspired/ DOS, can be used to develop compound libraries that can be 
screened against a biological target.  They also describe the high through-put nature 
of the chemical synthesis, in order to produce a large number of compounds to give 
a greater chance of success against their targets.  They utilise a variety of synthetic 
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procedures in peptide coupling, with a wide range of chemical scaffolds.  The 
development of these three approaches has occurred over a number of decades and 
often followed a structure-based drug design, using computational chemistry and 
structural biology to aid the synthesis of more potent compounds.  In each case there 
is often described an initial single compound from which a library of small molecules 
is designed following synthetic optimisation.   
Having discussed synthesis of molecules an assessment must be made of their PPI 
modulation via biophysical techniques. 
 Introduction to biophysical techniques 
In any structure-based drug design project for modulators of protein-protein 
interactions (PPIs) it is important to understand how the synthesised ligand interacts 
with the protein of interest, this will enable optimisation of the ligand in future 
synthesis.   
To do this there are a number of biophysical techniques which can be employed such 
as; X-ray crystallography; fluorescence polarisation (FP); nuclear magnetic 
resonance (NMR) spectroscopy; isothermal titration calorimetry (ITC) and intrinsic 
fluorescence spectrophotometry.  These techniques have been used extensively in 
many successful drug design projects that aim to target protein-protein interactions.  
It is the last three that are used in this thesis and shall be discussed briefly here, 
followed by the applications of those techniques in PPI investigations.   
1.6.1 Protein Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR spectroscopy is able to determine characteristic properties of molecules 
generally in solution.  Such properties include chemical and electronic information as 
well as more in depth three-dimensional information on structure and conformation.  
It is a technique that has been used for the characteristic determination of small 
molecules and is also a key biophysical technique for structural analysis of larger 
macromolecules such as proteins.[201]   
The phenomenon of NMR works under the principle that all matter is composed of 
different atoms which, are in turn made up of nuclei and electrons.[202]  When 
exposed to a magnetic field some of the nuclei align themselves to the applied field.  
Furthermore, each atomic nuclei have four properties including; mass, electronic 
charge, nuclear spin and magnetism.[203]  Nuclear spin can be observed as a 
frequency via NMR; the specific nuclei can be observed dependent  on their atomic 
properties. 
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When the atomic quantum number (I) = ½ the atoms may be observed by NMR.  Thus 
for NMR spectroscopy of biomolecules such as proteins, the most important nuclei 
are those which possess the characteristic I = ½ including 1H, 13C and 15N; their 
properties can be found in table 1.1. 
Table 1.1- The nuclei of interest’s characteristic properties.  Including; I the nuclear spin angular 
momentum, the natural abundance of each isotope measured as a percentage and γ the gyromagnetic 
ratio.[203] 
Nuclei I Natural Abundance (%) γ (Ts)-1 
1H ½ 99.9 2.6752 ×108 
13C ½ 1.07 6.728 ×107 
15N ½ 0.37 -2.73 ×107 
 
As naturally occurring proteins are composed of around 20 different amino acids 
which contain protons in different chemical environments, small local changes in 
magnetic fields around an atom due to its particular environment alters the frequency 
at which the protons come into resonance.  The different frequencies of the hydrogens 
results in different chemical shifts of those nuclei that are the same, but which are 
surrounded by a different chemical environment e.g. the protons on two alanine side 
chains in different chemical environments will differ.   
A chemical shift (δ) is defined as a specific resonance of a specific nucleus relative 
to reference, for 1H and 13C; this reference is usually tetramethylsilane (TMS) and the 
units of this values is given in parts per million (ppm).[203]  The different chemical 
shifts of a protein are determined by a number of factors such as if the hydrogens are 
in an aromatic environment (i.e. residues Phe, Tyr, Trp or His).[204]  Those in 
aliphatic regions include Leu, Ile, and Lys to name but a few.[204]  The methyl groups 
of the different amino acids occur at specific 1H 13C chemical shifts and the same can 
be said for some of the 1H 15N amide NH peaks.[204]  These differences are 
observable in different spectra, for example a simple one dimension (1-D) 1H 
experiment (Figure 1.26 C), a 1-D spectrum is simply the chemical shifts of the 1H 
nuclei within a molecule.   
There are also two and three dimensional (2-D, 3-D) experiments and these take into 
account the transfer of magnetisation from the 1H nucleus to the connected atom.  
Such 2-D experiments include 1H 13C and 1H 15N heteronuclear single quantum 
correlation (HSQC) (Figure 1.26, a and b).  Heteronuclear experiments show a one 
bond correlation between nuclei, in the case of a 1H 15N HSQC spectra, the number 
of peaks represent the number of amino acids within the protein excluding proline 
residues which are unobservable. 
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In the case of 2-D experiments such as a 1H 15N HSQC experiment the magnetisation 
is transferred from the hydrogen onto the attached 15N nuclei, the chemical shift is 
then derived from the nitrogen; magnetisation is next transferred back to the hydrogen 
where it is then detected.[203]   
These experiments together provide a comprehensive finger print of all the nuclei 
within the protein.  This is important in the determination of the proteins secondary 
structure.  Both 2-D and 3-D experiments are used in the resonance assignment of a 
protein spectrum.  Changes in the chemical environment of amino acids within a 
protein can occur due to interactions with a ligand or natural binding partner.  These 
changes can be monitored using a number of different experiments such as 2-D 
HSQC’s, 1-D saturation transfer difference (STD) and 1-D waterLOGSY experiments 
(Chapter 4.1.1). 
  
Figure 1.26- Example 1-D and 2-D spectra. (a) A 1H 13C HSQC spectra of NCS1 (500μM) with 
annotations relating to the assignment regions of specific carbon or hydrogen environments.  An 
example amino acid Lysine can be seen with the nomenclature annotated. (b) A 1H 15N HSQC spectra 
of NCS1 (500μM) each peak in the spectra relates to a specific backbone NH amide of a particular amino 
acid within the protein, the number of peaks within this spectrum provides a rough idea of the number of 
amino acids within a protein, excluding prolines.  The area highlighted in the red box relates the side 
chain NH’s of residues including Arg, Gln and Asn. (c) A 1-D 1H spectra of NCS1 (250μM) with the 
specific regions highlighted. (All data collected in this figure was collected at the University of Liverpool 
and used for the purposes of this research project). 
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The spectrometers used to collect the NMR data in this thesis include either a Bruker 
AVANCE II+ 600 MHz Ultrashield or 800 MHz US2 spectrometer, Bruker AXS Inc., 
Madison, Wisconsin, USA, each spectrometer is equipped with a 5 mm triple-
resonance cryoprobe.  The increase in field strength between 600 MHz and 800 MHz 
results in an increase in the resolution, the use of a cryoprobe increases the sensitivity 
of the 1H, 15N and 13C detection. 
 
Figure 1.27- The spectrometers employed at the University of Liverpool Centre for Structural 
Biology.  The Bruker AVANCE II+ 800 MHz and 600 MHz spectrometers, alongside a basic schematic 
of the setup of a spectrometer and processing equipment (Schematic adapted from www.varianinc.com). 
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1.6.2 Isothermal titration Calorimetry 
The term calorimetry is the description of a change in heat of a system that occurs as 
a result of a physical process.  Experimentally this change in heat is measured using 
a calorimeter.[205]  The technique has early origins and has been used extensively 
over the centuries to investigate numerous physical processes such as measuring 
the heat capacity of water carried out by Black in the late 1700’s.[206]  Calorimetric 
measurements can be used to explore systems in equilibria through a titration 
method.  Original chemical applications studied the exploration of acid- base equilibria 
and metal ion complexation reactions.[207,208]  It was not until later in 1989 that 
MicroCal developed a calorimeter to investigate the biological equilibria between 
Cytidine 2’-monophosphate (2’CMP) with the active site of ribonuclease.[209]  
Isothermal titration calorimetry is the measure of a change in heat of a physical 
process, with the sample of interest and reference sample kept at the same constant 
temperature during the experiment, hence its term isothermal.[210]   
 
ITC is able to provide a detailed thermodynamic characterisation of the interaction 
between a protein and a ligand or secondary binding peptide/ protein, such 
thermodynamic properties include enthalpy (ΔH) and entropy (ΔS), free energy (ΔG) 
and binding affinity (KD).[211]  Each thermodynamic property is related to the other 
using the following equations (1.1 and 1.2), ΔG and KD are derived from the measured 
thermodynamic properties, with ΔH and ΔS measured experimentally.  As a technique 
employed to investigate the interactions of biological systems it can be used alone; 
however generally it is used in conjunction with other complementary biophysical 
techniques such as NMR spectroscopy, tryptophan fluorescence and surface 
plasmon resonance (SPR).   
∆𝐺 = ∆𝐻 − 𝑇∆𝑆  1.1 
∆𝐺 = −𝑅𝑇𝑙𝑛𝐾𝐷 1.2 
The ITC200 Microcalorimeter (GE Healthcare, Figure 1.28 a) was the calorimeter 
used for the ITC experiments in this thesis, a schematic of the calorimeter (Figure 
1.28 b) highlights the three key components.  The reference cell (blue) which contains 
either a sample of water or the corresponding buffer, the sample cell (magenta) 
contains the titrand into which the computer controlled syringe (green) injects and 
stirs the titrant.  Both the reference cell and sample cell are maintained at a constant 
single temperature, upon injection of the titrant into the titrand any change in heat 
from the sample cell is measured and the data is then read by the computer for 
analysis.   
Introduction  
 
46 
 
 
Figure 1.28- (a) The ITC200 Microcalorimeter (GE Healthcare) of The University of Liverpool Centre for 
Structural Biology on which all experimental ITC within this thesis was conducted. (b)  A schematic 
representation of an ITC calorimeter with the three key components indicated.  The reference cell (blue) 
contains either a sample of water or buffer, the sample cell (magenta) contains the titrand into which the 
computer controlled syringe (green) injects the titrant.  As the experiment proceeds the syringe rotates 
for continual mixing and both the reference cell and sample cell are maintained at a constant single 
temperature.  Upon injection of the titrant into the titrand the change in heat from the sample cell is 
measured and the data is then read by the computer, (Image adapted from GE Healthcare MicroCal 
calorimeters manual). 
The raw data obtained from each experiment is analysed in Origin7 (OriginLab, 
Northampton, MA) using a curve fitting process in which a non-linear regression 
procedure is used to apply a specific mathematical model to the data (equation 
1.3).[212]  It works following an iterative process to minimise the chi-square (chi^2) 
values and obtain best fit parameters for the binding parameters.[213,214]  The fitting 
process involves, (a) initial estimates by the Origin software of the values for n, K and 
ΔH and (b) calculation of ΔQ (i) for each individual injection, these values are 
subsequently compared with the heat measured for the corresponding experimental 
injection.  Standard Marquardt methods (c) are used to improve the values of n, K 
and ΔH by continuous iteration of the procedure (a, b and c) until there is no 
improvement in the values.  
The analysis software is able to take the raw data and create an isotherm (Figure 
1.29), this is a plot of the change in heat (Kcal) as a function of the ratio of ligands 
concentration: protein concentration.  Subsequent analysis of the isotherm is able to 
minimise the chi-square values and calculate the ‘best fit’ values of the following 
binding parameters: n, the stoichiometry, KD the binding affinity, ΔH the change in 
enthalpy and ΔS the change in entropy.  The enthalpic contributions (ΔH) from any 
given experiment relate to the change in intermolecular bonds/ interactions, whether 
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this be formation or destruction of hydrogen bonding or van der Waals 
interactions.[211,213]  The entropic contributions (ΔS) of a reaction come from the 
change in solvation of the apolar protein surface, which could  be the burial of 
hydrophobic residues or the release of water molecules.[211,213]  For an ideal 
interaction the thermodynamic profile would be as follows: the enthalpy ΔH would be 
large and negative, the component TΔS would be small and positive thus resulting in 
a large and negative ΔG which is indicative of a tight binding interaction.[211,213]  
Further details of the ITC methodology are discussed in the relevant Chapter 2.3.5. 
∆𝑄(𝑖) = 𝑄𝑖 +
𝑑𝑉𝑖
𝑉𝑜
[
𝑄(𝑖)+𝑄(𝑖−1)
2
] − 𝑄(𝑖 − 1) 1.3 
 
Vo= active cell volume  
Vi= injection volume 
Q= total heat content in Vo 
ΔQi= heat released from the ith injection 
 
 
Figure 1.29- Examples of different isotherms (top) and resultant curves (bottom) acquired on a 
microcal200 in relation to the studies of the interaction of HIV-1-Protease with (a) Amprenavir (b) Acetyl 
Pepstatin and (c) Amprenavir and Acetyl Pepstatin (adapted from [210] and [215]). 
ITC has been used in a number of biological investigations such as the binding affinity 
and stoichiometry between two proteins and between proteins, peptides or small 
molecules.  However, as with any other technique it is not without challenges; it does 
have upper and lower limits with regards to binding affinities, which means that only 
those interactions within the range of 10 nM and 1 mM can be assessed effectively.  
In order to study interactions outside of this range competition experiments can be 
used for very strong or very weak binders.  This does mean that to obtain good data, 
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planning the experimental conditions has to be extremely thorough.  To do so requires 
a knowledge of an estimated binding constant, this enables the concentration of both 
the titrant and titrand to be calculated.  Other requirements that should be considered 
include the pH, temperature and buffer conditions of both the protein and the ligand 
to avoid any mismatch that could result in artefact heat changes.  
Despite these initial requirements it is still an extremely useful tool in the structure-
based drug design processes.  As changes to the instrument occur over time, making 
it more sensitive to those weaker interactions then its use will become even more 
prevalent.  
1.6.3  Fluorescence Spectrophotometry 
The emission of light from any given surface is known as luminescence and can be 
divided into two categories, fluorescence and phosphorescence, depending on the 
excited state.[216]  Here though we shall discuss fluorescence of which there are 
many applications for biological investigations such as, fluorescence resonance 
energy transfer (FRET), fluorescence polarisation (FP) or anisotropy (FA).   
Fluorescence polarisation assays are used widely in biological screening of small 
molecule interactions with proteins, it is based on the observation that when excited 
with plane polarised light, fluorescent molecules in solution will emit the light back to 
a specific plane so long as they remain stationary during the excitation 
phase.[217,218]  However, most molecules do not stay stationary; they may rotate or 
tumble which has an effect on the planes into which the emission of light will 
occur.[217]  Generally FP experiments are real-time experiments that are conducted 
in solution; they require the use of a fluorophore, and are very sensitive in nature.[217]   
Fluorescence anisotropy can be used in a similar manner to FP, however it describes 
the phenomenon whereby the light emitted by the fluorophore after excitation is has 
different intensities along different axes of polarisation.[219]  Fluorescence anisotropy 
has a number of applications and has been used to study the interaction of NCS1 
with D2R peptide.[220]   
Fluorescence resonance energy transfer (FRET), is the process of the transfer of 
energy from an excited fluorophore to another.[221]  It is useful in probing protein 
interactions as the transfer of energy will only occur when both the donor and acceptor 
fluorophores are in close proximity to one another, this is around 1 - 10 nm.[221]   
There is another fluorescence technique which does not rely on any external sources 
of fluorescence, intrinsic protein fluorescence.  In particular intrinsic protein 
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fluorescence has been used for the investigation of the binding interactions of a 
protein and more details of protein structure.  Intrinsic protein fluorescence exploits 
the naturally fluorescent aromatic sidechains of the amino acids tryptophan, tyrosine 
and phenylalanine within the protein itself, rather than a fluorescence label or 
dye.[216]   
 
Figure 1.30- Chemical representations of the three aromatic sidechains of the amino acid residues 
Tryptophan, phenylalanine and tyrosine.  Of which tryptophan is the most powerful fluorescence tool as 
it is stronger in emission than tyrosine or phenylalanine and is extremely sensitive to the local 
environment that surrounds the indole sidechain. 
For a particular type of fluorescence the sample is excited at a specific wavelength 
(λ) of light relating to that residue, for example in tryptophan fluorescence the 
excitation wavelength is 285 nm and the emission wavelength is between 300 - 350 
nm.  Tryptophan fluorescence is highly sensitive to the local environment that 
surrounds the tryptophan’s indole sidechain, hence tryptophan fluorescence can be 
used to detect conformational changes of a protein at low concentration.[216,222]  
These changes in conformation present themselves in two ways.  A blue shift in the 
fluorescence is observed in those circumstances where the tryptophan residues 
become more buried into the hydrophobic surface upon interaction of the protein with 
a particular ligand or interacting protein.[216]  A red shift in the tryptophan 
fluorescence occurs when the tryptophan residues become more exposed and this is 
a possible indication of protein unfolding.[216]  Both the red shift and blue shift 
present themselves in the following manner, a blue shift is a shift to the left of the 
native fluorescence i.e. less than 300 nm, a red shift is a shift to the right meaning the 
emission spectra would occur above 350 nm.   
It is a very useful method in detecting binding of a protein and ligand if the protein of 
interest is known to contain tryptophan residues in the binding site.  In this case a 
possible interaction between the protein and the ligand may be observed in the 
quenching or enhancing of the fluorescence emission.[223]  Not only is this technique 
able to determine structural changes in the protein upon ligand binding but it is also 
used to determine the binding affinity of the interaction.[223]  The tryptophan 
fluorescence data collected for this thesis was collected on a Cary Eclipse 
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Fluorescence spectrophotometer (Agilent technologies), the raw data was analysed 
in Origin7 (OriginLab, Northampton, MA). 
1.6.4 The applications of biophysical techniques: theory into practice 
With the theory behind each of the biophysical techniques briefly presented, it is 
important to put their uses into the context of a drug design project. 
Structure-based drug design revolves around the combined approach employing 
multiple disciplines; computational chemistry with synthetic chemistry and biophysical 
analysis, in order to determine hit compounds.  The biophysical techniques have been 
used extensively in many successful drug design projects of protein-protein 
interactions.  There have also been a number of instances where biophysical analysis 
has been used to confirm computational predictions in proof of principle situations.   
An example of this can be seen in the work conducted by Hamilton et al. and the 
development of some terphenyl derivatives.  A number of 1H 15N HSQC NMR 
experiments were used to confirm the docking poses of 1.52 with Bcl-xL.  
Identification of the amino acid residues of Bcl-xL affected by the ligand meant they 
were able to determine that 1.52 was interacting within in the Bak BH3 binding domain 
(Figure 1.31).[76]  By combining the two disciplines, computational docking with 
biophysical analysis, the group were able to definitively identify the binding pose of 
1.52 within Bcl-xL and hence use this to develop a second generation of scaffolds. 
 
Figure 1.31- A comparison between the molecular docking of a terphenyl compound developed 
by Hamilton et al. and the 15N HSQC results (adapted from [76]).  The amino acid residues of Bcl-xL 
that are effected by the addition of compound 1.52 are coloured in yellow and magenta. (a) The top three 
binding poses of compound 1.52. (b) An overlay of the best ranked binding pose of 1.52 with the Bak 
BH3 peptide (light blue), the three key sidechains of the amino acids Val74, Leu78 and Ile81 in the i, i + 
4 and i + 7 positions. 
With the second generation of compounds developed, the terephthalamides, 
Hamilton et al. used fluorescence polarisation alongside NMR spectroscopy to 
analyse the binding interactions of a number of the scaffolds.[77]  The fluorescence 
polarisation competition experiments indicated that the terephthalamide compound 
1.53, was able to displace the Bak peptide from the Bcl-xL surface.[77]  To further 
investigate this apparent competitive interaction, 1H, 15N-HSQC experiments were 
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employed which confirmed 1.53 was mimicking the helix of the Bak BH3 peptide 
(Figure 1.32).[77] 
 
Figure 1.32- NMR results of terephthalamide compounds. The chemical structure of the 
terephthalamide 1.53.  (a)  1H, 15N-HSQC of Bcl-xL 200 mM without ligand (blue), overlaid with Bcl-xL in 
the presence of 1.53 (red), the residues that are severely affected can be seen annotated on the spectra. 
(b) The crystal structure of the Bcl-xL surface with the effected residues highlighted, the top ranked 
binding pose of 1.53 can be seen superimposed with the Bak peptide (adapted from [77]). 
The final example of how biophysical techniques can be employed to analyse the 
binding interactions of designed compounds, can be observed in the development of 
the benzodiazepine scaffolds.  Again Hamilton et al. used a combination of 
techniques to explore the binding interactions of a number of his designed inhibitors.  
As before, a competitive fluorescence polarisation assay was one of the initial 
techniques used to determine affinity of a number of compounds.  Each compound 
was titrated into the fluorescent Bak peptide bound to Bcl-xL (Figure 1.33 (a)).[75]  
The most potent compound 1.54 was found to have a Ki = 2.4 μM and the least potent 
1.55 Ki = > 500 μM (Figure 1.33 (a)).[75]  Subsequently the thermodynamics of these 
binding interactions were investigated using ITC, 1.54 was found to have favourable 
enthalpic contributions, however the entropic values were small and negative and 
hence unfavourable for a tight interaction.[75]  This could then be compared to the 
ITC curve of 1.55, which supported its poor potency previously determined by 
fluorescence polarisation.[75]  Finally 1H, 15N HSQC experiments were used to 
determine the region of Bcl-xL effected by the ligand.[75]  This final experiment was 
able to confirm the competitive nature of ligand 1.54 as it indicated the residues 
effected as being in the Bcl-xL binding region.[75] 
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Figure 1.33– Bio-physical results of benzodiazepine compounds obtained by Hamilton et al.  (a) 
Fluorescence polarisation titration curves obtained for 1.54 and 1.55. (b) Normalised experimental ITC 
curve obtained from a titration of ligand 1.54 into Bcl-xL. (c) Normalised experimental ITC curve obtained 
from a titration of ligand 1.55 into Bcl-xL. (d) Crystal structure of Bcl-xL and Bak BH3 helix, with the 
residues effected by NMR studies of 1.54 highlighted (adapted from [75]). 
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 Summary 
This introductory Chapter has detailed the challenge and previous approached 
methods for targeting protein-protein interactions and reviewed the different 
approaches to discovering quality hit compounds as seen with the MDM2/ p53, and 
Bcl-xL/ Bak BH3 interactions.   
It has highlighted the pharmacophore-based virtual screening approach as the vital 
first step in the holistic structure-based design process and gave a detailed overview 
of the different computational processes that can be applied to aid the selection of hit 
compounds to synthesise and test.  Also considered here is the range of different 
synthetic organic chemistry protocols applied to synthesise some of the well-known 
scaffolds, from which successful PPI inhibitors were developed.   
The basis of the biophysical techniques used within this thesis has been introduced 
to provide an understanding as to the meaning of their results and their purpose within 
the grounds of a structure-based design protocol.  These three techniques will be 
used to design small molecule inhibitors of a previously unsuccessfully targeted 
protein-protein interaction such as NCS1 and D2R peptide.  Furthermore the research 
details the structural characteristics of the individual proteins NCS1 and D2, alongside 
that of the complex, the physiological implications of the interaction and hence 
presents it as a valid target of interest for research.   
 Project Aims  
Despite the evidence of the importance of the NCS1 D2R peptide interaction as a 
therapeutic target, the research into small molecule modulators of the NCS1 D2R 
peptide interaction had not been carried out.  Therefore, research focussed on the 
discovery and development of novel small molecule inhibitors through a structure- 
based design protocol is of great interest.  
The aim of this project is to discover novel small molecule inhibitors of the protein-
protein interaction between NCS1 and the D2R peptide, using a structure-based 
design strategy.   
In order to achieve this the project can be subdivided into four sections: 
1.  Development of a computational workflow involving a pharmacophore- 
based modelling, to screen a library of compounds and hence make a selection of 
ligands to synthesise (Chapter 2.1 and 3.1). 
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2.  Design and conduct efficient synthetic routes to a selected number of small 
molecule ligands (Chapter 2.2 and 3.2). 
3.  Analyse the interactions of the synthesised compounds with NCS1 using 
a variety of structural and biophysical techniques.  From the experimental 
measurement then optimise through molecular design, the next generation of 
compounds, for synthesis and testing (Chapter 2.3 and 3.3). 
4.  Investigation of a complementary approach through the use of a fragment 
library of compounds and apply a similar computational workflow processes to select 
compounds to purchase and screen against NCS1 using NMR-based methods 
(Chapter 4). 
The techniques employed during this research include;  
Computational Chemistry- pharmacophore approach to the structure-based drug 
design process, docking, scoring and ranking of compounds.  Programmes used 
were: ZINCPharmer, GOLD, Pipeline Pilot, Knime, Spartan and PyMOL. 
[92,99,124,125,224,225]   
Synthetic Organic Chemistry- Using synthetic organic chemistry methods to 
synthesise the selected inhibitors in an efficient manner.  
Protein Production- Following a protocol previously published protocol to produce 
unlabelled and isotopically labelled 1H 15N and 13C 15N NCS1 for the requirements of 
fluorescence assays, ITC and NMR analysis. 
Intrinsic Tryptophan Fluorescence- Employed as an initial screen to determine if 
there was an interaction between the ligands and the unlabelled NCS1. 
NMR Spectroscopy- Utilised as the method to determine the sidechain and 
backbone assignment of 13C 15N NCS1 and the location of any interactions between 
NCS1 and the inhibitors.  Use two-dimensional 1H 15N and 13C 15N HSQC experiments 
alongside some one-dimensional experiments such as saturation transfer difference 
(STD) and waterLOGSY (see Experimental Chapter 6 for further details) to screen for 
binding. 
Isothermal Titration Calorimetry (ITC) - The technique used to determine the 
binding affinity of any NCS1 ligand interaction and any thermodynamic parameters 
associated with any binding interaction. 
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2 Structure-based drug design: The First Generation 
The research detailed in this chapter, describes the structure-based molecular 
design, organic synthesis and biophysical assessment of a series of first generation 
compounds.  An outline of the research discussed in this chapter can be found below 
(Scheme 2.1).  It incorporates details of the computational design, synthetic approach 
and biophysical analysis of three inhibitors designed to target the protein-protein 
interaction between neuronal calcium sensor 1 (NCS1) and the dopamine receptor 2 
(D2R).   
The biological implications of the interaction between NCS1 and D2R include bi-polar 
and schizophrenia disorders, making it an important therapeutic target (a greater 
discussion of the implications of both NCS1 and D2R can be found in the introduction 
Chapter 1.1.1).  At the initiation of this project the crystal structure of the NCS1 D2R 
complex was unavailable.  However, the sequence of NCS1 was known and a 
sequence alignment between the yeast NCS orthologue frequenin (frq1) and rat 
NCS1, indicated that the two NCS proteins share a 60% sequence identity and an 
overall sequence similarity of 75%.  Therefore frq1 and its binding partner 
phosphatidylinositol 4-kinase (pik1) could be used as the model system for the 
computational design processes.  A sequence alignment between the two NCS 
proteins can be found in Chapter 2.1.6 and further details on the frq1 pik1 interaction 
can be found in the introduction Chapter 1.1.2.[226]   
 
Scheme 2.1- An outline of the research discussed within this chapter; Section 2.1 details the 
computational design processes including the alignment of the two protein sequences, Section 2.1.6 the 
three synthetic approaches of the first generation of inhibitors (Section 2.2) and Section 2.3 describes 
the biophysical techniques used including protein assignment and ligand binding studies by NMR, ITC 
and fluorescence spectroscopy. 
Structure-based drug design: The First Generation; Computational Design 
58 
 
 Computational Design 
2.1.1 Introduction  
Structure-based drug design is an approach in which computational modelling is used 
in conjunction with “hit identification” and “hit to lead” optimisation processes in a drug 
discovery pipeline.[80,81]  It is an iterative process that has been developed 
substantially over the past 40 years and involves progression over multiple cycles 
incorporating measured experimental data as feedback to optimise future generations 
of compounds with improved properties.   
Once the target has been identified, it is necessary to have structural information.  
This will either be of the whole protein or the relevant part.  The structure can be 
determined using X-ray crystallography, NMR spectroscopy or homology modelling, 
as part of the drug design process, or it is available from the Protein Database 
(PDB).[227,228]  Through structure determination with the natural binding partner for 
example, the residues within the binding site may be targeted in subsequent hit 
identification steps.[82]   
Concerning hit identification for protein-protein interactions, two strategies can be 
employed.  In the first de novo design strategy, the lead compounds are built “from 
scratch” by a computational algorithm in order to identify compounds which are highly 
complementary to the targeted binding site.  This process relies upon the identification 
and use of the pharmacophore for the target.[229]  The second which is virtual high 
through-put screening, is a computational adaptation of experimental high through-
put screening and it involves computationally screening libraries of compounds to fit 
the requirements of the biological target.[230]   
The strategy used in this project is a mixture of both design and virtual high through-
put screening; it was initially developed to target the protein-protein interaction that 
occurs between frq1, the yeast homologue of the neuronal calcium sensor 1 (NCS1) 
and a peptide from the pik1 protein (Figure 2.1).   
As previously discussed in the introduction (Chapter 1.2), a challenge encountered 
when targeting two interacting proteins with small molecules is that the interface 
between the two has a tendency to be large and flat.[231]  However, there are 
normally a number of key residues involved in binding one protein to another and 
these residues are known as “hotspots”.  These hotspot residues can be used to 
develop a pharmacophore and a process known as pharmacophore-based virtual 
screening can be used to search compound libraries.  A pharmacophore was defined 
as a molecular framework, composed of certain structural elements necessary for its 
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biological activity.[83,89,232]  In virtual screening, a pharmacophore can be used to 
extract the common features of a set of active molecules and this is known as ligand- 
based pharmacophore modelling.[83]  Structure-based pharmacophore modelling is 
when the hotspot residues are known and the pharmacophore is used to represent 
certain points in 3-D space; it could also incorporate certain functional groups to be 
mimicked.  Depending on the type of interaction, these could include hydrogen bond 
donors, hydrogen bond acceptors, aromatic rings, and charged moieties.[90,91] 
 
Figure 2.1- The frq1: pik1 complex.  Representation of the crystal structure of the frq1: pik1 complex, 
the model system (PDB 2JU0).  Pik1 (red) was shown to anchor itself to frq1 (green) at the C-terminal 
helix, this hotspot binding interaction involves six key residues on pik1 (coloured blue with the sidechains 
visible) Val156, Ala 157, Ala159, Leu160, Val161 and Met165.[233]  The C-terminal helix of pik1 interacts 
with the N-terminus of frq1 and the N-terminus of pik1 with the C-terminus of frq1. (a) View above the 
hydrophobic.  (b) Cross section view, the projection of the key amino acid sidechains of the C-terminal 
helix down into the hydrophobic cleft of frq1.  The amino acid sequence of pik1 can be seen below the 
crystal structures and is coloured red with the 6 key residues coloured in blue. 
With the structure of the pharmacophore defined, the virtual high throughput stage 
can be used to screen a 3-D database for compounds which fit the pharmacophore.  
There are a number of databases/ compound libraries that can be used.  
ZINCPharmer is the online interface to one such database ZINC and this online 
resource conducts pharmacophore searches of a library of purchasable 
compounds.[92]  The interface allows for different filters to be applied to a 
pharmacophore query; such filters include molecular weight (mw), root mean squared 
deviation (RMSD) and the number of rotatable bonds, all of which have been 
implicated in the design process of drug-like molecules.[95]  
Searching for compounds that fit a particular pharmacophore is achieved through the 
assessment of a compounds binding pose with respective protein.  This process is 
performed through docking calculations, and is central to the structure-based design 
strategy.   
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There are a number of algorithms that are available to rationalise the interactions 
between a ligand and a protein.[96]  A discussion of the different algorithms can be 
found in the introduction (Chapter 1.4.3), however the docking programme used for 
this project was Genetic Optimisation for Ligand Docking (GOLD).  Most docking 
programmes make the approximation that the protein a rigid entity and the ligand as 
being the flexible component.  GOLD, uses a genetic algorithm to investigate the 
different conformations, placement and rotations of a flexible ligand and takes into 
account the loss of water from a surface upon ligand binding.[97,109]   
As with most docking programmes GOLD is composed some main constituents; 1) a 
scoring function that is able to rank different binding modes and 2) a mechanism by 
which it explores the possible binding poses of a ligand.[99]  The different docking 
conformations of each ligand can be assessed for predicted strength of binding using 
scoring functions such as Astex Statistical Potential (ASP), Chemscore and Chem 
Piecewise Linear Potential (PLP).[99]  ASP uses a protein-ligand database to 
measure the atom-atom potential, Chemscore estimates the change in energy that 
occurs upon ligand binding and ChemPLP is an empirical fitness function which 
models the steric complimentary between the protein and the ligand.[99,111,112]   
The docking predictions between a protein and ligand are important in identifying the 
possible binding interactions.  However another vital part of structure-based drug 
design, is the calculation of a compounds drug-like ADMET properties.  The ADMET 
properties of a compound play a significant role in the overall potential for a molecule 
to have desired therapeutic potential.  Optimisation of the interactions between a 
ligand and macromolecule target such as a protein, call for alterations of the 
properties of a small molecule.[113]  Historically, there are a number of guidelines for 
the “ideal drug-like profile” that a compound should possess, this has changed 
numerous times as knowledge and understanding of macromolecule and ligand 
interactions has evolved.  However despite these continuous changes certain 
characteristics have remained, for a compound to be successful as a drug it must be 
well absorbed, metabolically stable, have minimal toxic effects and a good duration 
of activity.[113]   
In order to assess this, computational chemists must take into account a number of 
physical properties of a compound before it is selected, these include; size, molecular 
surface area, lipophilic profile (clogP), charge and hydrogen bond donors or 
acceptors.[113,234]  There are a number of chemoinformatic tools that can be used 
to calculate these parameters; one such programme is Pipeline Pilot which can be 
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used to generate a sequential workflow able to calculate the required 
chemoinformatic data (Section 2.1.4).[125] 
Overall structure-based drug design is vital in the development of new therapeutics, 
the computational processes remove the costly high-throughput chemical screening 
in experimental settings, thereby allowing for a more refined selection of compounds, 
with a greater chance of becoming a hit to lead success.  
2.1.2 Pharmacophore Generation 
In designing inhibitors for protein-protein interactions (PPIs), the complex nature of 
the systems involved means that conventional high through-put screening methods 
may not be as efficacious in generating hit compounds.[79]  With this in mind a 
computational pipeline was designed utilising a combination of online resources and 
local modelling algorithms to optimise the chemical structure of the protein with a 
number of compound.  Application of this approach to the model system of frq1 pik1, 
and informed by Ames et al. the identification of a key pharmacophore of pik1 was 
conducted in PyMOL.[41,224]  The pharmacophore was composed of the six 
hydrophobic residues Val156, Ala157, Ala159, Leu160, Val161, and Met165 (Figure 
2.2), the same residues as were indicated by Ames as being important in the binding 
of pik1 to frq1.[41]   
 
Figure 2.2- A stick representation of a backbone fragment from the C-terminal helix of pik1 (PDB 2JU0).  
The six key amino acid residues of the six point pharmacophore used to screen for compounds in 
ZINCPharmer labelled.  The hydrophobic pharmacophore points are indicated by green spheres. 
The pharmacophore screening approach searches for compounds that are able to 
match closely the desired pharmacophoric array via an energetically accessible 
molecular conformation (Figure 2.2).  It was used as an approach to conduct prior to 
molecular docking, because it was expected that the compounds able to replicate the 
pharmacophore would have better predicted “strength of binding”, than those 
randomly selected, importantly pharmacophore searching can be quicker than 
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docking.  The pharmacophore approach is an informed, data driven approach to 
identify compounds that could bind as desired.  Those compounds once identified 
undergo more thorough assessment via docking processes. 
Combinations of residues were varied systematically (as described below), and the 
selection decided by manual investigation and visualisation of the structure, which 
was further informed by what is known in the literature.[41]  This resulted in six 
different pharmacophore’s (Table 2.1) that were used as queries in 
ZINCPharmer.[224]  By selecting various combinations of residues involved in the 
pharmacophore definition, the size, shape (brought about through different 
substitution patterns) and chemical functionality of the compounds identified from 
each pharmacophore search will be different from one another.  For example 
inclusion of all 6 residues in a pharmacophore search may result in hit compounds 
that are slightly larger than those where the pharmacophore involves just four 
consecutive residues.  The minimum number of residues included in the 
pharmacophore selection was four, as it was suggested that compounds that only fit 
a three point pharmacophore or less may be too small, and result in a non-specific 
interaction in the resultant testing.[235]  The composition of the residues involved in 
the six different pharmacophore’s for each enquiry can be found in Table 2.1.   
Table 2.1- Pharmacophore generation.  A table highlighting the combination of the six key residues 
from the pik1 fragment that made up each enquiry for the pharmacophore searches.  The residues 
included in each enquiry are highlighted in red.   
Residue: Val156 Ala157  Ala159 Leu160 Val161 Met165  
Enquiry Number             
1             
2             
3             
4             
5             
6             
 
The ZINCPharmer database contains ≃ 35 million ligands and ≃ 200 million ligand 
energetically accessible conformations and is updated regularly.[224]  The molecular 
weights filter of the results was set such that they never exceeded 600 Da, as larger 
compounds may present challenging pharmacokinetic profiles.[43,44]  The root mean 
squared deviation (RMSD) is a value based upon the difference between 
pharmacophoric points in the query and those presented by a particular molecule’s 
conformation, therefore smaller RMSD values are preferred and a maximal threshold 
value of 2Å was used.[236]  The number of rotatable bonds is a measure of the 
molecular flexibility of a compound; it has been shown to be an important indicator of 
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oral bioavailability and includes any single bonds not bonded to a hydrogen atom, not 
involved in a ring system and does not include amide bonds.[95]   
The parameters applied to each pharmacophore search were as follows: molecular 
weight (Da) ≤ 600, ≤ 500, ≤ 300 and ≤ 150; RMSD ≤ 2, ≤ 1 and ≤ 0.5 and rotatable 
bonds ≤ 9 and between 9 and 1.  The results of the ZINCPharmer searches can be 
seen tables 2.2 - 2.7, the numbers within the table under each heading represent the 
number of molecules for that individual enquiry.  For example; enquiry 1 (Table 2.2) 
where the pharmacophore included the residues Val156, Ala159, Leu160 and 
Met165, those compounds within filter (a) with a molecular weight ≤600 Da, RMSD 
≤2 and number of rotatable bonds ≤9 included 1,302,105 compounds.  As the 
molecular weight, RMSD and number of rotatable bond values were decreased (filters 
b-k Table 2.2) so did the number of hit compounds.  
 
Table 2.2- Enquiry 1 results.  The table showing the ZINCPharmer results for Enquiry 1 targeting the 
residues: Val156, Ala159, Leu160 and Met165.  This table shows the number of compounds under each 
search criteria, for example Filter a- compounds with a molecular weight ≤600 Da, RMSD ≤2 Å and 
number of rotatable bonds ≤9 gives 1,302,105 compounds. 
 
 
Table 2.3- Enquiry 2 results.  The table showing the ZINCPharmer results for Enquiry 2 targeting the 
residues: Val156, Ala157, Ala159 and Leu160.  This table shows the number of compounds under each 
search criteria, for example Filter a- compounds with a molecular weight ≤600 Da, RMSD ≤2 Å and 
number of rotatable bonds ≤9 gives 3,162,529 compounds. 
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Table 2.4- Enquiry 3 results.  The table showing the ZINCPharmer results for Enquiry 3 targeting the 
residues: Ala157, Ala159, Leu160 and Val161.  This table shows the number of compounds under each 
search criteria, for example Filter a- compounds with a molecular weight ≤600 Da, RMSD ≤2 Å and 
number of rotatable bonds ≤9 gives 2,581,274 compounds. 
 
 
Table 2.5- Enquiry 4 results.  The table showing the ZINCPharmer results for Enquiry 4 targeting the 
residues: Val156, Ala157, Ala159, Leu160 and Met165.  This table shows the number of compounds 
under each search criteria, for example Filter a- compounds with a molecular weight ≤600 Da, RMSD 
≤2 Å and number of rotatable bonds ≤9 gives 12,351 compounds. 
 
 
Table 2.6- Enquiry 5 results.  The table showing the ZINCPharmer results for Enquiry 5 targeting the 
residues: Val156, Ala159, Leu160 and Val161.  This table shows the number of compounds under each 
search criteria, for example Filter a- compounds with a molecular weight ≤600 Da, RMSD ≤2 Å and 
number of rotatable bonds ≤9 gives 3,609 compounds. 
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Table 2.7- Enquiry 6 results.  The table showing the ZINCPharmer results for Enquiry 6 targeting the 
residues: Val156, Ala159, Leu160, Val161 and Met165.  This table shows the number of compounds 
under each search criteria, for example Filter a- compounds with a molecular weight ≤600 Da, RMSD 
≤2 Å and number of rotatable bonds ≤9 gives 21 compounds. 
 
 
The results indicate that the number of hits did not alter between the searches of max 
RMSD ≤ 2 Å and ≤ 1 Å in all enquiries, which suggested that the optimal RMSD range 
was be between 1 and 0.5 Å as the values between the two search parameters 
differed.  The number of hits was greatly reduced after limiting the search to 
compounds with a molecular weight ≤ 300 Da, suggesting that the key molecular 
weight range for maximising potential diversity of compounds discovered was 
between 600 - 300 Da, as a small compound would not be able to reach the 
pharmacophoric points which are far from each other.  This result is in line with 
previous studies which suggested that PPI inhibitors do not follow Lipinski’s “rule of 
5” and generally had molecular weights greater than 500 Da which could be explained 
due to the large size and topography of the binding site between two interacting 
proteins.[49,231]  The sixth enquiry saw a dramatically reduced number of hits with 
the broadest parameter setting of mw ≤ 600 Da, RMSD ≤ 2 Å and rotatable bonds ≤ 
9.  This suggests that the larger the number of pharmacophore points (amino acid 
residue targets) the fewer the number of possible compounds that are a good match; 
this could be useful for specificity.  The specificity of a compound is important in 
minimising the chance of off-target interactions.[237] 
In order for the ranking and selection of the most suitable compounds, a balanced 
selection process using several inputs (predicted strength of binding and predicted 
ADMET properties) was applied in order to select the most viable ligands for 
consideration for synthesis (Figure 2.3).  It follows an iterative process and involves, 
docking and scoring the compounds, calculation of the ADMET profiles to allow for 
the generation of the compound with the most suitable binding and “drug like” profile. 
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Figure 2.3- The overall approach of the balanced selection workflow for the larger enquiries.  Which 
involved taking the molecules from the online pharmacophore screening process, docking the 
compounds into frq1 using the docking software GOLD and utilising the scoring function Goldscore.  The 
Goldscore docking poses of each compound were subsequently re-scored in GOLD using the scoring 
functions ASP, ChemPLP and Chemscore (each scoring function works on different parameters see 
GOLD Docking Section 2.1.3 for more information).  The compounds ADMET properties were calculated, 
this along with each of the four scoring values were ranked in Knime and the ligand efficiency values 
calculated.  This was conducted in order to select the compounds with the best overall chemical profile 
and indicate which should be visually inspected.  
2.1.3 GOLD Docking Analysis 
Following the identification of compounds which matched various pharmacophores, 
the next step in the computational workflow was docking and scoring each of the 
compounds contained in tables 2.2 – 2.7 a- k (above) into frq1 using GOLD.[99]   
One particular enquiry, enquiry 6 (Table 2.7) contained only 21 virtual hit compounds 
from the Zinc searches; this enquiry was manually assessed and so will be discussed 
separately (Section 2.1.5). 
The process of docking involves the prediction of the conformation and orientation of 
ligand’s within the binding site.[238]  Initially the ligands in each file were scored using 
the Goldscore which generated a fitness value based upon the protein-ligand 
hydrogen bonding energy, protein-ligand Van Der Waals (VDW) energy, the ligand 
internal VDW energy and the internal torsional strain of the ligand.[99]  The better 
Goldscore’s are those of a higher value; they can subsequently be used to generate 
the ligand efficiency of each compound.   
Ligand efficiency is an estimation of the amount of binding per atom of the ligand with 
the target protein; an example of the calculated Goldscore and ligand efficiency 
values for the compounds within enquiry 6 can be seen in Table 2.8.[239]  As 
medicinal chemists strive to increase the potency of lead compounds, the optimisation 
processes involved in drug development often result in increasing molecular 
weight.[240]  The ligand efficiency is a simple metric that is important to optimise 
potency, whilst maintaining optimal molecular size for a “drug-like” compound.[239]   
The predicted Goldscore conformations of each compound were consequently 
rescored in GOLD using three different scoring functions, ASP, Chemscore and 
ChemPLP.  The consensus scoring process was used to ascertain an overall 
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assessment of the interaction profile between each compound and the target 
protein.[99]   
Consensus scoring is used to improve the hit rates when screening a library of 
compounds; it is a simple rescoring and re-ranking of docking solutions based on a 
different scoring function.[99]  The consensus scoring method is statistically 
improved, the mean of the samples is closer to a “true” sample than an individual 
value.[241]  The different methods focus on different aspects of ligand binding and so 
agree on an active compound more than an inactive one as well as providing a greater 
consistency across receptor systems.[241]  The consensus scoring approach has 
been indicated as leading to improvements in docking procedures, through the 
improved quality of results with less reliance on the correct selection of a scoring 
function.[242]  As such this consensus approach to the docking process of the ligands 
allows for a more informed selection that is not biased, but rather incorporates as 
many possible aspects of a binding interaction as possible. 
A subsequent process in the computational analysis was the docking of pik1 into frq1 
using GOLD to calculate its ligand efficiency from its Goldscore so to generate a 
benchmark for the compounds of each enquiries.  The key residues of frq1 identified 
by Ames were highlighted in a PyMOL representation of the protein (Figure 2.4 a) 
[224] and the top docking pose of the pik1 fragment was then read into the file to 
observe the key interactions between the protein and peptide (Figure 2.4 b). 
The drug-like profile of each compound is also necessary to predict their oral 
bioavailability and toxicity, to do this the solubility, surface area and volume, number 
of hydrogen bond donors and acceptors, ClogP and molecular weight were 
calculated.  The link between ADMET and the pharmacokinetic descriptors has been 
investigated extensively, one such investigation at GSK described how the variations 
of 12 molecular descriptors including hydrogen bond acceptors (HBA), hydrogen 
bond donors (HBD), molecular weight (MW), polar surface area (PSA) and rotatable 
bonds (bonds) could be described with four orthogonal components.[118]  The group 
found that of the four orthogonal components, molecular weight and ClogP were the 
two main characteristics that determine ADMET liabilities.[118]  The investigation 
detailed how the changes in the two key molecular properties, will affect a range of 
ADMET parameters including solubility, bioavailability permeability, volume of 
distribution, P450 inhibition (relating to metabolism) and in vivo clearance.[118] 
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Table 2.8- Enquiry 6 docking results.  The Goldscore and ligand efficiency values of the compounds 
from enquiry six (Table 2.7), the data set that was used to select the inhibitors for synthesis and testing, 
the ligand efficiency values are calculated as average Goldscore / molecular weight. 
Zinc code 
 
Average  
Goldscore 
 
Ligand 
efficiency  
 
Pik1  0.0375 
ZINC09276881 39.46 0.08 
ZINC09276880 41.23 0.08 
ZINC04792655 35.45 0.07 
ZINC01068766 40.45 0.08 
ZINC03191471 38.63 0.10 
ZINC03191471 37.89 0.10 
ZINC65321569 39.71 0.09 
ZINC12140543 41.37 0.08 
ZINC16268178 39.53 0.08 
ZINC24198265 42.88 0.09 
ZINC09276852 39.91 0.09 
ZINC09276853 40.57 0.09 
ZINC08812681 39.94 0.09 
ZINC09668287 39.33 0.09 
ZINC03403995 39.67 0.09 
ZINC20351159 37.92 0.08 
ZINC12242584 35.51 0.08 
ZINC68119468 37.56 0.10 
ZINC66781206 39.87 0.10 
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Figure 2.4- The GOLD docking poses of the frq1/ pik1 complex. (PDB 2JU0) (a) Frq1 (green) with 
the key hydrophobic residues (yellow) indicated by Ames et al. [4] as being the key hotspot of the protein 
for its interaction with its binding partner pik1 these residues include Trp30, Phe34, Phe48, Ile51, Tyr52, 
Phe55, Leu68, Phe85 and Leu89. (b) The protein-protein interaction between frq1 and the six 
hydrophobic residues Val156, Ala157, Ala159, Leu160, Val161, and Met165 from the C-helix of pik1 
thought to be necessary for anchoring the two proteins. 
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2.1.4 Physicochemical property determination and balanced selection 
Calculation of the physicochemical properties of each of the molecules was 
conducted in the scientific dataflow platform, Pipeline Pilot.[125]  Using Lipinski’s 
parameters as a guideline, a work flow was generated as a strategy to calculate 
specific physicochemical properties which influence ADMET properties.  Individual 
nodes were used to calculate, molecular weight, Log P, number of hydrogen bond 
acceptors and donors as well as the number of rotatable bonds, solubility and polar 
surface area for each compound from the pharmacophore searches (Figure 2.5).   
It is beneficial to calculate the physicochemical properties before synthesis of any 
compounds, as it can be used to predict the likely action of the body on the compound.  
Should the ligand be intended for use as a therapeutic agent, it may help to deselect 
those ligands with unfavourable ADMET profiles.[113]  An important physicochemical 
property is the solubility, not only is this important if the compounds are designed as 
a therapeutic agent, but also for the purposes of any biophysical analysis.  A 
compound with a poorly soluble profile is likely to pose problems in both testing and 
future rounds of the molecular design process. 
 
Figure 2.5- The sequential pipeline pilot workflow used to calculate the ADMET properties of each 
compound.  The data generated from this workflow was subsequently used to further filter the 
compounds and lead to the selection of a number of small molecules to synthesise. 
The files were then processed in Knime filtering off any undesirable ligands, those 
with negative docking fitness scores.  These compounds were disregarded as a 
negative fitness score relates to an extremely unfavourable predicted binding pose/ 
clash with protein.   
An overall average fitness score was calculated for each compound from the four 
scoring functions generated in GOLD, the ligand efficiencies of each molecule were 
calculated and then sorted into descending order of this value.  The ligand efficiency 
was then compared to that of the value calculated from the docking of pik1, the natural 
peptide ligand.  Molecules would be carried forward if they possessed better ligand 
efficiency than pik1 and these compounds were ranked using a Pareto optimisation. 
Pareto ranking is a method by which a compound is ordered with respects to the 
number of other compounds that are able to dominate it with respects to a number of 
objectives.  It is a multi-objective optimisation process to determine the overall 
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characteristics of a compound which can include their overall scoring function for 
example.[243]  The Pareto settings applied were as follows, molecular solubility was 
maximised, an optimal range of the number of hydrogen bond acceptors and donors 
was set as 1.0 - 10.0 and 1.0 - 5.0 respectively, in keeping with the Lipinski 
guidelines.[184]  The optimal range of A Log P was set to a range of 1.0 – 3.5 in order 
to maximise the solubility profile.  Consensus ranking and molecular weight were 
selected to be minimal values to improve the chances of a compound with good 
ADMET attributes.  This ranked list of ligands produced a single output file which 
could be visually inspected and analysed in PyMOL with frequenin as the binding 
partner (the Knime workflow system can be seen Figure 2.6).[123,224]  
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2.1.5 Enquiry Six  
The pharmacophore of enquiry number six included all six residues of the pik1 
fragment: Val156, Ala159, Leu160, Val161 and Met165, indicated by Ames et al. as 
being key to anchoring the C-terminal helix of pik1 to frq1.  This topologically large 
pharmacophore significantly restricted the number of compounds that were able to 
successfully match the pharmacophoric points.   
Twenty one virtual hits were identified from the pharmacophore search, although on 
closer inspection two compounds were conformers of the same compound.  The small 
number of molecules within enquiry six meant that selection of possible compounds 
was carried out manually without the use of Knime.  It involved analysis of each 
compound’s scoring function, along with their physicochemical properties and 
commercial availability.  Physicochemical analysis of enquiry 6 and the commercial 
availability of the compounds filtered out 11 of the 19 ligands.  Removing those with 
unfavourable molecular weights of around 600 Da and those which appeared 
commercially unavailable, resulted in 8 possible hit compounds.  The top scoring 
binding poses of the eight compounds were then loaded into the binding pocket of 
frq1 in PyMOL, to see how they were predicted to interact with frq1 and were 
compared to the binding orientation of pik1 around the key residues (Figure 2.8).  The 
top binding pose of ligands, were then overlaid with the pik1 pharmacophore and 
through visual analysis their relative merits were assessed (Table 2.9). 
 
Figure 2.7- The computational work flow of Enquiry 6.  Initial screening of the millions of compounds 
from the online database with the pharmacophore Val156, Ala159, Leu160, Val161 and Met165 led to 
21 hit compounds.  Subsequent docking, scoring and other computational screening strategies resulted 
in eight target compounds that were analysed visually through inspection of pharmacophore target and 
the small molecules.  This resulted in the selection of three compounds from the original 21 for synthesis 
and further biophysical analysis (to be discussed in later sections 2.2 and 2.3)  
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Table 2.9- Visual analysis of the six key residues of pik1.  A comparison of the 3-D space occupied 
by the compounds. The pharmacophore of enquiry 6 (table 2.7) overlaid with the eight compounds, those 
residues whose area in 3-D space appeared to be mimicked by a region of a specific compound are 
highlighted in red. 
Residue: Val156 Ala157  Ala159 Leu160 Val161 Met165  
Compound 2.1             
Compound 2.2             
Compound 2.3             
Compound 2.4             
Compound 2.5             
Compound 2.6             
Compound 2.7             
Compound 2.8             
 
Figure 2.8– Overlays between the compound structures and the pik1 peptide from the frq1 
complex. (a) The pik1 pharmacophore used for the enquiry 6 selection with the six key residues labelled. 
(b) An overlay of the pik1 pharmacophore with compound 2.7; Met165 and Ala159 are unsuccessfully 
mimicked; for Met165, this is possibly due to the fact that it is four residues away from the other key 
residues. 
These results show clearly Met165 has not been successfully mimicked by any of the 
docking solutions of the ligands from Enquiry 6 which is not surprising, as it is four 
residues away from the other residues.  However compounds 2.5 – 2.8 mimicked the 
greatest number of residues overall.  This filtered out compounds 2.1 - 2.4 as they 
only hit one of the target residues each.  Purchasing the compounds was not possible 
within the financial remits of this research and so the remaining four were analysed 
retro-synthetically, in order to find a plausible synthetic route to each one.  It was most 
difficult to design synthetic routes for Compounds 2.5 and 2.6 (e and f Figure 2.9). 
Whereas it was possible to find synthetic routes for Compounds 2.7 and 2.8 (g and h 
Figure 2.9).   
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Figure 2.9- The top docking poses of the first generation compounds 1 - 8 from Enquiry 6 generated 
using the docking programme GOLD.  Frq1 can be seen coloured in green with the key hydrophobic 
residues thought to anchor pik1 to frq1 coloured in yellow. 
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2.1.6 Applications of a frq1 inhibitor for rat NCS1 
At the initiation of this project the crystal structure of the NCS1 D2R peptide complex 
was unavailable; hence, the structure of the yeast orthologue frq1 in complex with the 
pik1 peptide (PDB 2JU0) was used to develop the strategy of virtual ligand screening 
as described above.  Both frq1 and NCS1 are predominantly α helical in nature, 
containing around 11 α helices, 4 β sheets which along with loop regions make up 
the characteristic 4 EF hand motifs.[38]  To ensure frq1 was suitable to use as a 
model system a comparison between the two sequences of NCS1 and frq1 was 
carried out comparing and contrasting the binding interactions and determine a 
possible conserved binding motif.   
The alignment of frq1 and NCS1 found that the pair shared a 60% sequence identity 
and an overall sequence similarity of 75%.  Of the eight hotspot amino acid residues 
between the interactions of the C-terminal helix of pik1 with the N-terminal helix of 
frq1 (Figure 2.10), seven are conserved in rat NCS1 and Leu68 is substituted for a 
valine.   
 
Figure 2.10 -Sequence alignment of Rat NCS1 and Yeast frq1.  Aligned sequences of frq1 (PDB 
2JU0) and NCS1 (PDB 5AER) with an average combined secondary structure, cylinders represent α 
helices and arrows β sheet.  Overall alignment of the two proteins is indicated as follows; * represent 
conservation of a residue “:” and “.” indicate that the residues are of a similar nature.  The residues 
coloured in grey are the cloning artefacts, the top lines are the frq1 sequence from Saccromyces 
cerevisiae, and those residues highlighted in yellow represent the key hydrophobic residues of frq1 that 
are important for the binding interaction with pik1.  The second sequence is that of NCS1 from Rattus 
Norvegicus used in our experiments.  Both human and Rattus Norvegicus NCS1 share a 100% sequence 
identity.  The key residues of frq1 found to anchor the C-terminal helix of pik1 were transposed onto 
NCS1, those in yellow indicate a conservation of sequence and cyan indicates the presence of a different 
amino acid.  The positions of the four EF hand motifs within the structure are also displayed.  Those 
residues in of frq1 that make contacts with pik1 are found within a red box, those of NCS1 that make 
contacts with the D2R peptide within the magenta boxes, finally the conserved residues of both proteins 
that make contacts with the respective binding partners within the blue box.  
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Figure 2.12- Comparison between crystal structures of frq1 and NCS1 with their native ligands. 
(a) The crystal structure of the frq1 pik1 complex downloaded from the pdb, code 2JU0.  Frq1 coloured 
in green with the single pik1 molecule coloured in red and the key residues of frq1 yellow. (b)  The crystal 
structure of the NCS1 D2R peptide complex downloaded from the protein data bank (pdb code 5AER), 
NCS1 can be seen coloured in green and the two C-terminal helices the D2R peptides can be see 
coloured in red, one is labelled c and the other c’ to indicate that they are from two different D2R 
molecules.  
After selecting inhibitors based on the model system of the frq1 pik1 pharmacophore 
and with the release of our NCS1 D2R peptide complex structure (PDB 5AER),[13] it 
was essential to ensure these molecules would also target NCS1. 
Interestingly when we compare the interactions of the compounds with frq1 to that of 
its mammalian orthologue, we observe different binding poses, although crucially they 
occur in the same hydrophobic binding groove.  Compounds 2.5, 2.7 and 2.8 can be 
seen to interact with the respective key residues on NCS1 but in different orientations 
(Figure 2.13).  With this data in hand, the analysis of the top binding pose of each of 
the three ligands with NCS1, can be used to target the protein-protein interaction 
between NCS1 and the dopamine receptor D2R.   
For the purposes of the synthesis, compound 2.8 was modified such that the chlorine 
group on the pyrazole ring (Figure 2.9, h) was replaced with a second methyl group; 
this was due to the commercial availability of the compounds used in the synthetic 
approach.  The synthesis of the compounds 2.7, 2.8 and 2.5 can be found in Section 
2.2, where they are now referred to, respectively, as Inhibitor 1, Inhibitor 2 and 
Inhibitor 3. 
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Figure 2.13- Comparisons between the top docking poses of Compounds 2.7, 2.8 and 2.5 in frq1 PDB 
2JU0 (a, c, e) and NCS1 PDB 5AER (b, d, f).  The key residues of the frq1 pik1 interaction highlighted 
in yellow.  (a) Compound 2.7 top docking pose in frq1 generated in GOLD. (b) Compound 2.7 top docking 
pose in NCS1 generated in GOLD. (c) Compound 2.8 top docking pose in frq1 generated in GOLD. (d) 
Compound 2.8 top docking pose in NCS1 generated in GOLD. (e) Compound 2.5 top docking pose in 
frq1 generated in GOLD. (f) Compound 2.5 top docking pose in NCS1 generated in GOLD. 
 
 
 
 
 
 
 
 
 
Structure-based drug design: The First Generation; Computational Design 
80 
 
2.1.7 Summary of Computational Approach 
The computational approach of this project was to identify hit small molecule 
compounds which would modulate protein-protein interactions.  The initial discovery 
pipeline was developed using the model system frq1 and pik1, this was then 
transferred to a therapeutic target of the mammalian orthologue of frq1, NCS1 and its 
binding partner D2R peptide.  The rationale is to design a ligand that may bind to all 
NCS1 orthologues, in order to target conserved and therefore more evolutionary 
relevant interactions.  This interaction is of significant biological relevance as it has 
been implicated in schizophrenia and bi-polar disorders.[244]  The novel pipeline 
utilised a mixture of structure-based design and high through-put screening.  Through 
combining the two techniques the screening process we would targeting the desired 
protein efficiently and generating drug-like hit compounds. 
With this first generation of inhibitors, the online interface ZINCPharmer allowed a 
library of purchasable compounds to be screened to fit a specific pharmacophore.  
The pharmacophore enquiries included a number of screening parameters such as 
molecular weight, AlogP, number of hydrogen bond donors and acceptors and 
molecular surface area, all of which have been implicated in improving the solubility 
profile of drug-like molecules and were used to remove any compounds with 
undesirable physiochemical parameters.  
Pharmacophore virtual screening was used to determine compounds to fit the specific 
points in 3-D space representing the six key residues of the pik1 fragment (Figure 
2.2).  Interestingly it was found that by increasing the number of the residues involved 
in the pharmacophore, the resultant number of hit compounds was significantly 
reduced (enquiry 6).  Enquiries 1 – 5 had resulted in millions of hit compounds and 
although they did undergo the rigorous docking, physicochemical calculations and 
Pareto ranking of the pipeline, the top compounds were not investigated any further 
due to time constraints.  However, future work could include revisiting these 
compounds to see if there are any that are predicted as having a better binding profile 
than the current targets.   
The results from enquiry six led to the selection of three target compounds for further 
computational analysis with the NCS1 D2R peptide system, synthesis (Section 2.2) 
and biophysical analysis (Section 2.3).
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 Synthetic Approach 
From the computational design processes, three compounds were selected for 
synthesis.  The synthetic routes to inhibitors 1, 2, and 3 were selected after a rigorous 
retrosynthetic investigation into possible routes in order to efficiently produce the 
desired compounds. 
2.2.1 Synthesis of Inhibitor 1 
The first compound selected for synthetic investigation, Inhibitor 1 was chosen due to 
its predicted ability to mimic four of the six desired pharmacophoric points (Compound 
2.7 Table 2.9).  The synthesis of Inhibitor 1 can be seen in Scheme 2.2 and involved 
four steps to achieve the desired compound. 
 
Scheme 2.2- Synthetic route to Inhibitor 1.  (a) HCl, 115°C 4 hrs, 25 °C, NaOH, 80%. (b) AcOH, 120 
°C 4 hrs, 83%. (c) i-PrOH, KOH, 83 °C 5 hrs, 25 °C, 2 M HCl, 72%. (d) N-N diisopropylethylamine, 1-
methyl-2-chloropyridinium iodide, anhydrous MeCN, 83 °C, 4 hrs 44%. (e) DCC, HOBt, anhydrous THF 
25 °C, 30 min, 25 °C (24hr), 50 °C (24hr), 28%. 
The first step in the synthesis involves a condensation reaction between 3-
aminocrotonitrile 2.9 and 3, 5-dimethylphenyl hydrazine hydrochloride 2.10.  The 
reaction was initially heated to 115 °C in a solution of 1 N HCl for four hours; 
basification of the reaction with the drop wise addition of 6 N NaOH at room 
temperature initiated cyclisation to form the amino pyrazole 2.11 (Scheme 2.3).  The 
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reaction afforded the desired product 2.11 with a good yield of 80% following 
modification of the published work up and isolation method.[245]  
 
Scheme 2.3– The proposed mechanism for the condensation and cyclisation reaction between 3-
aminocrotonitrile and 3, 5-dimethylphenyl hydrazine hydrochloride. 
The consecutive Combes-type condensation reaction (Scheme 2.4), between ethyl-
acetopyruvate 2.13 and 1,3 -dimethyl-1H-pyrazole-5-amine 2.12 was achieved 
following a procedure adapted from a reaction developed by Volochnyuk.[246]  
Combes reactions are used extensively in the synthesis of quinolines and typically 
involve a condensation reaction between an un-substituted aniline and a β-diketone, 
followed by an acid catalysed ring closure of the intermediate imine or enamine.[247]  
The procedure itself was straightforward and involved heating the reagents in acetic 
acid to reflux at 118 ˚C for four hours; however the initial attempt at this reaction gave 
the product in low 19% yield.  This was believed to be in part due to the workup 
procedure, in which the solvent was removed in vacuo, the resultant residue triturated 
with water and recrystallized from isopropanol (i-PrOH).[246]  Therefore repeating the 
procedure altering to the work up procedure, removing the trituration and 
recrystallization steps, replacing them with an organic extraction into dichloromethane 
(DCM) and a water wash.  This simple change substantially increased the yield 
achieving 83% of the desired pyrazolepyridine ester (2.14 Scheme 2.2).  Subsequent 
saponification of the ester 2.14 to the carboxylic acid derivative 2.15 was initially low 
with a recovery of around 33% of the desired product.  Once again this was attributed 
to the workup of the reaction, which was modified to organic extraction and led to an 
improved yield of 72%.  It should be noted that despite the improvement in the yield 
this method was not completely effective; the reaction was partially insoluble in 
organic solvent and so formed an emulsion at the organic/ aqueous interface which 
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was believed to lead to a slight loss of product.  However, the high solubility of the 
inorganic side products in the aqueous phase allowed for the isolation of the acid 
without need for further purification using flash column chromatography.  
 
Scheme 2.4- Proposed mechanism for the formation of ester 2.14. 
The final step in the synthesis of Inhibitor 1 was the amide coupling reaction between 
the amine 2.11 and the carboxylic acid 2.15.  The first reaction followed a procedure 
developed by Volochnyuk, using N,N’- diisopropylethylamine (DIPEA) as the organic 
base and 1-methyl-2-chloropyridinium iodide also known as “Mukaiyama Reagent” as 
the carboxylic acid activating agent.[246,248]  The reaction was successful in yielding 
the desired amide Inhibitor 1, with a low yield of 23%.  Proton NMR experiments 
indicated the possible presence of two rotameric forms of the product (Figure 2.14), 
this was observed through the presence of second peak for each hydrogen 
environment, with the integration of one eighth that of the parent peak.  This particular 
reaction was not investigated further, however temperature controlled NMR 
experiments could be used to confirm this. 
 
Figure 2.14- Two proposed rotameric forms of Inhibitor1 2.16 is the most favoured over 2.17. 
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The second methodology investigated, involved using N, N’-dicyclohexylcarbodiimide 
2.18 (DCC), a coupling reagent that belongs to a wider family of coupling agents 
known as the carbodiimides and the additive hydroxybenzotriazole 2.19 (HOBt).  The 
general mechanism involves reaction of the carboxylic acid with the carbodiimide, 
forming the O-acylurea intermediate which can then react with a number of 
nucleophiles such as the amine to form the desired product.[249]  However, problems 
with this mechanism include the formation of unwanted N-acyl urea side products, 
which can significantly reduce the reactivity of these reagents.  Therefore, additives 
such as HOBt or 4-dimethylaminopyridine (DMAP) are used to prevent such side 
reactions from occurring.[249,250]  They work by reacting it with the O-acylurea to 
give, in the case of HOBt, the hydroxybenzotriazole activated ester, which is thought 
to be more reactive towards amines, as it stabilises the approach of the amine through 
a series of hydrogen bonds.  The proposed mechanism of the reaction can be seen 
in Scheme 2.5.[250]  Inhibitor 1 was isolated with a yield of 28% and proton NMR 
indicated the presence of a single isomer assumed to be the more favoured product 
(2.16 Figure 2.14) and this material was used in vitro binding studies (Section 2.3). 
 
Scheme 2.5- The proposed mechanism of a DCC 2.18 and HOBt 2.19 peptide coupling reaction, to form 
2.16. 
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2.2.2 Synthesis of Inhibitor 2 
The second compound selected for synthesis was Inhibitor 2 (Scheme 2.6), the 
original scaffold selected from the screening procedures contained a chlorine group 
on the pyrazole ring (Compound 2.8 Figure 2.9).  However, for the purposes of the 
synthesis it was modified, such that the chlorine group on the pyrazole ring was 
replaced with a second methyl group.  This was selected due to the commercial 
availability of the pyrazole compound.   
 
Scheme 2.6- Synthetic route to Inhibitor 2.  (a) DCM, Ag2CO3, MeI 71%. (b) DMSO, KOH 80 °C 1 hr, 
PhCH2Br 2 hrs 25°C 70%. (c) Oxalyl chloride 63°C reflux 3 hrs. (d) LiAlH4, anhydrous Et2O, 2 hrs, 25 
°C, 2 hrs reflux, d’ NaOH 20%, 2.24, pyridine, 24 hrs 25°C 32%. 
In the synthetic route for Inhibitor 2 (Scheme 2.6), the first step of the synthesis was 
methylation of 2-hydroxy-4,6-dimethylnicotinonitrile 2.20.  The procedure was 
originally carried out by Wijtmans et al. on a similar starting material 3-bromo-4,6-
dimethylpyridone as a part of a larger synthesis of a final compound a substituted 
pyrindol.[251]  The reaction involved stirring the reagents in DCM at 25 °C for twenty 
four hours with protection from light sources to prevent the degradation of the 
sensitive silver carbonate Ag2CO3.  After several attempts use of fresh reagents gave 
a reasonable 71% yield of the methoxypyridone 2.21. 
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Scheme 2.7- Proposed methylation reaction of 2.20 to form 2.21. 
Benzylation of the pyrazole 2.22 was carried out using benzyl chloride in a solution of 
potassium hydroxide KOH and DMSO.  Benzylation reactions of unsymmetrical 
pyrazoles tend to be unselective for the nitrogen which reacts if an inorganic base is 
used, generating a mixture of isomers.[252]  This was not an issue with the symmetry 
involved and pyrazole 2.22 was N-benzylated with a pleasing yield of 70%.  The 
subsequent formation of the acid chloride 2.24, was performed through the reaction 
of compound 2.23 with refluxing oxalyl chloride 2.26.  Chiriac et al. indicated that the 
mechanism of the reaction occurred via the oxalyl intermediate, which could then 
eliminate a CO to form a ketene intermediate.  Finally this is then attacked by chloride 
giving the acid chloride product (Scheme 2.8).[253]  The product formation was 
followed by thin layer chromatography (TLC) and upon completion was not purified 
as it was believed that any remaining intermediate could be removed after the final 
coupling reaction.  Despite this, the crude product was analysed using infrared 
spectroscopy which indicated the presence of the carbonyl stretch at 1735 cm-1 
confirming the acid chloride 2.24 had successfully formed.  
 
Figure 2.16 - Proposed major undesired oxalyl side product 2.27. 
The final step in the synthesis combined two separate components in a one pot 
reaction (Scheme 2.6).  Initial reduction of the cyano group contained within 2.21 to 
the corresponding amine intermediate 2.25 was conducted using a LiAlH4 slurry in 
dry ether, the reaction was stirred for two hours at 25 °C and then heated to reflux for 
a further two hours.  Decomposition of the hydride was then carried out using the 
minimum volume of 20% aqueous NaOH.  Upon completion of the formation of the 
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amine intermediate, the crude acid chloride 2.24 was added dissolved in the minimum 
volume of dry ether, along with pyridine.  The reaction was then left to stir overnight 
at room temperature and after purification gave Inhibitor 2 in a slightly lower than 
expected yield of 30%.  This can be attributed to the formation of a major undesired 
side product (2.27 Figure 2.16) believed to form through reaction with the oxalyl 
intermediate of the acid chloride reaction (Scheme 2.8) and the amine 2.25.  This was 
confirmed by accurate mass spectrometry which indicated the presence of a second 
carbonyl group within the molecule.  The proton NMR did not indicate any change in 
the hydrogen environments; however an additional keto carbonyl peak in the carbon 
NMR spectrum (around 186 ppm) further confirmed the major product of the reaction 
was in fact the oxalyl amide (2.27 Figure 2.16).  This implies that the acid chloride 
should in future be purified to prevent a side reaction occurring between the 
intermediate oxalyl chloride and the amine 2.25.  Inhibitor 2 was tested in vitro, results 
of which can be found in Section 2.3, compound 2.27 however, was not tested using 
biophysical techniques. 
 
Scheme 2.8- Proposed mechanism of acid chloride formation via an oxalyl derivative. 
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2.2.3 Synthesis of Inhibitor 3 
The final compound selected from the computational design process was Inhibitor 3, 
which was predicted as being able to mimic three of the desired six pharmacophoric 
points (Compound 2.5, Table 2.9).  As with Inhibitor 2, due to the commercial 
availability of the precursor compound 2.28, the final target compound was modified 
such that the two meta-chloro groups on the pyridine fragment (Compound 2.5, Figure 
2.9) were removed. 
 
Scheme 2.9- Synthetic route to Inhibitor 3. (a) CS2, CHCl3, 2-hydrozinopyridine, reflux 20 hrs, 76% 
(b) 3,4,5-trimethoxyaneline, chloroacetyl chloride, triethylamine, reflux 15 hrs, 84%. (c) N-N-
diisopropylethylamine, anhydrous DMF, 120 ˚C, 1 hr, 65%. 
Inhibitor 3 was synthesised using a succinct route that involved only three steps 
(Scheme 2.9).  Firstly, 2-hydrazinopyridine 2.28 in chloroform was heated to reflux at 
62 ˚C along with carbon disulfide 2.29 for 20 hours, forming the known 
triazolopyridinethione 2.30.  This compound had been used previously as a fragment 
in an SAR study for hit to lead development of anti-malarial agents.[254]  The reaction 
mechanism is a cyclocondensation (Scheme 2.10) and afforded the product with a 
yield of 76%.  This was followed by N-acylation of 3,4,5-trimethoxy aniline 2.31 with 
chloroacetyl chloride 2.32 to form the corresponding amide 2.33 in 84% yield. 
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Scheme 2.10- Proposed cyclocondensation reaction mechanism between 2-hydrazinopyridine and 
carbon disulphide. 
The final step in the formation of Inhibitor 3 was the coupling reaction between the 
thione 2.30 and the acetamide 2.33, achieved by heating both precursors in 
anhydrous DMF for 1 hour.  The resultant crude product was purified using flash 
column chromatography to afford the final compound in 65% yield.  The Inhibitor was 
then tested in-vitro (Section 2.3). 
2.2.4 Summary of Synthesis 
The synthesis of the first generation inhibitors was successful in efficiently producing 
three diverse unrelated ligands.  These small molecules are designed to mimic the 3-
D pharmacophore and to disrupt the protein-protein interaction between NCS1 and 
D2R peptide.  Inhibitors 1 and 2 were synthesised in a reasonable yield, 28% & 32% 
respectively, in four or five synthetic steps respectively.  Inhibitor 3 was produced in 
an overall 65% yield in a three step procedure.  The ease of the synthesis would 
facilitate synthesis of analogues following in vitro binding.  Inhibitors 1, 2 and 3 were 
taken forward for biophysical analysis to determine their binding interactions with 
NCS1. 
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2.3 Binding assessment using Biophysical Methods 
In the design process for small molecule modulators of PPIs it is important to 
understand how the designed ligand interacts with the protein of interest.  To do this 
there are a number of biophysical techniques which can be employed such as; X-ray 
crystallography; fluorescence polarisation (FP); nuclear magnetic resonance (NMR) 
spectroscopy; isothermal titration calorimetry (ITC) and intrinsic fluorescence 
spectrophotometry.  It is the final three that were used in this research.  Each of these 
techniques were mentioned Section 1.6 of the Chapter 1 and will be described in 
greater detail in this chapter, with specific reference to the experiments used.  A 
detailed discussion of the results from the biophysical characterisation of the first 
generation of compounds will also be given 2.3.2. 
2.3.1 Introduction to protein assignment 
From basic biochemistry we know that proteins are composed of 20 different amino 
acids, although the number and composition of amino acids in each protein differs 
substantially.  The first step in the NMR study of protein structures and interactions is 
the assignment of NMR resonances to specific atoms of individual amino acids within 
the polypeptide chain of a protein.  To do this we employ a number of 2-D HSQC and 
3-D experiments that are able to determine the backbone and sidechains resonance 
assignments for different atoms in each amino acid residue within that protein.  As 
introduced in Chapter 1.6 the chemical shift (δ) for each of these atoms and therefore 
residues will be slightly different to the other as each shift is dependent on the 
chemical environment that surrounds it.  
In essence by employing NMR experiments such as the 2-D 1H 15N HSQC spectra of 
the highly sensitive NH atoms with other 3D experiments, we can obtain a fingerprint 
for our proteins that informs us how the residues are arranged.  The assignment can 
subsequently be used to inform us of the amino acid residues effected by the 
interactions of small molecules with the protein, this is conducted using chemical shift 
mapping (discussed in section 2.3.3 Introduction to ligand binding studies).  To 
understand backbone and sidechain assignment we must be aware of the basic 
nomenclature of the atoms that comprise each amino acid (Figure 2.17 and 2.18).  
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Figure 2.17- Amino acid nomenclature with respect to the sidechain of the amino acid lysine, the main 
chain is attached to the α CH. 
The backbone of a protein is composed of repeating units of amino acids which are 
made up of an NH group followed by a carbon atom Cα, which is attached to the 
carbonyl CO, in the amino acid these form a chain via the peptide bond joining the 
CO of one amino acid to the NH of the adjacent amino acid this continues in this way 
along the protein sequence (Figure 2.18).  The differences between amino acids 
occur at the sidechain which is connected to the backbone through the Cα, an 
example of a sidechain and its nomenclature for the amino acid lysine can be seen 
(Figure 2.17).  For the purposes of assignment the amino acid sequence is described 
using the terms i residue and i-1, meaning the current residue and the one which 
precedes it.  The backbone assignment utilise pairs of 3-D experiments whose 
magnetisation pathways are described in reviews ([255–261]). 
The methodology for backbone resonance assignment is sequential and occurs via 
the connections between HSQC-based experiments to link NH atoms of adjacent 
amino acids together through Cα correlations (in the case of CbCa(CO)NH and 
HNCaCb experiments Figure 2.18).  This can also be conducted through the CO 
correlations (HNCO and the HN(Ca)CO experiments Figure 2.19) finally, the CO of 
each amino acid can be correlated with the Hα and hence Hβ (HNCa and HN(CO)Ca 
experiments, Figure 2.20).[259,261]   
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Figure 2.18- The sequential backbone assignment method used for the assignment of NCS1 using two 
3-D experiments, the CbCa(CO)NH and HNCaCb.  The HNCaCb experiment is used to ‘connect’ the 
NH resonance with its own 13Cα and 13Cβ (seen in the solid blue lines) and to the 13Ca and 13Cb of the 
preceding residue (dotted blue lines).  The HNCaCb can then be correlated to the respective peak found 
in the CbCa(CO)NH (red pathway 1) which links a NH group of a residue to the 13Cα and 13Cβ of the 
residue that precedes it (both seen within the green boxes). This linking process allows for the 
identification of the (i -1) residue in front of the (i) residue in question.  In essence walking us along the 
protein backbone and linking each residue in the repeated consecutive pathway (seen in red steps 2 
and 3 etc.). 
In each case, the NH correlates to the preceding residues carbon and only in the 
HNCaCb, HN(Ca)CO, HNCa and HN(CO)Ca does the NH also correlate to the intra-
residual carbon, thus allowing for differentiation of intra and inter-residual correlation 
in order to assign each amino acid in the sequence. 
 
Figure 2.19- The transfer of magnetisation for the experiment HNCO (blue), the magnetisation originates 
on the 1H and is passed to the attached 15N (pathway 1), the 15NH 13CO selectively transfers the 
magnetisation to the CO (pathway 2) of the residue and is subsequently transferred back for detection.  
The HN(Ca)CO (red) where the magnetisation is transferred from 1H to the 15N (pathway 1) and then 
13Cα (pathway 2) finally it is transferred to the 13CO (pathway 3).  The process is then reversed as the 
magnetisation is transferred back to the 1H for detection. 
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Using these three different pairs of experiments allow us to follow the chain of amino 
acids along the backbone of the protein and provide us with full NMR backbone 
assignment.  It should be noted that prolines are unobservable, hence they often 
appear as a natural break along the chain.  
 
Figure 2.20- The transfer of magnetisation that occurs in the HNCa the magnetisation is transferred 
from 1H to the 15N (pathway 1) and then 13Cα (pathway 2) and subsequently transferred back for 
detection.  As with the coupling of 15NH group in the NH(Ca)CO experiment, the 15NH group is also 
coupled to the 13Cα of its own residue i and that of the preceding i-1.  In the HN(CO)Ca experiment the 
magnetisation is transferred from the 1H to the 15N (pathway 1) to the 13CO (pathway 2) and then onto 
the 13Cα (pathway 3), where it is then transferred back along the same path with no evolution of signal 
relating to the 13CO. 
To use the NMR data for investigative studies of ligand interactions it is important to 
note that complete backbone assignment should be accompanied by assignment of 
the side-chain residues.  To assign the side-chain of each residue, 3-D HC(C)H- total 
correlation spectroscopy (TOCSY) NMR experiments are used in conjunction with the 
previously collected backbone data.   
In a 3-D HC(C)H - TOCSY experiment, magnetisation is transferred from the 
sidechain hydrogen nuclei onto the attached 13C nuclei, where there is an isotropic 
13C mixing stage and the magnetisation is then transferred back to the sidechain 
hydrogens, hence the HC(C)H.  This experiment provides the carbon and hydrogen 
chemical shifts of the side-chains for most of the residues including Hγ, δ and Cγ, δ, 
ε (when the atoms are connected through the Cβ of a straight chain and excludes 
quaternary carbon connections).  Using the previously acquired Hα, β chemical shifts 
of each residue, it is possible to link the corresponding Hγ, δ, ε for that particular 
residue through TOCSY and hence assign the corresponding Cγ, δ, ε chemical shifts.  
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2.3.2 Backbone and sidechain assignment of NCS1 
General experimental procedures 
For NMR investigation all NMR spectra were acquired at 298K unless otherwise 
stated, on either a Bruker AVANCE II+ 600 MHz or 800 MHz spectrometers, each 
equipped with a 5 mm TCI triple-resonance cryoprobe.  The NMR samples were 
prepared to a volume of 550 µL including 10% (v/v) [2H2]O, the NMR buffer used was 
composed of 50 mM tris HCl, 50 mM NaCl, 5 mM CaCl2, pH 6.4.   
 
15N labelled and 13C 15N labelled NCS1 were prepared as will be described in detail 
in Chapter 6.  Briefly recombinant NCS1 was obtained from an expression construct 
containing the Rattus Norvegicus NCS1 gene, [262] inserted into a pETM-11 vector 
and subsequently transformed into BL21 DE3 E-coli competent cells (Novagen).[263]  
The N-terminally His6-tagged protein was purified using nickel affinity 
chromatography and size exclusion chromatography and the purified protein solution 
was buffer exchanged into NMR buffer using a Sephadex G-25 Medium Gravity-Flow 
PD-10 (GE Healthcare) column that had been pre equilibrated with the NMR buffer.   
 
Data collected was processed using Topspin 3.1 (Bruker) and the Azara processing 
package which is contained within the CCPN analysis software. The latter software 
was also used for resonance assignments.  Further experimental details can be found 
in Chapter 6 Section 6.3.2. 
 
2.3.2.1 Results and Discussion  
For the purposes of assigning the protein backbone and sidechain residues, triple 
resonance assignment was conducted using 2-D 1H 13C and 1H 15N HSQC spectra, 
which were used alongside specific pairs of experiments designed for backbone and 
sidechain assignment.[264]  These experiments included CbCa(CO)NH and 
HNCaCb, HNCa and HN(CO)Ca, HNCO and HN(Ca)CO (see 2.3.1 for a full 
explanation of the experiments).  Assignment of the sidechain residues was 
conducted using 2-D 1H 13C HSQC and HC(C)H TOCSY experiments (Figures 2.24, 
2.25, 2.26 and Appendix Tables A.2.1 and Table A.2.2) in the desired NMR buffer.   
A total of 91% of backbone atoms and 42.7% of the sidechain resonances were 
assigned. The final assigned 2-D 1H 15N HSQC backbone spectra can be seen (Figure 
2.22 and 2.23), alongside the assigned 2-D 1H 13C aliphatic and aromatic methyl 
sidechain spectra (Figure 2.24 and 2.26).   
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The secondary structure of NCS1 predicted from the backbone assignment and 
chemical shift index (CSI) [265] was then compared to that of the known structure 
PDB (protein data bank) code 5AER and can be seen (Figure 2.21), indicating the 
correct folded form of unbound NCS1.[266]  It can be seen that there are 10 α helices 
which form the four EF hands predicted using CCPN analysis and subsequently 
determined through crystallographic data, each pair of EF hands are connected by a 
hinge loop.[13,267] 
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2.3.3 Introduction to ligand binding studies  
With complete resonance assignment of a protein it is then possible to study the 
interactions with another protein, peptide or ligand.  Using NMR spectroscopy to do 
this provides us with information on any structural changes and indicates the residues 
and hence, the location involved in any interaction between the two partners.  It can 
also be used to determine binding affinity data; however, this can be complicated by 
chemical exchange at stoichiometric values of ligand which can cause peak 
broadening, preventing an accurate peak assignment and thus prevent accurate 
extrapolation of KD.  Therefore other methods outlined in subsequent sections 2.3.5 
and 2.3.6 were favoured.   
There are a number of ways to determine the residues implicated in an interaction 
with a binding partner or peptide of a particular protein.  One of the simplest 
experiments to do would be a 2-D 1H 15N HSQC experiment.  An initial spectrum of 
the protein alone would be used as a control spectrum followed by a secondary 
spectra of the protein and the ligand or binding partner.  To determine the residues 
involved in any interaction the two spectra can be overlaid, the peaks that shift due to 
a possible interaction can be tracked and the changes in chemical shift (peak 
perturbations) calculated using equation 2.1.[268]  Where ∆H and ∆N are, 
respectively, the proton and nitrogen chemical shift changes, and 0.15 is the scaling 
factor derived from the gyromagnetic ratios of the nitrogen and hydrogen nuclei.[269] 
∆δ= [ (∆H)2 + (0.15 ∆N)2 ]1/2 2.1 
One may also observe attenuation (disappearance) of the peak relating to an amino 
acid residue; this can be indicative of the protein being in an intermediate exchange 
state, or could correspond to aggregation of the protein.  Although the results from 
these experiments enable the determination of an interaction if any, between a protein 
and a ligand or binding partner, a more precise approach uses NOE-based 
experiments.  As NOE is a through space measurement and experimentally allows 
the identification of hydrogens that are within around 5Å of each other, whether that 
be within the protein, within the ligand itself or between a protein and a ligand.  A 13C 
15N filtered NOE experiment is used to selectively observe the interactions between 
isotopically 13C 15N labelled proteins and unlabelled ligands or small molecules that 
may be undergoing a binding interaction.   
The use of NMR spectroscopy for biophysical assessment of the binding interactions 
between a protein and ligand, means we are able to elucidate interaction hotspots 
between the protein and on the ligand itself.  It is an extremely useful method to further 
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our knowledge and understandings on the structure of proteins, enabling the design 
of small molecules to target them.  It can be used successfully on its own, or as in 
this project it can be used alongside a number of other biophysical techniques to 
further the structural understanding of the molecules that are important in almost all 
biological processes.  
2.3.4 First Generation Characterisation: Ligand Screening by 
NMR Spectroscopy 
General experimental procedures  
Full details of the analysis techniques and experimental procedures, including the 
conditions used to acquire the screening data of the small molecules with NCS1 by 
NMR spectroscopy, can be found in Chapter 6.3.2.7.  However briefly, for NMR 
investigation all NMR spectra were collected at 298K, on either a Bruker AVANCE II+ 
600 MHz or 800 MHz spectrometer, equipped with 5 mm TCI triple-resonance 
cryoprobes.  
All protein samples were prepared in the NMR buffer (50 mM tris HCl, 50 mM NaCl, 
5 mM CaCl2, pH 6.4) and protein samples were from the same 0.5 mM (m/v) NCS1 
stock solution, the NMR data collected for investigation included 2-D 1H 15N HSQC 
and 2-D 1H 13C HSQC TOCSY spectra.  The 2-D 1H 15N HSQC binding screens were 
carried out at a protein: inhibitor ratio of 1:10 whereby the protein concentration was 
50 μM and the inhibitors 500 μM respectively.  Inhibitor 1 interactions with NCS1 were 
also investigated at a 1:1 ratio as at the P:L ratio of 1:10 caused severe attenuation 
of the majority of the amino acid residues and so the data was unsuitable for analysis.   
The chemical shift perturbations caused upon an interaction of the small molecules 
with NCS1 are referenced against the interactions of NCS1 with the same 
concentration (v/v) of DMSO, which is controlled to be at the same percentage as in 
the presence of inhibitor and never exceeded 5% (v/v).   
Binding data was extrapolated from a 2-D 1H 15N HSQC spectra of 50 μM 1H 15N 
NCS1 and the chemical shift changes calculated using equation 2.1 (Section 
2.3.3).[268]  This is known as the “chemical shift perturbation”.  The total number of 
residues perturbed was calculated and from this value the top 10% and 20% ranges 
were determined.  The residues whose chemical shift perturbation sum fell within 
these two ranges were defined as being within the top 10 and top 20 percentile 
respectively.  Therefore the amino acids in the top 10 and 20 percentile ranges for 
each individual inhibitor was determined   
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The changes in chemical shift were then plotted against the protein sequence as a 
histogram; missing peaks were either attenuated, or un-assigned.  This could be due 
to the shifts being overlaped with other peaks, or where two residues occurred on one 
peak initially in the original protein assignment.  This would, therefore, prevent an 
accurate transfer of assignment to the spectra of NCS1 in the presence of the ligand.  
The residues of the top 10 percentile and top 20 percentile were then mapped onto 
the crystal structure of NCS1.  For the purposes of the discussion of the changes in 
the aliphatic and aromatic methyl spectra, the methyl groups of the amino acid 
residues are labeled in single letter nomenclature a=alpha, b=beta. 
2.3.4.1 Results and Discussion  
The first generation of inhibitors included three compounds designed and synthesised 
through the computational process and synthetic routes that can be found in sections 
2.1 and 2.2 respectively (Figure 2.27).  As previously mentioned these inhibitors were 
selected for synthesis and tested against the NCS1 D2R peptide interaction after a 
rigorous computational pharmacophore screen, followed by systematic computational 
analysis as described in 2.1.  The results of the computational docking predicted 
binding of the inhibitors within the targeted hydrophobic pocket of NCS1 around the 
key residues and the predicted poses can be found in 2.1.6.   
 
Figure 2.27- Chemical structures of the three inhibitors labelled accordingly, synthesised as described 
in Section 2.2. 
The initial NMR binding screen of the three inhibitors indicated a change in protein 
chemical shifts when each inhibitor was introduced to NCS1, albeit to differing 
degrees.  Inhibitor 1 at the initial ten-fold ligand protein concentration of 500 μM, 
caused severe peak broadening and also changes in chemical shift of a number of 
the amino acid residues (Figure 2.28).  Such severe line broadening is indicative of 
either the protein being in an intermediate exchange regime or aggregation.  At this 
concentration residues were either attenuated or they were ambiguously assigned 
due to being overlaped with other peaks, therfore preventing an accurate transfer of 
assignment.  Thus the data was not further analysed and so the protein ligand (P:L) 
ratio was decreased.   
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When the P:L ratio was decreased to 1: 1, (50 μM) the effect of the inhibitor appeared 
less severe (Figure 2.29).  Peaks belonging to residues of NCS1 such as Ile80, 
Trp103 and Ile161 were likewise attenuated.  
At the 1:1 P:L ratio, there were fewer peak shifts and peak attenuations of NCS1 
resonances in comparison to the effects of a higher concentration of ligand.  The 
changes in 1H and 15N chemical shift is a useful indicator of the degree of influence 
the small molecule has at that particular position on the protein backbone (Section 
2.3.3).  At 50 μM of Inhibitor 1 the residues within the top 10 percentile (Figure 2.30) 
experience only very small shift changes (between 0.04 - 0.025); these residues 
include: Tyr52, Asn70, Tyr129, Gly41, Val180, Phe55, Arg102, Phe34, Lys53, 
Asn134 and Glu171, with a high propensity to the α2 and α3 regions located within 
EF-1.  The residues of the top 20 percentile included:  Thr92, Gln49, Asp44, Gly172, 
Leu189, Ser83, Gly59, Glu141, Asp73, Asn143, Glu142, there appears to be no 
specificity as those residues affected are found across the four EF hands.   
At 50 μM Inhibitor 1, the number of residues who were attenuated was significatly 
reduced.  Those residues who experienced a change in chemical shift was not only 
greater, their position was infact on the correct face of the protein and closer to the 
targeted hydrophobic pocket (Figure 2.31).   
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Figure 2.28- Ligand binding screen NCS1 and Inhibitor 1.  An overlay of two 2-D 1H 15N HSQC 
spectra, the control spectra 1H 15N NCS1 NCS1 at a concentration of 50 μM in the presence of 1% DMSO 
(black).  The spectra of 1H 15N NCS1 50 μM with Inhibitor 1, 500 μM in the presence of 1% DMSO (P:L 
1:10) (red), show severe peak attenuation.  The residues highlighted within the box were selected to 
indicate changes in specific residues.  1H 15N NCS1 50 μM prepared in NMR buffer 50 mM tris HCl, 50 
mM NaCl 5 mM CaCl2 pH 6.4, acquired on Bruker AVANCE II+ 600 MHz spectrometer at 298K.  
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Figure 2.29- Ligand binding screen NCS1 and Inhibitor 1.  An overlay of two 2-D 1H 15N HSQC 
spectra, the control spectra 1H 15N NCS1 at a concentration of 50 μM in the presence of 0.1% DMSO 
(black).  The spectra of 1H 15N NCS1 50 μM with Inhibitor 1 50 μM in the presence of 0.1% DMSO (P:L 
1:1) (red), showing less severe peak attenuation and some changes in the chemical shift of a number of 
residues.  The residues highlighted within the box were selected to indicate changes in specific residues.  
1H 15N NCS1 50 μM prepared in NMR buffer 50 mM tris HCl, 50 mM NaCl 5 mM CaCl2 pH 6.4, acquired 
on Bruker AVANCE II+ 600 MHz spectrometer at 298K. 
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Figure 2.30– Inhibitor 1 Peak perturbation Histogram.  A Histogram of the perturbations of NCS1 
residues from ligand binding screen NCS1: Inhibitor 1, 50 μM.  Those residues whos chemical shift 
underwent a change in ppm in the top 10% or over can be seen above the red line and those residues 
include: Tyr52, Asn70, Tyr129, Gly41, Val180, Phe55, Arg102, Phe34, Lys53, Asn134 and Glu171.  The 
yellow line represents those residues who’s change in chemical shift was within the top 20% of changes 
and includes:  Thr92, Gln49, Asp44, Gly172, Leu189, Ser83, Gly59, Glu141, Asp73, Asn143 and 
Glu142.  Unassigned residues Single peaks assigned with two residues Proline. 
 
Figure 2.31– (a) Crystal structure of NCS1 in cyan with the corresponding residues perturbed by 
interactions with Inhibitor 1 at 50 μM determined from the corresponding histogram top 10% coloured in 
red and top 20% in yellow (PDB 5AER). (b) Chemical structure of Inhibitor 1. (c) Prediction of the binding 
pose for the interaction between Inhibitor 1 and NCS1 (Section 2.1.6) those key hotspot residues 
highlighted in orange. 
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As well as the change in chemical shift of the backbone residues brought about 
through the effects of Inhibitor 1, it is also useful to evaluate any changes in the 
sidechains.  A complete analysis of the changes in sidechain is hampered by the fact 
that only 42.7% of the sidechains is assigned.  Therefore, a more superficial analysis 
was conducted to determine which resonances are affected by the presence of the 
ligand.  In the case of the sidechains containing methyl groups, this may appear as 
complete attenuation of the relative peaks, or partial attenuation in those cases where 
the residue contains two methyl groups such as leucine but only one is attenuated.   
With the sidechain investigations of Inhibitor 1 the difference observed at a protein to 
ligand ratio of 1:10 was not as severe as that of the sensetive amide backbone 
experiments.  Therefore for equivalent comparison between all first generation 
inhibitors, the difference between the control 1H 13C HSQC spectra of 50 μM 1H 15N 
13C NCS1, 1% DMSO with the 1H 13C HSQC spectra of 50 μM 1H 15N 13C NCS1 and 
Inhibitor 1 500 μM (1:10 P:L ratio Figure 2.32) was used to investigate the 
interactions.  The investigations indicate an effect which is found to span across all 
four EF hand domains of NCS1, further details on the secondary structure of NCS1 
can be found in the introduction (Section 1.1, Figure 1.5).   
Of the twenty two methyl-containing sidechain residues affected, ten were completely 
attenuated which indicates the possibility that methyl sidechains that were once 
exposed, have become buried in the presence of Inhibitor 1.  These residues include; 
Leu43, Ile51, Val68, Thr92, Leu101, Ala104, Ile124, Leu138, Ile152 and Ala182, they 
are located across the four EF hands and are present in α helix, β sheet and loop 
regions.  Those 12 residues that underwent a partial attention of a single methyl group 
include Leua16, Vala27, Valb91, Leub97, Leub107, Leub110, Leub125, Ilea128, Vala132, 
Leub164, Ilea179 and Vala180, with a high propensity towards the EF-3 region, 
however some are also found on EF-1, EF-2 and EF-4.   
Sidechain assignment is not limited to those methyl-containing residues, aromatic 
residues such as phenylalanie, tyrosine and tryptophans were also assigned, the 
effects of Inhibitor 1 on these residues in comparison to the DMSO containing spectra 
is severe (Figure 2.33).  Here we observe the attenuation of a number of residues 
including Phe22, Tyr52, Phe67, Phe85, Tyr108, Tyr129, Phe153 and Phe169, located 
on EF-1, EF-2, EF-3 and EF-4.   
This methyl and aromatic sidechain data is in concordance with the 2-D 1H 15N HSQC 
data collected at the same protein to ligand ratio, indicating the widespread affect of 
Inhibitor 1 on the residues of NCS1 at a high concentration. 
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Figure 2.33- Two overlaid aromatic sidechain spectra of NCS1 with and without Inhibitor 1.  The 
aromatic 1H 13C spectra of 1H 15N 13C NCS1 50 μM and 1% DMSO purple overlaid with the 1H 13C spectra 
of1H 15N 13C NCS1 50 μM and Inhibitor 1 500 μM with 1% DMSO, the residues labelled are those for 
which the assignment was transferrable.  Those residues for which transfer of assignment was not 
possible include those which reside on the same peak for example or those which were attenuated by 
the presence of Inhibitor 1 including; Tyr52, Phe22, Phe67, Phe85, Tyr108, Tyr129, Phe153 and 
Phe169.  The spectra were acquired at 298K in NMR buffer pH 6.4 on Bruker AVANCE II 600 MHz 
spectrometer. 
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As with Inhibitor 1, the first NMR spectroscopy experiment with Inhibitor 2 was carried 
out at a P:L ratio of 1:10, with the results being different to that of Inhibitor 1.  The 
amino acid residues of the protein did not appear to be as strongly effected, in that 
the number of residues attenuated was reduced.  However, those residues that were 
affected underwent a substantial change in chemical shift.  Such residues include 
Ile80 and Trp103 (Figure 2.34).  These changes in chemical shift could suggest a 
binding interaction occurring between Inhibitor 2 and NCS1 which was further 
substantiated by intrinsic tryptophan fluorescence (2.3.8).   
The chemical shift changes for the effect of 500 μM Inhibitor 2 with NCS1 was 
calculated as a combined Δ H and Δ N shift.  The results of which can be found 
(Figure 2.35), the residues of the top 10 percentile experienced a change in chemical 
shift between 0.07 - 0.18.  Those residues which undergo changes within this range 
include: Gly172, Asp44, Lys36, Gln140, Leu166, Gly33, Thr96, located on the EF 
hands EF-1 and EF-4.  Those residues within the top 20 percentile include : Ala65, 
Thr165, Asp109, Val71, Tyr31, Ile80, Thr23 which are also located EF-2 and EF-3, 
more specifically α4, α5 and α6.   
From this data it is apparent that there is a noteable increase in the chemical shift 
change, between the NCS1 reference spectrum and the effect of 500 μM Inhibitor 2.  
When those peaks affected by Inhibitor 2, were mapped onto the crystal structure of 
NCS1 those residues that were identified as in the top 10 percentile were found to be 
on the same face as the hydrophobic groove.  Albeit not all were in the desired residue 
range, as they were located primarily on EF-1, EF-2 and EF-3.  The results from the 
residues of the top 20 percentile were less specific as many were on the opposite 
face of the protein. 
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Figure 2.34- Ligand binding screen with Inhibitor 2.  An overlay of two 2-D 1H 15N HSQC spectra, the 
control spectra 1H 15N NCS1 at a concentration of 50 μM in the presence of 1% DMSO (black).  The 
spectra of 1H 15N NCS1 50 μM with Inhibitor 2, 500 μM in the presence of 1.0% DMSO (P:L 1:10) (red) 
showing attenuation of some peaks and changes in chemical shift indicative of an interaction between 
the inhibitor and the protein.  The residues highlighted within the box were selected to indicate changes 
in specific residues within a conserved region of the HSQC spectra.  1H 15N NCS1 50 μM prepared in 
NMR buffer pH 6.4, acquired on Bruker AVANCE II+ 600 MHz spectrometer at 298K. 
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Figure 2.35- Inhibitor 2 Peak Perturbation Histogram.  A histogram of the perturbations in NCS1 
residues from ligand binding screen NCS1: Inhibitor 2 500 μM.  Those residues whos chemical shift 
underwent a change in ppm in the top 10% or over can be seen above the red line and those residues 
include: Gly172, Asp44, Lys36, Gln140, Leu166, Gly33, Thr96.  The yellow line represents those 
residues who’s change in chemical shift was within the top 20% of changes and includes: Ala65, Thr165, 
Asp109, Val71, Tyr31, Ile80, Thr23.  Unassigned residues Single peaks assigned with two residues 
Proline. 
 
Figure 2.36- (a) Crystal structure of NCS1 in cyan with the corresponding residues perturbed by 
interactions with Inhibitor 2 at 1 mM determined from the corresponding histogram top 10% coloured in 
red and top 20% in yellow (PDB 5AER).  (b) Chemical structure of Inhibitor 2  (c) Prediction of the binding 
pose for the interaction between Inhibitor 2 and NCS1 (Section 2.1.6) those key hotspot residues 
highlighted in orange. 
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As with Inhibitor 1, the possible binding interactions of Inhibitor 2 were not only 
investigated through determination of changes in chemical shift of the backbone 
residues.  The interactions of the methyl and aromatic sidechains of the residues were 
also evaluated.  This was carried out as before with Inhibitor 1 through the observation 
of changes in residues between the control spectra and the ligand containing sample 
(Figure 2.37). 
In the case of Inhibitor 2, of the 18 methyl-containing sidechains for which assignment 
transfer was possible, ten of the residues were completely affected in that all methyl 
groups were attenuated and they include; Leu43, Ile51, Val68, Thr92, Ala104, Ala104, 
Val125, Ile179, Ala182 and Val190.  These residues are located on α helices within 
EF-1, EF-2 and EF-3 with the final three residues being clustered in the terminal loop 
region.   
The eight residues that were only partially attenuated include: Leua16, Vala27, 
Leub125, Ileb12, Ilea128, leIa152, Leua164 and Valb180, located on EF-1, EF-3 and 
EF-4, unlike the fully attenuated residues there are no partial attenuations on EF-2.   
Evaluation of the effect that Inhibitor 2 has on the aromatic sidechain residues, 
indicate that Inhibitor 2 has a greater effect on the tyrosine (Tyr) ε residues that are 
located around 118 ppm (Figure 2.38).  In comparison to the DMSO control (Figure 
2.26 b), two of these such residues Tyr ε 52 and Tyr ε 108 are attenuated in the 
presence of Inhibitor 2.  The remaining aromatic sidechain residues affected by 
Inhibitor 2 include Phe22, Phe67, Phe85, Phe153 and Phe169, with a high propensity 
towards α helical locations across the four EF hands. 
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Figure 2.38- Two overlaid aromatic sidechain spectra of NCS1 with and without Inhibitor 2.  The 
aromatic 1H 13C spectra of 1H 15N 13C NCS1 50 μM and 1% DMSO purple overlaid with the 1H 13C spectra 
of 1H 15N 13C NCS1 50 μM and Inhibitor 2 500 μM with 1% DMSO (green), the residues labelled are 
those for which the assignment was transferrable.  Those residues for which transfer of assignment was 
not possible include those which reside on the same resonance or those which were attenuated by the 
presence of Inhibitor 2 including; Phe22, Tyr52, Phe67, Phe85, Tyr108, Phe153 and Phe169.  The 
spectra were acquired at 298K in NMR buffer pH 6.4 on Bruker AVANCE II 600 MHz spectrometer. 
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Inhibitor 3 was also subjected to the same spectroscopic experiments as inhibitors1 
and 2.  At the same initial protein: ligand ratio of 1: 10 the inhibitor appears to not 
have the same effect on the protein as the first two inhibitors.  This can be seen in in 
the 2-D 1H 15N HSQC overlay (Figure 2.39).   
 
Although Trp103 appears to undergo a change in chemical shift and Ile80 appears 
slightly attenuated, Ile161, Phe82 and Leu164 were unaffected.  This data is in 
concordance with that of the chemical shift perturbations (Figure 2.40), in that the 
residues of the top 10 percentile, undego changes in chemical shift over a smaller 
range than both that of Inhibitors1 and 2.  Residues within this range include: Leu183, 
Val180, Asp44, Gln181, Lys174, Tyr108, Arg102, Glu171, Lys53, Gly41, Lys106, 
Lys100, located in three clusters within the protein.  The largest cluster of residues 
peturbed are found on the α helices within EF-4 however, the remaining two clusters 
of residues peturbed can also be found along α2, α5 and α6.   
 
Those residues within the top 20 percentile include: Phe34, Glu141, Ala65, Tyr129, 
Asn70, Leu107, Cys38, Gln172, Gly33, Phe48, Ile152, Ser173.  The subsequent 
mapping of these residues onto the crystal structure appear to indicate the location 
to be mainly around the same face as the hydrophobic pocket, with a high propensity 
to the helices contained within EF-1.  
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Figure 2.39- Ligand binding screen with Inhibitor 3.  An overlay of two 2-D 1H 15N HSQC spectra, the 
control spectra 1H 15N NCS1 at a concentration of 50 μM in the presence of 1.0% DMSO (black).  The 
spectra of 1H 15N NCS1 50 μM with Inhibitor 2 500 μM in the presence of 1.0% DMSO (P:L 1:10) (red) 
showing attenuation of some peaks and changes in chemical shift indicative of an interaction between 
the inhibitor and the protein, however the quantity of shifts perturbed could possibly indicate non-specific 
binding.  The residues highlighted within the box were selected to indicate changes in specific residues 
within a conserved region of the HSQC spectra. 1H 15N NCS1 50 μM prepared in NMR buffer pH 6.4, 
acquired on Bruker AVANCE II+ 600 MHz spectrometer at 298K. 
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Figure 2.40– Histogram of the Perturbations in NCS1 residues from ligand binding screen NCS1: 
Inhibitor 3 500 μM.  Those residues whos chemical shift underwent a change in ppm in the top 10% or 
over can be seen above the red line and those residues include: Leu183, Val180, Asp44, Gln181, 
Lys174, Tyr108, Arg102, Glu171, Lys53, Gly41, Lys106, Lys100.  The yellow line represents those 
residues who’s change in chemical shift was within the top 20% of changes and includes: Phe34, Glu141, 
Ala65, Tyr129, Asn70, Leu107, Cys38, Gln172, Gly33, Phe48, Ile152, Ser173.  Unassigned residues 
Single peaks assigned with two residues Proline. 
 
Figure 2.41- (a) Crystal structure of NCS1 in cyan with the corresponding residues perturbed by 
interactions with Inhibitor 3 at 1 mM determined from the corresponding histogram top 10% coloured in 
red and top 20% in yellow (PDB 5AER). (b) Chemical structure of Inhibitor 3. (c) Prediction of the binding 
pose for the interaction between Inhibitor 2 and NCS1 (Section 2.1.6) those key residues indicated by 
Ames et al.highlighted in orange. 
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Again as with the previous two inhibitors, the possible binding interactions of Inhibitor 
3 with the backbone residues of NCS1 were investigated alongside the interactions 
of the methyl and aromatic sidechains of the residues.  To do this the difference 
between the control 1H 13C HSQC TOCSY spectra of 50 μM 1H 15N 13C NCS1 and 1% 
DMSO with the 1H 13C HSQC TOCSY spectra of 50 μM 1H 15N 13C NCS1 and Inhibitor 
3 500 μM (Figure 2.42), at a 1:10 P:L ratio were evaluated. 
In comparison to the results of Inhibitor 2 at the same concentration, the effects of 
Inhibitor 3 on the sidechain methyl groups are substantially reduced.  None of the 
methyl-containing residues are fully attenuated and only six residues undergo partial 
attenuation induced through the effects of the inhibitor.  The partial attenuations occur 
over the four EF hands, they include the residues Leua16, Ileb51, Vala71, Ileb128, 
Ilea152 and Valb190, present on α helices and the terminal loop.  
The Tyr ε residues are un-attenuated in the spectra of Inhibitor 3 (Figure 2.43) and 
the aromatic sidechain residues that underwent an interaction with Inhibitor 2 were 
also affected by Inhibitor 3 and they include; Phe22, Phe67, Phe85, Phe153 and 
Phe169. 
The effects of Inhibitor 2 and Inhibitor 3 on the methyl and aromatic sidechain 
residues of NCS1 are in concordance with the collected 2-D 1H 15N HSQC spectra, 
from which the chemical shift perturbation sum of the backbone residues was 
calculated.  In both cases we observe a more subtle change in the NCS1 backbone 
and sidechain residues in the presence of Inhibitor 3, with a greater effect being 
incurred in the presence of Inhibitor 2.  The results of the initial NMR spectrosopy 
binding screens for all three Inhibitors, present promising data that indicates all three 
inhibitors are interacting with the protein, allbeit at different degrees.   
 
The somewhat non specific binding, away from the intended targeted residues could 
merely be concentration dependent , in that too high a ligand concentration induces 
non specific binding.  In the case of Inhibitor 1, too high a concentration was found to 
possibly have a deleterious affect on the protein, observed through the severe peak 
broadening and attenuation of a large number of residues across the protein.  
However these effects could also indicate that a lower concentration of Inhibitor 2 and 
Inhibitor 3 are unable to saturate NCS1, this could be indicative of a weak interaction 
between the ligand and the protein.  Therefore to investigate this further and 
determine the binding affinity, the three inhibitors were subsequently investigated 
using Isothermal Titration Calorimetry (ITC) 2.3.5. 
Structure-based drug design: The First Generation; Binding assessment using biophysical methods 
122 
 
 
F
ig
u
re
 2
.4
2
- 
A
n
 o
v
e
rl
a
y
 o
f 
tw
o
 m
e
th
y
l 
s
id
e
c
h
a
in
 r
e
g
io
n
s
 o
f 
N
C
S
1
 w
it
h
 a
n
d
 w
it
h
o
u
t 
In
h
ib
it
o
r 
3
. 
 T
h
e
 1
H
 1
3
C
 H
S
Q
C
 s
p
e
c
tr
a
 o
f 
1
H
 1
5
N
 1
3
C
 N
C
S
1
 5
0
 μ
M
 a
n
d
 1
.0
%
 D
M
S
O
 
(p
u
rp
le
) 
o
v
e
rl
a
id
 w
it
h
 t
h
e
 1
H
 1
3
C
 T
O
C
S
Y
 s
p
e
c
tr
a
 o
f 
1
H
 1
5
N
 1
3
C
 N
C
S
1
 5
0
 μ
M
 a
n
d
 I
n
h
ib
it
o
r 
3
 5
0
0
 μ
M
 w
it
h
 1
%
 (
o
ra
n
g
e
).
  
T
h
o
s
e
 r
e
s
id
u
e
s
 o
f 
N
C
S
1
 r
e
la
te
d
 t
o
 t
h
e
 I
n
h
ib
it
o
r 
3
 
s
p
e
c
tr
a
 f
o
r 
w
h
ic
h
 t
h
e
 t
ra
n
s
fe
r 
o
f 
a
s
s
ig
n
m
e
n
t 
w
a
s
 p
o
s
s
ib
le
 c
a
n
 b
e
 s
e
e
n
, 
th
e
re
 a
 n
u
m
b
e
r 
o
f 
n
o
ta
b
le
 c
h
a
n
g
e
s
 i
n
 c
h
e
m
ic
a
l s
h
if
t 
in
c
lu
d
in
g
 I
le
8
0
, 
L
e
u
8
9
 a
n
d
 I
le
1
2
4
. 
 B
o
th
 s
p
e
c
tr
a
 
w
e
re
 a
c
q
u
ir
e
d
 a
t 
2
9
8
K
 i
n
 N
M
R
 b
u
ff
e
r 
p
H
 6
.4
 o
n
 B
ru
k
e
r 
A
V
A
N
C
E
 I
I 
6
0
0
 M
H
z
 s
p
e
c
tr
o
m
e
te
r.
 
 
Structure-based drug design: The First Generation; Binding assessment using biophysical methods 
123 
 
 
Figure 2.43- Two overlaid Aromatic sidechain spectra of NCS1 with and without Inhibitor 3.  The 
aromatic 1H 13C spectra of 1H 15N 13C NCS1 50 μM and 1.0% DMSO purple overlaid with the 1H 13C 
spectra of 1H 15N 13C NCS1 50 μM and Inhibitor 3 500 μM with 1% DMSO (orange), the residues labelled 
are those for which the assignment was transferrable.  Those residues for which transfer of assignment 
was not possible include those which reside on the same peak or those which were attenuated by the 
presence of Inhibitor 3 including; Phe22, Phe67, Phe85, Tyr129, Phe153 and Phe169F.  The spectra 
were acquired at 298K in NMR buffer pH 6.4 on Bruker AVANCE II 600 MHz spectrometer. 
.
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2.3.5 Introduction to Isothermal Titration Calorimetry (ITC) 
As introduced previously Chapter 1.6.2, isothermal calorimetry is the measure of a 
change in heat of a physical process, with the sample of interest and reference 
sample kept at the same constant temperature during the experiment, hence its term 
isothermal.[210]  ITC is able to provide a detailed thermodynamic characterisation of 
the interaction between a target receptor/ protein and a ligand or secondary binding 
partner.  Such thermodynamic properties include the directly obtained enthalpy (ΔH) 
and entropy (TΔS) and the derived Gibbs free energy (ΔG) and binding affinity 
(KD).[211]  The ΔH and TΔS contribute to ΔG, which is directly related to KD through 
equations 2.2 and 2.3. 
∆𝐺 = ∆𝐻 − 𝑇∆𝑆  2.2 
∆𝐺 = −𝑅𝑇𝑙𝑛𝐾D 2.3 
The ITC calorimeter is composed of two cells, a sample cell into which the titration is 
performed and a reference cell which contains water.[270]  Both cells are maintained 
at a constant temperature by a heater, which is in turn controlled by a power feedback 
system.[270]  
In the case of an exothermic experiment, upon the addition of the ligands heat is 
released if there is an interaction between the ligand and the therapeutic target.[270]  
If both cells are to remain at a constant temperature, the feedback system must 
reduce the power supplied to the heater of the sample cell, whilst maintaining that 
supplied to the reference cell.[270]  This difference in power between the two cells is 
recorded as a function of time and can be observed in curve (a Figure 2.44).[270]  
Subsequent integration of the power curve gives the heat change associated with 
each addition of ligand to the target in the sample cell (b Figure 2.44).[270]   
 
Figure 2.44- Example ITC data.  (a) Raw data of the difference in power supplied to the heaters as a 
function of time. (b) Integration of heat change per injection with best fitting curve applied (adapted from 
[270]). 
 
The large heat signals released upon the addition of ligand at the start of the titration, 
reflect the formation of ligand and target complexes at each injection point.[270]  At 
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the end of the titration, all binding sites on the target receptor should be occupied, the 
subsequent heat changes occur due to the dilution effects of the ligand in the sample 
cell.[270]  
This can be overcome by performing experimental standards, such as titrating ligand 
into buffer within the sample cell and titrating buffer into the target/ receptor within the 
sample cell.  The experimental standards can then be subtracted from the 
experimental data, providing a more accurate representation of the thermodynamics 
associated with the binding profile. 
Other experimental considerations include “buffer mismatch”; this occurs when the 
buffer used to solubilise the ligand in the syringe is not the same as that used in the 
sample cell with the target receptor.  This can result in artificial heat changes, 
therefore it is important to ensure the salt concentrations, pH and organic solvent 
concentrations are maintained between the two buffers of the syringe and cell 
samples.[210]   
Organic solvents such as DMSO are often used to solubilise ligands for the purposes 
of biophysical analysis.  As such, to minimise further chance of “buffer mismatch” it is 
important that the concentration of organic solvent within the syringe is identical to 
that of the target/ receptor within the sample cell.[210]  In some cases there may be 
some incidents of interactions between the organic solvent and the target/ receptor, 
which may obscure the binding affinity determination.  To take these organic solvent 
binding artefacts into consideration, the organic solvent can be added to the 
experimental standards discussed previously. 
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2.3.6 Binding affinity determination by ITC 
General experimental procedures  
The experimental procedure and the conditions used for the ITC experiments 
conducted in this section are discussed in detail in Chapter 6.  However, briefly all 
unlabelled protein samples were prepared in the ITC buffer consisting of 50 mM tris 
HCl, 50 mM NaCl, 5 mM CaCl2 at pH 7.5.   
The concentration of the protein and ligand were kept constant for the initial 
experiments of each inhibitor and subsequently varied as required to obtain an 
optimal binding curve.  Due to the restricted solubility of the ligands the experimental 
process was reversed, meaning that the protein NCS1 was titrated into the cell 
contatining the desired Inhibitor.   
2.3.6.1 Inhibitor1 
The binding between NCS1 and Inhibitor 1 was investigated using ITC, numerous 
experiments were performed changing the ratio of protein and ligand, the resultant 
data has been summarised (Table 2.10).  
Optimisation of the experiment was carried out, the resultant isotherm can be seen 
(Figure 2.45), analysis of the raw data from the experiment was conducted in the 
software package Origin7 (OriginLab, Northampton, MA).  The data indicates an 
interaction between NCS1 and Inhibitor 1 as observed with the NMR data.   
This experiment was carried out at the calculated concentrations of 400 μM NCS1 
and 400 μM Inhibitor 1, however analysis of the raw data failed to produce a line of 
best fit of any statistical significance.  It was noted during the experiment, that the 
solubility of the inhibitor in the aqueous buffer seemed limited (observed through 
precipitation of the ligand in aqueous solution), therefore it was postulated that the 
concentration of inhibitor in solution was significantly less than expected.   
Therefore the raw data was re-analysed and fitted under this assumption and the 
concentration of Inhibitor 1 was adjusted accordingly, the best fitting of the curve 
occurred when the concentration of the Inhibitor was estimated as being 50 μM.  The 
thermodynamic parameters for this interaction can be found in the appendix (Figure 
A.2.1) and are discussed in detail 2.3.6.3.  To support the theory that the 
concentration of Inhibitor 1 in solution was indeed 50 μM, the corresponding 
experiment was conducted in duplicate, the thermodynamic parameters can be found 
in the appendix table A.2.1, the resultant isotherms found in Figure 2.46.   
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From the thermodynamic data of the duplicate experiments, which do not match that 
of the adjusted data, it can be concluded that the concentration of Inhibitor 1 in 
solution was not 50 μM and hence it’s calculated KD is invalid.   
Table 2.10- ITC data of Inhibitor1. A table showing the thermodynamic properties from the ITC 
experiments of Inhibitor 1 with NCS1.  The statistical errors of the ΔH parameter calculated with Origin 
Pro7 can be seen for each experiment and is indicative of a poor goodness of fit for each experiment.  
Therefore the calculated KD is unreliable and inaccurate. 
Experiment Title 
 
ΔH 
(kcal mol-1) 
TΔS 
(kcal mol-1) 
ΔG 
(kcal mol-1) 
KD μM 
 
Chi^2 
NCS1 1 mM: 
Inhib 1 200 μM 
-25.09 
(±7876) 
+18.63 
 
-6.46 
 
18.4 
 
390300 
NCS1 1 mM: 
Inhib 1 400 μM 
-26.4  
(±6328) 
+20.00 
 
-6.4 
 
19.4 
 
2760 
 
NCS1 1 mM: 
Inhib 1 600 μM 
-46.4  
(±6328) 
+40.53 
 
-5.87 
 
58.14 
 
326200 
NCS1 400 μM: 
Inhib 1 400 μM 
-13.4 
(±1116) 
+6.2 
 
-7.2 
 
5.5 
 
969500 
NCS1 800 μM: 
Inhib 1 400 μM 
-35.9  
(±9948) 
+30.10 
 
-5.8 
 
59.88 
 
233300 
NCS1 600 μM: 
Inhib 1 400 μM 
-20.2 
(±990.4) 
+13.41 
 
-6.79 
 
15.26 
 
65500 
. 
2.3.6.2 Inhibitor 2 
The binding affinity of Inhibitor 2 with NCS1 was also investigated using ITC, as with 
Inhibitor 1 the solubility of the compound severely restricted the experimental 
technique.  The initial experiment was carried out at a concentration of 1 mM NCS1: 
100 μM Inhibitor 2, it is believed that even at the relatively low concentration 
precipitation of the inhibitor can be interpreted from the double heat spikes of the 
isotherm (Figure 2.47).  The thermodynamic data can be observed in the appendix 
(Table A.2.2 and Figure A.2.2) a more detailed discussion can be found in 2.3.6.3.  
From this data it can be concluded that the solubility of Inhibitor 2 prevents 
determination of an accurate KD.   
2.3.6.3 Comparison of binding affinity determination between 
inhibitors 1 and 2 with NCS1 
Broadly it can be observed that the thermodynamic properties of Inhibitor 1 and 
Inhibitor 2 share similarities in their profiles, both interactions appear enthalpically 
driven.  As previously discussed in 2.3.5, ΔH is a measure of the number of 
intermolecular interactions formed or broken during a binding event and TΔS is 
related to the displacement of water from apolar surfaces and or change in 
conformational entropy through the binding interaction.  In all experiments for Inhibitor 
1 the ΔH upon binding of the inhibitor to NCS1 appeared to be moderate and negative 
and hence is the greator contributer to the binding affinity, whereas TΔS is smaller 
and positive, it can therefore be considered as insignificant.   
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With Inhibitor 2, although the ΔH upon binding is still large and negative and the TΔS 
is a positive value, it is much larger than those determined for Inhibitor 1 and so could 
not be considered as being insignificant.   
The major limiting factor of both inhibitors with this experimental technique was their 
solubility, this meant that in many cases the goodness of fit chi-square values (Chi^2) 
were not minimal and hence determind binding affinity data was innacurate.[212–214]  
Therefore although it can be confirmed that there are interactions between the first 
generation of inhibitors and NCS1 as seen in the previously collected NMR data, 
determinaton of any affinity values using this technique are unreliable. 
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Figure 2.45- Binding affinity determination- Isothermal Titration Calorimetry Curve.  ITC Isotherm 
top) and resultant curve (bottom) from the experiment of NCS1 400 µM titrated in to Inhibitor 1, 400µM 
at 25 °C, 1.34% DMSO, 50 mM tris HCl, 50 mM NaCl, 5 mM CaCl2 pH 7.5.  Fitting of the curve using 
Origin Pro7 assuming the concentration of Inhibitor 1 is 50 μM using the single set of sites curve fitting 
model produced a 1:1 binding model, a derived binding affinity KD of 5.5 μM, ∆H= -13.4 Kcal mol-1, T∆S 
= 6.2 Kcal mol-1, ∆G= -7.2 Kcal mol-1, Chi^ 2= 969500. 
.
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Figure 2.47- Binding affinity determination Isothermal Titration Calorimetry Curve for Inhibitor 2.  
ITC Isotherm (top) and resultant curve (bottom) from the experiment of NCS1 1 mM, titrated in to Inhibitor 
2 100 µM at 25 °C, 0.34% DMSO, 50 mM tris HCl, 50 mM NaCl, 5 mM CaCl2 pH 7.5.  Double heat spikes 
seen in the top isotherm likely to have occurred due to the limited solubility of Inhibitor 2 resulting in 
precipitation.  Fitting of the curve was conducted in Origin Pro7 using the single set of sites curve fitting 
model produced a binding model with a derived binding affinity KD of 179.5 μM undesiarable enthalpic 
values as follows ∆H= -4.708 E8 Kcal mol-1, -T∆S= 4.71 E8 Kcal mol-1, ∆G= -9.42 E+05 Kcal, mol-1 
Chi^2= 252000. 
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2.3.7 Introduction to Fluorescence Spectrophotometry 
The emission of light from any given surface is known as luminescence and can be 
split into two categories, fluorescence and phosphorescence, depending on the 
excited state.[216]  Here though we shall discuss fluorescence, in particular the use 
of intrinsic fluorescence for investigation of the binding interactions of a protein.  
Intrinsic protein fluorescence is a product of the aromatic sidechain residues of the 
amino acids tryptophan, tyrosine and phenylalanine within the protein itself, rather 
than a fluorescence label.[216]   
 
Figure 2.48- Chemical structures of the three aromatic sidechains of the amino acid residues tryptophan, 
phenylalanine and tyrosine.  Of which tryptophan is the most powerful fluorescence tool as it is stronger 
in emission than tyrosine or phenylalanine and is extremely sensitive to the local environment that 
surrounds the indole sidechain. 
In a fluorescence experiment, the sample is excited at a specific wavelength of light 
relating to aromatic residue of interest; for example, in tryptophan fluorescence the 
excitation wavelength is 285 nm and the emission wavelength for detection is 
between 300 and 350 nm.  Tryptophan fluorescence is highly sensitive to the local 
environment that surrounds the tryptophan’s indole sidechain; hence tryptophan 
fluorescence can be used to detect conformational changes of a protein at low 
concentration.[216,222]   
These changes in conformation present themselves in two ways.  A blue shift in the 
fluorescence (a shift to the left of the native fluorescence i.e. less than 300 nm) is 
observed in those circumstances where the tryptophan residues become more buried 
into the hydrophobic surface upon interaction of the protein with a particular ligand or 
binding partner.[216]  On the other hand, a red shift in the tryptophan fluorescence (a 
shift to the right of the emission spectra i.e. above 350 nm) occurs when the 
tryptophan residues become more exposed and this is a possible indication of protein 
unfolding.[216]   
The tryptophan fluorescence data collected for this thesis was carried out on a Cary 
Eclipse fluorescence spectrophotometer (Agilent technologies), the raw data was 
analysed in Origin7 (OriginLab, Northampton, MA).
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2.3.8 Binding affinity determination using Fluorescence 
Spectroscopy 
General experimental procedures  
All fluorescence data of the first generation of inhibitors was collected by Dr Liam Dorr 
at The University of Liverpool on a Cary Eclipse Fluorescence spectrophotometer 
(Agilent technologies).  The raw data was analysed in Origin7 (OriginLab, 
Northampton, MA) by myself.   
Unlabelled NCS1 was prepared as described in Chapter 6.  Briefly, unlabelled NCS1 
was buffer exchanged into fluorescence buffer consisting of 50 mM tris HCl, 50 mM 
NaCl, 5 mM CaCl2 pH 7.5; and aliquoted into 17 samples at a final concentration of 1 
μM (v/v 200 μL).   
For the individual single point reads of the tryptophan fluorescence assay, each 
inhibitor was added in the required volume from a single stock solution in 100% 
DMSO, to the already aliquoted NCS1 samples contained in eppendorf microfuge 
tubes.  The concentration range for each inhibitor over the 17 samples was 0 - 90 μM.  
This process was repeated for all inhibitors.  Each individual assay sample was 
transferred to a quartz 16.160-F/Q/10 cuvette (Starna Scientific) and excited at a 
wavelength (λ) of 280 nm, with the excitation slit width 5 nm and the emission slit 
width 20 nm. 
2.3.8.3 Inhibitor binding assay 
Intrinsic fluorescence is highly sensitive to a change the local environment of 
tryptophan residues, the emission spectrum of tryptophan changes in response to 
conformational changes in the local environment.[271]  This makes tryptophan 
fluorescence a useful tool for the investigation of changes in a proteins structure, 
whether it be due to denaturation, interactions with a ligand, or a known binding 
partner, it can also be used to determine binding affinities.[272]   
Tryptophan fluorescence was used to investigate the interactions of NCS1 with 
inhibitors 1, 2 and 3 as NCS1 is known to contain two tryptophan residues in the 
hydrophobic binding cleft Trp30 and Trp103.  Experimentally the required 
concentration of the protein and the ligand is extremely small in comparison to that of 
NMR and ITC techniques.  The changes in tryptophan fluorescence of NCS1 upon 
the addition of 0 – 90 μM inhibitors 1, 2 and 3 can be seen (Figure 2.49).  Immediately 
from the plots of the raw data it is clear that each inhibitor has an effect on the 
tryptophan fluorescence of NCS1.   
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In the first instance, increasing the concentrations of Inhibitor 1 (Figure 2.49 a) caused 
a quenching of the tryptophan emission. 
The effects of increasing the concentrations of Inhibitor 2 upon NCS1, appear to 
cause a blue shift in the tryptophan fluorescence after 7.5 μM.  This change in the 
fluorescence emission, indicates that the indole ring of the tryptophan residue has 
become more buried within the cleft.[216]   
At increasing concentrations of Inhibitor 3, NCS1 appears to undergo the opposite 
change in structure as was caused by Inhibitor 2.  At 10 μM the intrinsic tryptophan 
fluorescence emission of NCS1 undergoes a red shift, this indicates that the 
tryptophan is now more.[216]   
The tryptophan fluorescence assays were used as an additional method to investigate 
the effects of the inhibitors on NCS1; however, no further determination of binding 
affinity was carried out using this technique due to the additional effects of red/blue 
shifts which complicated the analyses. Instead, the fact that there are effects on the 
tryptophan fluorescence by all 3 inhibitors suggest that that each on is interacting with 
NCS1 albeit differently. 
. 
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2.4 Summary 
The first generation of inhibitors designed to modulate the interaction between NCS1 
and D2R peptide, were analysed extensively using numerous biophysical techniques 
including; NMR spectroscopy, ITC and tryptophan fluorescence spectrophotometry.   
All three methods of analysis indicated an interaction between inhibitors 1, 2 and 3 
with NCS1, however limitations brought about due to their limited solubility in aqueous 
buffer at concentrations needed for these techniques meant that affinity of binding 
was unable to be determined accurately.  Therefore it was decided to develop a 
second generation of inhibitors that would exhibit an improved solubility profile.   
The approach towards the second generation compound is shown in the 
computational section (3.1) and the synthetic approach (Section 3.2).  The second 
generation of inhibitors were designed based on the structure of Inhibitor 2, from the 
NMR data Inhibitor 1 appeared to cause too much of a change in the secondary 
structure of NCS1 at lower concentrations.   
The effects of Inhibitor 3 upon the NCS1 residues at the same concentration as 
Inhibitor 1 and Inhibitor 2 (500 μM) did not appear to have an obvious effect on the 
targeted NCS1 residues, this along with the fluorescence data, that possibly indicated 
unfolding events at higher concentrations of Inhibitor 3, made it an unsuitable 
candidate for further development. 
Therefore Inhibitor 2 was selected, its NMR data indicated the possibility of a binding 
interaction with NCS1 and this was better observed than with Inhibitor 1 whose effect 
of severe peak broadening and attenuation meant that analysis of the residues 
perturbed by any possible interaction was not accurate.  The fluorescence data 
obtained from Inhibitor 2, also indicated a change in the accessibility of the tryptophan 
residues within the hydrophobic binding pocket, the lack of accurate ITC data 
obtained due to its limited solubility made Inhibitor 2 an obvious candidate for further 
structural development.   
Upon the synthesis of the second generation of inhibitors, the biophysical techniques 
to be applied for investigation of the interactions with NCS1 would be the same 
techniques as used for the first generation.  A detailed discussion of the results of this 
analysis can be found in Chapter 3 Structure-based drug design: The Second 
Generation Section 3.3 and includes an investigation using NMR techniques into the 
solubility of both the first generation of inhibitors compared to the second generation. 
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3 Structure-based drug design: The Second Generation 
3.1. Second Generation: Computational design 
3.1.1 Introduction 
Following the design and synthesis of the first generation of inhibitors (Chapter 2, 
sections 2.1 and 2.2) and the results of the biophysical analysis (Section 2.3), it was 
apparent that a major limiting factor in the first generation analogues was their very 
limited solubility.  Therefore the most promising inhibitor from the first generation was 
selected following a detailed analysis of the predicted binding poses from the 
computational modelling, rather than from experimental binding affinities.  From the 
resulting scaffold, a number of analogues were designed with solubilising groups 
incorporated into the scaffold.  Inhibitor 2 was selected due to the consistently 
predicted binding pose along the hydrophobic groove of NCS1.  Its selection was also 
in part due to the non-specific binding effects of Inhibitor 1 on NCS1 as observed from 
the NMR chemical shift perturbation experiments.  There was also a lack of 
observable binding with Inhibitor 3. 
Visual analysis of the single top binding pose predicted for Inhibitor 2 (Figure 3.1), 
indicated the location of a number of moieties within Inhibitor 2 in proximity to the side 
chains of NCS1.  From the computational docking we observed the methyl group was 
found to be orientated towards the phenyl ring of Phe48 at a distance of 4.2 Å (Figure 
3.1) and the position of the para methyl group on the pyridine ring was 1.8 Å from the 
phenyl ring of Tyr52.  The ortho methyl group of the pyridine ring was situated 3.1 Å 
from Ser184, with the methoxy group appearing to be 2.9 Å from Trp103.  Finally the 
methylene CH2 indicated by the blue box (Figure 3.1) was believed to orientate the 
aromatic ring into a position at the top of the binding groove around Leu43 at a 
distance of 3.5 Å. 
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Figure 3.1– Optimisation of Inhibitor 2.  Visual analysis of the top binding pose of Inhibitor 2 in the 
hydrophobic binding cleft of NCS1 was used to analyse any positions on the scaffold that could be 
optimised by the addition of a solubilising group.  The distances between the residues of NCS1 and the 
functional groups of Inhibitor2 are indicated in grey.  The methyl group was found to be orientated 
towards the phenyl ring of Phe48, at a distance of 4.2 Å.  Position of the methyl group found to be 1.8 Å 
from the phenyl ring of Tyr52.  Methyl group situated 3.1 Å from Ser184.  The methoxy group appears 
to be 2.9 Å from Trp130.  The methylene CH2 (blue box) orientates the aromatic ring, which is situated 
at the top of the binding groove around 3.5 Å from Leu43.  The red arrow represents an accessible 
position where a solubilising group could be incorporated into the scaffold, which is solvent exposed free 
space.   
3.1.2 Adapting the modelling pipeline: Computational optimisation 
techniques 
Based on the model described above it was apparent; that the unsubstituted position 
on the pyridine ring in inhibitor 2, would be the most suitable position for the addition 
of a solubilising group as it would be highly solvent exposed (red arrow Figure 3.1).  
The phenyl ring situated at the top of the binding groove, appears to anchor the ligand 
in position through interaction with Leu43.  Therefore following the Topliss scheme 
for optimisation of phenyl ring substitution, the only substitutions suggested in this 
region of the scaffold was the addition of a 4-chloro/ para-chloro group.[273]  Despite 
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the more lipophilic and electron withdrawing nature of the 4-chloro substitution, the 
ease of synthesis relative to other substituted compounds makes it a good first choice 
for optimisation processes.[273]  Furthermore the ortho and para substituted methyl 
groups on the pyridine ring were removed, due to the fact that their presence could 
render the molecule more lipophilic and thus less soluble.[274]  The ortho methoxy 
group of the pyridine ring was removed in favour of either a pyridine or pyridone ring 
which would allow for substitutions at both meta positions.  Finally selection of a 
suitable solubilising group, resulted in investigations in heteroaliphatic and 
heteroaromatic rings, to determine which ring type would be most suitable.[275]  The 
different types of rings chosen to be screened (Figure 3.2) included; N-methyl 
piperazine, morpholine, piperadine, imidazole and 1, 2, 4 triazole.   
With the structural analysis of Inhibitor 2 complete, four main scaffolds were designed 
(Figure 3.2), (a) and (b) pyridine, or (c) and (d) pyridone analogues, with meta 
substitutions (R) being either amide or amine.  This resulted in the design of 72 
analogues however, due to the lack of commercial availability of a number of the 
solubilising groups, only 54 of the 72 analogues of Inhibitor 2 (Appendix Figure A.3.1 
- A.3.3) were subsequently built and energy minimised in Spartan.[225] 
 
Figure 3.2- Inhibitor 2 analogue design.  The four main scaffolds can be observed with substitutions 
at the R (red) and R’ (blue) positions, resulted in 54 possible analogues of Inhibitor 2 to be 
computationally screened. 
As with the workflow of the first generation of compounds, the 54 analogues of 
Inhibitor 2 were docked into NCS1 using GOLD and their predicted binding 
interactions assessed scored using Goldscore.[99]  The one hundred docking poses 
of each of the compounds, were subsequently re-scored using the three scoring 
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functions, Astex statistical potential (ASP), Chemscore and Chem Piecewise Linear 
Potential (PLP).[99,111]  An average of the scoring functions was taken for each 
compound and the ADMET profiles (the physiochemical properties) were calculated 
in Pipeline Pilot.[125]  Despite the additional solubilising groups the solubility profile 
of the 54 compounds was not always ideal (Appendix Section A.3 Table A.3.1).  The 
predicted AlogP ranged from the unfavourable 3.787 to a much more favourable value 
of 0.413, which is considerably improved when compared to that of Inhibitor 2 whose 
AlogP was calculated as 3.737.  The molecular solubility was also calculated for the 
54 molecules and values ranged from the favourable -4.42 to a much less favourable 
value of -7.95, considerably less than that of Inhibitor 2 whose molecular solubility 
was calculated as -6.47.  In fact of the 54 compounds designed to have an improved 
solubility, 15 were found to have a poorer profile than the parent compound and a 
further 19 were more negative than -6.0.  
Due to the solubility issues of the first generation of inhibitors and the subsequent 
challenges that this caused with the in vitro binding studies, it was decided the 
selection process should filter out compounds with poor calculated molecular 
solubility.  Compounds with a molecular solubility more negative than that of Inhibitor 
2 were removed, the final 39 were ranked in ascending order of molecular solubility 
and the top 12 compounds (Table 3.1 and Figure 3.4) were selected for retro-
synthetic analysis to determine compounds to synthesise. 
 
Figure 3.3 - Second Generation Computational workflow.  The computational workflow applied to 
the Inhibitor 2 analogues adapted from the previous first generation computational workflow used to 
select inhibitors 1, 2 and 3 (Chapter 2, Section 2.1).  54 compounds were designed and built in the 
molecular modelling package Spartan, they were subsequently docked into NCS1 using the docking 
programme GOLD where their binding poses were scored and re-scored.  The ADMET profiles of each 
of the 54 compounds were then calculated and the ligands were ranked in order of their solubility and 
the top 10 compounds were selected for retro-synthetic analysis. 
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Table 3.1- Table showing the ADMET properties for the top 12 molecule derivatives on Inhibitor 
2.  Compounds are listed in descending order with respects to the overall best solubility profile.  The 
molecular weight and solubility functions are indicated using a traffic light system following the Lipinski 
parameters and the filter of molecular solubility of Inhibitor 2 as -6.0: good values (green), intermediate 
(amber) and poor values (red).   
Compound 3.13 has been included in the table in italics as it was selected for synthesis despite not 
ranking amongst the top 12 compounds. 
D2R peptide Ligand Efficiency = 0.061 
 
 
Figure 3.4- Top 12 compound derivatives of Inhibitor 2.  The compounds ranked in order of their 
solubility profile.  The relative ADMET properties for each compound can be seen in table 3.1. 
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After retrosynthetic analysis, 3.5 was selected for synthesis and the synthetic route 
outlined in Section 3.2.  Due to challenges encountered during the synthesis it was 
decided to also synthesise 3.13, a compound closely related to 3.5, the two only differ 
by a para-substituted chlorine (Figure 3.5).  Compound 3.13 was not within the top 
12 compounds with the best molecular solubility, however its predicted solubility was 
still predicted as being better that Inhibitor 2 (Table 3.1).  The top predicted binding 
pose for both 3.5 and 3.13 (Figure 3.5) indicate that the top binding pose of 3.5 is 
different to that of Inhibitor 2, in comparison to 3.13 which is predicted to bind in a 
similar manner down the groove albeit with the opposite orientation. 
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Figure 3.5- Predicted binding poses of 3.5 and 3.13. (a) The top predicted binding pose of 3.5 with 
NCS1 (green) and the key residues highlighted (yellow) [4] along with the chemical structure.  Compound 
3.5 appears to adopt a curved binding pose in the lower region of the key residues within the hydrophobic 
binding groove of NCS1. (b)  The top predicted binding pose of 3.13 and NCS1 (green) with the key 
residues highlighted (yellow) along with the chemical structure.  Compound 3.13 appears to adopt a 
similar binding pose to that of Inhibitor 2 along the hydrophobic binding cleft, however the orientation is 
reversed. 
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3.1.2 Summary 
The significantly reduced solubility profiles of each of the three inhibitors determined 
during the biophysical analysis (Chapter 2.3) led to the subsequent development of a 
second generation of inhibitors. 
Developing the second generation of inhibitors was conducted using Inhibitor 2 as a 
template due to its biophysical binding results (Chapter 2.3).  The computational 
approach involved a more manual design process informed by docking results, 
through the analysis of the predicted binding interactions of Inhibitor 2.  Compound 
design was informed by medicinal chemistry knowledge of solubilising groups.  The 
54 generated compounds were docked and their physiochemical properties 
calculated as with the first generation of inhibitors; however, the solubility profile of 
each compound was a key filter in the second generation selection process.  The 
solubility profiles of the compounds were compared to that of Inhibitor 2 and those 
whose profile was not significantly improved were discarded.  The remaining 
compounds were listed in ascending order with respect to their molecular solubility’s 
and the top 12 compounds were selected for retrosynthetic analysis.  Compound 3.5 
was intended to be the initial synthetic target, with the aim of synthesising a number 
of closely related analogues; however, due to the challenging synthetic route, 3.13 
was the only compound suitable.  This compound has a similar structure and 
predicted binding pose to that of Inhibitor 2 and, hence, deemed a suitable second 
generation compound. 
It has been said that the road to a successfully developed therapeutic is long, 
expensive and often frustrating.[117]  There are many different options when it comes 
to “how to best design” a compound or target a specific interaction and they are all 
valid in one way or another.  However the pipeline that has been developed here is a 
rationale and efficient method that combines different computational techniques, to 
produce the desired outcome of identifying hit compounds.  The methodology could 
be applied to other protein-protein interactions and could significantly reduce the cost 
associated with experimentally screening vast chemical libraries.  Although these are 
only calculated predictions and the experimental results may be found to differ, it is 
rational to start with a targeted approach.  
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3.2 Second Generation Inhibitor Synthesis  
3.2.1 Introduction  
The first generation of inhibitors designed to disrupt the interaction between NCS1 
and D2R peptide were analysed extensively using numerous biophysical techniques 
including NMR spectroscopy, ITC and tryptophan fluorescence (Chapter 2.3).  
However, limitations due to their limited solubility in aqueous buffer meant there were 
no quantifiable biophysical results.  Therefore, it was decided to develop a second 
generation of inhibitors that would exhibit an improved solubility profile without losing 
efficacy towards the target.  The selection process involved analysis of the predicted 
binding poses from the computational analysis of the first generation compounds; this 
was necessary since despite the extensive NMR experiments, there was a lack of 
accurate data that identified the exact binding locations of the inhibitors within NCS1.  
Inhibitor 2 was selected as the target scaffold because of the predicted binding pose 
along the hydrophobic groove of NCS1 (Chapter 2.1.5 Figure 2.13 d).  As discussed 
previously, the computational process in designing and selecting these new 
generation analogues involved the incorporation of solubilising groups such as N-
methylpiperazine, morpholine, piperidine, imidazole and 1,2,4-triazole.  The pipeline 
took the 54 designed compounds and filtered them based on their solubility profile 
(Section 3.1).  This resulted in 12 hit compounds that were analysed retrosynthetically 
to find a common route to synthesis that could be applied to all candidates.  This 
would allow synthesis of a number of ligands with identical core scaffolds, but different 
solubilising functional groups.  The first compound of the second generation, selected 
for synthesis and for the development of the synthetic route was 3.6, due to the 
commercial availability of the reagents. 
 
Figure 3.6- Initial synthetic target 3.6. 
  
3.6 
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3.2.2 Synthesis of Inhibitors 4 and 5 
The overal synthetic routes used in the synthesis of of the two second generation 
compounds Inhibitors 4 and 5 can be seen in Scheme 3.1 and 3.5.  The first five steps 
in the synthetic approach a-e 3.14 – 3.19 were developed to be applicable to seven 
of the original 12 molecular targets.   
 
Scheme 3.1- Synthetic route to Inhibitors 4 and 5. (a) Tertiary butanol, EDCI, DMAP, 25 ˚C 72 hrs. 
57%. (b) Pd2[dba]3 , 1,1'-Bis(diphenylphosphino)ferrocene, anhydrous dimethylacetamide, ZnCN2, Zn, 
90 ˚ C, 1 hr. 85%. (c) 25% NH3, raney nickel, EtOH:THF 1:1, H2, 25 ˚ C 3 hrs. (d) Trifluoroacetic anhydride, 
pyridine, DCM, 25 ˚C 16 hrs. 68%. (e) Trifluoroacetic acid, DCM, 25 ˚C, 3 hrs. (f) HATU, anhydrous 
DMF, DIPEA, Morpholine, 25 ˚C, 96 hrs. 55%. (g) 7M methanolic ammonia, 25 ˚C, 96 hrs, 31%. (h) 
HATU, anhydrous DMF,DIPEA, 3.25, 25 ˚C, 96 hrs. 36%. (i) HATU, anhydrous DMF, DIPEA, 3.28, 25 
˚C , 96 hrs. 34%. 
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The initial step in the synthesis was t-butyl protection of the carboxylic acid 
functionality 3.14; this was followed by cyanation of the aryl bromide 3.15 at the 5 
position.  Cyanation of aryl halides has previously been conducted using microwave 
irradiation and transition metal chemistry, with the displacement of halides from 
aromatic compounds using cheap and readily availiable cyano sources such as 
potassium cyanide or sodium cyanide.[276][277]  Palladium (Pd) catalysts were 
selected due to their ability to tolerate a variety of different functionalities and 
conditions.[278]  Microwave reactions require quite harsh conditions including high 
temperatures and pressures and the isolation of the product can be difficult resulting 
in low yields.[276]   
Initially cyanation reactions were conducted prior to t-butyl protection using copper 
cyanide in acetonitrile and the microwave reactions heated to 160 ˚C; however no 
products were isolated.  This was thought to be due to the difficulties with isolation of 
the pyridine carboxyllic acid, so protection of the carboxylic acid was then conducted 
as an initial step.  However, it was thought that the high temperatures and pressures 
of the experimental conditions of the microwave reaction, caused the t-butyl group to 
be cleaved.  This once again revealed the carboxylic acid and no product could be 
isolated.   
Therefore, it was decided to investigate cyanation of t-butyl protected nicotinic acid 
using palladium catalysts.  The t-butyl ester was introduced due to its stability to basic 
conditions and its lability under strongly acidic conditions, the reaction was successful 
yielding the product compound 3.16 with 57% yield.[279]  The mechanism of the 
cyanation reaction using palladium catalysts was originally postulated by Takagi et 
al. in 1976.  Mechanistic studies indicated that two cycles were involved in the 
reaction whereby one fed the other.[280]  The first cycle was thought to occur like that 
of a typical Pd cross coupling reaction; in the second the Pd was the cyanide 
carrier.[280]  More recently in an extensive review article, Anbarasan et al. suggested 
a similar catalytic cycle (Scheme 3.2).  Oxidative addition into the aryl halide by the 
palladium species forms a Pd(II) aryl halide complex.  This would then be followed by 
anion exchange replacing the halide and forming the Pd (II) cyano complex.[281]  The 
final step in the catalytic cycle would be reductive elimination, forming the 
corresponding aryl cyano compound and re forming the active Pd(0) compound.[281] 
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Scheme 3.2– The proposed catalytic cycle of cyanation including deactivation pathways suggested by 
Anbarasan et al. adapted from [281]. 
Sources of cyanide and suitable solvents for the reaction were thought to be the 
limiting factors and were dependent upon the respective solubility.  It was found that 
the higher the solubility of the cyanide salt the lower the reaction yield.[281,282]  
According to the original proposed mechanism, it was thought that problems with the 
reaction were due to the presence of water or excess cyanide, subsequently resulting 
in catalyst de-activation, both of which can be seen as side reactions in Scheme 
3.2.[280,281]  Water is believed to generate HCN which can lead to the formation of 
the inactive Pd (II) cyano complex.  It has also been postulated that it improves the 
solubility of the sources of cyanide in organic solvent.[283,284]  Excess cyanide was 
thought to inhibit the catalytic cycle through the interaction of the cyanide ions with 
the Pd (II) species, forming an inactive Pd (II) cyano complex that could not be 
reduced back to the active Pd (0) species.[280]  This could be due to the strongly 
binding cyanide anions and so resulting in the termination of the reaction.[280,281]  
However, this theory was found to not necessarily be the case in many of the reaction 
screens that were tested in this synthesis.  
Two types of palladium ligands were used, tris (tribenzylideneacetone)di-palladium(0) 
Pd2(dba)3 and bis(dibenzylideneacetone) palladium(0) Pd(dba)2 along with the ligand 
1,1’-Bis(diphenylphophino)ferrocene (DPPF) to complete the catalytic system.  The 
cyanide source used was zinc cyanide in conjunction with zinc powder, which was 
used to keep the palladium in the active oxidation state of 0.  Equimolar equivalent 
were used in the majority of the reactions and in all cases the zinc cyanide used was 
in excess with respect to the palladium catalyst and DPPF ligand.  Those reactions in 
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which the zinc cyanide was the limiting reagent, either failed or produced a yield of 
between 8 and 13% over the time scale of 48 – 72 hours.  For these reactions 
dimethylacetamide was the solvent selected.  Further literature indicated that the use 
of zinc acetate along with zinc cyanide and zinc powder prolonged the catalytic 
lifespan of the active palladium species and contradictory to previous literature, water 
was used alongside the organic solvent DMF.[285]  However, such procedures under 
reaction times of 24 – 96 hours, resulted in low yields of 12%, or failure to produce 
the desired compound at all.  Success was achieved using molar excess of zinc 
cyanide and zinc powder, Pd2(dba)3 and DPPF in anhydrous dimethylacetamide.  The 
reaction was heated to 120 ˚C for 1 hour yielding the desired nitrile 3.16 (Scheme 
3.1) in 85% yield. 
Initial attempts to reduce the nitrile to its corresponding primary amine 3.17 (Scheme 
3.1), involved refluxing the nitrile with the ligand NiCl2.6H2O and the reducing agent 
sodium borohydride in methanol for 12 hours; however no product was isolated.[286]  
Subsequent reaction of the nitrile with aqueous ammonia solution and Raney nickel 
under a hydrogen atmosphere, in a mixture of tetrahydrofuran and methanol at 25 ˚C 
for 3 hours,[287] gave the crude product which was confirmed by mass spectrometry, 
1H and 13C NMR.  The crude product was used without further purification in the 
following reaction, protection of the primary amine. 
When selecting the amino protecting group a number of considerations were taken 
into account, including the need for selective de-protection of the t-butyl ester without 
any effect upon the amine functionality.  This meant that the group introduced needed 
to be stable under acidic conditions and base labile.  The trifluoroacetamide group 
which at room temperature is stable under acidic conditions and can be removed 
under basic conditions (including pH 12), was selected as a suitable candidate.[279]  
Incorporation of the trifluoroacetamide group was successful, affording the desired 
compound 3.18 (Scheme 3.1) in a 68% yield.  With the amino functionality now 
protected, the t-butyl protecting group could then be removed, un-masking the 
carboxylic acid 3.19 for the coupling reaction with the selected solubilising groups.t-
Butyl ester cleavage was carried out using a 1:1 mixture of trifluoroacetic acid and 
DCM at 25 ˚C, giving full conversion to the TFA salt of the carboxylic acid 3.19 
(Scheme 3.1) after 3 hours.  As with the amine 3.17 (Scheme 3.1) the TFA salt of the 
carboxylic acid 3.19 was identified using mass spectrometry, 1H and 13C NMR and 
carried forward to the subsequent reaction without need for purification. 
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The outcome from the computational modelling indicated that the top 10 selected 
targets for synthesis contained N-methylpiperazine and morpholine derived amides 
or amines.  Peptide coupling reagents were used to introduce these groups using the 
crude carboxylic acid 3.19, the initial targets being the N-methylpiperazine derived 
amides.  Formation of the amide bond between the carboxylic acid 3.19 and the N-
methylpiperazine, was initially investigated using the coupling reagent EDCI.  
Coupling using EDCI and DMAP was unsuccessful with no product isolated.  
Consequently an alternative coupling reagent was used.  1-[Bis (dimethylamino) 
methylene]-1H-1,2,3-triazolo [4,5-b] pyridinium 3-oxihexafluorophosphate (HATU) 
belongs to another family of reagents associated with 1H-benzotriazole.[250]  There 
are two known forms of the reagents, the uronium species (or O-form 3.22) and the 
guanidinium species (N-form 3.23), which when in solution are believed to be in an 
equilibrium with one another (Scheme 3.3).[249,250]   
 
Scheme 3.3-  Equilibrium between the O-form and N-form of HATU adapted from [249]. 
The reduction of racemisation and efficiency of HATU with more sterically hindered 
reactants, make it a popular reagent for use in both solution and solid-phase peptide 
synthesis.[288]  The mechanism of the reaction involves activation of the carboxylic 
acid by HATU followed by N-acylation which can be seen in Scheme 3.4.  Initially the 
carboxylic acid is deprotonated by the organic base, thus forming the carboxylate 
anion which goes on to attack the O-form HATU 3.22 to form an unstable salt.  This 
unstable intermediate is rapidly converted to the activated ester of 7-aza-HOBt which 
is an extremely reactive species towards amines.  Finally, nucleophilic addition of the 
amine, results in N-acylation, yielding the desired amide product.[249,289] 
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Scheme 3.4- Proposed reaction mechanism of HATU (3.22) couplings with generic amines. 
With this in mind, a general procedure for the coupling of N-methylpiperazine to the 
acid 3.19 was explored; this involved dissolving the acid in anhydrous DMF followed 
by the addition of a molar excess of HATU, DIPEA and finally N-methylpiperazine.  
The reaction was heated to 40 ˚C for 48 hours but once again, as with the EDCI 
reaction, proved unsuccessful as no product was isolated upon workup. 
The coupling reactions for the formation of morpholine derived amides were also 
investigated using the HATU procedure.  Monitoring of the reaction using TLC 
indicated that what was believed to be the desired product was indeed forming, 
although slowly.  Despite initial attempts being low yielding, optimisation of the 
reaction was successful and isolation of the product after a total reaction time of 96 
hours at 25 – 40 ˚C afforded the desired amide 3.20 (Scheme 3.1) in a 55% yield.  
The resultant deprotection of the trifluoro acetylated amine to compound 3.21 
(Scheme 3.1) was carried out by stirring the precursor in 7N methanolic ammonia 
over 96 hours, generating the product in 31% yield.  The starting material was 
recovered and re-subjected to the reaction conditions to maximise the yield for the 
subsequent amide coupling with compounds 3.27 and 3.30.   
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Scheme 3.5- Synthetic route to fragments 3.27 and 3.30. (a) acetyl chloride, chloroform, Mg turnings, 
EtOH, toluene,119 ˚C, 24 hrs, 59%. (b) benzyl hydrazine, EtOH, 85 ˚C, 51%. (c) 1M NaOH, MeOH, 68 
˚C 1 hr, 25 °C 24 hr, 89%. (d) Hydrazine, EtOH, 25 °C, 16 hrs, 93%. (e) 4-chlorobenzylbromide, 
cyclohexanone, K2CO3, 155 ˚C, 51%. (f) 1M NaOH, MeOH, 68 ˚C 1hr, 25 °C 24 hrs, 34%. 
The synthetic route for the fragments 3.27 and 3.30 (Scheme 3.5) involved acylation 
of ethyl acetoacetate to ethyl 2-acetyl-3-hydroxybut-2-enoate 3.25, followed by a 
cyclo-condensation reaction to form the pyrazole ring of 3.26.  Subsequent ester 
hydrolysis afforded the fragment 3.27 with an 89% yield.[290]  The second fragment, 
3.30 (Scheme 3.5) was also formed by an initial cyclo-condensation of ethyl 2-acetyl-
3-hydroxybut-2-enoate 3.25 to 3, 5–dimethyl-1H-pyrazole-4-carboxylate 3.28.  
Benzylation with 4-chlorobenzylbromide of the pyrazole ester 3.28 to compound 3.29, 
was followed by ester hydrolysis to afford product fragment 3.30 in a 92% yield.  
Compounds 3.24 – 3.30 were synthesised by 4th year MChem student Solon 
Mardapittas following procedures previously devised for his project.   
With all three major fragments synthesised the final step in the synthesis of two of the 
analogues of Inhibitor 2 was the amide coupling reaction between the amine 3.21 and 
the two carboxylic acids 3.27 and 3.30 respectively.  The procedure employed was 
the HATU coupling reaction used previously, with substitution of the base DIPEA for 
potassium carbonate (K2CO3).  In both cases the reaction was successful in yielding 
the desired products Inhibitor 4 and Inhibitor 5 with yields of 36% and 34% 
respectively.  The two Inhibitors were then tested in vitro and the data can be found 
in the following Section 3.3. 
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3.2.3 Summary 
The initial aim of the second generation chemical synthesis was to synthesise a 
number of small molecule compounds, ligands which shared a common core scaffold 
with Inhibitor 2.   
The initial molecular target 3.6 was selected due to the prevalence of the N-methyl 
piperazine functional group (Figure 3.6) present within four of the 12 compounds.  The 
initial five steps of the synthetic route could be applicable to 7 of the desired 12 
compounds with possible modifications needed for those ligands containing pyridone 
moieties.  The numerous steps to reaching the carboxylic acid 3.19 were not without 
difficulties, as such the optimisation of these procedures required more time than 
expected.  The subsequent step involved coupling of the acid 3.19 to the different 
solubilising moieties, to produce the desired amide, for example 3.20, which could 
then be selectively reduced to the respective amine if required.  Initial efforts to couple 
N-methylpiperazine to 3.19 were unsuccessful.  As four of the top 12 compounds 
were morpholine analogues, this was the most logical next group to couple.  The 
HATU coupling procedure employed to access the desired amide 3.20 was 
successful with a pleasing yield of 55%.   
During the synthesis of compounds 3.14 – 3.21, 4th year MChem student Solon 
Mardapittas was working in parallel to synthesise the fragments 3.27 and 3.30.  These 
two fragments would be coupled with analogues such as 3.20, to achieve the desired 
amide final compound using the HATU procedure previously developed.  Restrictions 
in time, associated with the optimization of the synthetic route, meant that no further 
analogues were developed.  Instead Inhibitors 4 and 5 were synthesised with yields 
of 36% and 34% respectively and carried forward for biophysical analysis. 
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3.3 Binding assessment using Biophysical Methods 
With the second generation of inhibitors synthesised, biophysical assessments were 
made of the ligands interactions with NCS1.  To achieve this the experimental 
techniques used to analyse the first generation (Chapter 2.3), were again employed 
with these second generation molecules.  For further details on the techniques used 
please see Chapter 1.6 and Chapter 2 sections 2.3.3, 2.3.5 and 2.3.7. 
3.3.1 NMR Spectroscopy  
General experimental procedures  
The analysis techniques and experimental procedures, including the conditions used 
to acquire the NMR spectroscopy screening data of the small molecules interactions 
with NCS1, can be found in Chapter 6.3.2.7.  However, briefly for NMR investigation 
all NMR spectra were collected at 298K, on either a Bruker AVANCE II+ 600 MHz or 
800 MHz spectrometer, equipped with 5 mm TCI triple-resonance cryoprobes.   
All protein samples were prepared in the NMR buffer and were of the concentration 
50 μM, full details on the preparation of NCS1 can be found in Chapter 6.3.2.  The 
NMR data collected for investigation included 2-D 1H 15N HSQC, 1H 13C TOCSY.  The 
2-D HSQC binding screens were carried out at a protein: inhibitor ratio of 1: 10 and 
1: 20 whereby the protein concentration was 50 μM and the inhibitors 500 μM and 
1000 μM respectively.  For the purposes of the discussion of the changes in the 
aliphatic and aromatic methyl spectra, the methyl groups of the amino acid residues 
are labeled in single letter nomenclature a=alpha, b=beta. 
Inhibitors were kept in stock solutions at 100 mM (m/v) concentration in 100% DMSO 
and were added (v/v) to the NMR samples.  The chemical shift perturbations caused 
upon an interaction of the small molecules with NCS1 are referenced against the 
interactions of NCS1 with the same amount (v/v) of DMSO, which is at the same 
percentage as in the inhibitor sample and never exceeded 5% (v/v). 
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3.3.1.1 Solubility  
The reduced solubility of the first generation of inhibitors in aqueous buffer, prevented 
accurate quantitative assessment from the biophysical techniques.  It was found to 
be particularly detrimental to the determination of the binding affinity as discussed 
previously (Chapter 2 sections 2.3.5 and 2.3.6).   
The second generation of inhibitors were designed with the addition of a solubilising 
group to overcome this problem (3.1.2).  A simple 1-D experiment was conducted 
which involved making an NMR sample of each inhibitor at 500 μM (m/v) in NMR 
buffer with a reference solvent trimethylsilyl propanoic acid (TSP) at 100 μM (Figure 
3.7).   
The TSP reference peak can be seen at 0 ppm and the integral height for this peak 
is set to a standard value between each spectra.  From this data the concentrations 
in solution of inhibitors 1, 2 and 3 were significantly less than inhibitors 4 and 5.   
This is apparent in the aromatic region (Figure 3.7 c) and is indicative that one of the 
primary aims of the second generation of inhibitors “to improve the solubility” was 
achieved. 
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Figure 3.7- Solubility screen of inhibitors 1 - 5.  Inhibitor 1 (black), Inhibitor 2 (cyan), Inhibitor 3 (blue), 
Inhibitor 4 (purple) and Inhibitor 5 (magenta).  Concentration of all inhibitors 500 μM all samples prepared 
from separate 100 mM stock solutions made up in 100% DMSO added into NMR buffer pH 6.4 with 100 
μM TSP acquired on Bruker AVANCE II 600 MHz spectrometer at 298K total percentage of DMSO in 
each sample was 0.5%. (a) Aliphatic region enlargement. (c) Aromatic region enlargement.  The 
solubility of the second generation of inhibitors (4 and 5) can be seen as being greatly improved in 
comparison to those of the first generation (1, 2 and 3). 
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3.3.1.2 Ligand interactions by NMR spectroscopy 
With the improved solubility of the ligands, the next stage was characterisation of 
ligand interactions with the protein NCS1.  This was conducted at two protein: ligand 
ratios, 1:10 and 1:20, with their improved solubility the concentration of both inhibitors 
was achievable at a substantial excess of the protein.   
Despite the improved solubility of the second generation of inhibitors, they were still 
not fully water soluble at the desired concentrations and so were solubilised in DMSO 
for the purposes of biophysical characterisation.  As with the first generation of ligands 
it was imperative to carry out identical 2-D 1H 15N HSQC control experiments with the 
same concentration of DMSO as would be present in the inhibitor containing samples 
(Figure 3.9).  In doing so we were able to determine if the changes in the chemical 
shifts of the amino acid residues were true to the Inhibitor, or were an artefact of an 
interaction with DMSO.   
Inhibitors 4 and 5 are very similar in their chemical structure and only differ with the 
addition of a para-chloro group on the phenyl ring of Inhibitor 5 (Figure 3.8).  The 
additional 4-chloro/ para-chloro group was selected following the Topliss scheme for 
optimisation of phenyl ring substitution (discussed further in Section 3.1.2).[273] 
 
Figure 3.8- The chemical structures of the second generation of designed and synthesised small 
molecules, Inhibitor 4 and Inhibitor 5, both analogues of Inhibitor 2 (Figure 3.1). 
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Despite the almost identical chemical structures, it was apparent that Inhibitor 4 
appeared to exert a lesser effect on NCS1 than Inhibitor 5.  This can be inferred from 
analysis of the 2-D 1H 15N HSQC spectra (Figure 3.10), where there are fewer peak 
attenuations and the changes in chemical shift of the residues when inhibitor 4 is 
present.  As previously discussed in Chapter 2; calculation of the “chemical shift 
perturbation” (Chapter 2 Section 2.3 eqn 2.1), allows for the determination of residues 
within the protein that are effected by a ligand.  As previously defined the sum of the 
total number of residues perturbed was calculated and from this value the top 10% 
and 20% ranges were determined.  The residues whose chemical shift perturbation 
sum fell within these two ranges were defined as being within the top 10 and top 20 
percentile respectively. 
When comparing the values of the changes in chemical shift, Inhibitor 4 caused an 
average change of between 0.00043 and 0.0405 at 500 μM (P:L 1:10), which 
subsequently increased to between 0.0043 and 0.083 as the concentration of ligand 
was increased to 1 mM (P:L 1:20).  This indicated that saturation of the protein by the 
inhibitor had not been achieved even at 500 μM and also suggested that the binding 
affinity of Inhibitor 4 could be relatively weak as the ligand was now in a 20 fold molar 
excess to that of the protein.  
Further determination of the structural effects of Inhibitor 4 on NCS1 through 
interpretation of NMR chemical shift perturbation data, indicated that at a 
concentration of 500 μM the inhibitor induced attenuation of a number of residues.  
When compared to the DMSO control, in which no attenuation occurred it can be 
concluded that these attenuations occurred directly as a result of Inhibitor 4; affected 
resonances are from residues: Asp37, Tyr52, Ile179, Gln181 and Leu183.   
Furthermore, those residues whose shifts, rather than linewidths, are greatly affected 
by the presence of the inhibitor, are within the top 10 and 20 percentile group of 
residues that experience chemical shift effects.  By combining the attenuated residues 
with those found within the top 10 and 20 percentile ranges, allowed the regions of 
NCS1 that interact with the ligand to be identified. 
In the case of Inhibitor 4 the residues whose resonances are affected by its presence 
include residues from the hydrophobic binding groove (Figure 3.13).  The regions 
implicated in the interaction with the C-terminal helix of the D2R peptide are affected 
by the presence of Inhibitor 4.[38]  Interestingly of the residues affected three Asp37, 
Tyr52 and Val68 are the original key points of contact targeted in the initial design 
process of this project (Chapter 2.1.2 Figure 2.2), they are also found to be present 
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in the top binding pose of Inhibitor 4 determined through the GOLD docking analysis 
(Figure 3.13).  Increasing the concentration of Inhibitor 4 to 1 mM led to further 
attenuation of some residues including Val13, Leu101, Ala104 and Ile128 (Figures 
3.11 and 3.13).  The position of these residues indicates that increasing the 
concentration of the ligand, increases the non-specific binding tendencies, with 
further points of contact away from the desired hydrophobic face. 
 
Figure 3.10- Ligand binding screen NCS1 with Inhibitor 4.  A 2-D 1H 15N HSQC spectra of 1H 15N 
NCS1 50 μM and 0.5% DMSO black overlaid with 1H 15N NCS1 50 μM and Inhibitor 4 500 μM P:L ratio 
of 1:10, 1H 15N NCS1 50 μM prepared in NMR buffer pH 6.4, acquired on Bruker AVANCE II+ 800 MHz 
spectrometer at 298K.  .  Changes in chemical shift of some peaks such as Trp103 are indicative of an 
interaction between the inhibitor and the protein.  The residues highlighted within the box were selected 
to indicate changes in specific residues as examples. 
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Figure 3.11- Ligand binding screen NCS1 with Inhibitor 4.  A 2-D 1H 15N HSQC spectra of 1H 15N 
NCS1 50 μM and 1.0% DMSO black overlaid with 1H 15N NCS1 50 μM and Inhibitor 4 1000 μM P:L ratio 
of 1:20.  1H 15N NCS1 50 μM prepared in NMR buffer pH 6.4, acquired on Bruker AVANCE II+ 800 MHz 
spectrometer at 298K.  Increasing the concentration of Inhibitor 4 causes further changes in the chemical 
shift of some residues including Trp103 and Ile80 indicating the protein had not reached saturation at 
500 μM.  The residues highlighted within the box were selected to indicate changes in specific residues 
as examples.  
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Figure 3.12– (a) Histogram of the perturbations of NCS1 residues from ligand binding screen NCS1: 
Inhibitor 4 at 500μM P:L 1:10.  The changes in chemical shift pertubation for each residue was calculated 
using equation 2.1; the changes are classified as percentile values of the total number of residues 
affected for analysis.  Those residues whose chemical shift underwent a change in ppm in the top 10 
percentile can be seen above the red line and these include: Val68, Gly188, Thr92, Lys4, Val91, Asp176, 
Asp44, Glu171, Phe56, Lys174, Ile128, Ser93, Phe34, Asn70.  The yellow line represents those residues 
who’s change in chemical shift was within the top 20 percentile and includes Gly133, Gly41, Tyr108, 
Gly59, Phe67, Val190, Lys106, Ser178, Arg102, Ile152, Ser184, Gln49, Glu141, Phe169. (b) Histogram 
of the perturbations in NCS1 residues from ligand binding screen NCS1: Inhibitor 4 at 1 mM P:L 1:20, 
those residues whose chemical shifts underwent a shift in the top 10 percentile can be seen above the 
red line and these include: Gly188, Asp17, Val68, Glu171, Asp44, Val91, Ser184, Phe56, Thr92, Asn70, 
Gly41, Arg102, Ser93, Gly133.  The yellow line represents those residues whose chemical shift change 
were within the top 20 percentile and includes: Ser178, Glu142, Ile152 Ser173S, Phe34F, Tyr108, 
Lys106, Val190, Glu141, Gly59, Phe67, Val180, Ile80, Val125. Unassigned residues Single peaks 
assigned with two residues Proline peaks that became too broad to assign. 
 Structure-based drug design: The Second Generation; Binding assessment using biophysical methods 
 
165 
 
 
Figure 3.13 – (a) Crystal structure of NCS1 in cyan with the corresponding residues perturbed by 
interactions with Inhibitor 4 at 500 μM determined from the corresponding histogram, the residues within 
the top 10 percentile are coloured in red and top 20 percentile in yellow, those coloured in purple belong 
to the residues that were attenuated upon the addition of the ligand and not due to the affects of DMSO 
(PDB 5AER). (b) Prediction of the binding pose for the interaction between Inhibitor 4 and NCS1 (3.1.2) 
those key residues highlighted in orange.[4] (c) Crystal structure of NCS1 in cyan with the corresponding 
residues perturbed by interactions with Inhibitor 4 at 1 mM determined from the corresponding histogram 
the residues within the top 10 percentile in red and top 20 percentile in yellow, those coloured in purple 
belong to the residues that were attenuated upon the addition of the ligand and not due to the affects of 
DMSO (PDB 5AER). (d) Chemical structure of Inhibitor 4. 
 
Structure-based drug design: The Second Generation; Binding assessment using biophysical methods 
 
166 
 
As with the biophysical characterisation of the first generation of inhibitors, calculation 
of the chemical shift pertubation for the backbone residues was followed by analysis 
of the effects of Inhibitor 4 on the aliphatic methyl and aromatic sidechain residues.  
To perform this analysis of the difference between the control 1H 13C HSQC spectra 
of 1H 15N 13C NCS1 50 μM and 0.5% DMSO with the 1H 13C HSQC spectra of 1H 15N 
13C NCS1 50 μM and Inhibitor 4 500 μM (Figure 3.14) were evaluated.   
Inhibitor 4 appears to effect seven aliphatic methyl sidechain residues, of which only 
one residue is completely attenuated; Thr144 located on the loop of EF-4.  It does 
however, cause partial attenuation of 7 residues in that one of a pair of methyl groups 
are effected: Leua16, Vala71, Valb132, Ilea152, Vala180 and Valb190   As well as 
attenuations, Inhibitor 4 appears to also cause a number of notable changes in 
chemical shift including Ile51, Ile80 and Leu89 located on EF-1 and EF-2.  As with 
previous inhibitors these residues are not located in a specific region of NCS1 but are 
in fact found across the four EF hand regions on α helices and the terminal flexible 
loop.  
With the aromatic residues, as with the first generation ligand Inhibitor 3, the Tyrε 
residues are unaffected by Inhibitor 4 (Figure 3.15); however residues that are 
attenuated include: Phe22, Phe67, Phe85, Phe153 and Phe169 primarily located in 
α helical regions of EF-2 and EF-4.   
Analysis of the effects of Inhibitor 4 on the sidechain residues is in agreement with 
the 2-D 1H 15N HSQC spectra, in that the observed change in the presence of the 
inhibitor is more subtle. 
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Figure 3.15- Two overlaid aromatic sidechain spectra of NCS1 with and without Inhibitor 4.  The 
aromatic 1H 13C spectra of 1H 15N 13C NCS1 50 μM and 0.5% DMSO (purple) overlaid with the 1H 13C 
spectra of 1H 15N 13C NCS1 50 μM and Inhibitor 4 500 μM (blue), the aromatic residues labelled are 
those for which the assignment was transferrable.  Those residues for which transfer of assignment was 
not possible include those which reside on the same peak, or those which were attenuated by the 
presence of Inhibitor 4 including; Phe22, Phe67, Phe85, Phe153 and Phe169.  The spectra were 
acquired at 298K in NMR buffer pH 6.4 on Bruker AVANCE II 600 MHz spectrometer. 
Further to the investigation of the interaction between Inhibitor 4 and NCS1 in relation 
to the positions on the protein that are effected by the ligand, we were also able to 
determine the chemical moieties of the ligand that were implicated in the interaction 
with NCS1.   
To achieve this we employed two experiments: 1-D 1H saturation transfer difference 
(STD) and 1-D 1H water ligand observation with gradient spectroscopy 
(waterLOGSY).  The experimental processes shall not be discussed in detail in this 
chapter, more information can be found within Chapter 4.  However in short, both 
experiments work on the basis of the transfer of magnetisation, the difference 
between the two lies in where the saturation of magnetisation is initiated.  In the case 
of the STD experiment this is a resonance of the protein spectra where no ligand 
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signals can be found usually upfield of 0 ppm.[291]  With the waterLOGSY this 
position is the bulk water that can be found within binding regions between proteins 
and ligands.[292][293]  In the STD experiment, if there is a binding event, 
magnetisation is transferred from the irradiated protein to the bound ligand which is 
in a dynamic equilibrium with the free ligand in solution resulting in the appearance of 
the ligand signals within the difference spectra.  This process was conducted for 
inhibitors 1, 2 and 3; however due to their limited solubility, no meaningful data was 
obtained using this technique; example spectra can be found in the appendix (Section 
A.1). 
The STD and waterLOGSY spectra of Inhibitor 4 500 μM with NCS1 50 μM (Figure 
3.16 b) was compared to the same spectra of the Inhibitor alone in NMR buffer and 
at the same concentration; the presence of ligand signals in the difference spectra in 
the complex is indicative of a binding interaction.  This is observed when we directly 
compare the two STD spectra (Figure 3.16 a and b (black spectral line)), in the control 
STD experiment there is no evolution of the ligand signal as there is no protein present 
to be irradiated and hence no possible binding interaction.  In the presence of NCS1 
we are able to see the hydrogen signals from the following atomic positions: 1, 2, 3, 
4, 5, 6, 7, 9, 10 and 11 on the inhibitor (Figure 3.16 b).  This is in concordance with 
the magnetisation being transferred from the protein, to the bound ligand which is in 
an exchange equilibrium with free ligand in solution and hence detection of the ligand 
signals.   
Analysis of the two waterLOGSY spectra showed a reduction in the intensity of the 
ligand signals of Inhibitor 4 between the buffer control and the protein containing 
sample, indicative of an interaction between the protein and the Inhibitor.  The NH 
group 7 appears positive as it is exchangeable in nature.  Hence, both the STD and 
waterLOGSY experiment indicate that there is a binding event occurring between 
Inhibitor 4 and NCS1, although the relative affinity cannot be easily determined. 
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Figure 3.16- 1-D ligand screening spectra of Inhibitor 4.  (a) Buffer standard 500 μM Inhibitor 4 in 
NMR buffer; 1-D 1H spectra (blue), 1-D 1H waterLOGSY spectra (red) and 1-D 1H STD (black). (b)  
Binding screen 500 μM Inhibitor 4 and 50 μM NCS1 in NMR buffer; 1-D 1H spectra (blue), 1-D 1H 
waterLOGSY spectra (red) and 1-D 1H STD (black).  Comparison between the buffer controls (a) and 
the protein containing experiments (b) indicate possible binding events occurring at ligand positions 1, 
2, 3, 4, 5, 6, 7, 9, 10 and 11.  This is observable in the STD spectra where the relative ligand signals are 
apparent and negative in the waterLOGSY spectra the relative intensities of the peaks are reduced 
slightly.  Resonances 8, 12 and 13 are not observed as they appear in the regions 4.5 ppm and 3.74 - 
3.43 ppm respectively and these regions are obscured by the buffer water and DMSO in the samples. 
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As with Inhibitor 4, NMR spectroscopic methods were employed to investigate the 
interaction between NCS1 and Inhibitor 5.  As previously mentioned the similarity 
between the two compounds only varies with the additional para-chloro group present 
on the phenyl ring.  It was, therefore, surprising that with this small difference, Inhibitor 
5 appeared to display what could be interpreted as a much stronger interaction with 
NCS1.  This observation could be explained by the fact that the inclusion of chlorine 
makes the compounds more hydrophobic, which may fit in with overall characteristics 
of PPI binding (PPI interactions tend to be large, flat and hydrophobic in nature 
generally). 
This conclusion is implied through a number of experimental results, firstly the 
acquisition of a 2-D 1H 15N HSQC spectra at 500 μM Inhibitor 5 and 50 μM NCS1 
(Figure 3.17).  The subsequent “chemical shift perturbation” calculations elucidated 
that the change in chemical shifts ranged from 0.00138 - 0.08 which is substantially 
more than the changes incurred through the effects of Inhibitor 4 at the same 
concentration.   
Secondly there were a greater number of residues that were attenuated at 500 μM 
Inhibitor 5, 15 in total in comparison to the five induced through the effects of Inhibitor 
4.  Those 15 residues include; Asp37, Gln42, Tyr52, Lys53, Gly59, Arg94, Ala104, 
Asp126, Ile128I, Ile179I, Gln181, Leu183, Ser184 and Gly188, the position of the 
attenuated residues is not limited to a specific EF-hand region, although there are a 
large number found within the hydrophobic binding groove (Figure 3.20 a).   
The top binding pose predicted through GOLD docking analysis for Inhibitor 5 is more 
linear and lies along the hydrophobic binding groove (Figure 3.20 b), in comparison 
to that of Inhibitor 4 which appears to adopt a curved pose (Figure 3.13 b).  In light of 
this, through analysis of the attenuations or changes in chemical shift at 500 μM, three 
of those residues involved are of the original 6 that were used in the initial design 
process for the first generation of inhibitors (Chapter 2.1, Figure 2.2).   
No residues found on the first α helix appear to undergo significant changes in 
chemical shift, an observation also seen with the effects of Inhibitor 4.  There are a 
greater number of residues within the top 10 percentile located on EF-1 and EF-2, 
whereas those within the top 20 percentile tend to be located around EF-3 and EF-4.  
As the concentration of the inhibitor is increased to 1 mM (Figure 3.18 and 3.19), the 
range over which the changes in chemical shift of the residues occur, increases ever 
so slightly to between 0.006 and 0.105.  Again as with Inhibitor 4, this is indicative of 
the fact that the protein has not yet reached saturation of inhibitor, despite the protein 
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to ligand ratio now being increased to 1:20.  However as the difference between the 
two ranges is smaller than that of the difference between the two of Inhibitor 4, it could 
be inferred that the protein is reaching saturation faster with Inhibitor 5 than 4.  
Furthermore this could possibly indicate a stronger binding affinity, although this is 
not confirmed and could be done so through ligand titration analysis in future work.   
Increasing the concentraton of Inhibitor 5 lead to the attenuation of a number of the 
residues that underwent a large change in chemical shift at the lower concentration 
of 500 μM, including Val68, Leu101 and Val180.  It also increased a number of the 
“chemical shift perturbation” values for residues such as Asp44, Phe56 and Ser178.  
It did not however, affect the residues the regions that appeared to undergo the 
greatest number of significant changes EF-1 and EF-2.  In addition, the non-specificity 
of interaction did not increase as the concentration of the inhibitor was increased (as 
seen with Inhibitor 4). 
Following the first generation and Inhibitor 4, the effects of Inhibitor 5 on the aliphatic 
methyl and aromatic sidechain residues of NCS1 were also investigated.  To do this 
as with the previous analysis, the difference between the control 1H 13C HSQC 
TOCSY spectra of 50 μM 1H 15N 13C NCS1 and 0.5% DMSO with the 1H 13C HSQC 
TOCSY spectra of 50 μM 1H 15N 13C NCS1 and Inhibitor 5 500 μM (Figure 3.21) are 
evaluated.   
Inhibitor 5 appears to effect nine aliphatic methyl sidechain residues, of which only 
one residue is completely attenuated; Leu189 located on the terminal loop of EF-4.  
It does however, cause partial attenuation of eight residues, meaning that one of a 
pair of methyl groups are effected and those residues include; Leua16, Leub43, 
Vala71, Ilea128, Vala132, Ilea152, Vala180 and Valb190.  Along with the attenuation of 
the residues, there are a number of notable changes in chemical shift including Ile51, 
Ile80, Ile124 and Ile179.  As with previous inhibitors these residues are not located in 
a specific region of NCS1 but are in fact found across the four EF hand domains, on 
α helices and flexible loop regions.  As with the first generation ligand Inhibitor 3 and 
Inhibitor 4, the aromatic Tyrε residues are un-attenuated by Inhibitor 5 (Figure 3.22), 
however residues that are attenuated include; Phe22, Phe67, Phe85, Tyr129, 
Phe153 and Phe169 primarily located in α helical regions of EF-2 and EF-4. 
The effects of Inhibitor 5 on the aliphatic methyl and aromatic sidechain residues of 
NCS1, is in concordance with the 2-D 1H 15N HSQC spectra at the same 
concentration.  We observe more changes in the NCS1 backbone and sidechain 
residues in the presence of Inhibitor 5, in comparison to the same spectra in the 
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presence of Inhibitor 4.  The effects of both second generation inhibitors appear to be 
less than observed for Inhibitor 1 and Inhibitor 2, where we observed a large number 
of attenuations in sidechain residues. 
 
Figure 3.17- Ligand binding screen NCS1 with Inhibitor 5.  A 2-D 1H 15N HSQC spectra of 1H 15N 
NCS1 50 μM and 0.5% DMSO (black), overlaid with 1H 15N NCS1 50 μM and Inhibitor 5 500 μM (red) 
P:L ratio of 1:10, 1H 15N NCS1 50 μM prepared in NMR buffer pH 6.4, acquired on Bruker AVANCE II+ 
800 MHz spectrometer at 298K.  Changes in chemical shift and attenuation of a number of peaks relating 
to a number of residues including Trp103 and Ile80 is indicative of an interaction between the inhibitor 
and the protein that appears to be stronger than observed for Inhibitor 4.  The residues highlighted within 
the box were selected to indicate changes in specific residues within a conserved region of the HSQC 
spectra.  
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Figure 3.18- Ligand binding screen NCS1 with Inhibitor 5.  A 2-D 1H 15N HSQC spectra of 1H 15N 
NCS1 50 μM and 1.0% DMSO (black) overlaid with 1H 15N NCS1 50 μM and Inhibitor 5 1000 μM (red) 
P:L ratio of 1:20, 1H 15N NCS1 50 μM prepared in NMR buffer pH 6.4, acquired on Bruker AVANCE II+ 
800 MHz spectrometer at 298K.  Further changes in the chemical shift of some of peaks Trp103 and 
Ile80 is further indication of an interaction between the inhibitor and the protein.  It also highlights that 
increasing the concentration of the inhibitor is inducing further changes which is associated with the 
protein not being fully saturated at 500 μM.  The residues highlighted within the box were selected to 
indicate changes in specific residues within a conserved region of the HSQC spectra. 
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Figure 3.19– (a) Histogram of the perturbations of NCS1 residues from ligand binding screen NCS1: 
Inhibitor 5 at 500 μM, P:L 1:10.  The changes in chemical shift pertubation for each residue was 
subsequently calculated, and the difference changed into percentile values of the total number of 
residues affected for analysis.  Those residues whos chemical shift underwent a change in ppm within 
the top 10 percentile can be seen above the red line and those residues include: Val68, Gly133, Phe56, 
Asp44, Phe67, Thr92, Glu171, Phe34, Val91, Lys106, Glu142, Tyr108, Ile152.  The yellow line 
represents those residues who’s change in chemical shift was within the top 20 pecentile and includes 
Gly41, Ser178, Arg102, Asn134, Ser173, Val190, Ser93, Glu141, Ile86, Cys36, Trp103, Ala65, Val125. 
(b) Histogram of the perturbations in NCS1 residues from ligand binding screen NCS1: Inhibitor 5 at 1 
mM P:L 1:20, those residues whos chemical shift underwent a change in ppm within the top 10 percentile 
can be seen above the red line and those residues include: Gly133, Phe56, Glu171, Asp44, Phe67, 
Gly41, Ser178, Lys106, Arg102, Thr92, Ile152, Tyr108, Phe34.  The yellow line represents those 
residues who’s change in chemical shift was within the top 20 percentile and includes: Val91, Glu142, 
Val190, Ser173, Asn134, Glu141, Ser93, Ile86, Cys38, Leu43, Glu81, Phe169, Val125. Unassigned 
residues Single peaks assigned with two residues Proline peaks that became too broad to assign.
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Figure 3.20– (a) Crystal structure of NCS1 in cyan with the corresponding residues perturbed by 
interactions with Inhibitor 5 at 500 μM determined from the corresponding histogram the residues within 
the top 10 percentile coloured in red and top 20 percentile in yellow, those coloured in purple belong to 
the residues that were attenuated upon the addition of the ligand and not due to the affects of DMSO 
(PDB 5AER). (b) Prediction of the binding pose for the interaction between Inhibitor 5 and NCS1 (3.1.2), 
those key residues highlighted in orange.[4] (c) Crystal structure of NCS1 in cyan with the corresponding 
residues perturbed by interactions with Inhibitor 5 at 1 mM determined from the corresponding histogram, 
the residues within the top 10 percentile coloured in red and top 20 percentile in yellow, those coloured 
in purple belong to the residues that were attenuated upon the addition of the ligand and not due to the 
affects of DMSO (PDB 5AER). (d) Chemical structure of Inhibitor 5. 
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Figure 3.22- Two overlaid aromatic sidechain spectra of NCS1 with and without Inhibitor 5.  The 
aromatic 1H 13C spectra of 1H 15N 13C NCS1 50 μM and 0.5% DMSO (purple), overlaid with the 1H 13C 
spectra of 1H 15N 13C NCS1 50 μM and Inhibitor 5 500 μM (red), the aromatic residues labelled are those 
for which the assignment was transferrable.  Those residues for which transfer of assignment was not 
possible include those which reside on the same peak, or those which were attenuated by the presence 
of Inhibitor 5 including; Phe22, Phe67, Phe85, Tyr129, Phe153 and Phe169.  The spectra were acquired 
at 298K in NMR buffer pH 6.4 on Bruker AVANCE II 600 MHz spectrometer. 
As discussed previously the use of the 2-D 1H 15N HSQC experiment allowed the 
interpretation of the specific amino acids within NCS1 that underwent a change in 
chemical shift in the presence of Inhibitor 5.  However, other NMR experiments such 
as the STD and waterLOGSY experiments enable us to investigate what parts of the 
inhibitor interacting with the protein.  By combining the two sets of data a more 
detailed understanding of the interaction between the protein and the ligand can be 
determined.   
As with Inhibitor 4 the 1-D 1H saturation transfer resonance (STD) and water ligand 
observation with gradient spectroscopy (waterLOGSY) data for Inhibitor 5 provided 
quite conclusive indications of a binding event, and identified the regions of the 
inhibitor which make contact with the protein.  As explained with Inhibitor 4, there is 
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no ligand signal in the STD spectra of Inhibitor 5 on its own in NMR buffer, as there 
is no protein from which the magnetisation can be transferred.  
Upon closer inspection of the spectra (Figure 3.23) and comparison to that of the 
protein containing sample the ligand signals relating to resonances 1, 2, 3, 4, 5, 8, 9 
and 10 are strong and visible.  Resonances 7, 11 and 12 are not observed as they 
appear in the regions 4.5 ppm and 3.74 - 3.43 ppm respectively and these regions 
are obscured by the buffer, water and DMSO in the samples.  Examination of the 
results of the waterLOGSY spectra in parallel to that of the STD spectra, the 
resonances relating to positions 4 and 5 are inverted, and the resonances relating to 
positions 1, 2, 3, 8, 9 and 10 are significantly attenuated.  Both spectra strongly 
indicate that there is a binding event occurring between Inhibitor 5 and NCS1 and that 
the majority of the protons of the inhibitor are contributing to this binding interaction. 
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Figure 3.23- 1-D ligand screening spectra of Inhibitor 5. (a) Buffer standard 500 μM Inhibitor 5 in 
NMR buffer; 1-D 1H spectra (blue), 1-D 1H waterLOGSY spectra (red) and 1-D 1H STD (black). (b)  
Binding of 500 μM Inhibitor 5 to NCS1 50 μM in NMR buffer; 1-D 1H spectra (blue), 1-D 1H waterLOGSY 
spectra (red) and 1-D 1H STD (black).  Comparison between the buffer controls (a) and the protein 
containing experiments (b) indicate possible binding events occurring at ligand positions 1, 2, 4, 5, 6, 8, 
9, 10.  This is deduced in the STD spectra where the relative ligand signals appear strong and negative, 
the corresponding peaks in the waterLOGSY spectra for positions 1, 2, 8, 9 and 10 are completely 
reduced in intensity with peaks 4 and 5 flipped on the opposite phase compared with the other 
resonances.  The results of both experiments are indicative of a relatively strong binding interaction.  
Resonances 7, 11 and 12 are not observed as they appear in the regions 4.5 ppm and 3.74 - 3.43 ppm 
respectively and these regions are obscured by the buffer water and DMSO in the samples. 
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3.3.2 Binding affinity determination by ITC 
General experimental procedures  
The experimental procedure and the conditions used for the second generation 
characterisation using ITC experiments conducted in this section are discussed in 
detail in Chapter 6.3.2.9.  Briefly, all unlabelled NCS1 protein samples were prepared 
in the ITC buffer consisting of 50 mM tris HCl, 50 mM NaCl, 5 mM CaCl2 at pH 7.5.  
The concentration of the protein and ligand were kept constant for the initial 
experiments and subsequently varied as required.   
Due to the improved solubility of the inhibitors the experiments were conducted in the 
classical manner meaning that the ligand was titrated into the cell containing the 
protein NCS1.  As discussed previously, experimentally ITC allows the determination 
of the thermodynamic properties ΔH and ΔS for a paticular binding interaction, where 
ΔH is the enthalpy change and ΔS the change in entropy.  These properties can be 
interpreted, providing information on the changes occuring between two binding 
partners.  The details behind how the thermodynamic properties can be used to derive 
further information of the binding interaction has been discussed in detail previously 
in Chapter 2 and can be found in Section 2.3.5.  Analysis of the raw data was 
conducted in the software package Origin7 (OriginLab, Northampton, MA) and 
involved subtraction of a respective DMSO control experiment from the experimental 
data of each ligand.   
Due to the weaker nature of the interaction between Inhibitor 4 and NCS1 
demonstrated using NMR spectroscopy, only the binding affinity of the interactions 
between Inhibitor 5 and NCS1 were investigated using ITC.  The experimental results 
can be found in this section.   
3.3.2.1 Inhibitor 5 
With the improved solubility of the second generation of inhibitors, the experimental 
techniques used were able to follow more classical approach, the inhibitor titrated into 
the cell containing the protein.   
In the case of Inhibitor 5, a number of experiments were performed at different 
concentration ratios between the Inhibitor and protein, an optimised isotherm can be 
seen (Figure 3.26 a).  In this experiment Inhibitor 5 at a final concentration of 8 mM 
was titrated into NCS1 400 μM, the experiment was conducted at two temperatures 
25 ˚C and 10 ˚C.  Interestingly, variation of the temperature resulted in two different 
binding constants, at 25 ˚C; the KD was four times smaller than that at 10 ˚C, despite 
the thermodynamic data being similar (Table 3.2, Figures 3.24, 3.25). 
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Table 3.2- Inhibitor 5 ITC data.  A table showing the thermodynamic properties from the ITC experiment 
of 8 mM Inhibitor 5 and 400 μM NCS1 at two different temperatures.  Both sets of thermodynamic 
properties are similar although the derived KD is four fold higher at the higher temperature with both 
experiments having an improved goodness of fit in comparison to the first generation of inhibitors. 
Experiment Title 
 
ΔH  
(kcal mol-1) 
-TΔS  
(kcal mol-1) 
ΔG  
(kcal mol-1) 
KD 
 μM 
Chi^2 
10˚C Inhibitor 5 8mM:  
NCS1 400μM 
 
-0.738 
(±0.03912) 
 
-4.87 
 
-5.61 
 
47.2 
 
 
2262 
 
25˚C Inhibitor 5 8mM: 
 NCS1 400μM 
 
-1.012 
(±0.135) 
 
-4.02 -4.82 201.207 
 
 
400.8 
 
Figure 3.24- The thermodynamic parameters (dH= ΔH green, -TdS= -TΔS blue and dG= ΔG yellow) 
obtained from the ITC experiment of the binding interaction between Inhibitor 5 8 mM and NCS1 400 μM 
at 10 ˚C.  When determining ΔG the most influential value is ΔH, ideally it should be large and negative, 
-TΔS contributes substantially less to the value of ΔG and the binding affinity and tends to be small and 
positive or small and negative. 
 
Figure 3.25- The thermodynamic parameters (dH= ΔH green, -TdS= -TΔS blue and dG= ΔG yellow) 
obtained from the ITC experiment of the binding interaction between Inhibitor 5, 8 mM and NCS1 400 
μM at 25 ˚C.   
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When we compare the two isotherms more closely, we can see the goodness of fit 
value (Chi^2) for the experiment at 25 ˚C is more favourable as it is smaller.[212–214]  
Both experiments exhibit a negative T∆S value which can be inferred as hydrophobic 
interactions occurring, this data agrees with the nature of the NCS1 binding site and 
indicates the reaction is entropically driven.  There is also a difference in the 
stoichiometry of binding (n) at 10 ˚ C the ligand: protein ratio is 2:1, however increasing 
the temperature results in this stoichiometric ratio changing to 1:1.  The most likely 
explanation is that at the lower temperature NCS1 is a dimer, hence presenting two 
binding sites for Inhibitor 5.   
At both 10 ˚C and 25 ˚C neither experiments appear to reach saturation, infact 
continuation of each experiment followed by concatenation of the relative data sets 
revealed a major problem with using ITC to determine the binding affinity for this 
system.  The delay in injection between the first experiment and starting the second 
meant that the residual DMSO already in the cell had the chance to interact with 
NCS1.  This therefore resulted in an abnormal change in heat given off when the 
experiment was continued (concatenated figures of the experiment at 10 ˚C can be 
found in the appendix, Section A.4). 
Therefore, although the solubility of the inhibitors has improved allowing for a higher 
concentration to be used within the experiments, the percentage of DMSO used is 
also increased to a much greater percentage in comparison to that used for first 
generation characterisation.  The interactions of DMSO with NCS1 at this higher 
concentration, mean that ITC is an unsuitable technique for determining the binding 
affinity of the system, until the requirement for DMSO is diminished further. 
 
 Structure-based drug design: The Second Generation; Binding assessment using biophysical methods 
184 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 3
.2
6
- 
B
in
d
in
g
 a
ff
in
it
y
 d
e
te
rm
in
a
ti
o
n
, 
Is
o
th
e
rm
a
l 
T
it
ra
ti
o
n
 C
a
lo
ri
m
e
tr
y
 c
u
rv
e
s
 o
f 
N
C
S
1
 a
n
d
 I
n
h
ib
it
o
r 
5
. 
 T
w
o
 b
in
d
in
g
 is
o
th
e
rm
s
, 
IT
C
 I
s
o
th
e
rm
 (
to
p
) 
a
n
d
 r
e
s
u
lt
a
n
t 
c
u
rv
e
 (
b
o
tt
o
m
) 
fr
o
m
 t
h
e
 e
x
p
e
ri
m
e
n
t 
8
 m
M
 I
n
h
ib
it
o
r 
5
 a
n
d
 4
0
0
 μ
M
 N
C
S
1
 a
t 
1
0
 ˚
C
 (
a
) 
a
n
d
 2
5
 ˚
C
 (
b
) 
8
%
 D
M
S
O
, 
5
0
 m
M
 t
ri
s
 H
C
l,
 5
0
 m
M
 N
a
C
l,
 5
 m
M
 C
a
C
l 2
 p
H
 7
.5
. 
 F
it
ti
n
g
 o
f 
th
e
 c
u
rv
e
 w
a
s
 c
o
n
d
u
c
te
d
 i
n
 O
ri
g
in
 7
 u
s
in
g
 t
h
e
 s
in
g
le
 s
e
t 
o
f 
s
it
e
s
 c
u
rv
e
 f
it
ti
n
g
 m
o
d
e
l 
p
ro
d
u
c
e
d
 a
 b
in
d
in
g
 m
o
d
e
l 
w
it
h
 a
 d
e
ri
v
e
d
 b
in
d
in
g
 a
ff
in
it
y
 K
D
 o
f 
4
7
.2
 μ
M
 a
n
d
 2
0
1
.2
 μ
M
 f
o
r 
th
e
 e
xp
e
ri
m
e
n
ts
 a
t 
1
0
 ˚
C
 a
n
d
 2
5
 ˚
C
 r
e
s
p
e
c
ti
v
e
ly
. 
 B
o
th
 e
xp
e
ri
m
e
n
ts
 h
a
v
e
 i
m
p
ro
v
e
d
 C
h
i^
2
 v
a
lu
e
s
 r
e
la
ti
n
g
 t
o
 t
h
e
 g
o
o
d
n
e
s
s
 o
f 
fi
t.
 
 Structure-based drug design: The Second Generation; Binding assessment using biophysical methods 
185 
 
3.3.3 Binding affinity determination using Fluorescence Spectroscopy  
General experimental procedures  
All fluorescence data of the second generation of inhibitors was collected at The 
University of Liverpool on a Cary Eclipse Fluorescence spectrophotometer (Agilent 
technologies), the raw data was analysed in Origin 7 (OriginLab, Northampton, MA). 
Unlabelled NCS1 was prepared as described in Chapter 6.3.2.  Briefly, unlabelled 
NCS1 was buffer exchanged into fluorescence buffer consisting of 50 mM tris HCl, 
50 mM NaCl, 5 mM CaCl2 pH 7.5; and aliquoted into 11 samples at a final 
concentration of 1 μM (v/v) (200 μL).   
For the individual single point reads of the tryptophan fluorescence assay, Inhibitor 4 
and Inhibitor 5 were added in the required volume from a single stock solution in 100% 
DMSO, to the already aliquoted NCS1 samples contained in eppendorf’s.  The 
concentration range for each inhibitor over the 11 samples was 0 - 1 mM.  Each 
individual assay sample was transferred to a quartz 16.160-F/Q/10 cuvette (Starna 
Scientific) and excited at a wavelength (λ) of 280 nm, with the excitation slit width 5 
nm and the emission slit width 20 nm. 
3.3.3.1 Inhibitor binding assay 
In keeping with previous fluorescence assays performed on the first generation of 
inhibitors, the interactions between inhibitors 4 and 5 with NCS1 were investigated 
initially in an identical manner.  However it was apparent that the concentration range 
for the inhibitor of 0 - 90 μM should be increased as saturation was not achieved in 
this range, therefore the maximal concentration of inhibitors 4 and 5 were increased 
to 1 mM.  At this maximal molar excess of inhibitor, the protein ligand ratio (P:L) was 
1: 1000. 
As previously explained, intrinsic tryptophan fluorescence is highly sensitive to any 
changes in the local environment.  It is therefore a useful technique for evaluating 
changes in a proteins structure, induced through possible binding interactions and 
also in determining binding affinity.[216,294]  The pre-requisite for the experiment is 
the presence of tryptophan residues, especially if like in NCS1 they are located in any 
key binding domains.  In contrast to the first generation of inhibitors, it is apparent that 
both Inhibitor 4 and Inhibitor 5 had less of an effect with the fluorescence of NCS1.  
This can be interpreted from the fact that the inhibitors were unable to cause 
saturation of the tryptophan fluorescence of NCS1 at 90 μM (a 1:90 P:L ratio) and 
even when the concentration was increased to 1mM, Inhibitor 4 was still unable to 
cause saturation despite being in such great excess.  In fact Inhibitor 4 was unable to 
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cause a significant decrease in the fluorescence until it was at a concentration of 62.5 
μM (P:L 1: 62.5).   
The increasing concentrations of Inhibitor 4 and 5 also did not appear to cause any 
structural changes of the protein (Figure 3.27) as observed in the experiments of 
inhibitors 2 and 3 (Chapter 2.3.8, Figure 2.49).  However, these results do appear to 
be in concordance with the NMR data which suggests that Inhibitor 4 does not cause 
a significant change in the chemical shift of either Trp30 or Trp103 at a 20 fold molar 
excess.   
Inhibitor 5 does cause a more significant change in the chemical shift of Trp103 
although it is not attenuated, when comparing this observation to the tryptophan 
fluorescence we can infer that although saturation is not reached, it does have a 
greater effect on the tryptophan fluorescence of NCS1 than Inhibitor 4.  This does not 
mean that the inhibitors are not interacting with the protein, it simply means that any 
interactions may not involve the tryptophan residues.   
Binding affinity of the inhibitors using tryptophan fluorescence was not determined 
because as with the ITC data, the use of DMSO to solubilise inhibitors 4 and 5 
interfered with the fluorescence readings.  Any control experiments found that this 
interference changed over time and hence could not be used to normalise the data, 
therefore any binding constants derived from the experiments would be unreliable. 
 
 
 
 
 
 
 
 
 
 
 
 Structure-based drug design: The Second Generation; Binding assessment using biophysical methods 
187 
 
 
 
F
ig
u
re
 3
.2
7
- 
F
lu
o
re
s
c
e
n
c
e
 B
in
d
in
g
 t
it
ra
ti
o
n
 a
s
s
a
y
s
 o
f 
N
C
S
1
 1
μ
M
 w
it
h
 I
n
h
ib
it
o
rs
4
 a
n
d
 5
 o
v
e
r 
a
 r
a
n
g
e
 o
f 
0
 -
 1
 m
M
. 
(a
) 
In
h
ib
it
o
r 
4
 f
lu
o
re
s
c
e
n
c
e
 b
in
d
in
g
 a
s
s
a
y
, 
N
C
S
1
 
a
t 
1
 μ
M
 a
n
d
 I
n
h
ib
it
o
r 
4
 t
it
ra
te
d
 i
n
 t
o
 t
h
e
 i
n
d
iv
id
u
a
l 
p
ro
te
in
 s
a
m
p
le
s
 a
t 
c
o
n
c
e
n
tr
a
ti
o
n
s
 0
 μ
M
, 
0
.9
 μ
M
, 
1
.9
 μ
M
, 
3
.9
 μ
M
, 
6
.7
 μ
M
, 
1
5
.6
 μ
M
, 
3
1
.2
5
 μ
M
, 
6
2
.5
 μ
M
, 
1
2
5
 μ
M
, 
5
0
0
 μ
M
 
a
n
d
 1
 m
M
. 
 (
b
) 
 I
n
h
ib
it
o
r 
5
 f
lu
o
re
s
c
e
n
c
e
 b
in
d
in
g
 a
s
s
a
y
, 
N
C
S
1
 a
t 
1
μ
M
 a
n
d
 I
n
h
ib
it
o
r 
5
 t
it
ra
te
d
 i
n
 t
o
 t
h
e
 i
n
d
iv
id
u
a
l 
p
ro
te
in
 s
a
m
p
le
s
 a
t 
c
o
n
c
e
n
tr
a
ti
o
n
s
 a
s
 w
it
h
 I
n
h
ib
it
o
r 
4
. 
 I
n
 
b
o
th
 c
a
s
e
s
 w
e
 o
b
s
e
rv
e
 a
 q
u
e
n
c
h
in
g
 i
n
 t
h
e
 f
lu
o
re
s
c
e
n
c
e
. 
 
 Structure-based drug design: The Second Generation; Binding assessment using biophysical methods 
188 
 
Summary 
The structure-based development of inhibitors to target the protein-protein interaction 
between NCS1 and D2R peptide has involved the biophysical analysis of a first 
generation of molecules, the results of which subsequently led to the development 
and synthesis of a second generation.   
Designed around the most successful inhibitor of the first generation (Inhibitor 2) 
inhibitors 4 and 5 displayed an improved solubility profile (Figure 3.7), which aided 
the biophysical analysis of their interactions with NCS1.  The analysis of the 
interactions of the inhibitors with NCS1 using NMR spectroscopic methods, indicated 
that the additional para-chloro group of Inhibitor 5 appeared to improve the 
interaction.  This can be inferred from comparisons of the 2-D 1H 15N HSQC spectra 
(Figures 3.10, 3.11, 3.17, 3.18) where we observe, a greater number of changes in 
chemical shift of NCS1 residues in the presence of Inhibitor 5, than at the same 
concentrations of Inhibitor 4.   
Moreover when we subsequently compare this data to that of the first generation 
(Chapter 2.3.4, Figures 2.28, 2.29, 2.34, 2.39), we can deduce that inhibitors 4 and 5 
display an improved interaction with NCS1.  Furthermore there appears to be a 
greater number of residues that undergo a significant change in chemical shift around 
the hydrophobic binding groove (Figures 3.13 and 3.20), than seen with Inhibitor 3 or 
even the parent compound Inhibitor 2 (Chapter 2.3.4, Figure 2.34).   
Despite the improved solubility profiles of Inhibitors 4 and 5, determination of the 
binding affinity using ITC techniques was still not reliable.  It was ascertained that 
solubilising the compounds in DMSO caused difficulties with the results.  This is due 
to the fact that to reach the necessary concentration of Inhibitor 5 required to saturate 
NCS1 binding, the large amount of DMSO (8%) had a detrimental impact on the 
experimental readout.  DSMO was found to interact with the protein in a time 
dependent fashion, altering the thermodynamic results, such that any derived binding 
constant (KD) was not a clear measure of binding.  A similar phenomenon was 
observed in the tryptophan fluorescence experiments.  Future work to achieve an 
accurate binding constant using ITC and fluorescence techniques, could include 
using a different organic solvent that does not interact with NCS1 to solubilise the 
inhibitor further increase solubility so DMSO is not needed.   
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4. Small Molecule Compound Library 
4.1 Introduction- The role of NMR and computation in fragment-
based drug discovery. 
There are a number of different biochemical techniques often used in studying 
protein-ligand interactions including isothermal titration calorimetry (ITC), biosensor 
array systems (surface plasmon resonance (SPR) and Octet system), microscale 
thermophoresis, fluorescence polarisation (FP), fluorescence resonance energy 
transfer (FRET), enzyme linked immunosorbent assay (ELISA), nuclear magnetic 
resonance (NMR) and X-ray crystallography.  Each of these methods has its 
strengths and weaknesses and these are summarised in Table 4.1. 
The use of NMR spectroscopy to probe protein-ligand interactions is an important 
field in drug discovery and development, often used by research groups in fragment-
based drug discovery processes (Figure 4.1).[295]  In some cases libraries containing 
many thousands of small molecules are screened in a high throughput manner to 
discover novel hit compounds, the process can be both costly and time consuming, 
involving numerous multifaceted steps.[295]  To avoid wasting time and resources it 
is important for the design of the compound libraries to be well thought out, taking into 
account the likelihood of fragment: target interaction, diversity of the library ADMET 
properties such as solubility to reduce the number of false positives and enhance 
developability potential of any hits, before the experimental screening is 
undertaken.[296]   
The advances in computing mean that the time it takes to perform computational 
screening has become significantly reduced compared to a decade ago, making it a 
much more efficient process.  However the reliability with discovering hit compounds 
using this method in comparison to high throughput library screening is not as 
successful.[297]  As with the advances in computing, the knowledge of the structures 
of target proteins is also increasing, to date the number of distinct protein sequences 
in the PDB stands at 35639 and of those the structures of human sequences 
28941.[298]  Thus to improve the probability of finding quality hit molecules, 
computational techniques are used in combination with the known target structures 
in virtual screening processes such as molecular docking.[297]
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Table 4.1- A table comparing the advantages and disadvantages of a number of the biophysical 
techniques used to study protein- ligand interactions. 
Technique Description Advantages Disadvantages 
 
 
 
 
 
 
 
ITC [210] 
 
 
 
 
 
 
The direct 
measurement of the 
heat generated or 
absorbed during the 
interaction of two 
molecules. 
Able to determine 
binding affinity.  
Label free. 
No molecular weight 
limitations.  
Optical clarity un-
important. 
 
Requires estimate of KD to 
calculate concentrations of 
protein and ligand to use for 
initial experiment. 
Can only measure KD values 
between mM - nM, weaker 
binding interactions require 
a specific “low c-value” 
titration. 
Sensitive to differences in 
buffer, resulting in artificial 
heats. 
Sensitive to bubbles in the 
protein and any precipitation 
of protein or ligand. 
 
 
 
 
 
SPR [299] 
 
 
The label-free 
detection of bio-
molecular interactions 
using polarised light. 
Label free. 
Good for evaluation of 
macromolecules. 
Equilibrium 
measurements ∆H and 
KD. 
Able to detect low 
affinity interactions. 
Requires a small 
amount of protein. 
 
Not good for high throughput 
screening (HTS) and 
concentration assays. 
Optimal for large molecules 
> 1000 Da. 
Lengthy assay development. 
 
 
Octet System 
[300] 
 
Optical analytical 
technique for the real 
time analysis of 
biomolecular 
interactions. 
 
 
Optimised version of 
SPR technique able to 
withstand HTS whilst 
maintaining accuracy. 
Label free 
 
 
 
 
 
 
 
Microscale 
Thermophoresis 
[301] 
 
The quantitative 
analysis of protein 
interactions in free 
solution.  Using the 
directed motion of 
molecules in 
temperature gradients 
this is an all optical 
approach with 
fluorescence 
excitation. 
 
 
Can use sub-nM 
concentrations of 
protein. 
No need to immobilise. 
Measurements can be 
selective for the specific 
fluorescent label. 
Not limited by the 
molecular weight ratio of 
binding partners. 
Sensitive to low affinity 
interactions. 
 
 
Requires fluorescent labels. 
 
 
 
 
 
Fluorescence 
Polarisation 
[217] 
 
 
 
The use of plane 
polarised light to 
provide information on 
molecular orientation 
and mobility as well as 
the processes that 
modulate them such 
as protein-ligand 
interactions. 
 
Fast, accurate 
quantitative 
measurements therefore 
good for HTS. 
No need for solid 
supports. 
Sensitive to pico-molar 
range. 
No hazardous 
radioactive waste 
generated. 
Real-time 
measurements for 
kinetics. 
Insensitive to variations 
in concentration. 
 
 
Requires fluorescent labels. 
 
F.R.E.T 
[302] 
 
Detects the proximity 
of fluorescently 
labelled molecules 
over 10 - 100 Å. 
 
Selective to those 
molecules within 10 - 
100 Å of the protein. 
 
Requires fluorescent labels. 
The absorption spectrum of 
the acceptor must overlap 
with that of the donor. 
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ELISA 
 
 
A type of solid phase- 
enzyme assay to 
measure the presence 
of an analyte.  Can be 
used to detect binding 
interactions between a 
protein and ligand. 
 
 
Label free. 
Can be used for weak 
binding interactions. 
Good for HTS once 
optimisation complete. 
 
 
Requires specific antibody 
for protein. 
Requires immobilisation. 
Requires optimisation of 
assay. 
 
 
 
 
X-ray 
crystallography 
[303] 
 
 
 
Used to identify the 
atomic and molecular 
structure of a 
crystallised protein: 
ligand complex.  
 
 
 
A well-established 
technique. 
Data processing is 
highly automated.  
Can be used for large 
molecules. 
Can only be used to 
determine the structure of a 
protein-ligand complex not 
the kinetics of the 
interaction. 
Protein has to be able to 
form stable crystals that can 
diffract.  
Optimisation of 
crystallisation conditions for 
each protein: ligand complex 
can be time consuming.  
 
 
 
 
 
NMR 
 
 
The phenomenon of 
Nuclear Magnetic 
Resonance is used to 
determine protein 
ligand interactions as 
well as the affinity of 
binding.  
 
Reliable well established 
technique. 
Very sensitive. 
Able to determine KD of 
binding and the structure 
of the protein: ligand 
complex. 
Can be used for HTS. 
 
 
Requires higher 
concentrations of protein, 
which may lead to 
aggregation. 
Requires libelling such as 
15N and 13C. 
Can be labour intensive. 
 
There are many different docking programmes which operate a conformational and 
positional searching and scoring regime, the different poses of each ligand in the 
target protein can be proposed, scored and then ranked.[238]  These binding 
predictions are then combined with calculations of how the compounds may behave 
in vivo (eg: logD) if they are to be developed for therapeutic use.  However these 
computational simulations only aid the identification of compounds that make up a 
library, which must then subsequently undergo an actual screening process using a 
variety of biochemical and or biophysical techniques.  Following computational 
screening, the next step is often experimental screening using one or more of the 
methods listed above (Table 4.1).  Of these, the NMR method is widely used for 
fragment-based screening since this method is amenable for detection of binding over 
a very large affinity range; there are different NMR experiments which are suitable for 
the different affinities. 
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Figure 4.1– An example of a fragment-based drug discovery pipeline- The general workflow pipeline 
involved in a fragment-based approach.  Target selection and library design enables the fragment 
screening process using a number of biophysical techniques, to determine hit compounds.  Which are 
taken through an iterative optimisation process, involving determination of the binding mode along with 
affinity measurements resulting in possible drug candidates (adapted from [295]). 
4.1.1 NMR method for ligand screening 
The use of NMR in the screening process has developed over a number of years; 
some initial investigative studies used NMR for hit lead validation through 
identification of interactive sites.[304]  The original protein target was FKBP, a protein 
known to bind to FK506, inhibit calcineurin and block T-cell activation.[304]  The 
protein was known to have two interacting sites and so the fragment-based approach 
had two targets.[304]  The SAR process used fragment screening and optimisation 
processes to screen and optimise an initial ligand to fit the first target site and then 
screened a second set of fragments to fit the second site.[304]  These fragment 
compounds were then linked to create a larger compound with a KD of 100 nM.[304]  
Due to the low molecular weight nature of fragment-based drug design, the 
biophysical techniques used to screen the fragment-based libraries need to be able 
to detect weak binding interactions.[295]   
There are numerous experiments that can be used to do this such as SPR, thermal 
shift assays (TSA) and NMR experiments.[295]  These include 1-D 1H saturation 
transfer difference (STD) [305] and 1-D 1H water ligand observation with gradient 
spectroscopy (waterLOGSY).[306]   
The STD experiment was originally developed in 1979 for resonance assignments of 
a haem group within and enzyme; it was later used to characterise the interaction of 
a ligand binding to a receptor.[307,308]  The experiment uses a sample containing 
protein with the ligand present in a very large excess (typically over 50:1 ligand: 
protein ratio).  During the NMR experiment, the protein protons at a resonance 
position clear of ligand signals are irradiated with a radio frequency (upfield spectral 
regions above 0 ppm are normally used due to a lack of ligand signals in these 
regions).  The magnetisation experienced by that single protein resonance then 
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diffuses throughout the protein; if the ligand is bound then intermolecular transfer of 
the magnetisation to the bound ligand occurs, which in turn transfers the 
magnetisation to the free ligand in solution (Figure 4.2).  As a result this appears as 
strong ligand signals that are visible in the 1-D 1H difference spectrum and it allows 
us to visualise which parts of the small molecule are binding to the protein.  The 
relative intensity of ligand signal in an STD spectrum is not dependent on the strength 
of binding; rather, it is dependent on the “off rate” of the ligand under steady state 
equilibrium between the free and bound state of the ligand.[291]  As such the STD 
method is suitable for weakly binding ligands because of their fast off rates.  The off 
rate (Koff) is related to the affinity through the equation 4.1, where the on rate (Kon) is 
diffusion controlled around 10-9 M-1S-1.  We can therefore say that Koff is directly 
related to the affinity and hence the STD experiment will give an indication as to if 
there is weak or strong binding. 
𝐾D =  
𝐾𝑜𝑓𝑓
𝐾𝑜𝑛
 4.1 
A variant of the STD experiment is the waterLOGSY, it is a technique that is often 
used in place of the STD experiment, in those situations where the protein may be 
prone to aggregation.  The experiment relies on the bulk water which is the water 
found to bind at protein ligand interfaces and is often known to surround 
ligands.[292,293]  With this experiment the “on resonance” saturation is applied to 
the frequency at which water is found to occur, as with the STD if the ligand is bound 
then the magnetisation is transferred onto the ligand and signals from the hydrogens 
of the related ligand are detected.[293,309]   
 
Figure 4.2- A representation of the STD experiment (adapted from [291]).  A protein is irradiated at a 
selective position where no ligand signal exists, the protein becomes saturated and the bulk 
magnetisation is transferred to the bound ligand (protein ligand complex).  The ligand is in exchange 
between the bound and free form, the saturation is then transferred to the ligand.  If there is binding he 
resultant NMR spectrum contains the signals from protons in the ligand that are in close proximity to the 
protein.  This method can therefore be used to indicate which part of a small molecule forms the binding 
interface with the protein.  
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4.1.2 Examples of Fragment-based drug development 
A recent review by Turnbull et al. details some of the success stories and the 
techniques involved in fragment-based drug development.[310]   
One example is the bromo domain BRD4.  This protein has been implicated as a 
possible anti-cancer target and Zhao et al. describe the development of a fragment-
based library which was used to screen against this molecular target.[311]  The library 
was composed of fragments from the online database ZINCPharmer; which were 
selected through the application of a number of filters including “a molecular weight ≤ 
250 Da, number of rotatable bonds ≤ 5, logP ≤3.5 and 1≤ smallest set of smallest ring 
≤4”.[92,311]   
The computational filters were applied using the programme Pipeline Pilot, the 
fragments were then clustered according to their molecular structure and the central 
compound of each cluster was selected.[125,311]  From this computational protocol 
487 compounds were selected and their binding interactions with the BRD4 domain 
predicted using the molecular docking system Glide.[311,312]  The molecular docking 
elucidated 41 hit fragments which were subsequently crystallised with BRD4 
domain.[311]  The results of the crystal trials (Figure 4.3) resulted in 9 fragment leads 
including 4.1 - 4.4, that were taken forward through further optimisation 
processes.[311]  This research is an excellent example of the use of computational 
methods to develop compound libraries for screening purposes, it was published after 
the design and implementation of the approach used in this chapter which is very 
similar in its nature.   
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Figure 4.3- Co-crystal structures of the BRD4 domain with four fragments (4.1 - 4.4) developed by Zhao 
et al. (a) Fragment 4.1 PDB code 4HXO. (b) Fragment 4.2 PDB code 4HXK. (c) Fragment 4.3 PDB code 
4HXP. (d) Fragment 4.4 PDB code 4HXN (adapted from [311]). 
Other examples of protein-protein interactions that have been successfully targeted 
using a fragment-based screening approach include the BRCA2 - RAD51 interaction 
and Prostaglandin D synthase.   
The BRCA2 - RAD51 interaction occurs through eight repeating units of the BRC 
protein, the interaction is essential for DNA repair and its disruption could be 
employed to sensitise cancerous cells to DNA damaging agents.[313]  The 
identification of the crystal structure of the BRC unit BRC4 in complex with RAD51, 
elucidated a hotspot motif F-X-X-A (Figure 4.4).[314]  The phenylalanine (F) 
separated from the alanine (A) by two non-important amino acid residues, can be 
found in small well defined pockets that are able to encompass the side chains of the 
phenylalanine and alanine residues.[314]  
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Figure 4.4– A cartoon representation of the crystal structure of the BRCA2 - RAD51 interaction with the 
F-X-X-A motif highlighted in magenta with the side chains represented.(PDB 1N0W) [314] 
The fragment-based approach used to target this interaction employed an initial 
thermal shift assay screen of 1249 fragments, from which two hits, both with a central 
indole scaffold, were identified (4.5 and 4.6).[314]  Binding affinity studies using ITC 
determined both compounds as having a KD of 2.1 mM and crystal trials elucidated 
that they both bound within the pocket of the F-X-X-A motif.  Using the central indole 
scaffold, 42 compounds were designed to investigate the SAR further.[314]  To do 
this Scott et al. utilised competitive 1-D 1H STD experiments of the 42 ligands, where 
a compound known to undergo a binding interaction with the protein, 5-hydroxyindole 
was added to each NMR sample of protein and ligand.  The STD signals of 5-
hydroxyindole were monitored to observe any changes in intensity.  This was followed 
by the screening of another 120 fragments that were selected through in silico 
screening and evaluation of the commercial availability.[314]  These investigations 
resulted in six fragment hit compounds for further development (including 4.7, 4.8 and 
4.9), which bound to the target region with an improved affinity in the region of 430, 
460 and 570 μM respectively.[314]   
 
Figure 4.5– A selection of the hit fragments developed by Zhao et al. to target the BRCA2 - RAD51 
interaction.  The two initial indole scaffolds (4.5 and 4.6) from which the fragments (4.7 - 4.9) were 
developed (adapted from [310]). 
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Figure 4.6- A cartoon representation of the human (H) PGDS dimer (PDB 2VCQ). [315] 
Prostaglandin D synthase (PGDS) has been implicated in numerous physiological 
disorders such as asthma and as such is of interest for therapeutic development.[315]  
Hohwy et al. at AstraZeneca took two fragment libraries of 2450 compounds; the first 
was composed of 2000 non-specific fragments and the second contained 450 
compounds designed to be specific to the PGDS binding pocket.[315]   
The second PGDS designed library, was obtained from 20,670 “in-house” 
compounds, which underwent a series of computational processes.[315]  The first 
involved filtering to select those compounds with a molecular weight < 200 and c log 
P ≤ 2.[315]  The hit compounds were then docked into PGDS using the molecular 
docking programme GOLD and those compounds that were not found to undergo a 
hydrogen bonding interaction with the key residues Arg14 or Try152 were 
removed.[99,315]  This process resulted in 450 compounds that were used for 
biophysical screening.[315]  Their primary NMR screen involved testing drug cocktails 
containing 12 fragments (each at a concentration of 400 μM) against PGDS.[315]  
The techniques employed included both 1-D waterLOGSY experiments and 2-D 
HSQC experiments.[315]  This NMR based initial screen elucidated 24 possible hit 
compounds, six of which were found to be from the target specific library of 
compounds.[315]  The fragments were subsequently crystallised with PGDS and 
molecular docking simulations lead to a further selection of compounds from the “in-
house” collection.[315]  A second round of NMR screening was then used in 
conjunction with further in vitro assays, to identify the best binders and refine the 
SAR.[315]  Resulting in the identification of four lead chemical series (4.10 - 4.13) 
and an inhibitor (4.10) with an IC50 =21 nM.[315] 
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Figure 4.7- Compounds from the four hit series developed by Hohwy et al.  Developed to target 
PGDS elucidated through a fragment-based approach, resulting in a lead compound (4.6) with an IC50 
of 21 nM. (adapted from [315]) 
These examples highlight the combined use of computational design processes and 
biophysical analysis in the fragment screening of compounds to target different 
protein-protein interactions.   
4.1.2 Aims of Chapter 
As previously discussed in Chapter 1, a targeted methodology was developed and 
used in this thesis to design five small molecules that would perturb the protein-
protein interaction between NCS1 and the D2R peptide (Chapter 2 and Chapter 3).  
The initial screening section of this method involved applying a computational pipeline 
to a library of general chemical compounds, and lead to the selection of a number of 
small molecules for synthesis.   
This chapter describes the application of the same computational methodology on a 
library of small molecules that has been designed to be rich in compounds which have 
been found to perturb a range of different protein-protein interactions.  The chemical 
structures for this library was provided courtesy of Professor Raymond Norton, 
Monash institute of pharmaceutical sciences, Monash University, Melbourne 
Australia.  The original computational pipeline was adapted to initially focus on the 
solubility of the small molecules as this is often a limiting factor in early stages of drug 
design and development.  The previous examples of fragment-based studies have 
tended to involve a large amount of x-ray crystallographic data, however the 
biophysical screen developed for the purposes of this thesis revolves around a 
combination of NMR spectroscopic experiments. 
The exact computational design process developed will be discussed in further detail 
(Section 4.2), followed by a discussion on the biophysical analysis screen developed 
and tested, with examples presented relating to a number of small molecules from 
within the library (Section 4.3). 
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4.2. Computational Design 
The computational approach to designing small molecules to disrupt protein-protein 
interactions, is a technique that relies on a source of compounds to work.  Previous 
approaches used within this thesis found within Chapter 2.1, virtually screened an 
online database of commercially available compounds for ligands which match a 
specific pharmacophore target.  This chapter describes a different but complementary 
approach.  It uses the same computational analysis techniques previously described, 
for a compound library containing 1137 which have been previously refined as being 
suitable as starting compounds for development as potential protein-protein 
interaction inhibitors.  Utilising a technique similar to that suggested by Christopher 
Lepre, [296] we focussed the library on a desirable class of compounds, filtered out 
those which have undesirable ADMET properties and diversify the remaining 
selection.  
 
Figure 4.8- The computational workflow applied to the small molecule library of compounds.  The 
initial step in the computational protocol involved filtering those compounds that had a clogP ≤ 3 
removing 280 compounds.  When a secondary filter is applied to the 857 ligands to remove any that 
have do not have favourable ADMET parameters such as molecular weight < 300, hydrogen bond 
donors & hydrogen bond acceptors < 3 removing a further 145 ligands.  Molecules were taken forward 
if they possessed a “better than D2” score ≤ 4.0, this excluded 41 ligands and the final 671 were then 
ranked in descending order with respects to then “better than D2”.  The final stages in the pipeline 
involved the application of a number of clustering procedures, this finally resulted in 30 ligands selected 
for purchasing. 
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Due to previous problems encountered with the first generation of inhibitors, it was 
decided to avoid solubility of the ligand being a major limiting factor in the biophysical 
screening process, which may result in false positives and synthetic developability 
issues further down the line.  Consequently the first step in the screening protocol 
involved filtering any compounds that did not have a good solubility profile.  To do 
this, before any further computational screens were applied, the 1137 compounds 
available in 2-D standard delay format (SDF), were converted to 3-D and energy 
minimised using modelling programme Spartan ’08 V1.2.0 (full details found Chapter 
6.1.6.1 Protocol 10).   
The second step in the selection process involves the calculation of the ADMET 
properties (a Figure 4.8 the computational workflow), such as molecular weight and 
solubility (Figure 4.9 & 6.1.5.3).  It is beneficial to calculate these properties for the 
developability of a fragment library before selecting a candidate compound for testing.  
Should the ligand be intended for use as an orally available therapeutic agent, it can 
be used to predict the action of the body on the compound and may help to deselect 
unsuitable candidates.[113,184]  The ease with which a fragment can be optimised 
is important for the exploration and development of SAR, whilst increasing potency, 
maintenance of good “drug-like” properties is vital. 
With all the chemical data of each compound calculated, a final filter was then applied 
known as “the rule of three” (b Figure 4.8 the computational workflow).[185]  The rule 
of three is adapted from the original Lipinski’s parameters “rule of five” and has been 
indicated as a useful tool in the development of fragment libraries.[185]  As a starting 
point a work flow was generated as a strategy, with individual nodes used to select 
those compounds with (a) a molecular weight ≤ 300, (b) clogP ≤ 3 and (c) hydrogen 
bond donors and hydrogen bond acceptors ≤ 3 respectively being carried forward; 
those that did not fit the criteria were thus discarded (Chapter 6.1.6.3.2 Protocol 
13).[125]  Application of this filter removed 425 compounds from the library and 
resulted in 712 compounds to be taken forward into the next step. 
 
Figure 4.9- Pipeline Pilot workflow used to calculate the ADMET properties of each of the compounds 
within the compound library, providing a prediction on the action of the body on the compound and may 
help to deselect unsuitable candidates, should the ligand be intended for use as a therapeutic agent.  
The files are read into the programme in the SD format, each calculated property (represented by the 
blue processors) is summarised before the data is written in an output file in the SD format.  
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With all the ligands in 3-D form the next step involved docking and rescoring them (c, 
Figure 4.8 the computational workflow).  The process of docking involves the 
prediction of the conformation and orientation of ligand’s within the binding site.[238]  
There are many different docking programmes such as FlexX and Glide; each use 
different search algorithms and algorithm types.  The docking programme used in this 
thesis was GOLD Suite v5.2, which follows a genetic algorithm that is random or 
stochastic.[105,238,312]  Full details of the processes involved can be found in 6.1.3 
molecular docking methods protocols 3 and 4.   
Initially the ligands in each file were scored using Goldscore which generated 100 
poses in keeping with previous docking protocols employed in the design processes 
of the first and second generation inhibitors (Chapter 2.1 and 3.1).  A fitness value for 
each pose was generated, based upon the protein-ligand hydrogen bonding energy, 
protein-ligand Van Der Waals (VDW) energy, the ligand internal VDW energy and the 
internal torsional strain of the ligand.[99]  All files were then rescored in GOLD using 
three different scoring functions, Astex Statistical Potential (ASP), Chemscore and 
Chem Piecewise Linear Potential (PLP) (see Chapter 2.1.1 and 2.1.3 for further 
details of the scoring functions).[99]  This combined/ consensus scoring approach 
was used as each binding score investigates different aspects of the binding process 
and hence provides a comprehensive account of the predicted ligand binding pose 
(Figure 4.10).  The consensus scoring method is statistically improved, the mean of 
the samples is closer to a “true” sample than an individual value.[241]  The different 
methods focus on different aspects of ligand binding and so agree on an active 
compound more than an inactive one as well as providing a greater consistency 
across receptor systems.[241]  The consensus scoring approach has been indicated 
as leading to improvements in docking procedures, through the improved quality of 
results with less reliance on the correct selection of a scoring function.[242]  This 
consensus approach to the docking process of the ligands allows for a more informed 
selection that is not biased, but rather incorporates as many possible aspects of a 
binding interaction as possible. 
To aid the subsequent steps in the computational pipeline the 100 docking poses for 
each compound were separated.  The average Goldscore, ASP, Chemscore and 
ChemPLP values were calculated from the 100 poses of each individual compound 
and subsequently merged with the original compound library file (Chapter 6.1.6.3.1 
Protocol 12) resulting in a comprehensive file containing all the relevant docking and 
scoring data.   
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Figure 4.10- The crystal structure of NCS1 (green) and D2R peptide (red), compared to the top poses 
from the GOLD docking analysis of three ligands from the compound Library with NCS1. (a) 4.14, (b) 
4.21 and (c) 4.24.  NCS1 coloured in green those residues involved with interactions with the D2R 
peptide are coloured in purple.  The top pose for each of the three ligands all appear in a hydrophobic 
pocket of NCS1 around the EF-2 and EF-3 region. 
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To process the data, Knime was used (an open-source data integration, processing, 
analysis, and exploration platform).[124]  The four separate scoring files of the 712 
compounds (Goldscore, ASP, Chemscore and ChemPLP) were combined and the 
average ligand efficiencies for each compound was calculated.  The ligand 
efficiencies for each scoring function are calculated based on the average score as a 
function of the molecular weight (Chapter 6.1.6.3.3 Protocol 14).  The calculation for 
considering whether each docking pose was “Better than D2” was subsequently 
performed through combining the individual ligand efficiencies for each scoring 
function of each compound and compared this to that of D2R peptide (equation 4.2).  
These scores were compared and molecules were taken forward if they possessed a 
“better than D2” score ≤ 4.0, this excluded 41 ligands and the final 671 were then 
ranked in descending order with respects to the “better than D2” score. 
𝑌 =
𝜀𝐺
𝜀𝐺1
+
𝜀𝐴
𝜀𝐴1
+
𝜀𝐶
𝜀𝐶1
+
𝜀𝑃
𝜀𝑃1
  4.2 
Where Y is the “Better than D2” score and ƐG, ƐA, ƐC, ƐP represent the four compound 
“Ligand efficiencies” from “Goldscore”, “ASP”, “Chemscore” and” ChemPLP” 
respectively.  The values of ƐG1, ƐA1, ƐC1, ƐP1 are the respective ligand efficiency 
values for the D2R peptide, calculated from the “Goldscore”, “ASP”, “Chemscore” and 
“ChemPLP” results respectively. 
With ligands now listed in descending order of the “Better than D2” score, to further 
the selection process it was deemed necessary to diversify the remaining compounds 
by clustering them with respects to their “chemical neighbourhood”.[316,317]  The 
two successful applications are summarised by (d) and (e) Figure 4.8 the 
computational workflow, however a more description of the clustering processes shall 
be discussed in further detail below.  
A neighbourhood is defined as the area surrounding the ligand in multidimensional 
space; this is dictated by the properties of a compound as captured through molecular 
descriptors such as the molecular fingerprints/ ADMET properties of each 
ligand.[316,317]  In this case the chemical structure of the ligands were used as a 
“molecular fingerprint”. 
The distribution of the “Better than D2” score for each ligand was unimodal, with the 
values ranging from 4.5 - 15.5 and the highest frequency of scores between 8.6 and 
9.1 for 14% of the library (Figure 4.11 a).  Clustering is based upon the chemical 
diversity of the compounds; hence in order to cluster molecules the diversity can be 
specified as a distance between each compound within the clustering protocol 
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(Chapter 6.1.6.3.4), resulting in 112 separate clusters containing an average number 
of 6 ligands per cluster.  It was initially postulated that for the greatest diversity, the 
central ligand of each cluster/ neighbourhood should be selected and the distribution 
of the “Better than D2” values for these compounds investigated, ensuring the 
chemical space is sampled efficiently and effectively (Figure 4.11 b).  However this 
resulted in a selection of compounds with a lower maximal frequency of the scoring 
function to between 8.0 & 8.5 for 12.8% of the population.  It was decided that this 
would not be a good method of selection as it reduced the probability of finding a 
strong binder.   
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Figure 4.11- Histograms depicting distributions as a result of clustering. (a)  The distribution of the 
“Better than D2” score across the library before a cluster is applied, scores range from 4.5 -15.5 with the 
highest frequency score between 8.6 & 9.1 for around 14.0% of the population. (b)  The distribution of 
the “Better than D2” score after application of the cluster and selection of the central molecule within the 
cluster, the highest frequency score was between 8.0 & 8.5 for around 12.8% of the population. (c)  The 
distribution of the “Better than D2” score after application of the cluster and selection of the compound 
with the top “Better than D2” score, the highest frequency score was between 10 & 10.5 for around 
13.0% of the sample. 
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The next method examined, involved taking the top scoring “Better than D2” ligand 
for each 112 clusters and assessing the distribution of the “Better than D2” score 
across the sample.  It resulted in uneven distribution of the top “Better than D2” scores 
with a maximal score of 10 - 10.5 for around 13% of the sample (Figure 4.11 c).   
For the most diverse sample selection with the highest probability of a good binding 
interaction it was decided to select the top 50 compounds with the best “Better than 
D2” scores and cluster the remaining 620 compounds within the library similar to 
process employed previously.  From each cluster the compound with the best “Better 
than D2” score was selected, resulting in a sample of 102 ligands from the previous 
620.   
The distribution of the “Better than D2” scores were analysed and compared to 
previous results using the same methodology as observed above.  It was found that 
without applying a clustering method to the 102 compounds the most frequent “Better 
than D2” score was higher than previous.  It was observed that 22% of ligands had a 
score between 10.8 and 11.3 (Figure 4.12 a), compared to the values of the 
respective sample where only 14% of the population having a “Better than D2” of 8.5 
and 9.0 (Figure 4.11 a).   
If the 102 compounds were clustered and the central compound of each cluster 
selected, the distribution of the “Better than D2” score was highest between 11.3 and 
11.8 with around 22.5% of the population within this pool (Figure 4.12 b).  Compared 
to the previous corresponding protocol applied to the 620 ligands where the most 
frequent “Better than D2” was observed between 8.0 and 8.5 for around 12.5% of the 
population (Figure 4.11 b). 
If the clustering was carried out and the compound with the maximal “Better than D2” 
score selected from each cluster, the distribution of the “Better than D2” score was 
found to be highest between the values of 11.3 and 11.8 for around 26% of the 
population (Figure 4.12 c).  This appears to be much greater than that of 
corresponding clustering and selection protocol of the 620 ligands, where we observe 
the most frequent “Better than D2” to be between 10 and 10.5 for 13.5% of the 
population (Figure 4.11 c).  Also more favourably, the overall distribution of the “Better 
than D2” scores were much more even and encompassed the higher range of values.  
Inferring that a better sampling of ligand space had been achieved. 
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Figure 4.12- Histograms depicting distributions as a result of clustering the 102 compounds. (a)  
The distribution of the “better than D2” score across the library before a cluster is applied, scores range 
from 6.3 -15.8 with the highest frequency score between 10.8 & 11.3 for around 22.0% of the population. 
(b)  The distribution of the “better than D2” score after application of the cluster and selection of the 
central molecule within the cluster, the highest frequency score was between 11.3 & 11.8 for around 
22.5% of the population. (c)  The distribution of the “better than D2” score after application of the cluster 
and selection of the compound with the top “Better than D2” score, the highest frequency score was 
between 11.3 & 11.8 for around 26.0% of the sample. 
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The distribution of scores in Figure 4.12 c, indicated that this clustering protocol was 
a good methodology to select the compound sub-library for screening.  In order to 
achieve an economically viable number of compounds (around 30), that our 
resources would allow, the protocol was repeated.  This final selection process took 
the 102 ligands, the top 15 molecules were selected and the remaining 87 compounds 
were clustered into 15 clusters.  Again the ligand with the best “Better than D2” score 
from each cluster was selected, affording 30 purchasable compounds for testing. 
Table 4.2- Table containing the 30 compounds selected from the screening process of the 1137 within 
the original compound library.  The final two ligands (*) were unavailable for purchase and so only 28 
ligands were tested. 
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4.3. NMR Analysis of Small Molecule Interactions 
The computational efforts afforded a targeted compound library, containing 28 small 
molecules which were subsequently purchased from Life Chemicals-Building blocks© 
and Chembridge©.  The binding interactions of the compound library with NCS1 were 
investigated using NMR spectroscopy, employing 1-D 1H STD 1-D 1H waterLOGSY 
and 2-D 1H 15N HSQC experimental techniques; results for each compound within the 
library can be found in the appendix Section A.5.  Each small molecule was dissolved 
in DMSO achieving a stock concentration of 100 mM (w/v), 1H 15N NCS1 was 
prepared as described in full in the experimental Section 6.3.2; very briefly the protein 
was buffer exchanged into the desired NMR buffer and concentrated to achieve a 
stock concentration of 96.5 μM (m/v).  All NMR spectra were collected at 298K unless 
otherwise stated, on a Bruker AVANCE II+ 600 MHz spectrometer, equipped with 5 
mm triple-resonance cryoprobe, the data collected was processed using Topspin 3.1 
(Bruker).  The NMR samples were prepared to a volume of 550 µL including 10% 
(v/v) [2H2]O and the NMR buffer was composed of 50 mM tris-HCl, 50 mM NaCl, 5 
mM CaCl2 at pH 6.4. 
The experimental screening process followed a two-step protocol; 
1) For each compound acquire 1H 1-D, 1-D 1H STD and 1-D 1H waterLOGSY 
NMR spectra of 1 mM compound in NMR buffer and these will be the 
reference data.  Then acquire the same 1-D data but with a sample of 1 mM 
ligand and 20 μM 1H 15N NCS1. 
2) If the above experiments, termed the primary screen indicated binding 
between the ligand and protein, then the secondary screen is used: 1H 1-D, 
1-D 1H STD, 1-D 1H waterLOGSY and 2-D 1H 15N HSQC experiments.  Here 
the concentration of 1H 15N labelled NCS1 was increased to 50 μM (v/v), 
making the final Protein: Ligand ratio to be 1: 20. 
The 1-D experiments determined which chemical groups of the small molecule were 
interacting with NCS1.  They do not however, provide any information on the protein 
interaction sites.  A 2-D 1H 15N HSQC spectra allow identification of the amino acid 
residues whose resonances are affected by the presence of the ligand; when mapped 
onto the structure of the protein, it is often the case that the protein resonances most 
affected by the presence of the ligand are from residues that reside in and around the 
binding site and some of these residues will be in direct contacts (hydrogen bond or 
hydrophobic interactions) with the ligand.  All the 1H 15N HSQC were acquired for 
proteins dissolved in NMR buffer containing 1% DMSO.  The “chemical shift 
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perturbation sum” (CSP) is calculated from the shift differences between the 
reference spectra of the protein alone (in 1% DMSO) and in the presence of 20 molar 
equivalent of the ligand (P:L 1:20) and using equation 2.1 from Chapter 2.  Where ∆H 
and ∆N are, respectively, the protein and nitrogen chemical shift changes, and 0.15 
is the scaling factor derived from the gyromagnetic ratios of the nitrogen and hydrogen 
nuclei.[269]   
∆δ = [ (∆H)2 + (0.15 ∆N)2 ]1/2  2.1 
Histograms of the CSP will contain gaps which can be explained by a lack of 
assignment for the backbone residue, for example, for residues whose peaks overlap, 
if the residue has been attenuated or if the peak cannot be determined.  Subsequently 
the sum of total number of residues perturbed was calculated and from this value the 
top 10% and 20% ranges were determined.  The residues whose CSP fell within these 
two ranges were defined as being within the top 10 and top 20 percentile respectively.  
This is a direct result of the number amino acids for which assignment has been 
possible for the individual experiments in question.  Therefore making the amino acids 
of the top 10 and 20 percentile ranges specific to each 2-D 1H 15N HSQC experiment, 
of each individual compound.   
4.3.1 Primary Screen 
The results of the entire screening process is summarised in Scheme 4.1; of the 28 
compounds the first round of screening experiments which included 1-D 1H, 1-D 1H 
STD spectra & 1-D 1H waterLOGSY, indicated that eight compounds did not display 
any form of a possible binding interaction.   
The STD data is presented as a difference spectrum; ligand signals that experience 
a magnetisation transfer from the protein will appear in the opposite phase to that of 
the irradiated protein resonance.  In the case of the 1-D 1H waterLOGSY experiment, 
binding is indicated by an attenuation of some of the ligand proton resonances. 
Figure 4.13, shows the data of two compounds, 4.19 and 4.25. The waterLOGSY 
spectrum of the buffer standards are identical to that of the corresponding sample 
containing 20 μM NCS1; this is the first indication of no interaction between these two 
compounds and NCS1.  The lack of binding is subsequently confirmed with the 1-D 
1H STD spectra, where no peaks are likewise observed in the 1-D STD spectrum 
(Figure 4.13 (black traces)).  4.19 and 4.25, have a similar chemical structure with a 
central benzimidazole core (Figure 4.13). 
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Both the spectra for 4.19 and 4.25 demonstrate that there is no corresponding ligand 
signals and hence can be concluded that neither ligands are undergoing a binding 
interaction with NCS1. 
 
 
Scheme 4.1- The NMR screen process applied to the compound library.  The first round of testing 
rejected 8 compounds of the original 28 as they did not display any precedence for binding to NCS1 in 
the 1-D 1H STD experiments.  20 candidates of the compound library showed evidence of binding (strong 
evolution of ligand signals) or a weaker binding interaction (weaker evolution of some but not necessarily 
all ligand signals).  Subsequently the concentration of NCS1 in each of the 20 candidates NMR samples 
were increased to 50 μM and the previous 1-D 1H, 1-D 1H STD and 1-D 1H waterLOGSY experiments 
were collected for a second time along with an additional 2-D 1H 15N HSQC spectrum.  Of the 20 
compounds 10 that were thought to display weak binding were rejected as being false positives as there 
were no observable changes in the 2-D 1H 15N HSQC spectrum.  Leaving 10 candidate compounds, 5 
of these were still thought to display weak binding interactions as the changes in the 2-D 1H 15N HSQC 
spectrum were very minor, this resulted in 5 hit compounds. 
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Figure 4.13- Compound library screening data- Two negative compounds from the primary screen 
applied to the compound library, (a) and (b) spectral overlays of compound 4.19, (c) and (d) spectral 
overlays of 4.25.  The overlay is composed of the 1-D 1H spectra blue, 1-D 1H waterLOGSY spectra red 
and 1-D 1H STD black, for both compounds the buffer standard spectral overlay is labelled (a) and the 
protein containing spectra (b).  With both ligands there is no apparent difference between the 
waterLOGSY spectra of the buffer standard and the waterLOGSY spectra of the ligand with the protein, 
the first indication that there is no interactions occurring between the two.  The broad signals in the 
aromatic region of 4.25 correspond to the rapidly exchanging NH signals from the amide moiety, an 
artefact of the waterLOGSY experiment.  The lack of a binding interaction is then confirmed by the STD 
spectra, no appearance of ligand signal indicates that there is no transfer of magnetisation between the 
protein and a bound ligand. (4.19 ligand signal 1 and 4.25 signal 4 are masked by peaks arising from 
tris HCl buffer ≈ 3.8 ppm, residual 1H DMSO ≈ 2.9 ppm [318]). 
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4.3.1. Secondary Screen 
The subsequent step in the screening process (Scheme 4.1 c), required the addition 
of 1H 15N NCS1 to the refined 20 compounds to achieve a final concentration of 50 
μM (v/v), and 2-D 1H 15N HSQC spectra were acquired.  In addition, the 1-D STD and 
waterLOGSY experiments are also repeated if a compound from the primary screen 
was believed to be a weak binder; this step would confirm or reject compounds which 
were borderline cases in the primary screen.  The secondary screen also provided 
more structural information on the interacting residues of the protein; this along with 
the data on the interaction with respect to the ligand moieties involved could elucidate 
a binding pose of the ligand with the protein.  Of the 20 compounds that were selected 
for the secondary screening, 14 compounds displayed a weak binding interaction with 
NCS1 and 6 compounds showed clearer/ stronger signals in the STD experiments 
and hence regarded as more promising leads.   
An additional compound 4.14 (Figure 4.14) was used as a negative control; it 
displayed no signs of binding to NCS1 in the primary screening process, a conclusion 
that was confirmed by the secondary screen.  There was no discernible difference 
between the waterLOGSY spectra of free 4.14 (Figure 4.14 a) and that of the sample 
containing the protein (Figure 4.14 b).  Furthermore, the 2-D 1H 15N HSQC spectra of 
NCS1 with 1 mM 4.14 show no major changes in the chemical shift protein NH or 
peak intensities of any of the resonances fond in the spectrum of the control (NCS1 
in 1% DMSO).  A plot of the combined chemical shift perturbations of the backbone 
residues of NCS1 with 4.14 (Figure 4.15) indicate that the changes appear small and 
negligible ranging from 0.00049 - 0.015.  Within the overall range of changes in 
chemical shift, those residues who fall within the top 10 percentile include; Thr17, 
Gln28, Lys36, Asp37, Asp60, Asn70, Phe72, Phe85, Leu89, Ala104 and Ser184.  All 
but Ser184 are found in the first three EF-hands.   
Further analysis of those residues that fall within the 20 percentile include; Val13, 
Leu16, Thr19, Phe22, Tyr31, Lys32, Gly33, Phe55, Phe56, Asp73, Val180 and 
Leu189.  Again excluding the final two amino acid residues of Val180 and Leu189, 
the position of the amino acids effected lies within the first two EF-hands of NCS1.  
As the changes in chemical shift are not of significant ppm value, in comparison for 
example to that of 4.24 and 4.21, it can be deduced that 4.14 does not bind to NCS1. 
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Figure 4.14 -Compound 4.14 NMR screening data. (a) Buffer standard 1 mM 4.14 in NMR buffer + 
1% DMSO; 1-D 1H spectra (blue), 1-D 1H waterLOGSY spectra (red) and 1-D 1H STD (black). (b) Binding 
screen 1 mM 4.14 & NCS1 20 μM in NMR buffer + 1% DMSO; 1-D 1H spectra (blue), 1-D 1H waterLOGSY 
spectra (red) and 1-D 1H STD (black). (c) 1mM 4.14 & NCS1 20μM in NMR buffer; an overlay of two 2-
D 1H 15N HSQC spectra, NCS1 50 μM and NMR buffer + 1% DMSO (black) 4.14 1 mM in DMSO 1% 
and NCS1 50 μM (red).  Compound 4.14 showed no binding indications in the primary NMR 
investigations, comparison of the control waterLOGSY spectrum shows no apparent difference, this 
observation is confirmed in the 1-D 1H STD spectra where the relative ligand signals do not appear, 
indicating that no transfer of magnetisation is occurring and hence it can be concluded that there is no 
binding interaction between NCS1 and 4.14.  As a negative control a 2-D 1H 15N HSQC spectrum was 
acquired an overlay with the NCS1 and DMSO control, no apparent change in the chemical shifts of the 
amino acid residues of NCS1 further indicate there is no binding interaction. 
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Figure 4.15- (a) Top docking pose of 4.14 in NCS1 (grey) with the side chains of the surrounding amino 
acids coloured in green and labelled according. (b) A plot of the chemical shift pertubation sum 
differences between free NCS1 with 1% DMSO annd NCS1 with 4.14 and 1% DMSO (Protein:Ligand 
1:20).  With the protein secondary structure above the histogram.  The change in chemical shift of the 
residues of NCS1 due to the effects of 4.14 appear small and negligible ranging from 0.0005 - 0.02 ppm.  
Demonstrating that 4.14 does not undergo a binding interaction with NCS1.  The red line represents 
those residues who’s change in chemical shift was within the top 10 percentile, the residues that falls 
within this range are Thr17, Gln28, Lys36, Asp37, Asp60, Asn70, Phe72, Phe85, Leu89, Ala104 and 
Ser184..  The position of these residues within NCS1 are based within the first two EF-hands α helices 
1-5 (α1 - α5).  The yellow line line represents those residues that change in chemical shift was within the 
top 20 percentile, Val13, Leu16, Thr19, Phe22, Tyr31, Lys32, Gly33, Phe55, Phe56, Asp73, Val180 and 
Leu189.  These residues are situated across three of the four EF-hands, EF-1, EF-2 and EF-4, indicating 
no specificity to one particular location.  Gaps within the plots of chemical shift perturbation sum can be 
explained by:  Unassigned residues.  Single peaks assigned with two residues.  Proline.  Peaks 
too become too broad to assign. 
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The 14 compounds of the original 20 (Scheme 4.1 c), that displayed weaker STD 
signals indicated a possible binding interaction with NCS1; however further spectral 
data was required to confirm this.  When analysing the STD spectra it is important to 
remember that the strength of the ligand signal is not directly related to the binding 
constant.[291]  Those compounds with a weaker STD signal may not be binding with 
a weaker binding constant, they may in fact have a slower off rate (the rate of which 
the bound ligand exchanges with free ligand in solution).  Therefore other spectral 
data are used along with the STD to deduce the binding mode of the compound.   
An example of a compound within the library that was thought to have a weak 
interaction with NCS1 was 4.24 (Figure 4.16).  The STD spectra of the primary 
screening process contained what appeared to be weak ligand signals relating to the 
hydrogens of positions 2 and 3 (Figure 4.16 a and b).  A comparison between the 
waterLOGSY experiment of the buffer control and the protein containing sample 
(Figure 4.16 a and b red spectra) indicate a reduction in the relative signal intensities 
of the ligand at the corresponding positions 2 and 3 in the aromatic region.  A 
reduction in ligand signal intensity, when compared to the buffer control experiment 
in which the ligand is having no interactions, indicates that the presence of ligand 4.24 
is having an effect on the bulk water of the protein.  This is inferred as the 
experimental design of a waterLOGSY pulse sequence works by saturating the bulk 
water, it is well documented that water can play a pivotol role in protein-ligand binding 
interactions.[292][293]  In previously documented NMR studies water molecules were 
found to be present at the binding interface.[306]  Some were believed to act like a 
shell of squeezed water, others involved extensive hydrogen bonded water molecules 
surrounding the ligand.[306]  So by saturating the bulk water with magnetisation if a 
ligand is undergoing a binding interaction that is mediated by water, then as with the 
STD experiment the magnetisation will be transferred.  However in contrast to the 
STD experiment this is observed as a reduction in the intensity of the ligand signal.   
The use of the STD experiment provides knowledge of which proton environments of 
the ligand are effected by a possible binding interaction with NCS1, which can be 
used alonside analysis of a 2-D 1H 15N HSQC spectra and enables the relative amino 
acids of the protein effected by the ligand to be deduced.  To do this the 2-D 1H 15N 
HSQC spectra of NCS1 with the ligand is overlaid with a 2-D 1H 15N HSQC spectra of 
NCS1 (50 μM) and with 1% DMSO, any changes in peak intensity or perturbations in 
chemical shift of a residue indicative of an interaction between the ligand and NCS1.   
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With 4.24 the chemical shift perturbation sum and changes in peak intensity are again 
very subtle (Figure 4.17).  Changes in chemical shifts were larger than those seen 
with the effects of 4.14, with values ranging from 0.001 - 0.035.  The residues that 
undergo changes in chemical shift greater than 0.015 are within the top 10 percentile.  
They include Gln28, Lys36, Asp37, Cys38, Gln54, Asn70, Glu81, Ala104, Tyr108, 
Gln181, Leu183 and Gly188.  The residues most severely effected appear to be 
situated in two clusters, those around α2 on EF-1 and α9 EF-4.  Furthermore the 
residues that are found to undergo a change between 0.011 - 0.015 are defined as 
being within the 20 percentile range.  Those residues include; Ile35, Gly41, Asp44, 
Phe55, Leu110, Asp123, Ile128, Gly133, Ser173, Ile179, Val180, Val190.  Found to 
be situated across all four EF-hands these residues indicate the non specific effect of 
this ligand within this shift range.   
This data further indicates that there is a possible weak binding effect occurring 
between a small number of residues from NCS1 with the ligand 4.24, which is 
concordant with the best predicted binding pose from the GOLD docking (Figure 4.17 
a).  This is observed in a small cluster of residues around Leu183 highlighted in red 
in the histogram (Figure 4.17 b), which appear to have slightly higher chemical shift 
perturbations in comparison to the consensus shift changes of the residues of the 
whole protein (excluding Asp37). 
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Figure 4.16- Compound 4.24 NMR screening data. (a) Buffer standard 1 mM 4.24 in NMR buffer + 
1% DMSO; 1-D 1H spectra (blue), 1-D 1H waterLOGSY spectra (red) and 1-D 1H STD (black). (b) Binding 
screen 1 mM 4.24 & NCS1 50 μM in NMR buffer + 1% DMSO; 1-D 1H spectra (blue), 1-D 1H waterLOGSY 
spectra red and 1-D 1H STD (black). (c) 1 mM 4.24 & NCS1 50 μM in NMR buffer; an overlay of two 2-
D 1H 15N HSQC spectra, NCS1 50 μM and DMSO 1% (black) 4.24 1 mM in DMSO 1% and NCS1 50 μM 
(red).  The results of the primary screen for 4.24 indicated the possibility of a weak binding interaction 
between the ligand and NCS1.  A comparison of the ligand signals 2 and 3 in the waterLOGSY of the 
negative control (a) with that of the protein containing spectra (b) show a reduction in signal intensity.  
Secondly, analysis of the STD experiment indicates the weak presence of the ligand signal in the 
downfield aromatic region.  Further investigation into the binding interaction through analysis of the 2-D 
1H 15N HSQC spectra (c) is indicative of a weak interaction, with slight perturbations in chemical shift 
and reductions in the intensities of some signals, for example some changes belong to residues present 
on the α helix α3 and α5, β-sheet β1 and β2 and in the terminal flexible linker region.  This data also 
indicates that 4.24 does not bind in a specific region. 
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Figure 4.17- (a) Top docking pose of 4.24 in NCS1 (grey) with the side chains of the surrounding amino 
acids coloured in green and labelled according. (b) A full plot of the chemical shift pertubation sum 
differences between free NCS1 with 1% DMSO annd NCS1 with 4.24 and 1% DMSO (P:L 1:20).  The 
protein secondary structure shown above the histogram.  The red line represents those residues who’s 
change in chemical shift was within the top 10 percentile, the residues that fall within this range are 
include Gln28, Lys36, Asp37, Cys38, Gln54, Asn70, Glu81, Ala104, Tyr108, Gln181, Leu183 and 
Gly188.  The residues most severely effected appear to be situated in two clusters, those around α2 on 
EF-1 and α9 EF-4.  The yellow line line represents those residues who’s change in chemical shift was 
within the top 20 percentile, Ile35, Gly41, Asp44, Phe55, Leu110, Asp123, Ile128, Gly133, Ser173, 
Ile179, Val180, Val190.  Found to be situated across all four EF-hands these residues indicate the non 
specific effect of this ligand within this shift range.  Gaps within the plots of chemical shift perturbation 
sum can be explained by:  Unassigned residues.  Single peaks assigned with two residues.  
Proline.  Peaks too become too broad to assign. 
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As described previously, of the 20 compounds that were selected for the secondary 
screening (scheme 4.1 c), 14 compounds displayed a weak binding interaction with 
NCS1 and 6 compounds showed clearer/ stronger signals in the STD experiments 
and hence regarded as more promising leads.  Of the 14 possible weak binding 
ligands only four were shown to have an effect on NCS1 through the secondary 
screening process therefore, 10 ligands were rejected as false positives (scheme 4.1 
d).  
The process above had further refined the library, of those 10 remaining compounds 
it was found that five have only weak effects as monitored by the waterLOGSY and 
HSQC methods (scheme 4.1 e).  This left five possible hit ligands.  These five final 
ligand candidates were first marked as being potential hits in the primary screen, this 
was subsequently confirmed in the secondary round of testing, the 5 compounds are 
4.21, 4.28, 4.36, 4.40 and 4.41 (see appendix A.5 for all experimental results).  One 
of the most promising of the five ligands is 4.21, a phenyl pyrazole (Figure 4.18); when 
analysing the data an obvious observation is the complete attenuation of the ligand 
resonances 1, 2, 4, 5 & 6 in the waterLOGSY spectrum for the protein containing 
sample (Figure 4.18 b); a second observation from this spectra is the inversion of the 
methyl ligand signal 3.  This is in stark contrast to the signals observed for 4.21 in the 
buffer standard experiment (Figure 4.18 (a)) where all ligand NMR signals are 
observable and are of the opposite phase to the protein.  When we overlay the 
waterLOGSY spectra with that of the STD, we notice that the corresponding peaks of 
the ligand are very much present and that their intensity is very strong.  The 
observable intensity of the ligand signals within the STD spectra is not directly related 
to the binding constant of the interaction, it is related to the rate at which the ligand is 
able to disassociate from the protein complex and transfer the bulk saturation to the 
free ligand in solution.  But it can also be inferred that if a ligand has a weaker binding 
interaction then the probability of it being bound to the protein is less, hence less 
magnetisation can be transferred resulting in weak signal.[291]   
To once again validate the STD and waterLOGSY data of the primary screen, the 
interaction was further investigated through the use of a 2-D 1H 15N HSQC 
experiment.  When overlaid with a negative control of NCS1 with DMSO, binding 
interactions were indicated through the change in chemical shifts of a number of 
amino acid residues, some of which are present on the α helices α2, α3, α6 and α9, 
β-sheet β1 and β2 and four separate flexible linker regions.  A number of the residues 
affected are located within the hydrophobic binding pocket.   
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The plot of the chemical shift perturbation sum (Figure 4.19), indicates that the 
change in chemical shift brought about by the effect of 4.21 on NCS1 occurs over a 
range of 0.003 - 0.09.  This is a substantial increase in the change in chemical shift 
when compared to the effects caused by both 4.24 and negative control 4.14.  The 
top 10 percentile are found above 0.065, the residues that fall within this range are 
Cys38, Asp44, Gln54, Asn70, Thr92, Tyr108, Val125, Ile128, Gly133, Gln181, 
Leu183 and Gly188.  The positions of these residues cannot be located to one single 
region on NCS1; rather they occur over all four EF hands but do not occur on α1 or 
α8.  In addition to this, the residues whose CSP is greater than 0.048 but less than 
0.065 are defined as being within the 20 percentle range.  Those residues include 
Asp37, Gly41, Phe56, Gly59, Phe67, Phe69, Ile86, Gln87, Leu110, Phe169, Gly171 
and Ser184, once again they can be found over all four EF hands although not in α1 
or α8.   
Interestingly four of the residues within the 10 percentile threshold are found in the 
same region of NCS1 as predicted through the GOLD docking analysis, two of which 
Thr92 and Leu183 are conserved.  It should be noted that the chemical shift 
perturbation sum is derived from the backbone residues it does not take into account 
the side chains, it is observable in the 2-D 1H 15N HSQC spectra that there is a major 
change in the chemical shift or the side chain of Trp103, a residue that was also 
present in the GOLD docking predicted binding pose.  Although the amino acid 
residues implicated in the binding interaction appear to encompass all four EF hands 
of NCS1, there is not a systemic change in the chemical shift of all the amino acid 
residues within the protein.  Suggesting that there is a binding interaction occurring 
between 4.21 and NCS1 however, whether or not this effect is the additive effect of 
more than one 4.21 ligand would need to be determined.  To further investigate this 
conclusion a STD competition experiment with the native ligand D2R peptide was 
performed. 
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Figure 4.18- Compound 4.21 NMR screening data.  (a) Buffer standard 1 mM 4.21 in NMR buffer + 
1% DMSO; 1-D 1H spectra (blue), 1-D 1H waterLOGSY spectra (red) and 1-D 1H STD (black).  (b) Binding 
screen 1 mM 4.21 & NCS1 50 μM in NMR buffer + 1% DMSO; 1-D 1H spectra (blue), 1-D 1H waterLOGSY 
spectra (red) and 1-D 1H STD (black). (c) 1 mM 4.21 & NCS1 50 μM in NMR buffer + 1% DMSO; an 
overlay of two 2-D 1H 15N HSQC spectra, NCS1 50 μM and DMSO 1% (black) 4.21 1 mM in DMSO 1% 
and NCS1 50 μM (red).  The experimental data of 4.21 indicates that the binding interaction between 
the ligand and NCS1 could be termed as relatively strong.  Analysis of the waterLOGSY and STD spectra 
in the presence of protein (b) are comparable in that the ligand signals 1, 3, 4, 5 & 6 are extremely strong 
in the STD spectra, suggesting that there is a transfer of magnetisation between the protein and the 
ligand in this region, also confirmed by the waterLOGSY where the corresponding signals lose all 
intensity and are completely attenuated.  The ligand signal 2 which is also very intense in the STD 
spectra is then inverted in the corresponding waterLOGSY experiment.  This promising interaction was 
further investigated through the use of a 2-D 1H 15N HSQC experiment which when overlaid with a 
negative control indicated binding interactions through the perturbations of a number of residues some 
of which are present a number of which have been labelled, including Ile80, Thr92, TrpΣ103, Gly172, 
Leu183 & Gly188. 
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Figure 4.19- (a) Top docking pose of 4.21 in NCS1 (grey) with the side chains of the surrounding amino 
acids coloured in green and labelled according. (b) A plot of the chemical shift pertubation sum 
differences between free NCS1 with 1% DMSO annd NCS1 with 4.21 and 1% DMSO (P:L 1:20).  The 
protein secondary structure shown above the histogram.  The change in chemical shift of the amino acid 
residues of NCS1 due to the effects of 4.21 occur over a range from 0.0019- 0.12.  A large number of 
residues of NCS1 are affected by 4.21, the red line represents those residues who’s change in chemical 
shift was within the top 10 percentile.  The residues that fall within this range are Cys38, Asp44, Gln54, 
Asn70, Thr92, Tyr108, Val125, Ile128, Gly133, Gln181, Leu183 and Gly188.  The positions of these 
residues cannot be located to one single regoin on NCS1, they occur over all four EF hands but do not 
occur on α1 or α8.  The yellow line line represents those residues who’s change in chemical shift was 
within the top 20 percentile, and includes Asp37, Gly41, Phe56, Gly59, Phe67, Phe69, Ile86, Gln87, 
Leu110, Phe169, Gly171 and Ser184.  . Gaps within the plots of chemical shift perturbation sum can be 
explained:  Unassigned residues.  Single peaks assigned with two residues.  Proline.  Peaks too 
become too broad to assign. 
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To determine if the binding interactions experienced by the 10 ligands including 4.21 
were orthosteric or allosteric in nature.  To do this the native binding partner D2R 
peptide, was used in equimolar concentrations to that of NCS1, this is because D2R 
peptide is known to bind to NCS1 in a 2:1 ligand: peptide ratio with a binding affinity 
of 30 μM.  The results of all 10 compounds used in the competition studies can be 
found in the appendix A.6 however the results for 4.21 can be seen below in Figure 
4.20.   
Interestingly upon the addition of D2R peptide there is no apparent change in the 
ligand signals of the STD spectra, however the intensity of the signals within the 
waterLOGSY experiment Figure 4.20 (red line), appear increased and much more 
defined in comparison to that of just the ligand and the protein (Figure 4.18 b).  This 
result could indicate a possible synergistic effect between the D2R peptide and the 
ligand 4.21.  However problems with the solubility of the D2R peptide in the NMR 
samples meant that any results from these experiments were inconclusive and cannot 
be discussed further at this time. 
 
 
Figure 4.20- Competition experiments of 4.21 with D2R peptide- A 1-D 1H NMR spectra of 50 μM 
NCS1, 1 mM 4.21 and 50 μM D2R peptide (blue) overlaid with a 1-D 1H waterLOGSY spectra (red) and 
1-D 1H STD spectra (black).  It is apparent that upon the addition of D2R peptide there is no change in 
the ligand signals of the STD spectra (black), however the intensity of the signals within the waterLOGSY 
experiment (red) appear increased and much more defined. 
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4.3.2. Summary 
This chapter has presented an approach to the design of small molecule modulators 
of protein-protein interactions.  It employed a modified version of the computational 
screening pipeline developed for the purposes of this thesis, adapting the source of 
the small molecule library.  The computational screening was able to focus the library 
from 1137 ligands to a select number of 28 purchased for screening against NCS1 
using biophysical methods.   
The biophysical screening process encompassed protein expression, purification and 
a variety of NMR spectroscopic techniques such as 1-D 1H, 1-D 1H STD and 1-D 1H 
waterLOGSY & 2-D 1H 15N HSQC.  The two step biophysical screening process 
allowed for the determination of five hit compounds from the original 28, which were 
found to undergo a binding interaction with NCS1 and five other compounds that had 
a weaker interaction.  Determination of the binding affinities of the five ligands using 
isothermal titration calorimetry (ITC), and investigations into improving the solubility 
of the native D2R peptide for competition experiments would be vital for any future 
work.  As well as optimisation studies of the five weaker interacting ligands. 
One of the most important aspects of this work, is the proof of principle behind the 
GOLD docking pose of 4.21 with NCS1.  Computational modelling predicted the top 
binding pose of 4.21 was situated around the residues of Thr92, Trp103, Ala182, 
Leu183 and Ser184.  The experimental results of the chemical shift perturbation sum 
indicated three of the above residues were conserved between the prediction and the 
data.  Also it is evident through analysis of the HSQC spectra that the chemical shift 
of the NH side chain belonging to TrpΣ103 is also severely altered.  Interestingly 4.21 
shares a commonality in chemical structure with that of the second generation hit 
Inhibitor 5; they both contain a substituted pyrazole moiety, Inhibitor 5 is N-benzylated 
whereas 4.21 has a phenyl substitution at the 4 position. 
Finally this research highlights the beneficial nature of combining two screening 
techniques, computational modelling and biophysical analysis specifically NMR 
spectroscopy, in the design of small molecules to target protein-protein interactions.  
The results of which have led to a promising hit for a small molecule inhibitor of NCS1. 
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5. Conclusions and Future Work 
5.1. Targeting NCS1 PPI 
Protein-protein interactions (PPIs) are involved in nearly all biological processes and 
have been implicated in numerous diseases and disorders.[42]  Due to their 
ubiquitous nature and central role, there has been an increasing interest in targeting 
the interface between two interacting proteins for therapeutic benefit.[42,43]  The 
surfaces involved in PPIs are typically large and flat.  As such the molecules which 
target them tend to have a high molecular weights and are often not traditionally 
“drug-like” in nature.[43–45,49]   
The aim of this research was to discover novel small molecule inhibitors for the 
interaction between the protein NCS1 and the peptide from the D2 receptor through 
structure-based drug design.  This physiologically relevant interaction has been 
implicated in such disorders as bi-polar disorder and schizophrenia, areas where 
novel drug treatments are in high demand (Chapter 1.3.1).[30]   
5.1.1 Structure-based drug design 
The structure-based drug design process involved the design and implementation of 
a computational workflow, whereby a pharmacophore-based screening approach of 
a library of known purchasable compounds was conducted.  Optimisation, filtering 
and validation processes lead to the selection of three of the purchasable compounds 
which were synthesised (as it was financially unviable to purchase them).  The 
structure-based drug design approach used in this research have never been applied 
to the NCS1 D2R peptide interaction.  
 
Figure 5.1- The chemical structures of the first generation of inhibitors developed against the NCS1 D2 
interaction.  Details of the computational workflow, synthesis and biophysical analysis can be found in 
Chapter 2. 
The three designed inhibitors of the first generation were, synthesised efficiently in 
three to four steps, with yields of 28%, 32% and 65% respectively.  The interactions 
of each ligand with NCS1 were investigated using NMR spectroscopy.  2-D 1H 15N 
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and 1H 13C HSQC experiments showed changes in the amino acids resonances of 
NCS1, most likely induced through interactions between NCS1 and the molecules.  
Higher concentrations of Inhibitor 1 were found to cause changes in the spectra 
indicative of a non-specific interaction (as discussed in Chapter 2.3). 
The tryptophan fluorescence results showed a possible change in the folding of the 
secondary structure of NCS1 in the presence of inhibitors 2 and 3 (due to the 
observed red and blue shifts in the fluorescence signal), whereas Inhibitor 1 was 
shown to cause quenching of the fluorescence.  To further investigate the binding 
interactions of the first generation with NCS1, binding affinity was explored using 
isothermal titration calorimetry (ITC). 
Full characterisation of the binding affinity was not possible due to problems 
associated with the solubility of the inhibitors in aqueous buffer.  The solubility issues 
encountered are a common problem associated with targeting PPIs with small 
molecules; this is more than likely due to the nature of the interaction sites being 
hydrophobic.[251,319,320]   
The limited solubility of the first generation of inhibitors restricted further biophysical 
analyses; therefore the logical progression was to develop a second generation of 
inhibitors with improved solubility to facilitate accurate binding measurements.   
In an effort to solubilise the next generation compounds, a variety of solubilising 
groups were incorporated to the core scaffold of Inhibitor 2 and a number of structural 
changes were made (Chapter 3.1 Figure 3.2).  The computational design efforts and 
screening pipeline afforded 12 candidate compounds for synthesis.  However, 
challenges encountered during the synthesis (Chapter 3.2) meant that only two of the 
intended compounds were synthesised; Inhibitors 4 and 5 in yields of 36% and 34% 
respectively (Figure 5.2). 
 
Figure 5.2- The chemical structures of the second generation of inhibitors developed against the NCS1 
D2 interaction.  Details of the computational approach, synthesis and biophysical analysis can be found 
in Chapter 3. 
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Fluorescence and NMR investigations indicated more specific but weaker binding of 
the second generation inhibitors compared with first generation.  This result was 
observed in the 2-D 1H 15N and 1H 13C HSQC where Inhibitor 4 appeared to have less 
of an effect on the amino acid residues of NCS1 than Inhibitor 5.  A greater quenching 
of the intrinsic fluorescence in the presence of Inhibitor 5 than Inhibitor 4 was 
observed at identical concentrations.  Secondly, the concentrations of the second 
generation required to cause quenching of the tryptophan fluorescence was over 100 
times greater than the first generation (as discussed Chapter 2.3.8 Figure 2.48 and 
Chapter 3.3.3 Figure 3.27).   
Despite the improved solubility of the second generation inhibitors, DMSO was still 
required to dissolve the compounds at the millimolar concentrations required for the 
ITC experiments.  However, because DMSO interacts with NCS1, this method could 
not be used to obtain more precise KD values.   
The removal of compounds with more unfavourable physicochemical properties, and 
unfavourable predicted binding poses, meant that the computational protocol was 
successful in its ability to select compounds with a greater probability of interacting 
with the target protein.  The first and second generation compounds have been shown 
to undergo an interaction with NCS1, however biophysical analyses were limited due 
to the solubility challenges the compounds present.  These challenges do not 
discredit the interactions observed between the ligands and the protein in ITC and 
fluorescence investigations, however it does limit the determination of any 
quantitative affinity value.  To reduce the challenges associated with the use of DMSO 
and NCS1, a different organic solvent that does not have any effect on the protein 
should be used to solubilise the compounds for future testing of other ligands.  
5.1.2 The fragment-based approach 
As an alternative to identify potential hit compounds, a fragment-based approach was 
also carried out.  The computational pipeline previously developed, was adapted and 
applied to a library of small molecule fragments (~1,137), designed to be rich in 
compounds which have been found to perturb a range of different protein-protein 
interactions (Professor Raymond Norton, Monash institute of Pharmaceutical 
Sciences, personal communication).   
Due to the solubility restrictions encountered with the structure-based drug design of 
the first and second generation compounds, the computational pipeline was adapted 
to circumvent this with the fragment approach.  A minimum solubility filter was applied 
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by application of the “rule of three”, this enabled exclusion of the more insoluble 
compounds and resulted in a selection of 28 ready to purchase fragments.   
A biophysical screening strategy was developed focusing on a pipeline of NMR 
spectroscopic experiments in order to efficiently screen the 28 compounds and 
discover those which bind with NCS1.  Of the 28 compounds, eight were identified as 
not interacting with NCS1 through 1-D STD/waterLOGSY NMR experiments (Chapter 
4.3.1 Scheme 4.1 a and b).  Of the 20 compounds that were identified as interacting 
with NCS1, 5 underwent a binding interaction with NCS1 and 15 were either false 
positives or the binding interaction with NCS1 was very weak.  Biophysical screening 
resulted in identification of 5 hit compounds, one of which is an extremely promising 
lead candidate for the development of inhibitors of the NCS1 D2 interaction due to its 
greater perturbation of the targeted amino acid residues of NCS1. 
 
Figure 5.3. The chemical structure of the lead fragment compound 4.21.  Details of the computational 
workflow applied to the fragment library and biophysical analysis can be found in Chapter 4. 
5.1.3 Concluding remarks 
We have identified and verified several small molecules that bind NCS1 via two 
differing screening strategies, one which used computational applications to select 
compounds to synthesise and the other to select fragments to screen.  From each 
approach one molecule has been highlighted as a hit compound for the future 
development of inhibitors of the NCS1 D2 interaction; Inhibitor 5 and 4.21 (Figure 
5.3).  Interestingly both compounds share a commonality in their chemical structure; 
they both contain a substituted pyrazole moiety, Inhibitor 5 is N-benzylated whereas 
4.21 has a phenyl substitution at the 4 position.  Both approaches to select these 
compounds involved an initial computational screening protocol, which was key in 
removing those compounds which were unlikely to bind as wished and those with 
unfavourable physicochemical properties prior to candidate selection.   
The nature of the fragment screening approach made it a much more suitable and 
efficient method for identifying NCS1 binding compounds and is a method that has 
been successful in targeting a number of other PPIs.[310]  The improved solubility of 
the smaller fragments in comparison to that of the larger compounds of the first and 
second generation, improved the handling for biophysical characterisation.  From this, 
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hit fragments then provide a core scaffold which can be further developed into larger 
compounds able to overcome any non-specific binding interactions that may occur as 
a result of their smaller size. 
This research contributes greatly to the understanding of the challenges associated 
with targeting the NCS1 D2R peptide interaction with small molecules, specifically 
highlighting the challenges associated with using organic solvents such DMSO with 
NCS1.  These compounds however, present an exciting initiation point for further 
investigations into the druggability of this important PPI.   
5.2. Future NCS1 research 
After reviewing the previous work into the development of inhibitors of PPIs and the 
research detailed in this thesis, the future research into the development of inhibitors 
of the NCS1 D2 interaction could include: 
Further investigation of the binding interactions of Inhibitor 5 and 4.21 through 
systematic mutagenesis of the eight key residues of the NCS1 binding groove.  This 
will enable the determination of which portion of the binding site is interacting with the 
compounds.  
Using the structural information collected for all the compounds screened against 
NCS1 in this thesis, a new chemical scaffold could be designed.  This would include 
an improved solubility profile to allow the investigations of the binding affinity in 
aqueous buffer without the influences of DMSO.  The efficiency and ease of the 
synthesis should be improved in comparison to that of the second generation; with 
the aim of generating a higher number of compounds to test.  Use of solid matrix lead 
binding tests such as surface plasmon resonance (SPR) [299] could be used to 
circumvent any solubility issues that may arise.  Finally all structural investigations 
should be verified through the use of cellular based assays such as ELISA, which 
have been used previously in investigations of the distribution of NCS1 in the rat 
brain.[321] 
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6 Experimental 
 Computational Protocols Ligand-based Virtual Screening 
Methods 
6.1.1 Pharmacophore Selection Protocol 1 
Selection of the initial pharmacophore of the frequenin (frq1) and phosphatidylinositol 
4-kinase (pik1) interaction was carried out informed by previous structural work 
previously conducted by Ames et al. and using PyMOL version 1.3.[34][224]  The 
NMR derived structure of the frq1 pik1 complex was downloaded from the RSCB 
protein data bank (PDB) (PDB code 2JU0) and loaded into PyMOL.[34]  The key 
hydrophobic residues of pik1 Val-156, Ala-157, Ala-159, Leu160, Val-161, and Met-
165 indicated by Ames et al. were selected from the PDB file in PyMOL and the subset 
of the complex saved for pharmacophore screening.[224]  
6.1.2 Online Screening Database Protocol 2 
Virtual screening of ligand databases for matches to the selected pharmacophore 
was conducted using the online pharmacophore search software database 
ZINCPharmer.[92]  The pik1 file prepared in PyMOL (6.1.1 Protocol 1) was selected, 
excluding the hydrogen donors, acceptors and those hydrophobic residues not 
indicated by Ames et al. as being involved in the key interactions.  Hit reduction and 
hit screening filters were then applied to each individual search.  For each of the six 
different pharmacophore’s (defined Chapter 2.1) the search filters applied were as 
follows; molecular weight (Da) ≤ 600, ≤ 500, ≤ 300 and ≤ 150; root mean squared 
deviation (RMSD) ≤ 2, ≤ 1 and ≤ 0.5 and rotatable bonds ≤ 9 and 9-1, the results for 
these screens can be seen in Chapter 2.1.2 Table 2.2 – Table 2.7.  For each different 
search the ligand files were downloaded and saved to a directory locally for further 
analysis. 
6.1.3 Molecular Docking Methods 
Initially the ligands downloaded for each pharmacophore were docked and scored 
using the software GOLD Suite v5.1 with the function “Goldscore” (Protocol 3), they 
were then rescored using Astex statistical potential “ASP”, “Chem Score” and Chem 
Piecewise Linear Potential “ChemPLP” respectively (Protocol 4).[99]  Secondary 
docking studies were conducted upon the ligands interactions with NCS1 (pdb code 
5AER) following the same protocols 3 and 4 with amendments to the protein pdb 
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code.  With the NCS1 docking the binding site was determined as 6 Å of “L_1, 
C:\backup\Helix 1 dopamine.pdb” (one dopamine c terminal helix).[99]  
6.1.3.1 Protocol 3 
 Load appropriate file of frq1 active site (pdb format). 
 Setup and perform docking calculations using “Wizard”. 
 “Add all hydrogens” to the protein (1391 in total). 
 Define the binding site as 6 Å around the reference position of the pik1 
fragment (pik1 residues Ala157-Met167) “L_1Scitegic02071211143D”. 
 Select “Detect Cavity”. 
 Select “Solvent Accessible.” 
 Select ligands saved from protocol 5.1.2. 
 Within “Fitness and Search Options” select “Docking” and “Goldscore” as 
default, select “Allow early termination” and use “Internal ligand energy offset”. 
 “Output Options” select “Structure Data (SD) file format”, define output 
directory and deselect “Save Lone pairs”. 
 Submit calculation by selecting “Run Gold” and review results saved 
automatically in output directory. 
6.1.3.2 Protocol 4 
 Load appropriate file of frq1 active site (pdb format). 
 Select “Gold” tab, “Set up and run a docking”, “Load existing”. 
 Select the corresponding previously run Gold docking “conf” file to load the 
ligands results from the previous docking. 
 Keep all settings the same as the default except within “Fitness and Search 
Options” where “Docking” should be deselected. 
 Select “Rescore” and set “Rescoring function” to either “ASP”, “Chem Score” 
or “ChemPLP”. 
 Within “Output Options” define a new output directory for the new file type. 
 Submit calculation by selecting “Run Gold” and review results saved 
automatically in output directory. 
6.1.4 Ligand-based Screening and Selection 
6.1.4.1 Physiochemical Properties Protocol 5.[125] 
Physiochemical properties of the ligands docked in 6.1.3.1 Protocol 3 and 6.1.3.2 
Protocol 4 were calculated in Pipeline Pilot Student Edition version 6.1 using the 
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following components in a sequential protocol (this process was repeated for the 
NCS1 docking); 
  “Chemistry Readers”; “SD Reader”. Imports a file in the structural data file 
format. 
 “Calculators”; including “Solubility”, “Surface Area and Volume”, “Number of 
Hydrogen Acceptors and Donors”, “ALogP, “Molecular Weight” and 
“Molecular Properties” specifically selected to calculate the number of 
rotatable bonds.  Used to calculate the ADMET properties using a number of 
components. 
 “Chemistry Writers”; “SD Writer”.  The data files can be extracted and saved 
in the SD format using for use in the balanced selection process 6.1.4.2 
Protocol 6. 
6.1.4.2 Balanced Selection Protocol 6.[124] 
The balanced selection protocol was conducted in Knime 2.5.1 and the workflow 
protocol can be seen below.  
 SDF Reader:  Read in each SDF file for each of the four scoring functions. 
 Row Filter:  Remove any negative fitness scores. 
 Math Formula:  Calculate Ligand Efficiency according to the formula: 
 Ligand efficiency = Goldscore ÷ molecular weight 
 Column Filter:  Remove any unwanted or unnecessary information leaving 
only the following as columns of data- “Molecule Name”, “Fitness Score 
Solubility”, “Surface Area and Volume”, “Number of Hydrogen Acceptors and 
Donors”, “A LogP”, “Molecular Weight”, “number of rotatable bonds” and 
“Ligand efficiency”. 
 Sorter:  Sort the ligands into descending order with respects to the “Ligand 
efficiency”. 
 Math Formula:  Calculate the average score for the scoring function (ASP, 
Chemscore, ChemPLP), hence rank each ligand and append as new column. 
 Sorter:  Re-sort the ligands into ascending order with respects to the row key. 
 Joiner:  Join two of the ranking files. 
 Column Filter:  Exclude any duplicate information. 
 Joiner:  Combine the results from the four different ranking files. 
 Column Filter:  Exclude any other duplicates 
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 Math Formula:  Calculate a “Consensus ranking”, this is the sum of all four 
ranking scores round (“ASP rank” + “GOLD rank” + “Chemscore rank” + 
“Chem PLP rank”) and appends as a new column. 
 Math Formula:  Calculate if the molecules have a better “Consensus rank” 
than that generated for pik1 and appends a new column. 
 Numeric Row Splitter:  Remove any ligands with a “Consensus rank” 4, below 
that of pik1. 
 Numeric Row Splitter:  Remove any ligands with a “Solubility” (logS) less than 
-4. 
 Pareto Ranking:  List of all columns which may be used for ranking.  Only 
numeric columns are supported currently.  
 Sorter:  Sort the “Pareto ranking” into ascending order. 
 SD Writer:  Create an output file containing all the information calculated in an 
SDF format (See Chapter 2.1 Figure 2.6). 
6.1.5 Second Generation Inhibitors 
6.1.5.1 Design Protocol 7 
Second generation inhibitor design was carried out using Inhibitor 2 as a template as 
it scored most highly using 6.1.1 - 6.1.4, optimisation was conducted in concordance 
with the docking pose of the Inhibitor 2 NCS1 complex determined under 6.1.3 
Molecular Docking Methods Protocols 3 and 4.  Solubilising groups were then 
selected with the aim to improving the ADMET parameters of the new inhibitors and 
hence 55 structurally diverse variants of Inhibitor 2 were designed and modelled using 
Spartan 08 V1.2.0.[225] 
6.1.5.2 Molecular Docking Methods 
The analogues were docked using GOLD Suite v5.2 following 6.1.3 Molecular 
Docking Methods protocols 3 and 4,[99] with an amendment to the protein file used, 
replacing the frq1 pik1 complex (pdb 2JU0)[34] with the NCS1/ D2R peptide complex 
(pdb code 5AER).[267]  The binding site was determined as 6 Å of “L_1, 
C:\backup\Helix 1 dopamine.pdb” (one dopamine c terminal helix). 
6.1.5.3 ADMET Properties Protocol 8. [125] 
ADMET properties of the analogues were calculated in Pipeline Pilot Student Edition 
version 8.5 using the following components in a sequential protocol; 
 “Chemistry Readers”; “SD Reader” reads in the SD file from the Goldscore 
docking results calculated in 5.1.5.2 Molecular Docking Methods.[99]  
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 The ADMET properties were calculated using a number of components found 
under “Calculators”; including “Solubility”, “Surface Area and Volume”, 
“Number of Hydrogen Acceptors and Donors”, “A LogP, “Molecular Weight” 
and “Molecular Properties” specifically selected to calculate the number of 
rotatable bonds. 
 “Chemistry Writers”; “SD Writer” and “Excel Report Writer”.  Creates two 
output formats, one an SD file and the other lists all the information calculated 
under 6.1.5.2 and 6.1.5.3 in an xls file spreadsheet that can used under 
6.1.5.4 “Ranking and Selection”. 
6.1.5.4 Ranking and Selection 
The scoring output spreadsheet (xls) was analysed using Microsoft office Excel 2007, 
with the ligand efficiency of each analogue calculated using the formula found within 
the 6.4.2 Balanced Selection Protocol 6.  The analogues were then ranked in order 
of their “Molecular solubility” and the top 12 molecules with best predicted solubility 
were selected for synthesis.  
6.1.6 Fragment Library 
6.1.6.1 Construction  
The small molecule library of 1137 compounds was initially stored in a Microsoft 
Office Excel® 2007(Redmond, Washington: Microsoft) format.  For the purpose of 
computational modelling, this file was converted into a SDF format with each 
individual molecule in three dimensional energy minimised form.  This was carried out 
using Pilot Student Edition version 8.5, 6.1.6.1.1 Protocol 9.[125]  The SDF file was 
then modelled in Spartan ’08 V1.2.0 Protocol 10.[225] 
6.1.6.1.1 Protocol 9[125] 
 “File Reader”; “Delimited text reader”.  Reads in excel files also known as 
delimited text files. 
 “Chemistry”; “Data Access and Manipulation”; “Converters”; “Molecule from 
text” (simplified molecular-input line-entry system “SMILES” format).  
Converts the chemical name of a compound into its molecular structure 
specifically in a SMILES data format.  
 “Chemistry”; “Data Access and Manipulation”; “Manipulators”; “Add 
hydrogen’s”. 
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 “Chemistry”; “Data Access and Manipulation”; “Manipulators”; “3-D Methods”; 
“3-D co-ordinates”.  Creates 3-D conformer of each compound from the 2-D 
SMILES file. 
 “Chemistry”; “Data Access and Manipulation”; “Manipulators”; “3-D Methods”; 
“Minimise molecule”.  Creates an energy minimised conformation of each 
compound. 
 “Chemistry Writers”; “SDF writer”.  Exports files in SD format. 
6.1.6.1.2 Protocol 10 [225] 
 File Open SDF file. 
 Setup; Calculations; Equilibrium Geometry;-Molecular mechanics.  This 
carries out an energy minimisation optimisation.[322][225] 
 Submit. 
 File; save as in “SDF” and “Spartan formats”. 
6.1.6.2 Molecular Docking Methods[99] 
The 1137 small molecules from 6.1.6.1 were docked and rescored using GOLD Suite 
v5.2 following protocol 6.1.3 Molecular Docking Methods protocols 3 and 4, with an 
amendment to the protein file used replacing the  frq1 pik1 complex (pdb 2JU0) with 
NCS1 D2R peptide (pdb code 5AER). [99][34][267]  The binding site was determined 
as 6 Å of “L_1, C:\backup\Helix 1 dopamine.pdb” (one dopamine c terminal helix).  
The 100 docking poses for each compound were then separated using Pipeline Pilot 
Student Edition version 8.5 using 5.1.6.2.1 Protocol 11.[125]  
6.1.6.2.1 Protocol 11 
 SD Reader- Reads in the SD file. 
 Custom manipulator- manipulates the data. 
 “Group data by tag”-All 100 docking poses for each compound are grouped 
using “mol name”. 
 “Sub protocol 1”, individual mol sdf files generated, Pwd: (c) \programme 
files\Accelrys\PPs\public\users\jh0u700c.  Used to extract the 100 docking 
poses for each compound as one file. 
6.1.6.3 Selection Methods 
The individual Goldscore files were grouped for each molecule and an average 
Goldscore was calculated, the values were then merged with the compound library 
file, conducted using Pipeline Pilot Student Edition version 8.5, 6.1.6.3.1 Protocol 12.   
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The second step in the selection process was the calculation of the ADMET 
parameters the protocol followed was that of 6.1.5.3.[184]  A final filter applied known 
as “the rule of three”,[323] those compounds with a molecular weight ≤300, AlogP ≤ 
3 hydrogen bond donors and hydrogen bond acceptors ≤ 3 respectively were carried 
forward, those that did not fit the criteria were discarded.  This process was carried 
out using Pipeline Pilot Student Edition version 8.5 following 6.1.6.3.2 Protocol 
13.[125]  Protocols 12 and 13 were then repeated for the rescoring functions ASP, 
Chemscore and ChemPLP.[99]   
The four separate files generated from these processes were combined and the 
compounds ranked using Knime 2.5.1, 6.1.6.3.2 Protocol 14.[124]  Finally, the SDF 
file generated from Protocol 14 was then recombined with the original spreadsheet. 
6.1.6.3.1 Protocol 12 
 “SD Reader”- Read in SD file from 6.1.6.2.1 
 “Custom manipulator”- Find “molname” 
 “Group data” by tag- Group data according to the “molname” column 
 “Calculate average nodefine”- Expression: #Root=DataRoot(); 
#SumGoldscore=(); For # I in 1… NodeNumChildren (#Root)loop; 
#child:= nodeithchild (#Root, #i); #SumGoldscore+ = Nodeproperty 
(#child,’Gold.Goldscore.Fitness’); End loop; 
AvgGoldscore:=SumGoldscore/NodeNumChildren(#Root)- Calculate 
average scoring function such as “Goldscore”, creates column 
AvgGoldscore. 
 “Keep properties”- molname, AvgGoldscore - Filter unnecessary 
data. 
 “Remove group data” - Remove duplicates. 
 “Rename property”- Rename “molname” to “Name”. 
  “SD Reader”-  Import 6.1.6.1 SD library file  
o Merge data- merge both sets of data using “Name”. 
 “Output”- “SD writer” and “HTML Viewer”- Export results in two file 
formats SD and an online molecular viewer. 
6.1.6.3.2 Protocol 13 
 “SD Reader”. 
 “Property value”: “threshold filter 1”- Select for compounds with a 
molecular solubility ≥3. 
 “Sort data”. 
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 “Property value”: “threshold filter 2” - Select for compounds with ALogP 
≤ 3. 
 “Sort data”. 
 “Property value”: “threshold filter 3” - Select for compounds with 
molecular weight ≤300. 
 “Sort data”. 
 “Property value”: “threshold filter 4” - Select for compounds with number 
of hydrogen bond acceptors ≤ 3. 
 “Sort data”. 
 “Property value”: “threshold filter 5” - Select for compounds with number 
of hydrogen bond donor’s ≤ 3. 
 “Sort data”. 
 “Remove hydrogens”. 
 “2-D co-ordinates”- Generate 2-D molecular structure. 
 “Output options”: “Excel structure viewer”, “SD writer” and “HTML 
molecular viewer”. 
6.1.6.3.3 Protocol 14 
 “SD Reader”- Read in the SD file from 6.1.6.3.2 Protocol 13. 
 “Row filter”- Select the column to test: “Average ASP”. 
 “Math formula”- Calculate the “ligand efficiency” (average score/ 
molecular weight). 
 “Joiner”- Join the output from two scoring functions. 
 “Column filter”- Delete duplicates. 
 “Joiner”- Collate all four columns into one single output. 
 “Math formula”- Calculate the “Better than D2” score using the following 
equation. 
𝑌 =
𝜀𝐺
𝜀𝐺1
+
𝜀𝐴
𝜀𝐴1
+
𝜀𝐶
𝜀𝐶1
+
𝜀𝑃
𝜀𝑃1
 
Y- Better than D2 score 
ƐG, ƐA, ƐC, ƐP- Compound “Ligand efficiencies” from “Goldscore”, “ASP”, 
“Chemscore” and” Chem PLP”. 
ƐG1, ƐA1, ƐC1, ƐP1- D2 Ligand efficiencies from “Goldscore”, “ASP”, 
“Chemscore” and “ChemPLP” respectively. 
 “Numeric row splitter”- “BetterthanD2” score≤ 4. 
 “Sorter”- Sort the “BetterthanD2” score in descending order. 
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 SD writer. 
6.1.6.3.4 Clustering and data analysis  
With the compound library now listed in descending order with respects to the 
“BetterthanD2” score calculated previously in 6.1.6.3.3 Protocol 14 it was deemed 
necessary to cluster the compounds.  This was carried out in Pipeline Pilot Student 
Edition version 8.5 using a number of different protocols to compare and contrast the 
data.[125]   
6.1.6.3.4.1 Protocol 15 
 “SD reader”- Read in SD file from 6.1.6.3.3 Protocol 14. 
 1) “Cluster molecules”- Cluster the compounds with an “average number 
per cluster”: “6 cluster centres”. 
o “Histogram numerical”. 
o “HTML report viewer”. 
o “Pdf report writer”. 
 2) “Histogram numerical”- data series 1; property “Better than D2”. 
o “HTML report Viewer”. 
o “Pdf report viewer”. 
6.1.6.3.4.2 Protocol 16 
 “SD reader”- Read in SDF file from 5.1.6.3.3 Protocol 14, then split into 
branches 1 and 2. 
 1) “Rename property”- “BetterthanD2”. 
o 3) “Cluster molecules”- Cluster into an average number of 6 
molecules per cluster, select “cluster centres and members”. 
 “Sort data”- Sort the cluster into ascending numbers, with 
the “BetterthanD2” into descending numbers. 
 “Group data by tag”- The data is grouped by each cluster. 
 “Find maximum value for each cluster”- Calculate the 
maximum ligand efficiency value for each cluster. 
 “Histogram numerical”- Generate a histogram with 
“maximum ligand efficiency”; bin size 0.5; for the ligand 
efficiency per cluster. 
o 4) “Cluster molecules”- Cluster with an average number of 6, 
select “cluster centres”, and generate the mean of each cluster 
by selecting “mean centres and scale”. 
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 “Sort data”- Sort the cluster into ascending numbers, with 
the “BetterthanD2” into descending numbers.  
 “Histogram numerical”- Create a Histogram of 
the“BetterthanD2”; bin size 0.5; along with the ligand 
efficiency all molecules. 
 2) “Histogram numerical”- Create a histogram with no clustering of 
“BetterthanD2”; bin size 0.5; ligand efficiency all molecules 
 Joining branches 1 and 2. 
 5) Tile horizontal. 
 6) Output options: HTML report viewer and pdf writer. 
6.1.6.3.4.3 Protocol 17 
 1) “SD reader”- Read in SDF file from 6.1.6.3.3 Protocol 14, then split 
into branches 1 and 2. 
1. 2) “Top N filter”- Keep top 50 molecules. 
2. 3) “Sort data”- Sort the “BetterthanD2” column in descending order. 
3. 4) “Cluster molecules”- Create a larger cluster with an average number 
per cluster of 12, select “cluster centres and members”. 
o i) “Count and index data”. 
o ii) “Group data by tag”- Group using cluster. 
o iii) “Select molecules”. 
 “Ungroup data”. 
 “Sort data”- “BetterthanD2” descending. 
 “Top N filter”- “BetterthanD2” true max number of 
records. 
o iv) “2-D co-ordinates”- Generate the 2-D co-ordinates of each 
molecule. 
4. Join the “BetterthanD2” scores for the molecules from each cluster by 
joining the outputs from 3) and 4). 
5. “Output options”- “SD writer”. 
6.1.6.3.4.4 Protocol 18 
6. 1) “SD reader”- Read in SDF file from 6.1.6.3.5 Protocol 17 containing 
102 molecules. 
7. 2) “Top N filter”- Keeps top 15 molecules.  
8. 3) “Sort data”- Sort the remaining data with respects to “BetterthanD2” 
in descending order. 
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9. 4) “Cluster molecules”- Cluster the remaining 87 with an average 
number per cluster of 6, select “cluster centres and members”. 
o ii) Group data by tag- group using cluster. 
o iii) Select molecules.  
 Ungroup data. 
 “Sort data”- Sort by “BetterthanD2” in descending order. 
 “Top N filter”- “BetterthanD2” true max number of 
records. 
o iv) 2-D co-ordinates. 
10. Join the “BetterthanD2” scores for the molecules from each cluster by 
joining the outputs from 3) and 4). 
6.1.6.3.4.5 Protocol 19 
 1) “SD reader”- Read in SDF file from 6.1.6.3.6 Protocol 18 
o Tag data. 
 2) “Delimited text reader”- Read in original excel spreadsheet from 6.1.6.1 
o Rename property- changes “molecular name” to “name”. 
 “Merge data”- Combines data from 1 and 2 using ‘name’ as the recognition 
point. 
 “Property defined filter”. 
 “Output”: “HTML molecular table viewer”, “SD writer”, “Delimited text writer”. 
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 Chemical Procedures 
6.2.1 Analysis Techniques and Reagents  
The following general techniques for organic synthesis and analysis in this 
experimental chapter were employed;  
6.2.1.1 Thin layer chromatography (TLC)  
Analytical thin layer chromatography was performed on silica gel 60 coated aluminium 
TLC plates.  Once developed the chromatographs were detected and analysed using 
a UV lamp (254 nm) and stained using an appropriate dip, developed using a heat 
gun.   
6.2.1.2 Flash column chromatography 
The required amount of silica (particle size 40 – 63 µm, supplied by Aldrich) was made 
into slurry with the appropriate volume of the desired eluent system; it was then 
applied to a column over a thin base layer of sand.  The crude product was applied 
to the column, either dissolved in the minimum volume of the eluent system or pre 
absorbed onto a small amount of silica.  The column was then eluted with the eluent 
and fractions were collected and analysed using TLC. 
6.2.1.3 Nuclear Magnetic Resonance spectroscopy (NMR) 
1H and 13C NMR spectra were both recorded on a Bruker AMX-400 Spectrometer in 
deuterated solvents as indicated within the experimental data, 1H spectra were 
recorded at operating frequency of 400 MHz and 13C at 100 MHz.  The chemical shifts 
are reported in ppm and the coupling constants (J) in hertz (Hz). 
6.2.1.4 Mass Spectrometry  
Mass Spectrometry was performed using an in house service within the Chemistry 
Department of the University of Liverpool and was conducted on a VG analytical 
7070E machine and a Frisions TRIO spectrometers using electronic ionisations (EI), 
chemical ionisations (CI) and electro spray (ES). 
6.2.1.5 Solvents 
Analytical grade solvents were prepared for reactions involving the use of semi 
aqueous media, anhydrous or purified solvents were obtained in the following 
manner: 
Tetrahydrofuran (THF)- Dried from a sodium and benzophenone still under nitrogen 
for 2-3 hours until purple. 
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Diethyl ether- Dried from a sodium and benzophenone still under nitrogen for 2-3 
hours until purple. 
Toluene- Sureseal™ anhydrous solvent purchased from Aldrich, used without 
modification. 
N,N-Dimethylformamide (DMF)- Sureseal™ anhydrous solvent purchased from 
Aldrich or distilled from calcium hydride before use.  
Dimethylacetamide (DMA)- Sureseal™ anhydrous solvent purchased from Aldrich, 
used without modification. 
Methanol (MeOH)- Sureseal™ anhydrous solvent purchased from Aldrich or dried 
from a magnesium with iodine still under nitrogen for 2-3 hours. 
Ethanol (EtOH)- Dried from a magnesium with iodine still under nitrogen for 2-3 hours.
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6.2.2 1-(3,5-dimethylphenyl)-3-methyl-1H-pyrazole-5-amine[245] 
 
 
2.11 
A solution of 3-aminocrotonitrile (1.25g, 15.2 mmol) in HCl (1M, 50 mL) and 3, 5-
dimethyl-phenylhydrazine (2.5g, 15.2 mmol) were refluxed at 115 °C for four hours.  
The solution was then cooled to 25 °C and made basic by the drop wise addition of 
NaOH (6M).  The reaction was extracted with DCM (3 × 50 mL), the organic fractions 
were combined and dried with anhydrous MgSO4.  The solvent was removed in vacuo 
to afford an off white solid without further purification (2.00 g, 9.94 mmol, 80.3%). 
Rf = 0.44 (1:9 MeOH: DCM).  1H NMR (400 MHz, CDCl3): δ 7.12 (2H, s, Ar CH), 6.95 
(1H, s, Ar CH), 5.42 (1H, s, CH), 3.79 (2H, br s, NH2), 2.34 (6H, s, 2×CH3), 2.22 (3H, 
s, CH3).  13C NMR (100 MHz, CDCl3): δ 149.5, 145.6, 139.7, 138.8, 129.2, 121.9, 
90.8, 21.6, 14.3.  NRMS Calculated for C12H15N3 + H+ [M + H+]: 202.2 Da.  Found: [M 
+ H+] 202.2 Da.  Elemental analysis calculated (%) for C12H15N3: C 71.61, H 7.51, N 
20.88.  Found: C 71.23, H 7.58, N 20.71. 
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6.2.3 1,3,6-trimethyl-1H-pyrazolo-3,4-pyridine-ethylester[246] 
 
 
2.14 
1,3-Dimethyl-1H-pyrazole-5-amine (2.0 g, 17.9 mmol) and ethyl acetopyruvate (2.53 
mL, 17.9 mmol) in AcOH (90 mL) were refluxed for four hours.  The reaction was 
allowed to cool to 25 ˚ C and the AcOH removed in vacuo.  To afford the crude product, 
a dark brown oil which was extracted into DCM (20 mL) and washed once with water 
(20 mL) and once with sodium bicarbonate (20 mL).  The organic layer was dried over 
anhydrous MgSO4 and the solvent removed in vacuo yielding a brown solid as a crude 
product without further purification (3.5 g, 15.01 mmol, 83.4%).   
Rf = 0.27 (1:1 EtOAc: Hex)  1H NMR (400 MHz, CDCl3): δ 7.40 (1H, s, Ar CH), 4.40 
(2H, q, J=7.2 Hz, CH2), 4.04 (3H, s, N-CH3), 2.67 (3H, s, CH3), 2.65 (3H, s, CH3), 1.40 
(3H, t, J=7.2 Hz, CH3).  13C NMR (100 MHz, CDCl3): δ 169.5, 158.6, 152.7, 140.6, 
133.6, 117.7, 109.5, 62.2, 33.9, 25.1, 16.5, 14.6.  NRMS Calculated for C12H15N3O2 + 
H+ [M + H+] 234.2 Da.  Found: [M + H+] 234.2 Da.  Elemental analysis calculated 
(%) for C12H15N3O2: C 61.79, H 6.48, N 18.01.  Found: C 61.65, H 6.53, N 17.92. 
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6.2.4 1,3,6-trimethyl-1H-pyrazolo-3,4-pyridine-carboxylic acid[246] 
 
 
2.15 
To a stirring solution of 2.14 (3.5 g, 14.4 mmol) in i-PrOH (100 mL), was added KOH 
(1.68 g, 29.8 mmol) and the reaction refluxed for 5 hours.  The solution was allowed 
to cool to 25 ˚C, acidified by the drop wise addition of HCl (2 M), precipitating a white 
solid.  The solution was then partitioned between water (20 mL) and DCM (20 mL) 
and the pure product filtered and dried under Kugelrohr conditions yielding a fine 
white powder without further purification (2.21 g, 10.7 mmol, 72%).  
Rf =0.08 (1:9 MeOH: DCM)  1H NMR (400 MHz, MeOD): δ 7.51 (1H, s, CH), 4.05 (3H, 
s, N-CH3), 2.72 (3H, s, CH3), 2.66 (3H, s, CH3).  13C NMR (100 MHz, MeOD): δ 167.2, 
158.3, 151.9, 139.5, 134.4, 117.1, 108.8, 33.6, 24.5, 15.8. NRMS Calculated for 
C10H11N3O2 + H+ [M + H+]: 206.2 Da.  Found: [M + H+] 206.2 Da.  Elemental analysis 
calculated (%) for C10H11N3O2: C 58.53, H 5.40, N 20.48.  Found: C 58.52, H 5.41, N 
20.38. 
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6.2.5 Inhibitor 1 
 
  
Inhibitor 1 
6.2.5.1 Procedure 1[246] 
Acid 2.15 (200 mg, 1.0 mmol), amine 2.11 (210 mg, 1.1 mmol), N,N-
diisopropylethylamine (DIPEA) (0.505 mL, 2.9 mmol) and 1-methyl-2chloropyridinium 
iodide (370 mg, 1.5 mmol) were refluxed in anhydrous MeCN (3 mL) for 4 hours.  The 
solvent removed in vacuo and the crude product analysed using 1H NMR, without 
further purification (88.1 mg, 0.2 mmol, 23%).   
Rotamers 
Rf =0.22 (1:1 EtOAc:Hex)  1H NMR (400 MHz, CDCl3): Major peaks δ 8.10 (1H, s, 
NH), 7.05 (1H, s, CH), 6.91 (1H, s, CH), 6.81 (1H, s, CH), 6.61 (1H, s, CH), 4.0 (3H, 
s, CH3), 2.61 (3H, s, CH3), 2.44 (3H, s, CH3), 2.32 (3H, s, CH3), 2.31 (6H, s, 2× CH3).  
Minor peaks δ 8.40 (1H, s, NH), 6.87 (1H, s, CH), 6.81 (1H, s, CH), 6.35 (1H, s, CH), 
6.12 (1H, s, CH), 2.49 (3H, s, CH3), 2.25 (3H, s, CH3), 2.20 (3H, s, CH3), 2.17 (6H, s, 
2× CH3).   
6.2.5.2 Procedure 2 
To a stirring solution of acid 2.15 (200 mg, 1.0 mmol) in anhydrous THF (10 mL), DCC 
(310.6 mg, 1.5 mmol) and HOBt (197.5 mg, 1.5 mmol) were added and allowed to 
react at 25 ˚C for 30 minutes.  Amine 2.11 (215.6 mg, 1.1 mmol) was added and the 
reaction was left stirring at 25 ˚C for 24 hours.  The reaction was followed by TLC and 
after 24 hours it was deemed necessary to heat the reaction to 50 °C for a further 24 
hours.  The crude product was partitioned between water (1× 50 mL) and DCM (3×50 
mL) and purified using column chromatography in a solvent system of concentration 
gradient of EtOAc in Hexane.  Yielding the product which appeared as an off white 
powder (109 mg, 0.3 mmol, 28%).  
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Rf= 0.22 (1:1 EtOAc: Hex).  1H NMR (400 MHz, CDCl3): δ 7.90 (1H, br s, NH), 7.10 
(1H, s, CH), 7.02 (1H, s, CH), 6.95 (1H, s, CH), 6.68 (1H, s, CH), 4.04 (3H, s, N-CH3), 
2.60 (3H, s, CH3), 2.50 (3H, s, CH3), 2.40 (3H, s, CH3), 2.30 (6H, s, 2× CH3).  13C 
NMR (100 MHz, CDCl3): δ 169.5, 163.6, 152.2, 149.8, 140.2, 140.1, 137.9, 137.4, 
135.4, 130.5, 122.6, 114.2, 109.0, 99.7, 33.9, 25.1, 21.6, 14.8, 14.3.  IR ṽ = 3200 (m; 
v (N-H)), 1662 (s; v (C=O)).  HRMS Calculated for C22H24N6O + Na+ [M + Na+]: 
411.1909 Da.  Found [M + Na+]: 411.1912 Da (+0.7 ppm).  Elemental analysis 
calculated (%) for C22H24N6O: C 68.0, H 6.2, N 21.6.  Found: C 67.3, H 6.1, N 20.5. 
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6.2.6 2-methoxy-4,6-dimethylnicotino-3-nitrile[251] 
 
 
2.21 
2-Hydroxy-4,6-dimethylnicotino-3-nitrile (1.0 g, 6.7 mmol) was dissolved in DCM (52 
mL).  To this solution silver carbonate (2.61 g, 9.5 mmol) and methyl iodide (4.41 mL, 
70.8 mmol) were added with protection from light.  The reaction was stirred at 25 ˚C 
for 24 hours, then the solvent was removed in vacuo to afford the crude product which 
was purified using column chromatography in a solvent system of EtOAc and Hexane.  
The pure product appeared as a fine white powder (767 mg, 4.7 mmol, 70.1%).   
Rf= 0.83 (7:3 EtOAc: Hex).  1H NMR (400 MHz, CDCl3): δ 6.68 (1H, s, CH), 4.01 (3H, 
s, OCH3), 2.45 (3H, s, CH3), 2.44 (3H, s, CH3).  13C NMR (100 MHz, CDCl3): δ 164.6, 
161.1, 154.6, 117.8, 115.5, 94.2, 54.6, 24.9, 20.4.  NRMS Calculated for C9H10N2O 
+H+ [M + H+]: 163.2 Da.  Found [M + H+]:163.1 Da.  Elemental analysis calculated 
(%) for C9H10N2O: C 66.65, H 6.21, N 17.27.  Found: C 66.42, H 6.24, N 17.05. 
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6.2.7 N-Benzyl-3,5-dimethylpyrazole[324]  
 
 
2.23 
3,5-Dimethylpyrazole (1.0 g, 10.5 mmol) was added to a solution of KOH (0.88 g, 15.6 
mmol) in DMSO (14.5 mL).  The mixture was stirred at 25 ˚C and then heated at 80 
°C for one hour, before being cooled to 25 ˚ C and benzyl chloride (1.2 mL, 10.4 mmol) 
was added.  The reaction mixture was stirred at 25 ˚C for a further two hours.  The 
mixture was poured into water (50 mL) and extracted into DCM (4 × 50 mL).  The 
organic layers were combined, washed with water (4 × 50 mL), saturated NaCl (1 × 
50 mL), dried over anhydrous sodium sulphate and the solvent was removed in 
vacuo.  The crude product was purified using column chromatography in a solvent 
system of EtOAc and Hexane to yield the product which appeared as a yellow oil 
(1.35 g, 7.3 mmol, 70%).   
Rf = 0.22 (5:95 EtOAc: Hexane).  1H NMR (400 MHz, CDCl3): δ 7.30-7.00 (5H, m, 
Ph), 5.80 (1H, s, CH), 5.20 (2H, s, CH2), 2.20 (3H, s, CH3), 2.10 (3H, s, CH3).  13CNMR 
(100 MHz, CDCl3): δ 147.9, 139.6, 137.8, 129.9, 127.8, 126.9, 105.9, 53.0, 13.9, 11.5.  
IR ṽ = 1554 (m; v (C=C)), 1455 (m; v (C=C)).  NRMS Calculated for C12H14N2 + H+ [M 
+ H+]: 187.2 Da.  Found [M + H+]: 187.2 Da.   
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6.2.8 N-Benzyl-3,5-dimethyl-1-H-pyrazole-4-carbonylchloride[253] 
 
 
2.24 
Acid 2.23 (1.4 g, 7.3 mmol) and oxalyl chloride (2.5 mL, 29 mmol) were refluxed for 3 
hours.  The excess oxalyl chloride was removed in vacuo yielding the crude product 
which appeared as a thick orange oil and was carried forward into the next step 
without purification and full characterisation.  
IR ṽ =: 1735 (s; v (C=O)), 1616 (m; v (C=C)), 1427 (m; v (C=C)), 701 (m; v (C-Cl)). 
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6.2.9 Inhibitor 2[325]  
 
 
 
 
 
 
 
Inhibitor 2 
Nitrile 2.21 (0.3 g, 1.8 mmol) dissolved in the minimum amount of anhydrous Et2O (3 
mL) was added to a slurry of lithium aluminium hydride (0.14 g, 3.7 mmol) in 
anhydrous Et2O (3 mL).  The reaction was stirred at 25˚C for two hours and then 
heated for two hours at reflux.  The excess hydride was decomposed by the careful 
addition of the minimum amount of 20% NaOH (2 mL).  Crude acid chloride 2.24 was 
then added slowly (1.6 g, 5.6 mmol) along with pyridine (2 mL) and the reaction was 
left stirring at 25 ˚C for 16 hours.  Upon completion the mixture was basified with the 
addition of aqueous NaHCO3, filtered and washed with hot toluene (2 × 10 mL) and 
DCM (2 × 10 mL).  The filtrate was extracted into DCM (3× 10 mL) and the combined 
organic fractions were dried over anhydrous MgSO4.  The solvent was removed in 
vacuo and purified using column chromatography, in a solvent system of EtOAc and 
Hexane.  Yielding the product which appeared as a fine white powder (225 mg, 0.6 
mmol, 32%). 
Rf = 0.20 (50:50 EtOAc: Hex))   1H NMR (400 MHz, CDCl3): δ 7.30-7.03 (5H, m, Ph), 
6.50 (1H, s, CH), 5.20 (2H, s, CH2), 3.90 (3H, s, O-CH3), 2.42 (3H, s, CH3), 3.40 (3H, 
s, CH3), 2.37 (6H, s, 2 × CH3) 13C NMR (100 MHz, CDCl3): δ 164.5, 162.3, 154.7, 
148.2, 146.2, 142.4, 136.6, 129.2, 128.1, 127.0, 119.1, 116.4, 114.3, 53.7, 53.1, 34.8, 
30.1, 24.2, 19.4, 14.4, 11.3.  HRMS Calculated for C22H26N4O2 + Na+ [M + Na+]: 
401.1953 Da.  Found [M + Na+]: 401.1964 Da (-2.9ppm).  Elemental analysis 
calculated (%) for C22H26N4O2: C 69.8, H 7.06, N 14.8.  Found: C 69.3, H 7.1, N 14.4.  
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6.2.10  (1,2,4)-triazolo (4,3-a) pyridine-3 (2H)-thione[326]  
 
 
2.30 
2-Hydrazinopyridine (1.0 g, 9.16 mmol) was added to a solution of carbon disulfide 
(2.4 mL, 40.3 mmol) in CHCl3.  The reaction was refluxed for 20 hours, after which 
time the product had crystallised out of solution.  The crystals were filtered and dried 
under vacuum yielding the product which appeared as fine off white crystals with no 
further purification (1.1 g, 7.0 mmol, 76.4%). 
1H NMR (400 MHz, CDCl3): δ 8.35 (1H, dt, J=7.0, 1.0 Hz, CH), 7.49 (1H, dt J=9.0, 1.1 
Hz, CH4), 7.36 (1H, ddd, J=9.0, 6.0, 1.2 Hz, CH3), 6.87 (1H, ddd J=7.5, 6.0, 1.0 Hz 
,CH2).  13C NMR (100 MHz, CDCl3): δ 159.5, 146.5, 131.4, 125.4, 115.9, 114.2.  NRMS 
Calculated for C6H5N3S + H+ [M + H+]: 152.2 Da.  Found [M + H+]:152.2 Da.  
Elemental analysis calculated (%) for C6H5N3S : C 47.66; H 3.33; N 27.79.  Found: 
C 47.76, H 3.31, N 27.98.  
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6.2.11 2-chloro-N-(3,4,5- trimethoxyphenyl)acetamide[327]  
 
 
2.33 
Chloroacetyl chloride (0.6 mL, 8.2 mmol) and NEt3 (1 mL) were added to a stirring 
solution of 3, 4, 5-trimethoxy aniline (1.0 g, 458 mmol) in anhydrous toluene (20 mL).  
The reaction was refluxed for 15 hours forming a dark brown solid precipitate.  All 
solvents were removed in vacuo, the crude mixture was re-suspended in DCM and 
washed with toluene (3 × 10 mL).  The DCM was then removed in vacuo and the 
crude product purified using column chromatography, yielding the product which 
appeared as an off white powder (1.2 g, 4.6 mmol, 83.9%). 
Rf =0.50 (80:20 EtOAc: Hex).  1H NMR (400 MHz, CDCl3): δ 8.17 (1H, br s, NH), 6.840 
(2H, s, Ar CH), 4.19 (2H, s, CH2), 3.86 (6H, s, 2×OMe), 3.83 (3H, s, OMe).  13C NMR 
(100 MHz, CDCl3): δ 164.6, 153.6, 135.4, 133.5, 98.3, 61.3, 56.4, 43.4.  HRMS 
Calculated for C11H14ClNO4 + Na+ [M + Na+]: 282.0509 Da.  Found [M + Na+]  282.0503 
Da (-2.1 ppm).  Elemental analysis calculated (%) for C11H14ClNO4: C 50.88, H 5.43, 
N 5.39.  Found: C 51.07; H 5.47; N 5.31.  
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6.2.12 Inhibitor 3 
 
 
Inhibitor 3 
N,N-diisopropylethylamine (0.54 mL, 3.1 mmol) was added to a stirring solution of 
thione 2.30 (815 mg, 5.4 mmol) and chloramide 2.31 (200 mg, 0.7 mmol) in anhydrous 
DMF (10 mL) and the reaction heated to 120 °C for one hour.  The product was 
purified using flash column chromatography in a solvent system of EtOAc and 
Hexane.  Yielding the product with appeared as an off white solid (0.189 g, 0.5 mmol, 
65%).   
Rf = 0.35 (50:50 EtOAc: Hex)  1H NMR (400 MHz, CDCl3): δ 10.20 (1H, br s, NH), 
8.10 (1H, d, J= 7.0 Hz, CH), 7.80 (1H, d, J= 9.3 Hz CH), 7.36 (1H, ddd, J= 9.3, 6.6, 
1.0 Hz, CH), 6.97 (1H, td, J = 6.9, 0.8 Hz, CH), 6.90 (2H, s, 2×CH), 4.10 (2H, s, CH2), 
3.80 (6H, s, 2×OMe), 3.70 (3H, s, OMe).  13C NMR (100 MHz, CDCl3): δ 166.5, 153.6, 
151.2, 142.1, 135.1, 143.6, 128.9, 123.5, 116.6, 115.2, 97.9, 61.3, 56.5, 38.5.  HRMS 
Calculated for C11H14ClNO4 + Na+ [M + Na+]: 397.0946 Da.  Found [M+ Na]+ 397.0960 
Da (+3.4 ppm).  Elemental analysis calculated (%) for C11H14ClNO4: C 54.5; H 4.9; 
N 14.9.  Found C 54.7; H 4.9; N 14.2.  
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6.2.13 tert-Butyl-5-bromonicotinate[328]  
 
 
3.15 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (8.43 g, 54.3 mmol) was added to a 
stirring solution of 2,5-bromonicotinic acid (10 g, 49.4 mmol) in CHCl3 (100 mL), 
dimethyl amino pyridine (DMAP) (6.6 g, 54.3 mmol) and t-butanol (18.6 mL, 197.6 
mL).  The reaction was stirred at 25 ˚C for 72 hours and purified using flash column 
chromatography in a solvent system of EtOAc and Hexane.  Yielding the product 
which appeared as a white solid (7.3 g, 28.7 mmol, 57%).   
Rf = 0.87 (50:50 EtOAc: Hex)  1H NMR (400 MHz, CDCl3): δ 9.06 (1H, s, CH), 8.80 
(1H, s, CH), 8.35 (1H, s, CH), 1.60 (9H, s, 3×CH3) 13C NMR (100 MHz, CDCl3): δ 
163.05, 154.01, 148.84, 139.39, 129.05, 120.47, 28.10.  HRMS Calculated for 
C10H12BrNO2 + H+ [M + H+]: 258.0124 Da.  Found [M + H+]: 258.0126 Da (-0.65 ppm).  
Elemental analysis calculated (%) for C10H12BrNO2: C 46.53, H 4.69, N, 5.43.  
Found: C 46.91, H 4.69, N 5.24. 
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6.2.14  tert-Butyl-5-cyanonicotinate[329] 
 
3.16 
To bromopyridine 3.15 (500 mg, 1.9 mmol) in anhydrous dimethylacetamide (12.15 
mL) Pd(dba)2 (88.5 mg, 0.1 mmol), dppf (53.6 mg, 0.1 mmol), zinc cyanide (250.3 mg, 
2.1 mmol) and zinc (139.3 mg, 2.1 mmol) were added.  The reaction was heated to 
120 °C for 5 hours, the reaction solution was filtered through celite and extracted into 
EtOAc (30 mL), washed with saturated NaCl (3 ˣ 30ml) and dried over anhydrous 
Na2SO4the solvent removed in vacuo.  The product purified using flash column 
chromatography in a solvent system of EtOAc and Hexane yielding the product an off 
white solid (281.9 mg, 1.4 mmol, 71.3%). 
Rf = 0.79 (1:1 EtOAc: Hex)  1H NMR (400 MHz, CDCl3): δ 9.25 (1H, d, J= 1.9 Hz, CH), 
8.93 (1H, d, J= 1.9 Hz, CH), 8.43 (1H, t, J= 2.0 Hz, CH), 1.55 (9H, s, 3×CH3).  13C 
NMR (100 MHz, CDCl3): δ 162.23, 154.95, 153.64, 140.15, 127.90, 115.81, 109.93, 
83.57, 28.03.  IR ṽ= 2234 (m; v (C≡N)), 1707 (s; v (C=O)), 1597 (m; v (C=C)), 1443 
(m; v (C=C)).  HRMS Calculated for C11H13N2O2 + H+ [M + H+]: 205.0972 Da.  Found 
[M + H+] 205.0972 Da (-0.35 ppm).  Elemental analysis calculated (%) for 
C11H13N2O2 : C 64.69, H 5.92, N 13.72  Found C 65.41, H, 5.91, N 13.16.
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6.2.15 tert-Butyl-5-(aminomethyl)nicotinate[287] 
 
3.17 
25% NH3 solution (304 µL) and a water slurry of Raney nickel (304 µL, 4.9 mmol) was 
added to a solution of nitrile 3.16 (100 mg, 0.5 mmol) in EtOH (4 mL) and THF (4 mL).  
The reaction was degassed and under a hydrogen atmosphere stirred at 25 ˚C for 3 
hours.  The solution was filtered and the solvent removed in vacuo, the orange 
residue was partitioned between EtOAc (10 mL) and NaHCO3 (10 mL), the organic 
layer was then washed with saturated NaCl and dried over anhydrous Na2SO4, filtered 
and the solvent removed in vacuo.  The crude product was not purified but carried 
forward to the subsequent step, it appeared as an orange oil and was analysed using 
1H, 13C NMR and mass spectrometry before use.   
Rf = 0.53 (1:9 MeOH: DCM).  1H NMR (400 MHz, CDCl3): δ 9.01 (1H, s, CH), 8.68 
(1H, s, CH), 8.19 (1H, s, CH), 3.95 (2H, s, CH2), 2.94 (2H, br s, NH), 1.58 (9H, s, 
3×CH3).  13C NMR (100 MHz, CDCl3): δ 165.37, 153.13, 150.38, 136.88, 128.62, 
83.11, 44.28, 29.12.  HRMS Calculated for C11H17N2O2 + H+ [M + H+]: 209.1285 Da.  
Found [M + H+]:  209.1290 Da (-2.67 ppm). 
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6.2.16 tert-Butyl 5-((2,2,2-trifluoroacetamido)methyl)nicotinate[330]  
 
 
3.18 
Crude 3.17 (700 mg, 3.4 mmol) was dissolved in DCM (21 mL), to this solution 
pyridine (1.6 mL, 20.2 mmol) and trifluoro acetic anhydride (2.4 mL, 16.8 mmol) were 
added.  The reaction was stirred at 25 ˚C for 16 hours, diluted further with DCM and 
washed with water.  The organic layer was dried over Na2SO4 and the solvent 
removed in vacuo and purified using flash column chromatography to yield the pure 
product which appeared as an off white crystalline solid (701.9 mg, 2.3 mmol, 68%). 
Rf = 0.46 (1:1 EtOAc: Hex).  1H NMR (400 MHz, CDCl3): δ 9.03 (1H, s, CH), 8.64 (1H, 
s, CH), 8.15 (1H, s, CH), 7.69 (1H, br s, NH), 4.58 (2H, d, J= 5.8 Hz, CH2), 1.58 (9H, 
s, 3×CH3).  13C NMR (100 MHz, CDCl3): δ 163.86, 125.24, 150.24, 136.56, 131.86, 
127.98, 117.21, 114.35, 82.71, 41.00, 28.06.  HRMS Calculated for C13H15F3N2O3 + 
Na+ [M + Na+]: 327.0932 Da.  Found [M + Na+]: 327.0924 Da (-2.6 ppm). 
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6.2.17   5-((2,2,2-trifluoroacetamideo)methyl)nicotinic acid[331]  
 
 
3.19 
3.18 (100 mg, 0.328 mmol) was dissolved in 1.5 mL of DCM, to this stirring solution 
was added trifluoroacetic acid (1.5 mL, 19.6 mmol).  The reaction was stirred at 25 
˚C for 3 hours, the solvent removed in vacuo and the residue re-suspended in water 
(5 mL) and extracted into EtOAc (3 × 5 mL).  The organic layer was dried over 
Na2SO4, filtered and the solvent removed in vacuo to afford the crude product which 
appeared as a pale yellow solid (54.1 mg, 0.2 mmol). 
Rf = 0.10 (2:8 MeOH: DCM).  1H NMR (400 MHz, MeOD): δ 9.17 (1H, s, CH), 8.87 
(1H, s, CH), 8.66 (1H, s, CH), 4.67 (2H, s, CH2).  13C NMR (100 MHz, MeOD): δ 
173.10, 166.18, 150.05, 147.73, 141.84, 136.99, 130.08, 115.96, 41.34.  HRMS 
Calculated for C9H8F3N2O3 + Na+ [M+ Na+]: 249.0482 Da.  Found [M+ Na+]: 249.0482 
Da (-3.52 ppm). 
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6.2.18 2,2,2-trifluoro-N-((5-(morpholino)pyridin-3-ylmethanone[288,332] 
 
 
3.20 
3.19 (1.03 g, 2.8 mmol) was dissolved in anhydrous DMF (11.6 mL), to this solution 
HATU (1.9g, 5.1 mmol) was added the resultant mixture was stirred at 25 ˚C for 30 
minutes.  After this time DIPEA (1.9 mL, 11.4 mmol) was added and again the reaction 
was left stirring at 25 ˚C for 30 minutes.  Finally morpholine (0.6 mL, 7.1mmol) was 
added, the reaction was heated to 40 ˚C for 24 hours, cooled to 25 ˚C and stirred for 
a further 48 hours.  The solvent was removed in vacuo, the residue was re-suspended 
in EtOAc (20 mL) and washed with NaHCO3 (3 ˣ 20 mL) and water (3 ˣ 10 mL).  The 
organic layer was dried over anhydrous Na2SO4 and the solvent removed in vacuo, 
the crude product was purified using flash column chromatography to afford the pure 
product which appeared as a pale orange oil (496.3 mg, 1.5 mmol, 55%). 
Rf = 0.35 (1:19 MeOH: DCM).  1H NMR (400 MHz, CDCl3): δ 8.52 (1H, s, CH), 8.48 
(1H, s, CH), 8.32 (1H, br s, NH), 7.62 (1H, s, CH), 4.52 (2H, d, J=6.0 Hz, CH2), 3.77- 
3.41 (8H, m, 4×CH2).  13C NMR (100 MHz, CDCl3): δ 167.44, 158.05-157.68, 150.47, 
147.18, 134.76, 132.76, 131.30, 120.26, 111.68, 66.80, 42.84.  HRMS Calculated for 
C13H15F3N3O + Na+ [M+ Na+]: 318.106 Da.  Found [M+ Na+]: 318.1069 Da (-2.79 ppm).   
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6.2.19 (5-(aminomethyl)pyridin-3-yl)(morpholino)methanone[333]  
 
 
3.21 
3.20 (320.4 mg, 1.4 mmol) was dissolved in 7 N methanolic ammonia (5.5 mL), the 
reaction was stirred at 25 ˚C for 96 hours.  After this time the solvent was removed in 
vacuo and the crude residue purified using column chromatography (72.3 mg, 0.4 
mmol, 31%). 
Rf = 0.18 (1:19 MeOH: DCM & 0.5% NEt3).  1H NMR (400 MHz, MeOD): δ 8.64 (1H, 
s, CH), 8.53 (1H, s, CH), 7.91 (1H, s, CH), 3.92 (2H, s, CH2), 3.77-3.66 (8H, Br M, 
4×CH2).  13C NMR (100 MHz, MeOD): δ 168.02, 149.66, 145.88, 137.41, 134.63, 
131.49, 66.33, 52.21, 42.04. HRMS Calculated for C11H16N3O2 + H+ [M + H+]: 
222.1243 Da. Found [M + H+]: 222.1240 Da (-1.1 ppm). 
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6.2.20 (E)-ethyl 2-acetyl-3-hydroxybut-2-enoate[290]  
 
 
3.25 
Magnesium turnings (1.9 g, 78.6 mmol), ethyl acetoacetate (10 mL, 78.5 mmol), 
anhydrous EtOH (15.5 mL), carbon tetrachloride (2 mL) and anhydrous toluene 
(197.4 mL) were combined under a nitrogen atmosphere.  The reaction was left to stir 
at 25 ˚C for 45 minutes and then heated to reflux for one hour.  Upon completion the 
reaction mixture was then cooled to 0 °C and acetyl chloride (5.6 mL, 79.6 mmol) was 
added drop wise over a period of 30 minutes to solution, after which time it was then 
allowed to warm to 25 ˚C and stirred for a further hour.  5% aqueous HCl (125 mL) 
was added to the reaction at 0 °C.  The organic layer was further washed with 
saturated NaHCO3 solution (3 × 50mL) and saturated NaCl solution (3 × 50mL), dried 
over MgSO4 and the solvent removed in vacuo.  This resulted in the crude product a 
yellow liquid which was subsequently purified using column chromatography (7.7 g, 
45.12 mmol, 59%). 
 
Rf = 0.28 (1:19 EtOAc:Hex).  1H NMR (400MHz, CDCl3): δ 4.25 - 4.31 (2H, q, J= 7.15 
Hz, CH2), 2.38 (6H, S, 2×CH3), 1.35 (3H, t, J= 7.15 Hz, CH3 ).  13C NMR (400MHz, 
CDCl3): δ 196.57, 167.15, 108.64, 60.69, 25.89, 14.22.  NRMS Calculated for 
C8H12O4 + NH3+ [M + NH3+]:190.1 Da.  Found [M + NH3+] 190.1 Da.  
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6.2.21  Ethyl N-benzyl-3,5-dimethyl-1H-pyrazole-4-carboxylate[290]  
 
 
3.26 
3.25 (2.2 g, 16.2 mmol) was dissolved in anhydrous EtOH (20 mL), the reaction was 
cooled to 0 °C and benzyl hydrazine monohydrochloride (2.8 g, 17.8 mmol) was 
added over 10 minutes. The reaction was warmed to 25 ˚C for 30 minutes and 
refluxed for 3 hours. Upon completion the solvent was removed in vacuo and the 
crude mixture, purified by flash column chromatography. (2.2 g, 8.3 mmol, 51%).   
 
Rf = 0.77 (6:4 EtOAc:Hex).  1H NMR (400MHz, CDCl3): δ 7.08-7.34 (5H, M, CH) ), 
5.25 (2H, S, CH2), 4.26-4.31 (2H, q, J=7.1 Hz, CH2), 2.45 (3H, S, CH3), 2.44 (3H, S, 
CH3), 1.35 (3H, t, J=7.1 Hz, CH3).  13C NMR (400MHz, CDCl3): δ 164.63, 150.64, 
144.20, 136.16, 128.8, 127.81, 126.66, 110.11, 59.63, 52.83, 14.40, 14.38, 11.34.  
NRMS Calculated for C15H18N2O2 +H+ [M+H+]: 259.14 Da.  Found [M+H+] 259.15 Da. 
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6.2.22 N-benzyl-3,5-dimethyl-1H-pyrazole-4-carboxylic acid[290] 
 
 
3.27 
3.26 (1.3 g, 5.03 mmol) was dissolved in MeOH (17.3 mL) and 1M NaOH solution 
(17.3 mL, 17.3 mmol) was added.  The mixture was refluxed for 1 hour and the solvent 
evaporated in vacuo.  The crude product was taken up into distilled water (20 mL), 
the aqueous layer was then washed with Et2O (3 × 20 mL) and cooled 0 °C.  
Concentrated H2SO4 was added drop wise, the pure carboxylic acid precipitated out 
and was filtered and washed further with diethyl ether (5 mL) (1.0 g, 4.3 mmol, 86%).   
 
Rf = 0.46 (6:4 EtOAc:Hex).  1HNMR (400MHz, CDCl3): δ 7.11-7.35 (5H, M, CH), 5.29 
(2H, S, CH2), 2.49 (3H, S, CH3), 2.48 (3H, S, CH3).  13CNMR (400MHz, CDCl3): δ 
169.72, 151.62, 145.35, 135.95, 128.88, 127.90, 126.72, 109.31, 52.90, 14.30, 11.43.  
IR (neat) ṽ = 2511 (s; br,v(O-H)), 1682 (s; v,(C=O)), 1577 (m; v (C=C)), 1533 (m; v 
(C=N)), 1458 (m; v  (C=C)).  HRMS Calculated for C13H15N2O2 +H+ [M+H+]: 231.1128 
Da.  Found [M+H+]: 231.1.1123 Da (+2.25 Da).   
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6.2.23  Inhibitor 4[288,332] 
 
 
Inhibitor 4 
3.27 (103.5 mg, 0.5 mmol) and HATU (346.0 mg, 0.9 mmol) were stirred in anhydrous 
DMF (1.3 mL) at 25 ˚C for 20 minutes, after this time potassium carbonate (K2CO3) 
(250 mg, 1.8 mmol) was added and the reaction stirred for a further 30 minutes at 25 
˚C.  3.21 (100 mg, 0.5 mmol), dissolved in anhydrous DMF (1 mL) was then added 
and the reaction stirred at 25 ˚C for 48 hours.  The crude product was purified using 
flash column chromatography (70 mg, 0.2 mmol, 36%).   
Rf = 0.14 (1:19 MeOH:EtOAc).  1H NMR (400 MHz, CDCl3): δ 8.62 (1H,app d, J= 1.8 
Hz,  CH), 8.52 (1H,app d, J= 1.8 Hz,  CH), 7.74 (1H,s, CH), 7.31-7.22 (3H, m, 3×CH), 
7.065 (2H, d, J= 7.0 Hz, 2×CH), 6.16 (1H, br s, NH), 5.21 (2H, s, CH2), 4.615 (2H, d, 
J= 6.0 Hz, CH2), 3.74-3.43 (8H, br m, 4×CH2), 2.41 (3H, s, CH3), 2.40 (3H, s, CH3) . 
13C NMR (100 MHz, CDCl3): δ 167.63, 164.95, 150.21, 146.75, 145.85, 142.46, 
136.04, 134.76, 134.54, 131.03, 128.86, 127.88, 126.73, 113.29, 66.77, 52.83, 42.53, 
40.64, 14.38, 11.12.  HRMS calculated for C24H27N5O3 + Na+ [M + Na+]: 456.2012 Da.  
Found [M+ Na+]: 456.2013 Da (+0.3 ppm).   
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6.2.24  Ethyl 3,5-dimethyl-1H-pyrazole-4-carboxylate[290] 
 
 
3.28 
Ethyl 2-acetyl-3-hydroxybut-2-enoate (2.2 g, 12.5 mmol) was dissolved in anhydrous 
EtOH (50 mL) under a nitrogen atmosphere and to the reaction mixture hydrazine 
monohydrochloride (1.1 g, 15 mmol) was added. The reaction was stirred at 25 ˚C for 
16 hours and then refluxed for a further hour, which drove the reaction to completion. 
The solvent was removed in vacuo and the crude product triturated with Et2O (75 mL) 
resulting in the pure product which appeared as white crystals (1.9 g, 11.5 mmol, 
93%).  
Rf = 0.4 (1:9 MeOH:DCM)  1H NMR (400MHz, CDCl3): δ 4.32-4.41 (2H, q, J= 7.1 Hz, 
CH2), 2.70 (6H, S, CH3),1.39 (3H, t, J= 7.1 Hz, CH3).  13C NMR (400MHz; CDCl3): δ 
162.02, 148.07, 110.86, 61.03, 14.25, 11.90.  HRMS calculated for C8H12N2O2 + H+ 
[M+ H+]: 169.0972 Da.  Found [M+ H+]: 169.0978 Da (-3.99). 
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6.2.25 Ethyl N-(4-chlorobenzyl)-3,5-dimethyl-1H-pyrazole-4-
carboxylate[252]  
 
 
3.29 
3.28 (500 mg, 2.9 mmol), 4-chlorobenzylbromide (672.3 mg, 3.3 mmol), K2CO3 (452 
mg, 3.3 mmol) and cyclohexanone (6 mL) were heated to reflux for 5 hours.  The 
reaction was filtered to remove the K2CO3 and the cyclohexanone removed in vacuo, 
the crude reaction residue was taken up into CHCl3 (20 mL) and washed with 1 M 
NaOH (3 × 15 mL) and distilled water (3 × 15 mL).  The organic layer was dried over 
Na2SO4, filtered and the solvent removed in vacuo, finally the crude product was 
purified using flash column chromatography (526.5 mg, 1.8 mmol, 60%).   
Rf = 0.74 (6:4 EtOAc:Hex)  1H NMR (400 MHz, CDCl3): δ. 7.28 (2H, d, J=8.4 Hz, 
2×CH), 7.03 (2H, d, J=8.4Hz, 2×CH), 5.20 (2H, s, CH2), 4.31 - 4.26 (2H, q, J=7.1Hz, 
CH2), 2.44 (3H, s, CH3), 2.43 (3H, s, CH3), 1.35 (3H, t, J=7.1Hz, CH3).  13C NMR (100 
MHz, CDCl3): δ. 164.48, 150.80, 144.10, 134.68, 133.75, 129.03, 128.08, 110.29, 
59.67, 52.11, 14.39, 14.35, 11.28.  HRMS calculated for C15H18ClN2O2 + H+ [M+ H+]: 
293.1051 Da.  Found [M+ H+] 293.1054 Da (-0.88 ppm).  Elemental analysis 
calculated (%) for C15H18ClN2O2: C 61.54, H 5.85, N 9.57.  Found C 61.49, H 5.84, N 
9.12. 
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6.2.26 N-(4-chlorobenzyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic 
acid[334]  
 
 
3.30 
3.29 (150 mg, 0.5 mmol) was dissolved in MeOH (5 mL) to this solution 1 M NaOH 
(2.1 mL, 2.1 mmol) was added and the reaction refluxed for 3 hours.  The solvent was 
removed in vacuo and the resultant off white solid was dissolved in distilled water (10 
mL), the aqueous layer was then washed with Et2O (3 × 10 mL).  The aqueous layer 
was acidified with the drop wise addition of concentrated H2SO4 at 3 ˚C precipitating 
the carboxylic acid product.  The product was extracted into EtOAc (3 × 10 mL), the 
organic fractions combined, dried over Na2SO4.  The solvent was removed in vacuo 
yielding the product as a tan solid (124.8 mg, 0.5 mmol, 92%).   
Rf = 0.63 (1:9 MeOH:DCM)  1H NMR (400 MHz, MeOD): δ 7.23 (2H, d, J=8.5 Hz, 
2×CH), 6.99 (2H, d, J=8.5 Hz, 2×CH), 5.17 (2H, s, CH2), 2.36 (3H, s, CH3), 2.29 (3H, 
s, CH3).  13C NMR (100 MHz, MeOD): δ167.38, 152.36, 146.36, 136.56, 134.71, 
129.96, 19.47, 111.28, 52.57, 14.57, 11.30.  HRMS calculated for C13H14N2O2 + H+ 
[M + H+]: 265.0744 Da.  Found [M+ H+]: 265.0742 Da (-0.7 ppm).   
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6.2.27  Inhibitor 5[288,332] 
 
 
Inhibitor 5 
3.30 (113.5 mg, 0.4 mmol) and HATU (3286.0 mg, 0.9 mmol) were stirred in 
anhydrous DMF (1.1 mL) at 25 ˚C for 20 minutes, after this time K2CO3 (237.7 mg, 
1.7 mmol) was added and the reaction stirred for a further 30 minutes at 25 ˚C.  3.21 
(95.3 mg, 0.4 mmol), dissolved in anhydrous DMF (1 mL) was then added and the 
reaction stirred at 25 ˚C for 60 hours.  The solvent was removed in vacuo, and the 
dark orange oil residue was taken up into EtOAc (10 mL) and washed with saturated 
NaHCO3 (3 × 20 mL) and distilled water (3 × 20 mL).  The organic layer was dried 
over anhydrous Na2SO4, filtered and the solvent removed in vacuo, the crude product 
was purified using flash column chromatography (68 mg, 0.1 mmol, 33.9%).  
Rf = 0.10 (1:19 MeOH:EtOAc).  1H NMR (400 MHz, CDCl3): δ 8.65 (1H,s, CH), 8.55 
(1H, s, CH), 7.77 (1H, s, CH), 7.30 - 7.28 (2H, d, J= 8.3 Hz, 2×CH), 7.04 (2H, d, J= 
8.3 Hz, 2×CH), 6.12 (1H, br s, NH), 5.20 (2H, s, CH2), 4.65 (2H, d, J= 6.0 Hz, CH2), 
3.77 - 3.45 (8H, br m, 4×CH2), 2.43 (3H, s, CH3), 2.42 (3H, s, CH3).  13C NMR (100 
MHz, CDCl3): δ 167.62, 164.81, 150.21, 146.78, 146.00, 142.48, 134.70, 134.57, 
134.53, 133.84, 131.06, 129.06, 128.16, 113.41, 66.78, 52.11, 48.22, 40.65, 14.40, 
11.09.  HRMS calculated for C24H26N5O3 + Na+ [M + Na+]: 490.1622 Da.  Found [M + 
Na+]: 490.1611 Da (-2.2 ppm).  
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6.2.28  tert-Butyl-5-bromo-2-oxo-1,2-dihydropyridine-3-carboxylate[328]  
 
 
i 
To a stirring solution of 5-bromo-2-oxo-1,2-dihydropyridine-3-carboxylic acid (500 mg, 
2.3 mmol) in CHCl3 (5 mL), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) 
(393.5 mg, 2.5 mmol), DMAP (309.5 mg, 2.5 mmol) and t-butanol (0.8 mL, 9.2 mmol) 
was added.  The reaction was left stirring at 25 ˚C for 72 hours and purified using 
flash column chromatography (204.5 mg, 0.7 mmol, 32.5%). 
Rf = 0.52 (50:50 EtOAc: Hex)  1H NMR (400 MHz, CDCl3): δ 8.34(1H, s, CH), 8.18(1H, 
s, CH), 1.61(9H, s, 3×CH3).  13C NMR (100 MHz, CDCl3): δ 166.93, 164.00, 153.32, 
142.36, 111.80, 108.82, 84.75, 28.09.  HRMS calculated for C10H12BrNO3 + H+ [M + 
H+] : 274.0073 Da.  Found [M + H+] 274.0073 Da (-0.1 ppm). 
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6.2.29  tert-Butyl-5-(9H-fluorenylmethoxycarbonyl)-amino methyl 
nicotinate[335]  
 
 
ii 
To a solution of 3.17 (100 mg, 0.5 mmol) in anhydrous MeOH (3.6 mL) at 0 °C Nickel 
(ii) chloride hexahydrate  (11.5 mg 0.05 mmol) followed by sodium borohydride 
(NaBH4) (129.5 mg, 3.4 mmol) were added in portions over 30 minutes.  The reaction 
was warmed to 25 ˚C and left stirring for 4 hours with monitoring using TLC after 
which time there appeared to be no starting material present.  
Fluorenylmethyloxycarbonyl chloride (Fmoc-cl) (253 mg, 1.0 mmol) was then added 
and the reaction left stirring for 16 hours, upon complete reaction of the amine 
intermediate the crude reaction was purified using flash column chromatography to 
afford the product which appeared as an orange oil. (8.6 mg, 0.04%).   
 
Rf = 0.38 (1:1 EtOAc: Hex)  1H NMR (400 MHz, CDCl3): δ 9.04(1H, s, CH), 8.64(1H, 
s, CH), 8.16 (1H, s, CH), 7.74(2H, d, J = 6.9 Hz, 2×CH), 7.56(2H, d, J = 6.7 Hz, 2×CH), 
7.38 (2H, t, J = 6.8 Hz, 2×CH) 7.31- 7.25 (2H, m, 2×CH), 4.42 (4H, app dd, J= 14.5, 
5.6 Hz, 2×CH2), 4.19 (1H, t, J= 5.9 Hz, CH), 2.20(1H, s, NH), 1.59 (9H, s, 3×CH3).  
13C NMR (100 MHz, CDCl3): δ 164.57, 156.92, 152.47, 150.09, 144.15, 141.68, 
136.50, 134.43, 128.10, 127.45, 125.34, 120.37, 82.69, 67.28, 58.63, 47.56, 28.50.  
HRMS calculated for C26H26N2O4 + H+ [M + H+]: 453.1790 Da.  Found [M + H+] 
453.1789 Da (-0.3 ppm). 
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6.2.30 3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl N-benzyl-3,5-dimethyl-1H-
pyrazole-4-carboxylate[288,332] 
 
 
iii 
3.25 (67.4 mg, 0.3 mmol), was dissolved in anhydrous DMF (0.7 mL), to this solution 
was added HATU (201.1 mg, 0.5 mmol) and the solution left to stir at 25 ˚C for 30 
minutes, after this time DIPEA (203.8 µL, 1.2 mmol) was added and the reaction left 
for a further 30 minutes at 25˚C.  ii (64.7 mg, 0.3 mmol) dissolved in anhydrous DMF 
(0.5 mL) was then added and the reaction left to stir at 25 ˚C for 24 hours.  After this 
time the solvent was removed in vacuo, the residue partitioned between EtOAc (5 
mL) and NaHCO3 (5 mL), the organic layer was washed a further 3 × NaHCO3 (10 
mL) and dried over Na2SO4.  The solvent removed in vacuo to afford the crude product 
which appeared as a dark orange solid (131 mg).   
Rf =0.80 (1:19 MeOH:DCM)  1H NMR (400 MHz, CDCl3): δ 8.73 (1H, dd, J= 4.4, 1.0 
Hz, CH), 8.44 (1H, dd, J= 8.4, 1.1 Hz, CH), 7.46 - 7.42 (1H, m, CH), 7.38 - 7.29 (3H, 
m, 3×CH), 7.15 (2H, app d, J = 7.1 Hz, 2×CH), 5.33 (2H, s, CH2), 2.60 (3H, s, CH3), 
2.56 (3H, s, CH3).  13C NMR (100 MHz, CDCl3): δ 159.75, 152.09, 151.74, 146.99, 
141.00, 135.26, 135.08, 129.54, 129.04, 128.21, 126.80, 120.79, 104.90, 53.36, 
14.67, 11.91.  HRMS calculated for C18H16N6O2 + H+ [M + H+]: 371.1232 Da.  Found 
[M + H+] 371.1222 Da (-2.8 ppm). 
Experimental  
282 
 
6.2.31 N,1-dibenzyl-3,5-dimethyl-1H-pyrazole-4-carboxamide[288,332] 
 
 
iv 
iii (87.6 mg, 0.3 mmol) was dissolved in anhydrous THF (1.2 mL) to this solution 
benzyl amine (41.2 µL, 0.7 mmol), DIPEA (131.1 µL, 0.7 mmol) and anhydrous DMF 
(5 drops) were added.  The reaction was stirred at 25 ˚C for 96 hours, after this time 
the solvent was removed in vacuo.  The residue partitioned between EtOAc (5 mL) 
and NaHCO3 (5 mL), the organic layer was washed a further 3× NaHCO3 (10 mL) and 
dried over Na2SO4.  The solvent removed in vacuo to afford the crude product which 
appeared as an off white solid (52.8 mg, 0.2 mmol). 
1H NMR (400 MHz, CDCl3): 7.34-7.25 (8H, m, 8× ar CH), 7.08 (2H, d, J=7.1 Hz, 2×ar 
CH), 5.21 (2H, s, CH2), 4.59 (2H, d, J= 5.6 Hz, CH2) 2.42 (6H, app d, J= 3.5 Hz, 
2×CH3).  13C NMR (100 MHz, CDCl3): δ 164.68, 145.85, 142.13, 138.56, 136.22, 
128.82, 128.78, 127.81, 127.69, 127.50, 126.73, 113.86, 52.76, 43.53, 14.25, 11.03.  
HRMS calculated for C20H21N3O + H+ [M + H+]: 342.1582 Da.  Found [M + H+]: 
342.1576 Da (-1.8ppm).
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 Biological Materials and Methods 
6.3.1 Materials 
6.3.1.1 Media  
General Solutions 
There were two types of water used in the biophysical analysis of the compounds 
within this thesis, within this specific chapter they are listed as being either RO water, 
or MilliQ water.   
RO water is that which has been de-ionised and distilled, it was used for those 
purposes such as media solutions whereby sterilisation by autoclave is a general 
method involved in ensuring aseptic materials.   
MilliQ water was obtained by the use of a “Synergy Water Purification system 
(Millipore) fitted with a SynergyPak® 1 cartridge and a MilliPak-20 Express system”, 
the purity of this water meant that it was used for buffer solutions.  Organic solvents 
such as Ethanol and Methanol were obtained from Fisher Scientific and any reagents 
used in the methods were supplied by Sigma-Aldrich at general laboratory grade.  All 
pH measurements were made at 25˚C and adjusted using 1M HCl of 1M NaOH. 
SOC Media 
Make up to 200mL using RO water do not add glucose until autoclaved as heat 
degrades it, sterile filter (22μM Millex® HA syringe-driven filter unit) into 50mL 
falcon tubes for storage. 
o RO water (200 mL) 
o Tryptone (20 g) 
o Yeast extract (5 g) 
o NaCl (10 mM) 
o KCl (25 mM) 
o MgCl2.6H2O (10 mM) 
o pH 7.0 
o Autoclave 
o Glucose (20 mM) 
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LB Broth 
Autoclave before the addition of sterile filtered (Millex® HA syringe-driven filter 
unit) kanamycin (adding prior to this will render the antibiotic ineffective). 
o LB broth granules (25 g/1 L RO water) 
o Kanamycin (32 μg/mL) 
LB Agar 
Autoclave before the addition of sterile filtered (Millex® HA syringe-driven filter 
unit) kanamycin (adding prior to this will render the antibiotic ineffective). 
o LB Agar granules (37 g/1L RO water) 
o Kanamycin (32 μg/mL) 
Minimal Media A 
o RO water 
o Na2HPO4 (88 mM) 
o KH2PO4 (55 mM)  
o pH= 7.2 
Minimal Media B 
o RO water 
o Thiamine.HCl (30 µM) 
o CaCl2.2H2O (135 µM) 
o MgSO4.7H2O (1 mM)  
o NH4Cl (20 mM)  
o Glucose (20 mM) 
6.3.1.2 Buffer Solutions 
HisTrap A (loading/running buffer) 
o MilliQ water (1 L) 
o Tris/HCl (50 mM) 
o NaCl (500 mM) 
o pH 7.5 
o Filter (Millipore) and de-gas 
HisTrap B (elution buffer) 
o MilliQ water (1 L) 
o Tris/HCl (50 mM) 
o NaCl (500 mM) 
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o Imidazole (500mM, Fluka) 
o pH 7.5 
o Filter (Millipore) and de-gas 
Gel Filtration Buffer 
o MilliQ water (1 L) 
o Tris/ HCl (50 mM) 
o NaCl (150 mM) 
o pH 7.5 
15% PAGE Resolving Gel (6.3.2.6 experimental procedure) 
o MilliQ (2.4 mL) 
o 30% bis-acrylamide (5 mL) 
o Tris HCl pH 8.8 (2.5 mL) 
o 10% (w/v) sds (100 µL)  
o TEMED (7.5 µL)  
o 10% APS (75 μL) 
4% PAGE Stacking Gel (6.3.2.6 experimental procedure) 
o MilliQ (6.1 mL) 
o 30% bis-acrylamide (1.3 mL) 
o Tris HCl pH 6.8 (2.5 mL) 
o 10% (w/v) sds (100 µL)  
o TEMED (7.5 µL)  
o 10% APS (75 μL) 
10×SDS-PAGE Running Buffer (6.3.2.6 experimental procedure) 
o MilliQ water (1 L) 
o Tris HCL (250 mM) 
o Glycine (1.92 M) 
o SDS (1%) 
PAGE Coomassie G250 Stain (6.3.2.6 experimental procedure) 
o Coomassie Blue G250 (0.1%) 
o MeOH (45%) 
o MilliQ (44.9%) 
o Acetic Acid (10%) 
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PAGE De-Stain (6.3.2.6 experimental procedure) 
o MeOH (45%) 
o MilliQ (45%) 
o Acetic Acid (10%) 
NMR Buffer (proteins)  
o Tris HCl (50 mM) 
o NaCl (50 mM) 
o CaCl2 (5 mM) 
o pH 6.4 
o Filter (Millipore) and de-gas 
ITC Buffer 
o Tris HCl (50 mM) 
o NaCl (50 mM) 
o CaCl2 (5 mM) 
o pH 7.5 
o Filter (Millipore) and de-gas 
Fluorescence Spectrophotometry Buffer 
o Tris HCl (50 mM) 
o NaCl (50 mM) 
o CaCl2 (5 mM) 
o pH 7.5 
o Filter (Millipore) and de-gas 
6.3.2 Methods  
6.3.2.1 General Equipment 
The methods detailed below describe the use of specific volumes, to ensure accuracy 
all measurements under 10 mL were carried out using Gilson single channel pipettes 
(Pipetman) anything above 10 mL was carried out using graduated measuring 
cylinders.  Specific machinery has been detailed, including the make and model and 
unless otherwise stated is available for use within the Institute of Integrative Biology, 
Department of Biochemistry, University of Liverpool. 
6.3.2.2 Transformation 
NCS1 was obtained from an expression construct of Rattus Norvegicus,[18] it was 
sub-cloned from a p-GEX-6p plasmid expressing NCS1 [336] into a pETM-11 vector 
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and subsequently transformed into BL21 DE3 E-coli competent cells (Novagen).  The 
NCS1 construct in pETM-11 vector was obtained from another member within the lab, 
however the transformation method is detailed here:  2 μL of the NCS1 containing 
plasmid was added to 50 μL of BL21 DE3 E-coli competent cells (Novagen), the 
solution was mixed and incubated at 0 oC for 30 minutes.  Following this the cells 
were incubated at 42 oC for 30 seconds and then cooled back to 0 oC for a further 5 
minutes.  After this time 200 μL of a pre-prepared SOC media was added and the 
solution incubated with shaking at 180 rpm for an hour at 37 oC.  200 μL of this solution 
was subsequently pipetted under aseptic conditions onto a kanamycin containing 
agar plate, spread evenly over the surface and the plate allowed to dry at 25 oC for 
around 20 minutes.  The agar plate was then incubated at 37 oC for 16 hours without 
shaking, it was allowed to cool to 25 oC for around 30 minutes and finally was sealed 
with Parafilm® and stored at 4 oC for a maximum of two weeks. 
6.3.2.3 NCS1 expression in Minimal Media 
A starter culture of Luria Broth (LB) with kanamycin of a final concentration 32 µg/ 
mL, was inoculated with a single colony from the LB agar/ kanamycin transformed 
plate of NCS1 and incubated at 37 oC with shaking at 180 rpm for 7 hours.  A 
preparation of Minimal Media A (MMA) and B (MMB) solutions were produced.  MMA 
solutions were autoclaved and MMB syringe-filtered through a 0.22 µM Millex® 
Millipore HA filter unit.  The minimal media solutions (500 mL MMA with 6.5 mL MMB) 
were supplemented with 32 µg/mL kanamycin, to 10 mL of this solution 100 µL of the 
starter culture was added and incubated overnight at 37 oC with shaking.  This cell 
suspension was then added to the minimal media solution and an initial optical density 
(OD600) reading was taken (ca 0.05 - 0.1).  The cells were grown at 37 ºC for 6 hours 
to reach an OD600 = 0.8; this was followed by induction of expression through the 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, final concentration 1 mM) 
and then incubated at 18 ºC for 16 hours with shaking.  Centrifugation of the cells was 
carried out at 1519 g for 20 minutes at 4 oC and the subsequent supernatant was 
discarded.  The cells were harvested and re-suspended in HisTrap buffer A, to this 
solution a complete EDTA free protease inhibitor tablet (Roche) pre-dissolved in 1 mL 
of HisTrap A buffer was then added, the mixture was flash frozen using liquid nitrogen 
and stored at -80 oC until purification. 
6.3.2.4 NCS1 expression in LB Media 
A 50mL solution of Kanamycin selective LB solution was inoculated with a single 
colony from the transformed plate of NCS1, it was subsequently incubated at 37 oC 
with shaking at 180 rpm for 16 hours (overnight).  The cells were centrifuged at 3,000 
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g and a temperature of 4 oC for 14 minutes, the pellet was re-suspended in a total 
volume of 5 mL kanamycin selective LB.  The cell suspension was then added to a 1 
L solution of kanamycin selective LB in a 2 L conical flask and an initial optical density 
(OD600) reading was taken (normally around 0.05 - 0.1).  The cells were incubated at 
37 ºC until they reached an OD600 = 0.8 which normally occurred within 4 hours.  
Following this the cells were induced with the addition IPTG at a final concentration 1 
mM and then incubated at 18 ºC for 16 hours with shaking.  The induced cells were 
centrifuged at 1519 g for 20 minutes at 4 oC and the subsequent supernatant was 
discarded.  The cells were harvested and re-suspended in HisTrap buffer A, to this 
solution a complete EDTA free protease inhibitor tablet (Roche) pre-dissolved in 1 mL 
of HisTrap A buffer was then added, the mixture was stored at -80 oC until purification. 
6.3.2.5 Protein Purification Methods  
6.3.2.5.1 Cell Lysis 
The frozen cells stored at -80 ˚C were thawed gently on ice and treated with 
ribonuclease1 from bovine pancreas (sigma) to promote nucleic acid breakdown, a 
final concentration 12 µg/mL and the solution incubated for 10 minutes at 4°C.  The 
cells were lysed mechanically at 0 ˚C in 10 mL portions using a Stansted ‘Pressure 
Cell’ Homogeniser (SFP Ltd), at 1000 P.S.I.  This was followed by centrifugation of 
the cells at 47,813 g for 30 minutes at 4 oC to pellet any insoluble cell debris.  The 
resultant supernatant was decanted and sterile filtered through a 0.45 μM Millex® HA 
syringe-driven filter unit in preparation for the subsequent purification using liquid 
chromatographic techniques.   
6.3.2.5.2 Ni2+ Affinity Chromatography 
The His-tagged protein solution was then purified using Ni2+ affinity chromatography 
using a HisTrapFF 5 mL column (GE Healthcare) on an ÄKTA purifier system (GE 
Healthcare).  The column was been washed with MilliQ and then pre-equilibrated with 
4 column volumes of HisTrap buffer A and the imidazole containing buffer B at a flow 
rate of 2.5 mL/min.  The filtered cell supernatant was loaded onto the column at a flow 
rate of 2.5 mL/min, the His-tagged protein that bound to the column was then eluted 
by increasing the gradient of imidazole at a flow rate of 2.5 mL/min.  Eluent was 
fractionated with a sample size of 5 mL, analysis of the fractions was conducted using 
Sodium Disulfate Polyacrylamide (SDS) polyacrylamide gel electrophoresis (SDS 
PAGE 6.3.2.3).  Those observed as being protein containing fractions (observed as 
containing the desired gel band) were pooled in preparation for concentration. 
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6.3.2.5.3 Concentration and Buffer exchange of protein samples  
Following Ni2+ affinity chromatography the combined protein fractions were 
concentrated using an Amicon Ultra Centrifugal Filter at 3,500 g which had been 
previously washed with MilliQ and equilibrated in HisTrap buffer A.  The protein 
solution was concentrated to the desired final volume, the eluent that passed through 
the membrane was analyzed using SDS PAGE to ensure that none of the protein of 
interest had passed through.  The concentration units were subsequently washed 
with MilliQ and 20% EtOH by centrifugation at 3,500 g after which they were then 
stored for reuse.  The protein solution was then buffer exchanged back into a non-
imidazole containing buffer HisTrap A using a desalting column (Sephadex G-25 
Medium Gravity-Flow PD-10 (GE Healthcare)) that had been washed with MilliQ and 
pre equilibrated with HisTrap A.  The process of column equilibration involved washing 
the column with 25 mL of MilliQ followed by 25 mL of HisTrap A, the protein was 
subsequently loaded onto the column in a volume of 2.5 mL and any flow through at 
this time was discarded.  The sample was then eluted by the addition of 3.5 mL 
HisTrap A, this process was repeated until all the protein sample had been buffer 
exchanged as the maximum volume of protein that can be added to the column at 
any one time is 2.5 mL.  The protein sample was collected for the subsequent 
cleavage process and the PD-10 column was washed with 25 mL of MilliQ and 25mL 
20% EtOH, it was stored in 20% EtOH at room temperature. 
6.3.2.5.4 Tobacco Etch Virus (TEV) protease cleavage of Histidine tag and 
reverse purification  
A 20:1 protein: protease ratio of Tobacco Etch Virus (TEV) was added to the protein 
solution after the buffer exchange process, the solution was left inverting at 4 °C 
overnight.  The cleavage solution was then passed back through the Ni2+ affinity 
column at 2 mL/min, any un-cleaved protein would remain on the column and the 
cleaved protein is eluted in HisTrap buffer A.  The cleaved tag or un-cleaved protein 
that had remained on the column was then eluted in HisTrap buffer B.   
6.3.2.5.5 Size exclusion Chromatography 
This cleaved NCS1 after the reverse purification protocol was then concentrated to 5 
mL and size exclusion gel filtration chromatography was conducted using a Hi Load 
26/60 Superdex 75 column (Amersham Biosciences).  The column was connected to 
an AKTApurifier10 FPLC system and was initially washed with MilliQ before 
equilibration with gel filtration buffer containing 50 mM tris/ HCl, 150 mM NaCl at pH 
7.5.  The protein was manually injected using a 10 mL injection loop which was 
connected to the FPLC, loading of the sample onto the column was then carried out 
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at a flow rate of 3 mL/min.  Increasing volumes of gel filtration buffer eluted the protein 
into fractions that were analyzed using SDS PAGE, those fractions containing NCS1 
at the desired molecular weight were pooled and then flash frozen using liquid 
nitrogen and stored at -80 °C. 
6.3.2.6 Sodium Disulfate Polyacrylamide Gel Electrophoresis (SDS PAGE) 
SDS PAGE was used to monitor the expression and purification process of NCS1 and 
to assess the purity of the final protein sample using a method developed by 
Laemmli.[337]  Full casting required a 15% resolving gel (R) prepared using 2.4 mL 
of water, 5 mL 30% bis-acrylamide, 2.5 mL tris HCl buffer pH 8.8 and 100 µL of 10 × 
SDS solution, to this solution 7.5 µL of tetramethylethylenediamine (TEMED) was 
added along with 75 µL of a 10% solution of ammonium persulfate (APS).  The 
solution was pipetted into a cast of two glass plates and a small volume no greater 
than 500 µL of butanol was pipetted on top of the R gel to remove any air trapped.  
The gels were left to polymerize for 20 minutes, during which time 10 mL of a 4% 
stacking gel (S) was prepared with 6.1 mL of water, 1.3 mL 30% bis-acrylamide, 2.5 
mL tris/ HCl buffer pH 6.8 , 100 µL 10× SDS.  Once the R layer had polymerized the 
butanol layer was removed, 7.5 µL of TEMED was added with 75 µL of a 10% solution 
of APS to the S layer solution this was pipetted onto the R gel layer and either a 10 
or 15 sample well comb was inserted.  The S gel was then allowed to polymerize for 
a further 20 minutes.   
The gel samples were prepared by diluting the protein sample with up to a volume of 
20 µL of water and 20 µL of 2× running buffer was then added.  The samples were 
then heated to 100 °C and 7.5 µL of each were loaded into individual wells on the gel, 
7.5 µL of a Sigma low molecular weight marker (sigma m3913) was also added to a 
separate lane.   
The gels were removed from the glass cast and washed with RO water, before 
staining with a stain solution containing Coomassie blue G250 (0.1%), MeOH (45%), 
MilliQ water (44.9%) and acetic acid (10%) was added to the gel which was then 
incubated and left to stain with agitation at room temperature for 10 minutes.  The 
stain was decanted off and the gels were again washed with water, de-stain solution 
(MeOH (45%), MilliQ water (45%) and acetic acid (10%)) was then added and the 
gels left for 12 hours at 20-25°C with agitation to remove any remaining stain.  The 
gels were then visualised using an image scanner (Image III GE Healthcare).  
Experimental 
 
291 
 
 
Figure 6.1- SDS-Page Electrophoresis Gel of NCS1- MM unlabeled protein preparation of NCS1 
monitored using gel electrophoresis; Lane1: Low molecular weight marker, Lane 2: Supernatant, Lane 
3: Pellet, Lane 4: HisTrap fraction 2, Lane 5: HisTrap fraction 6,Lane 6: HisTrap fraction 18, Lane 7: 
Pre TEV cleavage, Lane 8: Post TEV cleavage, Pre buffer exchange, Lane 9: Post buffer exchange, 
Lane 10:Conc down sample, Lane 11: 1st His elute, Lane 12: 2nd His elute, Lane 13: Gel filtration fraction 
18. 
6.3.2.7 NMR 
General  
All NMR spectra were collected at 25 ˚C unless otherwise stated, on either a Bruker 
AVANCE II+ 600 MHz Ultrashield or 800 MHz US2 spectrometer, equipped with (TCI) 
triple-resonance cryoprobes.  The NMR samples were prepared to a volume of 550µL 
including 10% 2H2O and the NMR buffer used was composed of 50 mM tris HCl, 50 
mM NaCl, 5 mM CaCl2, pH 6.4.  Data collection used Topspin 3.1 (Bruker, UK) and 
sample quality was assessed using comparison to earlier spectra collected 15N and 
13C NCS1. 
6.3.2.7.1 Backbone Assignment 
A 0.967 mM sample of 1H 15N 13C NCS1 was exchanged into NMR buffer using a 
desalting column (Sephadex G-25 Medium Gravity-Flow PD-10 (GE Healthcare)).  
The method for protein back bone assignment has been described previously (2.3.1) 
and the methodology utilises the following experiments: 2-D 1H 15N Heteronuclear 
Single Quantum Coherence spectra (HSQC) and 3-D triple resonance experiments 
HCCH TOCSY, CbCa(CO)NH, HNCaCb, HNCO, HN(Ca)CO, the types of experiments 
used has been extensively reviewed.[255–261,338]  Data collection was conducted 
using standard practises and data was analysed using the Collaborative 
Computational Project for NMR (CCPN) Analysis software programme.[339] 
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6.3.2.7.2 First Generation Ligand Screening. 
A 29.95 mM stock solution for each inhibitor was prepared by dissolving the 
appropriate mass of inhibitor in the required volume of dimethyl sulfoxide (DMSO).  A 
0.5 mM stock solution of 1H 15N NCS1 was prepared in 50 mM tris HCl, 50 mM NaCl, 
5 mM CaCl2, pH 6.4 (NMR buffer), this was diluted to 97.9 µM and the required ligand 
stock added to yield a final NCS1: ligand ratio of 1:1 and 1:10 for Inhibitor 1, 1:10 for 
Inhibitor 2 and Inhibitor 3 along with 10% 2H2O (50 μL).  To ensure that any 
perturbations seen upon addition of the ligand were due to binding and not an artefact 
of DMSO binding to the protein, the appropriate volume of DMSO for each inhibitor 
were added to the apo sample of 1H 15N NCS1 and the spectrum collected for 
comparison. 
6.3.2.7.3 Second Generation Ligand Binding Screening. 
A 100 mM stock solution for Inhibitor was prepared by dissolving the appropriate 
mass of inhibitor in the required volume of DMSO as with the first generation of 
inhibitors.  A 96.5 μM stock solution of 1H 15N NCS1 was prepared in NMR buffer, the 
required volume of protein to achieve a concentration of 50 μM in a total final volume 
of 550 μL was added to an eppendorf along with 10% 2H2O (50 μL) and the required 
volume of inhibitor stock solution to yield a final concentration of 500 μM or 1 mM 
respectively.  Therefore the ligand to protein ratio was either 10:1 or 20:1.  As with 
the first generation of inhibitors to ensure that any perturbations seen upon addition 
of the ligand were due to binding and not an artefact of DMSO binding to the protein, 
the appropriate volume of DMSO for each inhibitor were added to the apo sample of 
1H 15N NCS1 and the 1H NMR spectrum collected for comparison. 
6.3.2.7.4 Solubility comparison experiment 
From the stock solutions of the Inhibitors made previously (6.3.2.7.2 and 6.3.2.7.3) 
the required volume of inhibitor was added to an eppendorf to achieve a final 
concentration of 500 μM in a final volume of 550 μL, 100 μM TSP was added from a 
stock solution of 1 mM along with 10% 2H2O (50 μL).  A 1H 1-D NMR spectrum was 
collected, the reference TSP height was adjusted so that it was consistent within each 
experiment and the inhibitor peaks interpreted accordingly. 
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6.3.2.8 Small Molecule Compound Library Protocols 
6.3.2.8.1 Initial Screen 
Each of the 28 compounds were dissolved in the required volume of DMSO to achieve 
a stock concentration of 100 mM.  A 96.5 μM stock solution of 1H 15N NCS1 was 
prepared in NMR buffer.  For each compound sample the required volume of protein 
to achieve a concentration of 20 μM was subsequently added in an eppendorf 
containing the required volume of small molecule to achieve a 1 mM concentration 
along with 10% 2H2O (50 μL).  1H 1-D NMR spectra and saturation transfer difference 
(STD) experiments were collected.[307,308]  This data was compared to a number 
of standards which include the same experiments collected on the following: a sample 
of 1 mM compound along with 10% 2H2O (50 μL) in NMR buffer and a 20 μM sample 
of NCS1 along with 10% 2H2O (50 μL) and the required volume of DMSO to achieve 
the same concentration as that which is added with the small molecules. 
6.3.2.8.2 Secondary Testing 
To the samples of those small molecules which appeared to display an interaction 
with the protein a further aliquot of NCS1 was added to achieve the final concentration 
of 50 μM.  1H, STD, waterLOGSY and 1H 15N HSQC spectra were collected and 
compared to the standards which included the same experiments collected on the 
following samples: 1mM compound along with 10% 2H2O (50 μL) in NMR buffer and 
a 50 μM sample of NCS1, 10% 2H2O (50 μL) and the required volume of DMSO to 
achieve the same concentration as that which is added with the small 
molecules.[292,293] 
6.3.2.8.3 D2 Competition Experiments 
D2R peptide was dissolved in the required volume of MilliQ water to achieve a stock 
concentration of 1 mM at pH of 6.4, it was aliquoted into 28.89 μL volumes in a series 
of eppendorf’s and freeze dried for 16 hours.  The dried D2R peptide was then re-
suspended in the NMR sample from 6.3.2.8.2 to achieve a 50 μM final concentration 
of the peptide.  1H 1-D  STD, 1H 1-D waterLOGSY and 1H 15N HSQC spectra were 
collected and compared to the standards which included the same experiments 
collected on the following samples: 1 mM compound along with 10% 2H2O (50 μL) in 
NMR buffer, a 50 μM sample of NCS1, 10% 2H2O (50 μL), 50 μM D2R peptide and 
the required volume of DMSO to achieve the same concentration as that which is 
added with the small molecules and a 50 μM sample of D2R peptide in NMR buffer.  
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6.3.2.9 Isothermal Titration Calorimetry (ITC) Protocol 
ITC experiments were conducted at 25 oC and were run on an iTC200 Microcalorimeter 
(MicroCal), this has a 200 µL cell capacity and syringe volume 40 µL.  Due to solubility 
issues with both the protein and inhibitors all experiments of the first generation were 
run in reverse, meaning the ligand was held within the cell and the protein titrated in 
from the syringe, the concentration ranges for protein and inhibitor are as follows 
unlabelled NCS1: 1 mM - 400 µM, Inhibitor 1; 600 µM - 100 µM.  The preparation of 
NCS1 and inhibitors for all experiments used a salt buffer of 50 mM tris HCl, 50 mM 
NaCl, 5 mM CaCl2 at pH 7.5.  Data collected was analysed using Origin®7 software 
and a full description of the calorimeter and the analysis software can be found in 
2.3.5.  Second generation experiments were conducted at 25 oC and 10 oC in the 
classical method of titrating the ligand into the cell containing NCS1, the concentration 
of protein and inhibitor are as follows unlabelled NCS1: 400 µM, Inhibitor 5; 8 mM. 
6.3.2.10 Fluorescence Spectrophotometry 
All fluorescence data of the first generation of inhibitors was collected by Dr Liam 
Dorr, second generation inhibitor data collected by myself at The University of 
Liverpool on a Cary Eclipse Fluorescence spectrophotometer (Agilent technologies).  
The raw data of both generations of inhibitors was then analysed as part of this 
project/ thesis in Origin7 (OriginLab, Northampton, MA).  A stock solution of 
unlabelled NCS1 45 μM was prepared in fluorescence buffer (50 mM tris HCl, 50 mM 
NaCl, 5 mM CaCl2 pH 7.5); and aliquoted into 17 samples at a final concentration of 
1 μM v/v (200 μL).  For the individual single point reads of the tryptophan fluorescence 
assay, each inhibitor was added in the required volume from a single stock solution 
of 100 μM in 100% DMSO, to the already aliquoted NCS1 samples contained in 
eppendorf’s.  The concentration range for each inhibitor over the 17 samples was 0-
90 μM. This process was repeated for all inhibitors, each individual assay sample was 
transferred to a quartz 16.160-F/Q/10 cuvette (Starna Scientific) and excited at a 
wavelength (λ) of 280 nm, with the excitation slit width 5nm and the emission slit width 
20 nm.   
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Appendix 
The following figures and tables relate to data discussed within the relevant 
chapters contained within this thesis. 
A.1 NMR Spectroscopy: First Generation Compounds 
Table A.1.1- Aliphatic methyl sidechain transfer of assignment.  A table of the amino acid residues 
of NCS1 for which the assignment of the corresponding aliphatic methyl groups was possible.  This table 
lists those residues that were unaffected by the corresponding inhibitor in relation to their position within 
the four EF hand motifs of NCS1.  With the DMSO spectra as the control, those residues present in each 
column for each Inhibitor can be deemed unaffected.  However those methyl groups missing possibly 
indicate either an interaction between the inhibitor and the sidechain at that specific residue, or that there 
are considerable structural changes involving the residues whose resonances were missing.  Complete 
attenuation of a single methyl group for those residues that contain only one, or both for those residues 
that contain two groups indicate a possible change in structure where the amino acid may have become 
buried. 
(For the purposes of this table residues are labeled in single letter nomenclature a=alpha, b=beta) 
 
 
Table A.1.2- Aromatic methyl sidechain transfer of assignment.  A table depicting the transfer of 
assignment of the aromatic sidechain residues of NCS1 to the DMSO control and subsequent 
comparison between those residues assigned for the control spectra with those affected by the individual 
inhibitors.  The results indicate a large change in the regions EF-2 and EF-4 of NCS1, an effect caused 
by all five inhibitors, this is noted as the change in the individual spectra meant that the residues could 
be assigned.  Inhibitor 1 appears to cause the greatest change in the aromatic amino acid residues of 
NCS1, such that the transfer of assignment for the majority of residues was impossible. 
(It should be noted that the transfer of assignment between the control and the individual inhibitors was 
not possible if the peaks were attenuated, broadened or if they were untraceable.  For the purposes of 
this table residues are labeled in single letter nomenclature a=alpha, b=beta). 
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STD and waterLOGSY spectra acquired for the first generation inhibitors 1, 2 & 3, 
see Chapter 2.3 and 3.3 for further details. 
 
Figure A.1.1- -Inhibitor 1 Ligand screening spectra.  (a) Buffer standard 500μM Inhibitor 1 in NMR 
buffer; 1-D 1H spectra blue, 1-D 1H waterLOGSY spectra red and 1-D 1H STD black. (b)  Binding screen 
500 μM Inhibitor 1 & NCS1 50 μM in NMR buffer; 1-D 1H spectra blue, 1-D 1H waterLOGSY spectra red 
and 1-D 1H STD black.  Comparison between the buffer controls (a) and the protein containing 
experiments (b) are obscured by the reduced solubility of the inhibitor meaning that concentration of 
ligand in solution is significantly less than required. 
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Figure A.1.2- -Inhibitor 2 Ligand screening spectra.  (a) Buffer standard 500μM Inhibitor 2 in NMR 
buffer; 1-D 1H spectra blue, 1-D 1H waterLOGSY spectra red and 1-D 1H STD black. (b)  Binding screen 
500 μM Inhibitor 2 & NCS1 50 μM in NMR buffer; 1-D 1H spectra blue, 1-D 1H waterLOGSY spectra red 
and 1-D 1H STD black.  Comparison between the buffer controls (a) and the protein containing 
experiments (b) are obscured by the reduced solubility of the inhibitor meaning that concentration of 
ligand in solution is significantly less than required. 
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Inhibitor 3 
Figure A.1.3- -Inhibitor 3 Ligand screening spectra.  (a) Buffer standard 500μM Inhibitor 3 in NMR 
buffer; 1-D 1H spectra blue, 1-D 1H waterLOGSY spectra red and 1-D 1H STD black. (b)  Binding screen 
500 μM Inhibitor 3 & NCS1 50 μM in NMR buffer; 1-D 1H spectra blue, 1-D 1H waterLOGSY spectra red 
and 1-D 1H STD black.  Comparison between the buffer controls (a) and the protein containing 
experiments (b) are obscured by the reduced solubility of the inhibitor meaning that concentration of 
ligand in solution is significantly less than required. 
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A.2 First Generation Isothermal Titration Calorimetry  
A.2.1 One Set of Sites fitting functions [212] 
The equation used for the fitting of ITC data in Chapter 2.3 and 3.3 is derived from 
the following equations: 
𝐾 =
𝛳
(1−𝛳)[𝑥]
 A.1 
 
Xt = [x] + 𝑛𝛳𝑀𝑡 A.2 
  
𝛳2 − 𝛳 [1 +
Xt
𝑛𝑀𝑡
+
1
𝑛𝐾𝑀𝑡
+
𝑋𝑡
𝑛𝑀𝑡
] = 0 A.3 
 
𝑄 = 𝑛𝛳𝑀𝑡𝛥𝐻𝑉𝑜 A.4 
 
𝑄 =
𝑛𝑀𝑡𝛥𝐻𝑉𝑜
2
[1 +
Xt
𝑛𝑀𝑡
+
1
𝑛𝐾𝑀𝑡
− √(
Xt
𝑛𝑀𝑡
+
1
𝑛𝐾𝑀𝑡
)2 −
4𝑋𝑡
𝑛𝑀𝑡
] A.5 
K = binding constant 
n = number of sites 
Vo = active cell volume  
Mt = bulk concentration of macromolecule in Vo 
[m] = free concentration of macromolecule in Vo 
Xt = bulk concentration of ligand 
[x] = free concentration of ligand 
ϴ = fraction of sites occupied by the ligand x 
Q = total heat content in Vo 
ΔQi = heat released from the ith injection 
ΔH = molar heat of ligand binding  
 
Fitting of the experimental data involves the following processes: 
1) Initial estimates by origin of the values for n, K , and ΔH 
2) Calculation of ΔQ(i) for each individual injection, these values are 
subsequently compared with the measured heat measured for the 
corresponding experimental injection  
3) Improvement of n, K , and ΔH by standard Marquardt methods  
4) Continuous iteration of the procedure (1, 2 & 3) until there is no improvement 
in the values. 
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A.2.2 Inhibitor 1 
Data expanded from Chapter 2, Section 2.3.6 
 
Figure A.2.1- The thermodynamic parameters (dH= ΔH green, -TdS= -TΔS blue and dG= ΔG yellow) 
obtained from the ITC experiment of the binding interaction between NCS1 400μM and Inhibitor 1 50 
μM.  When determining ΔG the most influential value is ΔH, ideally it should be large and negative, -TΔS 
contributes substantially less to the value of ΔG and the binding affinity and tends to be small and positive 
or small and negative. 
Table A.2.1- A table showing the thermodynamic properties from the duplicate ITC experiments of 50 
μM Inhibitor 1 with NCS1 400μM.  It can be seen that the calculated values do not match those that were 
obtained from the duplicate experiments and so it can be concluded that the solubility difficulties of 
Inhibitor 1 prevent any reliable determination of binding affinity. 
NCS1 400μM: 
Inhibitor 1 
50μM 
ΔH  
(kcal mol-1) 
-TΔS  
(kcal mol-1) 
ΔG 
 (kcal mol-1) 
KD μM 
 
Chi^2 
Data adjusted in 
Origin 
-13.4 
(±209.5) 
6.2 
 
-7.2 
 
5.5 
 
69790 
1 
 
-1.8 
(±148.2) 
2.6 
 
-4.4 
 
3.90E+06 
 
17230 
2 
 
-1.9 
(±199.4) 
-3.8 
 
5.7 
 
60.9 
 
68980 
-15
-10
-5
0
5
10
kc
al
 m
o
l-1 dH
-TdS
dG
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A.2.3 Inhibitor 2 
Table A.2.2- A table showing the thermodynamic properties from the ITC experiment of 1 mM NCS1 
and 100 μM Inhibitor 2.  The value of each property and the calculated error for ΔH are extremely large, 
indicating a poor goodness of fit.  This could be due to the possible precipitation of the inhibitor observed 
during the experiment and in the related isotherm, hence making the derived KD unrealistic. 
Experiment Title 
 
ΔH 
(kcal mol-1) 
-TΔS 
(kcal mol-1) 
ΔG 
(kcal mol-1) 
KD 
μM 
Chi^2 
NCS1 1mM:  
Inhibitor 2 100μM 
-4.708E5 
(±1.003E11) 
4.71E+08 
 
-4.70E+08 
 
179.5 
 
252000 
 
Figure A.2.2- The thermodynamic parameters (dH= ΔH green, -TdS= -TΔS blue and dG= ΔG yellow) 
obtained from the ITC experiment of the binding interaction between NCS1 1mM and Inhibitor 1 100 μM.  
When determining ΔG the most influential value is ΔH, ideally it should be large and negative, -TΔS 
contributes substantially less to the value of ΔG and the binding affinity and tends to be small and positive 
or small and negative. 
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A.3 Second generation Computational Design- 
The compounds designed as analogues of Inhibitor 2 for the second generation (see 
Chapter 3 for further details). 
 
Figure A.3.1- The chemical structures of Inhibitor 2 analogues molecules A.1 - A.20 that were 
subsequently screened using the computational techniques discussed in Chapter 3.1 Second 
Generation Inhibitor design. 
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Figure A.3.2- The chemical structures of Inhibitor 2 analogues molecules A.21 – A.40 that were 
subsequently screened using the computational techniques discussed in Chapter 3.1 Second 
Generation Inhibitor design. 
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Figure A.3.3- The chemical structures of Inhibitor 2 analogues molecules A.45 – A.54 that were 
subsequently screened using the computational techniques discussed in Chapter 3.1 Second 
Generation Inhibitor design. 
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A.4 Second Generation Isothermal Titration Calorimetry  
The isotherm is expanded from Chapter 3.3.2 
 
Figure A.4.1- Binding affinity determination- Isothermal Titration Calorimetry Curve - ITC Isotherm 
(top) and resultant curve (bottom) from the two sequential experiments of Inhibitor 5 8 mM titrated in to 
NCS1 400 µM at 10°C, 8% DMSO, 50 mM tris HCl, 50 mM NaCl, 5 mM CaCl2 pH 7.5.  A large change 
in heat between the the end of the first experiement and the start of the second, meaning that the 
goodness of fit (Chi^2) was extremly large and unfavourable.  Fitting of the curve was conducted in 
Origin 7 using the single set of sites curve fitting model produced a binding model with a derived binding 
affinity KD of 152.9 μM undesiarable enthalpic values as follows ∆H= -1.446 Kcal, -T∆S= 2.604Kcal ∆G=-
4.05 Kcal. 
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A.5 Small Molecule Compound Library experimental spectra 
Table A.5.1- A table containing the details of the 28 chemical compounds within the chemical library, 
including the individual chemical structures of each compound, with details of the results of the 
experiments performed; 1-D 1H saturation transfer difference (STD), 1-D 1H waterLOGSY and 2-D 1H 
15N HSQC.  If the compound did not appear to have an effect upon the protein in the initial STD screen 
then the secondary waterLOGSY and HSQC experiments were not applicable (N/A).  All data was 
collected on a 600 MHz spectrometer equipped with a cryoprobe at 298K.  The initial screen used the 
STD experiment, the NMR sample 550μL was composed of NCS1 20μM (v/v), small molecule 1mM (v/v) 
dissolved in 100% DMSO, with 10% (v/v) 2D2O/H2O, further details of the experiment can be found in 
6.3.2.10.  The indication of an interaction between the protein and small molecule was observed through 
the re-occurrence of the ligand signal in the STD experiment.  This was then confirmed by the use of a 
WaterLOGSY experiment, where the corresponding ligand peak intensity would be reduced, disappear 
completely or become positive (the opposite to the STD spectra).  From the initial screen those 
compounds that appeared to undergo an interaction with NCS1 were then tested further, increasing the 
concentration of NCS1 in the NMR sample to 50μM the STD and waterLOGSY experiments were 
repeated and a further 1H 15N HSQC spectra was collected to observe those residues of NCS1 that were 
affected by the small molecule. 
Compound 
Name 
 
Indication 
of binding 
through 
STD 
Indication of 
binding 
through 
WaterLOGSY 
Indication 
of binding 
through 
HSQC 
 
4.14 
 
 
No 
 
No  
 
No 
 
4.15  
 
No 
 
N/A 
 
N/A 
 
4.16 
 
 
Possibly 
weak 
Aliphatic 
region 
 
Yes weak 
binding 
 
Yes weak 
binding 
 
4.17 
 
 
Possible 
weak 
binding 
 
No 
 
No 
 
4.18 
 
 
No 
 
 
N/A 
 
N/A 
 
4.19 
 
 
No 
 
N/A 
 
N/A 
 
4.20 
 
 
 
Possibly 
weak 
binding 
 
 
No 
 
 
No 
 
4.21 
  
 
Yes 
 
Yes 
 
 
Yes 
 
4.22 
  
Possible 
although 
weak 
 
No 
 
No 
 
 
4.23 
 
Possibly 
weak  
 
 
No 
 
No 
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4.24 
 
 
 
 
Possibly 
weak  
 
 
Yes weak 
binding 
 
 
Yes weak 
binding 
 
4.25 
 
 
No 
 
N/A 
 
N/A 
 
4.26 
 
 
No 
 
N/A 
 
N/A 
 
4.27 
 
 
No 
 
N/A 
 
N/A 
 
4.28 
 
 
 
Yes 
 
 
Yes 
 
 
Yes 
 
4.29 
 
 
No 
 
 
N/A 
 
N/A 
 
4.30 
 
 
Possibly 
weak  
 
No 
 
No 
 
4.31 
 
 
Possibly 
weak 
 
Yes weak 
binding 
 
Yes weak 
binding 
 
4.32 
 
 
Possibly 
weak 
 
Yes weak 
binding 
 
Yes weak 
binding 
 
4.33 
 
 
Possibly 
Weak 
 
No 
 
No 
 
4.34 
 
 
 
Possible 
but weak 
 
No 
 
No 
 
 
4.35 
 
 
 
Yes 
 
 
No 
 
 
No 
 
 
4.36  
 
Yes 
 
Yes 
 
Yes 
 
4.37 
 
 
Possibly 
weak 
 
No 
 
No 
 
4.38 
 
Possibly 
weak 
aromatic 
region 
 
No 
 
No 
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4.39 
 
 
 
Possibly 
weak 
aromatic 
region 
 
No 
 
No 
 
4.40 
 
 
 
Yes 
 
Yes 
 
Yes 
 
4.41 
 
 
Yes 
 
Yes 
 
Yes 
 
 
 
 
Figure A.5.1- NMR spectra collected for Compound 4.14.  (a) The buffer standard, 1 mM 4.14 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in red and STD experiment 
black. (b)  1 mM 4.14 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and 
STD experiment black.  It was thought a possible indication of a weak interaction was observed in these 
experiments.  However (c) an overlay of two 2-D HSQC spectra, the control spectra of NCS1 50μM and 
Appendix 
  
342 
 
DMSO 1% (black) with the spectrum of the ligand 1mM in DMSO 1% and NCS1 50 μM red indicated no 
interaction. 
 
Figure A.5.2- NMR spectra collected for Compound 4.15.  (a) The buffer standard, 1 mM 4.15 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in red and STD experiment 
black. (b)  1 mM 4.15 and 20 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in 
red and STD experiment black.  No indication of an effect of the ligand on NCS1 was observed in these 
experiments and so a 1H 15N HSQC spectra was not collected. 
 
Figure A.5.3- NMR spectra collected for Compound 4.16.  (a) The buffer standard, 1 mM 4.16 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. (b)  
1 mM 4.16 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak interaction was thought to be observed in the aliphatic region of the 
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STD spectra.  This was confirmed by (c) an overlay of two 2-D HSQC spectra, the control spectra of 
NCS1 50 μM and DMSO 1% (black) with the spectrum of the ligand 1 mM in DMSO 1% and NCS1 50 
μM red, whereby some of the residues appear partially perturbed  
 
Figure A.5.4- NMR spectra collected for Compound 4.17.  (a) The buffer standard, 1 mM 4.17 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. (b)  
1 mM 4.17 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak interaction was thought to occur between 4.17 and NCS1, in the 
aliphatic region of the STD spectra.  However the waterLOGSY experiment and (c) an overlay of two 2-
D HSQC spectra, the control spectra of NCS1 50 μM and DMSO 1% (black) with the spectrum of the 
ligand 1 mM in DMSO 1% and NCS1 50 μM red, both suggested that this was a false result. 
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Figure A.5.5- NMR spectra collected for Compound 4.18.  (a) The buffer standard, 1 mM 4.18 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in red and STD experiment 
black. (b)  1 mM 4.18 and 20 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in 
red and STD experiment black.  No indication of an effect of the ligand on NCS1 was observed in these 
experiments and so a 1H 15N HSQC spectra was not collected. 
 
Figure A.5.6- NMR spectra collected for Compound 4.19.  (a) The buffer standard, 1 mM 4.19 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in red and STD experiment 
black. (b)  1 mM 4.19 and 20 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in 
red and STD experiment black.  No indication of an effect of the ligand on NCS1 was observed in these 
experiments and so a 1H 15N HSQC spectra was not collected.  
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Figure A.5.7- NMR spectra collected for Compound 4.20.  (a) The buffer standard, 1 mM 4.20 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. (b)  
1 mM 4.20 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak interaction was thought to occur between 4.20 and NCS1 in the 
aliphatic region of the STD.  However the waterLOGSY experiment and (c) an overlay of two 2-D HSQC 
spectra, the control spectra of NCS1 50μM and DMSO 1% (black) with the spectrum of the ligand 1mM 
in DMSO 1% and NCS1 50 μM red both suggested that this was a false result. 
 
Figure A.5.8- NMR spectra collected for Compound 4.21.  (a) The buffer standard, 1 mM 4.21 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. (b)  
1 mM 4.21 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible interaction between 4.21 and NCS1 can be observed in the aromatic and 
aliphatic regions of the STD and waterLOGSY spectra.  This is observed as the ligand signals appear in 
the STD and their corresponding signals in the waterLOGSY are reduced or positive.  An interaction 
between the small molecule and NCS1 was confirmed in (c) an overlay of two 2-D HSQC spectra, the 
control spectra of NCS1 50 μM and DMSO 1% (black) with the spectrum of the ligand 1 mM in DMSO 
1% and NCS1 50 μM red with numerous amino acid residues appearing to be perturbed by the presence 
of 4.21.  All three experimental results are indicative of a possible binding interaction. 
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Figure A.5.9- NMR spectra collected for Compound 4.22.  (a) The buffer standard, 1 mM 4.22 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. (b)  
1 mM 4.22 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak effect of 4.22 on NCS1 was thought to be observed in the aliphatic 
region of the STD spectra.  However the waterLOGSY experiment and (c) an overlay of two 2-D HSQC 
spectra, the control spectra of NCS1 50 μM and DMSO 1% (black) with the spectrum of the ligand 1 mM 
in DMSO 1% and NCS1 50 μM red both suggested that this was a false result. 
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Figure A.5.11- NMR spectra collected for Compound 4.23.  (a) The buffer standard, 1 mM 4.23 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b)  1 mM 4.23 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak interaction between 4.23 and NCS1 was thought to be observed in 
the aliphatic region of the STD spectra.  However the waterLOGSY experiment and (c) an overlay of two 
2-D HSQC spectra, the control spectra of NCS1 50 μM and DMSO 1% (black) with the spectrum of the 
ligand 1mM in DMSO 1% and NCS1 50 μM red, both suggested that this was a false result. 
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Figure A.5.12- NMR spectra collected for Compound 4.24  (a) The buffer standard, 1 mM 4.24 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b)  1 mM 4.24 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak interaction between the ligand NCS1 was observed in the aromatic 
region of the STD.  This was confirmed by reduced intensity of the corresponding signals in the 
waterLOGSY spectrum and (c) an overlay of two 2-D HSQC spectra, the control spectra of NCS1 50 μM 
and DMSO 1% (black) with the spectrum of the ligand 1 mM in DMSO 1% and NCS1 50 μM red, whereby 
some of the residues appear partially perturbed. 
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Figure A.5.13- NMR spectra collected for Compound 4.25.  (a) The buffer standard, 1 mM 4.25 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in red and STD 
experiment black. (b)  1 mM 4.25 and 20 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum 
seen in red and STD experiment black.  No indication of an effect of the ligand on NCS1 was observed 
in these experiments and so a 1H 15N HSQC spectra was not collected. 
 
 
 
Figure A.5.14- NMR spectra collected for Compound 4.26.  (a) The buffer standard, 1 mM 4.26 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in red and STD 
experiment black. (b)  1 mM 4.26 and 20 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum 
seen in red and STD experiment black.  No indication of an effect of the ligand on NCS1 was observed 
in these experiments and so a 1H 15N HSQC spectra was not collected. 
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Figure A.5.15- NMR spectra collected for Compound 4.27.  (a) The buffer standard, 1 mM 4.27 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in red and STD 
experiment black. (b)  1 mM 4.27 and 20 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum 
seen in red and STD experiment black.  No indication of an effect of the ligand on NCS1 was observed 
in these experiments and so a 1H 15N HSQC spectra was not collected. 
 
Figure A.5.16- NMR spectra collected for Compound 4.28.  The buffer standard, 1 mM 4.28 in NMR 
buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. (b)  
1 mM 4.28 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  An effect of the ligand on NCS1 can be observed in the aromatic and aliphatic regions 
of the STD where the ligand signals appear in the STD and waterLOGSY where their corresponding 
signals in the waterLOGSY are reduced or positive.  An interaction between the small molecule and 
NCS1 was confirmed in (c) an overlay of two 2-D HSQC spectra, the control spectra of NCS1 50 μM 
and DMSO 1% (black) with the spectrum of the ligand 1 mM in DMSO 1% and NCS1 50 μM red with 
numerous amino acid residues appearing to be perturbed by the presence of 4.28.  All three experimental 
results are indicative of a possible binding interaction. 
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Figure A.5.17- NMR spectra collected for Compound 4.29. (a) The buffer standard, 1 mM 4.29 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum seen in red and STD 
experiment black. (b)  1 mM 4.29 and 20 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum 
seen in red and STD experiment black.  No indication of an interaction was observed in these 
experiments and so a 1H 15N HSQC spectra was not collected. 
 
Figure A.5.18- NMR spectra collected for Compound 4.30.  (a) The buffer standard, 1 mM 4.30 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b)  1 mM 4.30 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak effect was thought to be observed in the aliphatic region of the STD.  
However the waterLOGSY experiment and (c) an overlay of two 2-D HSQC spectra, the control spectra 
of NCS1 50 μM and DMSO 1% (black) with the spectrum of the ligand 1 mM in DMSO 1% and NCS1 
50 μM red, both suggested that this was a false result. 
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Figure A.5.19- NMR spectra collected for Compound 4.31.  (a) The buffer standard, 1 mM 4.31 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.31 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak effect was observed up-field in the aliphatic region of the STD.  This 
was confirmed by reduced intensity of the corresponding signals in the waterLOGSY spectrum and (c) 
an overlay of two 2-D HSQC spectra, the control spectra of NCS1 50 μM and DMSO 1% (black) with the 
spectrum of the ligand 1 mM in DMSO 1% and NCS1 50 μM red, where some of the residues appear 
partially perturbed.  
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Figure A.5.20- NMR spectra collected for Compound 4.32. (a) The buffer standard, 1 mM 4.32 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.32 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak effect was observed up-field in the aliphatic region of the STD.  This 
was confirmed by reduced intensity of the corresponding signals in the waterLOGSY spectrum and (c) 
an overlay of two 2-D HSQC spectra, the control spectra of NCS1 50 μM and DMSO 1% (black) with the 
spectrum of the ligand 1 mM in DMSO 1% and NCS1 50 μM red, where some of the residues appear 
partially perturbed. 
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Figure A.5.21- NMR spectra collected for Compound 4.33.  (a) The buffer standard, 1 mM 4.33 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b)  1 mM 4.33 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak effect between 4.33 and NCS1 was observed up-field in the aliphatic 
region of the STD.  However the waterLOGSY experiment and (c) an overlay of two 2-D HSQC spectra, 
the control spectra of NCS1 50 μM and DMSO 1% (black) with the spectrum of the ligand 1 mM in DMSO 
1% and NCS1 50 μM red, both suggested that this was a false result. 
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Figure A.5.22- NMR spectra collected for Compound 4.34.  (a) The buffer standard, 1 mM 4.34 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.34 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak effect between 4.34 and NCS1 was observed up-field in the aliphatic 
region of the STD.  However the waterLOGSY experiment and (c) an overlay of two 2-D HSQC spectra, 
the control spectra of NCS1 50 μM and DMSO 0.95% (black) with the spectrum of the ligand 1 mM in 
DMSO 0.95% and NCS1 50μM red, both suggested that this was a false result. 
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Figure A.5.23- NMR spectra collected for Compound 4.35  (a) The buffer standard, 1 mM 4.35 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.35 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak effect between 4.35 and NCS1 was observed up-field in the aliphatic 
region of the STD.  However the waterLOGSY spectra and (c) an overlay of two 2-D HSQC spectra, the 
control spectra of NCS1 50 μM and DMSO 1% (black) with the spectrum of the ligand 1 mM in DMSO 
1% and NCS1 50 μM red, both suggested that this was a false result. 
Appendix 
  
357 
 
 
Figure A.5.24- NMR spectra collected for Compound 4.36.  (a) The buffer standard, 1 mM 4.36 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.36 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  An effect of the ligand upon NCS1 can be observed in the aromatic region of the STD 
spectra where the ligand signals are apparent and waterLOGSY experiment where the corresponding 
signals are reduced or positive.  An interaction between the small molecule and NCS1 was confirmed in 
(c) an overlay of two 2-D HSQC spectra. The control spectra of NCS1 50 μM and DMSO 1% (black) with 
the spectrum of the ligand 1 mM in DMSO 1% and NCS1 50 μM red, with the chemical shift of some 
amino acid residues appearing to be perturbed by the presence of 4.36.  All three experimental results 
are indicative of a possible binding interaction. 
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Figure A.5.25- NMR spectra collected for Compound 4.37. (a) The buffer standard, 1 mM 4.37 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.37 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak interaction was thought to occur between 4.37 and NCS1, in the 
aliphatic and aromatic region of the STD spectra.  However the waterLOGSY experiment and (c) an 
overlay of two 2-D HSQC spectra, the control spectra of NCS1 50 μM and DMSO 1% (black) with the 
spectrum of the ligand 1 mM in DMSO 1% and NCS1 50 μM red, both suggested that this was a false 
result. 
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Figure A.5.26- NMR spectra collected for Compound 4.38. (a) The buffer standard, 1 mM 4.38 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.38 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak interaction was thought to occur between 4.38 and NCS1, 
observable in the aromatic region of the STD spectra.  However the waterLOGSY experiment and (c) 
an overlay of two 2-D HSQC spectra, the control spectra of NCS1 50 μM and DMSO 1% (black) with the 
spectrum of the ligand 1 mM in DMSO 1% and NCS1 50 μM red, both suggest that this was a false 
result. 
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Figure A.5.27- NMR spectra collected for Compound 4.39. (a) The buffer standard, 1 mM 4.39 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.39 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  A possible weak interaction was thought to occur between 4.39 and NCS1, in the 
aliphatic region of the STD spectra.  However the waterLOGSY experiment and (c) an overlay of two 2-
D HSQC spectra, the control spectra of NCS1 50 μM and DMSO 1% (black) with the spectrum of the 
ligand 1 mM in DMSO 1% and NCS1 50 μM red, both suggested that this was a false result. 
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Figure 8.5.28- NMR spectra collected for Compound 4.40  (a) The buffer standard, 1 mM 4.40 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.40 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  An effect of the ligand upon NCS1 can be observed in the down-field aromatic region 
of the STD spectra where some of the ligand signals are apparent and waterLOGSY experiment where 
the corresponding signals are reduced or positive.  An interaction between the small molecule and NCS1 
was confirmed in (c) an overlay of two 2-D HSQC spectra. The control spectra of NCS1 50 μM and 
DMSO 1% (black) with the spectrum of the ligand 1 mM in DMSO 1% and NCS1 50 μM red, with the 
chemical shift of some amino acid residues appearing to be perturbed by the presence of 4.40.  All three 
experimental results are indicative of a possible binding interaction. 
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Figure A.5.29- NMR spectra collected for Compound 4.41. (a) The buffer standard, 1 mM 4.41 in 
NMR buffer with the 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
(b) 1 mM 4.41 and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  An effect of the ligand upon NCS1 can be observed in the up-field aliphatic region of 
the STD spectra where some of the ligand signals are apparent and waterLOGSY experiment where the 
corresponding signals are reduced or positive.  An interaction between the small molecule and NCS1 
was confirmed in (c) an overlay of two 2-D HSQC spectra. The control spectra of NCS1 50 μM and 
DMSO 1% (black) with the spectrum of the ligand 1 mM in DMSO 1% and NCS1 50μM red, with the 
chemical shift of some amino acid residues appearing to be perturbed by the presence of 4.41.  All three 
experimental results are indicative of a possible binding interaction. 
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A.6 D2R Competition experiments 
To determine if the hit binding compounds of the small molecule library were allosteric 
or orthosteric in nature, competition experiments were designed using the peptide 
D2R.  However as seen in the D2R peptide standard (Figure A.6.1), the peptide is 
poorly soluble at the desired concentration and so may not be at the required 
concentration to out compete the ligands.  
 
Figure A.6.1- D2R peptide standard. (a) 50 μM D2R peptide in NMR buffer, 1-D 1H spectra seen in 
blue, waterLOGSY spectrum red and STD experiment black. (b) Two 2-D 1H 15N HSQC spectra. The 
control spectra of NCS1 50 μM in NMR buffer (black) with the spectrum of the peptide 50 μM NCS1 50 
μM red with no apparent changes in the residues observed. 
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Figure A.6.2– 4.16, NCS1and D2R peptide. (a) 1 mM 4.16 and 50 μM NCS1, 1-D 1H spectra seen in 
blue, waterLOGSY spectrum red and STD experiment black.  A possible weak interaction was thought 
to be observed in the aliphatic region of the STD spectra (b) 1 mM 4.16 with 50 μM D2R peptide and 50 
μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black.  No 
apparent change in the STD or waterLOGSY profiles when compared to the previously collected ligand 
and NCS1 spectra. 
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Figure A.6.3– 4.17, NCS1 and D2R peptide. (a) 1 mM 4.17 and 50 μM NCS1, 1-D 1H spectra seen in 
blue, waterLOGSY spectrum red and STD experiment black.  A possible weak interaction was thought 
to occur between 4.17 and NCS1, in the aliphatic region of the STD spectra. (b) 1 mM 4.17 with 50 μM 
D2R peptide and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  No apparent change in the STD or waterLOGSY profiles when compared to the 
previously collected ligand and NCS1 spectra.  
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Figure A.6.4– 4.21, NCS1 and D2R peptide. (a) Two 2-D 1H 15N HSQC spectra. The control spectra of 
1 mM C9, NCS1 50 μM in NMR buffer (black) with the spectrum of the 4.21 50 μM, peptide 50 μM and 
NCS1 50 μM red with no apparent changes in the residues observed. (b) 1 mM 4.21 with 50 μM D2R 
peptide and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment 
black 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black. 
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Figure A.6.5- 4.23, NCS1 and D2R peptide. (a) 1 mM 4.23 and 50 μM NCS1, 1-D 1H spectra seen in 
blue, waterLOGSY spectrum red and STD experiment black.  A possible weak interaction between 4.23 
and NCS1 was thought to be observed in the aliphatic region of the STD spectra (b) 1 mM 4.23 with 50 
μM D2R peptide and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  No apparent change in the STD or waterLOGSY profiles when compared to the 
previously collected ligand and NCS1 spectra. 
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Figure A.6.6- 4.24, NCS1 and D2R peptide. (a) 1 mM 4.24 and 50 μM NCS1, 1-D 1H spectra seen in 
blue, waterLOGSY spectrum red and STD experiment black.  A possible weak interaction between the 
ligand NCS1 was observed in the aromatic region of the STD.  This was confirmed by reduced intensity 
of the corresponding signals in the waterLOGSY spectrum.  (b) 1 mM 4.24 with 50 μM D2R peptide and 
50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD experiment black.  No 
apparent change in the STD or waterLOGSY profiles when compared to the previously collected ligand 
and NCS1 spectra. 
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Figure A.6.7- 4.28, NCS1 and D2R peptide. (a) 1 mM 4.28 and 50 μM NCS1, 1-D 1H spectra seen in 
blue, waterLOGSY spectrum red and STD experiment black.  An effect of the ligand on NCS1 can be 
observed in the aromatic and aliphatic regions of the STD where the ligand signals appear in the STD 
and waterLOGSY where their corresponding signals in the waterLOGSY are reduced or positive.  (b) 1 
mM 4.28 with 50 μM D2R peptide and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum 
red and STD experiment black.  No apparent change in the STD or waterLOGSY profiles when compared 
to the previously collected ligand and NCS1 spectra. 
Appendix 
  
370 
 
 
Figure A.6.8- 4.31, NCS1 and D2R peptide. (a) 1 mM 4.31 and 50 μM NCS1, 1-D 1H spectra seen in 
blue, waterLOGSY spectrum red and STD experiment black.  A possible weak effect was observed up-
field in the aliphatic region of the STD.  This was confirmed by reduced intensity of the corresponding 
signals in the waterLOGSY spectrum. (b) 1 mM 4.31 with 50 μM D2R peptide and 50 μM NCS1, 1-D 1H 
spectra seen in blue, waterLOGSY spectrum red and STD experiment black.  No apparent change in 
the STD or waterLOGSY profiles when compared to the previously collected ligand and NCS1 spectra. 
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Figure A.6.9- 4.36, NCS1 and D2R peptide. (a) 1 mM 4.36 and 50 μM NCS1, 1-D 1H spectra seen in 
blue, waterLOGSY spectrum red and STD experiment black.  An effect of the ligand upon NCS1 can be 
observed in the aromatic region of the STD spectra where the ligand signals are apparent and 
waterLOGSY experiment where the corresponding signals are reduced or positive. (b) 1 mM 4.36 with 
50 μM D2R peptide and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum red and STD 
experiment black.  No apparent change in the STD or waterLOGSY profiles when compared to the 
previously collected ligand and NCS1 spectra. 
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Figure A.6.10- 4.41, NCS1 and D2R peptide. (a) 1 mM 4.41 and 50 μM NCS1, 1-D 1H spectra seen in 
blue, waterLOGSY spectrum red and STD experiment black.  An effect of the ligand upon NCS1 can be 
observed in the up-field aliphatic region of the STD spectra where some of the ligand signals are 
apparent and waterLOGSY experiment where the corresponding signals are reduced or positive. (b) 1 
mM 4.41 with 50 μM D2R peptide and 50 μM NCS1, 1-D 1H spectra seen in blue, waterLOGSY spectrum 
red and STD experiment black.  No apparent change in the STD or waterLOGSY profiles when compared 
to the previously collected ligand and NCS1 spectra. 
 
